EntryID,Date,Ligand,Value,Symbol,Type,Unit,PDBID,Title,StructureTitle,StuctureKeywords,GeneName,ECNumber,AnnotationIdentifier,PolymerEntityID,EntryIdPolymerEntityIdentifiers,TargetProtein,AccessionCode,DatabaseName,LigandFormula,LigandMW,LigandID,LigandName,LigandSMILES,NonPolymerEntityID
7QOX,1,,,,,,7QOX,Plasma kallikrein structure reveals apple domain disc rotated conformation compared to factor XI.,Factor XI and Plasma Kallikrein apple domain structures reveals different kininogen bound complexes,BLOOD CLOTTING,KNG1/ BDK/ KNG,,GO:0072562/ GO:0062023/ GO:0005788/ GO:0070062/ GO:0005576/ GO:0005615/ GO:0005886/ GO:0031093/ GO:0004869/ GO:0004866/ GO:0008201/ GO:0005102/ GO:0008270/ GO:0061844/ GO:0007596/ GO:0006954/ GO:0031640/ GO:0030195/ GO:0007162/ GO:0010951/ GO:0045861/ GO:0043065/ GO:0007204/ GO:0042311/ IPR000010/ IPR046350/ IPR002395/ IPR027358/ IPR018073/ P01042,2,7QOX,Wildtype,P01042,UniProt,C16 H34 O8,354.436,PE4,2-{2-[2-(2-{2-[2-(2-ETHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHOXY]-ETHOXY}-ETHANOL,CCOCCOCCOCCOCCOCCOCCOCCO,5
7QTM,1,,,,,,7QTM,Transition state analogue of small G protein in complex with relevant GAP,Transition state analogue of small G protein in complex with relevant GAP,HYDROLASE,ARHGAP1/ CDC42GAP/ RHOGAP1,,GO:0005737/ GO:0005829/ GO:0010008/ GO:0070062/ GO:0048471/ GO:0045296/ GO:0005096/ GO:0017124/ GO:0031267/ GO:0016197/ GO:2001136/ GO:0051056/ GO:0007266/ GO:0007264/ GO:0033572/ IPR001251/ IPR036865/ IPR008936/ IPR000198/ Q07960,1,7QTM,mutant,Q07960,UniProt,C10 H15 N5 O11 P2,443.201,GDP,GUANOSINE-5'-DIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,3
7QU4,1,,,,,,7QU4,Structural and oxidative investigation of a recombinant high-yielding fetal hemoglobin mutant.,Recombinant Human Fetal Hemoglobin mutant - alpha subunit mutations K11E/K56E/N78D/K90E,OXYGEN TRANSPORT,HBA1/ HBA2,,GO:0072562/ GO:0005829/ GO:0022627/ GO:0071682/ GO:0070062/ GO:0005576/ GO:0005615/ GO:0031838/ GO:0005833/ GO:0016020/ GO:0001664/ GO:0020037/ GO:0005506/ GO:0043177/ GO:0019825/ GO:0005344/ GO:0015670/ GO:0098869/ GO:0042744/ GO:0030185/ GO:0015671/ GO:0042542/ IPR000971/ IPR009050/ IPR012292/ IPR002338/ IPR002339/ P69905,2,7QU4,mutant,P69905,UniProt,C34 H32 Fe N4 O4,616.487,HEM,PROTOPORPHYRIN IX CONTAINING FE,Cc1c2n3c(c1CCC(=O)O)C=C4C(=C(C5=[N]4[Fe]36[N]7=C(C=C8N6C(=C5)C(=C8C)C=C)C(=C(C7=C2)C)C=C)C)CCC(=O)O,3
7QUI,1,,,,,,7QUI,Structures of the Inhibitory Receptor Siglec-8 in Complex with a High-Affinity Sialoside Analogue and a Therapeutic Antibody.,Crystal structure of the N-terminal domain of Siglec-8 in complex with sulfonamide sialoside analogue,IMMUNE SYSTEM,SIGLEC8/ SAF2,,GO:0005886/ GO:0030246/ GO:0033691/ GO:0004888/ GO:0007155/ GO:0007165/ IPR007110/ IPR036179/ IPR013783/ IPR003599/ IPR003598/ IPR013106/ Q9NYZ4,1,7QUI,mutant,Q9NYZ4,UniProt,C35 H49 N3 O23 S2,943.9,F9I,(2~{S}/4~{S}/5~{R}/6~{R})-5-acetamido-2-[(2~{S}/3~{R}/4~{S}/5~{S}/6~{R})-2-[(2~{R}/3~{S}/4~{R}/5~{R}/6~{R})-5-acetamido-2-(hydroxymethyl)-4/6-bis(oxidanyl)oxan-3-yl]oxy-3/5-bis(oxidanyl)-6-(sulfooxymethyl)oxan-4-yl]oxy-6-[(1~{R}/2~{R})-3-(naphthalen-2-ylsulfonylamino)-1/2-bis(oxidanyl)propyl]-4-oxidanyl-oxane-2-carboxylic acid,CC(=O)NC1C(CC(OC1C(C(CNS(=O)(=O)c2ccc3ccccc3c2)O)O)(C(=O)O)OC4C(C(OC(C4O)OC5C(OC(C(C5O)NC(=O)C)O)CO)COS(=O)(=O)O)O)O,2
7RB3,1,,,,,,7RB3,Molecular role of NAA38 in thermostability and catalytic activity of the human NatC N-terminal acetyltransferase.,Cryo-EM structure of human binary NatC complex with a Bisubstrate inhibitor,TRANSFERASE,NAA35/ EGAP/ MAK10,,GO:0005737/ GO:0005829/ GO:0031417/ GO:0005654/ GO:0005886/ GO:0017196/ GO:0006474/ GO:0043066/ GO:0048659/ IPR007244/ Q5VZE5,1,7RB3,Wildtype,Q5VZE5,UniProt,C23 H38 N7 O18 P3 S,825.57,CMC,CARBOXYMETHYL COENZYME *A,CC(C)(COP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)n2cnc3c2ncnc3N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSCC(=O)O)O,3
7SZA,1,,,,,,7SZA,Crystal Structure Analysis of human PRPK complex with a compound,Crystal Structure Analysis of human PRPK complex with a compound,TRANSFERASE,TP53RK/ C20orf64/ PRPK,3.6/ 2.7.11.1,GO:0005737/ GO:0000408/ GO:0005654/ GO:0005634/ GO:0005524/ GO:0016787/ GO:0002039/ GO:0106310/ GO:0004674/ GO:0006468/ GO:1901796/ GO:0008033/ GO:0070525/ IPR022495/ IPR011009/ IPR000719/ IPR008266/ Q96S44,1,7SZA,Wildtype,Q96S44,UniProt,C13 H11 N3 O4,273.244,DUI,4-amino-2-[(3R)-2/6-dioxopiperidin-3-yl]-1H-isoindole-1/3(2H)-dione,c1cc2c(c(c1)N)C(=O)N(C2=O)C3CCC(=O)NC3=O,3
7SZB,1,,,,,,7SZB,Crystal Structure Analysis of human PRPK complex with a compound,Crystal Structure Analysis of human PRPK complex with a compound,TRANSFERASE,TP53RK/ C20orf64/ PRPK,3.6/ 2.7.11.1,GO:0005737/ GO:0000408/ GO:0005654/ GO:0005634/ GO:0005524/ GO:0016787/ GO:0002039/ GO:0106310/ GO:0004674/ GO:0006468/ GO:1901796/ GO:0008033/ GO:0070525/ IPR022495/ IPR011009/ IPR000719/ IPR008266/ Q96S44,1,7SZB,Wildtype,Q96S44,UniProt,C13 H11 N3 O4,273.244,DQ4,5-amino-2-[(3R)-2/6-dioxopiperidin-3-yl]-1H-isoindole-1/3(2H)-dione,c1cc2c(cc1N)C(=O)N(C2=O)C3CCC(=O)NC3=O,3
7TAI,1,,,,,,7TAI,Structure of STEAP2 in complex with ligands,Structure of STEAP2 in complex with ligands,OXIDOREDUCTASE,STEAP2/ PCANAP1/ STAMP1/ UNQ6507/PRO23203,1.16.1,GO:0005829/ GO:0005769/ GO:0005768/ GO:0010008/ GO:0000139/ GO:0005886/ GO:0030140/ GO:0008823/ GO:0052851/ GO:0046872/ GO:0015677/ GO:0098705/ GO:0006897/ GO:0006893/ GO:0098711/ GO:0045055/ GO:0009725/ IPR013130/ IPR036291/ IPR028939/ Q8NFT2/ Transmembrane.Alpha-helical polytopic.Electron transport chain complex II superfamily.Transmembrane ferric reductase/ Generic PDBTM,1,7TAI,Wildtype,Q8NFT2,UniProt,C34 H32 Fe N4 O4,616.487,HEM,PROTOPORPHYRIN IX CONTAINING FE,Cc1c2n3c(c1CCC(=O)O)C=C4C(=C(C5=[N]4[Fe]36[N]7=C(C=C8N6C(=C5)C(=C8C)C=C)C(=C(C7=C2)C)C=C)C)CCC(=O)O,3
7TAI,1,,,,,,7TAI,Structure of STEAP2 in complex with ligands,Structure of STEAP2 in complex with ligands,OXIDOREDUCTASE,STEAP2/ PCANAP1/ STAMP1/ UNQ6507/PRO23203,1.16.1,GO:0005829/ GO:0005769/ GO:0005768/ GO:0010008/ GO:0000139/ GO:0005886/ GO:0030140/ GO:0008823/ GO:0052851/ GO:0046872/ GO:0015677/ GO:0098705/ GO:0006897/ GO:0006893/ GO:0098711/ GO:0045055/ GO:0009725/ IPR013130/ IPR036291/ IPR028939/ Q8NFT2/ Transmembrane.Alpha-helical polytopic.Electron transport chain complex II superfamily.Transmembrane ferric reductase/ Generic PDBTM,1,7TAI,Wildtype,Q8NFT2,UniProt,C21 H28 N7 O17 P3,743.405,NAP,NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE,c1cc(c[n+](c1)C2C(C(C(O2)COP(=O)([O-])OP(=O)(O)OCC3C(C(C(O3)n4cnc5c4ncnc5N)OP(=O)(O)O)O)O)O)C(=O)N,4
7TAI,1,,,,,,7TAI,Structure of STEAP2 in complex with ligands,Structure of STEAP2 in complex with ligands,OXIDOREDUCTASE,STEAP2/ PCANAP1/ STAMP1/ UNQ6507/PRO23203,1.16.1,GO:0005829/ GO:0005769/ GO:0005768/ GO:0010008/ GO:0000139/ GO:0005886/ GO:0030140/ GO:0008823/ GO:0052851/ GO:0046872/ GO:0015677/ GO:0098705/ GO:0006897/ GO:0006893/ GO:0098711/ GO:0045055/ GO:0009725/ IPR013130/ IPR036291/ IPR028939/ Q8NFT2/ Transmembrane.Alpha-helical polytopic.Electron transport chain complex II superfamily.Transmembrane ferric reductase/ Generic PDBTM,1,7TAI,Wildtype,Q8NFT2,UniProt,C27 H33 N9 O15 P2,785.55,FAD,FLAVIN-ADENINE DINUCLEOTIDE,Cc1cc2c(cc1C)N(C3=NC(=O)NC(=O)C3=N2)CC(C(C(COP(=O)(O)OP(=O)(O)OCC4C(C(C(O4)n5cnc6c5ncnc6N)O)O)O)O)O,2
7TKX,1,,,,,,7TKX,Crystal structure of R14A human Galectin-7 mutant in presence of 4-O-beta-D-Galactopyranosyl-D-glucose,Crystal structure of R14A human Galectin-7 mutant in presence of 4-O-beta-D-Galactopyranosyl-D-glucose,SUGAR BINDING PROTEIN,LGALS7/ PIG1/ LGALS7B,,GO:0005829/ GO:0070062/ GO:0005615/ GO:0005634/ GO:0030246/ GO:0016936/ GO:0006915/ GO:0007157/ GO:2000562/ GO:0032689/ GO:0010628/ IPR013320/ IPR044156/ IPR030640/ IPR001079/ P47929,1,7TKX,mutant,P47929,UniProt,C12 H22 O11,342.296,LBL,(2~{R}/3~{R}/4~{R}/5~{R})-4-[(2~{S}/3~{R}/4~{S}/5~{R}/6~{R})-6-(hydroxymethyl)-3/4/5-tris(oxidanyl)oxan-2-yl]oxy-2/3/5/6-tetrakis(oxidanyl)hexanal,C(C1C(C(C(C(O1)OC(C(CO)O)C(C(C=O)O)O)O)O)O)O,2
7TMC,1,,,,,,7TMC,TMEM106B filament from human brain,TMEM106B singlet filament extracted from MSTD neurodegenerative human brain,NEUROPEPTIDE,TMEM106B,,GO:0005768/ GO:0031902/ GO:0005765/ GO:0005764/ GO:0051117/ GO:0048813/ GO:0007042/ GO:1905146/ GO:0007041/ GO:0032418/ GO:0007040/ GO:0070050/ GO:1900006/ GO:0051345/ GO:1905671/ IPR009790/ Q9NUM4,1,7TMC,mutant,Q9NUM4,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,2
7UCD,1,,,,,,7UCD,Chemically targeting the redox switch in AP1 transcription factor Delta FOSB.,Transcription factor FosB/JunD bZIP domain covalently modified with the cysteine-targeting alpha-haloketone compound Z2159931480,DNA BINDING PROTEIN,FOSB/ G0S3,,GO:0000785/ GO:0043231/ GO:0005654/ GO:0005634/ GO:0003677/ GO:0001228/ GO:0000981/ GO:0000978/ GO:1990837/ GO:0071277/ GO:0032870/ GO:0007565/ GO:0000122/ GO:0006357/ GO:0051591/ GO:0051412/ GO:0009612/ GO:0043278/ GO:0032570/ GO:0009410/ GO:0006366/ IPR000837/ IPR004827/ IPR046347/ IPR029813/ P53539,1,7UCD,Wildtype,P53539,UniProt,C11 H10 O4,206.195,MV0,7-acetyl-4-methoxy-1-benzofuran-3(2H)-one,CC(=O)c1ccc(c2c1OCC2=O)OC,3
7UD6,1,,,,,,7UD6,Designer installation of a substrate recruitment domain to tailor enzyme specificity.,Designed Enzyme SH3-588 (Catechol O-methyltransferase catalytic domain and Src homology 3 binding domain fusion),TRANSFERASE,FYN,2.1.1.6,GO:0030424/ GO:0044297/ GO:0005829/ GO:0030425/ GO:0043197/ GO:0016020/ GO:0045211/ GO:0016206/ GO:0102084/ GO:0000287/ GO:0008171/ GO:0102938/ GO:0042424/ GO:0016036/ GO:0032502/ GO:0042420/ GO:0042417/ GO:0008210/ GO:0007565/ GO:0007612/ GO:0032259/ GO:0048609/ GO:0045963/ GO:0035814/ GO:0048662/ GO:0042135/ GO:0050668/ GO:0051930/ GO:0043627/ GO:0032496/ GO:0014070/ GO:0048265/ GO:0009410/ GO:0046498/ GO:0046500/ GO:0007614/ IPR017128/ IPR029063/ IPR002935/ GO:0005886/ IPR035750/ IPR000980/ IPR036860/ IPR036028/ IPR001452/ P22734,1,7UD6,mutant,E5RFS5,UniProt,C14 H20 N6 O5 S,384.411,SAH,S-ADENOSYL-L-HOMOCYSTEINE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)CSCCC(C(=O)O)N)O)O)N,2
7WMM,1,,,,,,7WMM,alpha-synuclein fibril-F0502B complex,alpha-synuclein fibril-F0502B complex,PROTEIN FIBRIL,SNCA/ NACP/ PARK1,,GO:0015629/ GO:0070161/ GO:0030424/ GO:0043679/ GO:0005938/ GO:0005737/ GO:0005829/ GO:0005576/ GO:0005615/ GO:0030426/ GO:0016234/ GO:0005764/ GO:0016020/ GO:0005739/ GO:0043025/ GO:0005634/ GO:0048471/ GO:0005886/ GO:0098794/ GO:0032991/ GO:0099512/ GO:0030672/ GO:0003779/ GO:0043014/ GO:0005509/ GO:0005507/ GO:1903136/ GO:0043027/ GO:0070840/ GO:0008198/ GO:0042393/ GO:0030544/ GO:0042802/ GO:0019894/ GO:0000287/ GO:0016491/ GO:0005543/ GO:0051219/ GO:0004860/ GO:0000149/ GO:0048156/ GO:0000976/ GO:0008270/ GO:0006919/ GO:0008344/ GO:0071280/ GO:0071872/ GO:0034599/ GO:0007268/ GO:0042416/ GO:0051583/ GO:0060079/ GO:0006631/ GO:0060291/ GO:0001774/ GO:0042775/ GO:0007006/ GO:0043066/ GO:1904715/ GO:0043154/ GO:0051585/ GO:0045920/ GO:0035067/ GO:0031115/ GO:1902957/ GO:0032769/ GO:0043524/ GO:1901215/ GO:0051622/ GO:0010642/ GO:0006469/ GO:0051612/ GO:0070495/ GO:0000122/ GO:0032410/ GO:0051402/ GO:0006638/ GO:0006644/ GO:0043065/ GO:0045807/ GO:0045921/ GO:1903284/ GO:1903285/ GO:0050729/ GO:0060732/ GO:1901216/ GO:0001956/ GO:0033138/ GO:0071902/ GO:0001921/ GO:0051281/ GO:0035543/ GO:0031648/ GO:0051262/ GO:0031623/ GO:0050812/ GO:0014059/ GO:0014048/ GO:0040012/ GO:0048169/ GO:0043030/ GO:1901214/ GO:0051621/ GO:0010517/ GO:1905606/ GO:1903426/ GO:1903421/ GO:0022898/ GO:0034341/ GO:0070555/ GO:0010040/ GO:0032496/ GO:0032026/ GO:0009410/ GO:0035493/ GO:0097435/ GO:0050808/ GO:0048488/ GO:0016079/ GO:0016082/ GO:0048489/ IPR001058/ IPR002460/ P37840,1,7WMM,Wildtype,P37840,UniProt,C21 H22 Br F N2 O2 S,465.379,1KI,2-bromanyl-4-[(~{E})-2-[6-[2-(2-fluoranylethoxy)ethyl-methyl-amino]-5-methyl-1/3-benzothiazol-2-yl]ethenyl]phenol,Cc1cc2c(cc1N(C)CCOCCF)sc(n2)C=Cc3ccc(c(c3)Br)O,2
7WR3,1,,,,,,7WR3,Structural mechanisms of calmodulin activation of Shigella effector OspC3 to ADP-riboxanate caspase-4/11 and block pyroptosis.,Crystal structure of MBP-fused OspC3 in complex with calmodulin,TRANSFERASE,CALM1/ CALM/ CAM/ CAM1,,GO:0034704/ GO:1902494/ GO:0005813/ GO:0005737/ GO:0005829/ GO:0005576/ GO:0043209/ GO:0005654/ GO:0005634/ GO:0005886/ GO:0032991/ GO:0030017/ GO:0097225/ GO:0005876/ GO:0000922/ GO:0031982/ GO:0008076/ GO:0010856/ GO:0008179/ GO:0019855/ GO:0005509/ GO:0048306/ GO:0097718/ GO:0030234/ GO:0019904/ GO:0019901/ GO:0072542/ GO:0043539/ GO:0031432/ GO:0044325/ GO:0016240/ GO:0005513/ GO:0007186/ GO:0000086/ GO:1990456/ GO:1905913/ GO:1901842/ GO:0010801/ GO:0060315/ GO:0140056/ GO:0051343/ GO:0043388/ GO:0010800/ GO:0032516/ GO:0031954/ GO:0035307/ GO:0071902/ GO:0060316/ GO:0050848/ GO:0098901/ GO:0055117/ GO:0010881/ GO:1901844/ GO:0032465/ GO:0002027/ GO:0010880/ GO:0060314/ GO:0051592/ GO:0021762/ IPR011992/ IPR018247/ IPR002048/ P0DP23,2,7WR3,mutant,P0DP23,UniProt,C6 H6 N2 O,122.125,NCA,NICOTINAMIDE,c1cc(cnc1)C(=O)N,5
7WR5,1,,,,,,7WR5,Structural mechanisms of calmodulin activation of Shigella effector OspC3 to ADP-riboxanate caspase-4/11 and block pyroptosis.,Crystal structure of OspC3-calmodulin-caspase-4 complex binding with 2'-aF-NAD+,TRANSFERASE,CASP4/ ICH2,3.4.22.57,GO:0097169/ GO:0005737/ GO:0005829/ GO:0005783/ GO:0005789/ GO:0005576/ GO:0072557/ GO:0005739/ GO:0072559/ GO:0005886/ GO:0032991/ GO:0050700/ GO:0004197/ GO:0097199/ GO:0006915/ GO:1904646/ GO:0050830/ GO:0006954/ GO:0045087/ GO:0097193/ GO:0070059/ GO:0050729/ GO:2000494/ GO:1903265/ GO:0016540/ GO:0006508/ GO:0070269/ GO:0042981/ GO:0050727/ IPR001315/ IPR029030/ IPR033139/ IPR016129/ IPR011029/ IPR002398/ IPR002138/ IPR001309/ IPR015917/ P49662,3,7WR5,mutant,P49662,UniProt,C21 H27 F N7 O13 P2,666.424,5ZV,[[(2~{R}/3~{R}/4~{S}/5~{R})-5-(3-aminocarbonylpyridin-1-yl)-4-fluoranyl-3-oxidanyl-oxolan-2-yl]methoxy-oxidanyl-phosphoryl] [(2~{R}/3~{S}/4~{R}/5~{R})-5-(6-aminopurin-9-yl)-3/4-bis(oxidanyl)oxolan-2-yl]methyl hydrogen phosphate,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OCC4C(C(C(O4)[N]5=CC=CC(=C5)C(=O)N)F)O)O)O)N,4
7WR6,1,,,,,,7WR6,Structural mechanisms of calmodulin activation of Shigella effector OspC3 to ADP-riboxanate caspase-4/11 and block pyroptosis.,Crystal structure of ADP-riboxanated caspase-4 in complex with Af1521,HYDROLASE,AF_1521,3.2.2,GO:0140293/ GO:0140291/ IPR002589/ IPR043472,2,7WR6,mutant,O28751,UniProt,C21 H32 N8 O14 P2,682.472,5ZY,[[(3~{a}~{S}/5~{R}/6~{R}/6~{a}~{R})-2-azanylidene-3-[(4~{R})-4-azanyl-5-oxidanylidene-pentyl]-6-oxidanyl-3~{a}/5/6/6~{a}-tetrahydrofuro[2/3-d][1/3]oxazol-5-yl]methoxy-oxidanyl-phosphoryl] [(2~{R}/3~{S}/4~{R}/5~{R})-5-(6-aminopurin-9-yl)-3/4-bis(oxidanyl)oxolan-2-yl]methyl hydrogen phosphate,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OCC4C(C5C(O4)N(C(=N)O5)CCCC(C=O)N)O)O)O)N,3
7WVD,1,,,,,,7WVD,Structural basis for a human broadly neutralizing influenza A hemagglutinin stem-specific antibody including H17/18 subtypes.,Crystal structure of H14 complexed with SIA28,VIRUS,HA,,GO:0016324/ GO:0020002/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0075512/ GO:0039654/ GO:0019064/ GO:0046761/ GO:0019062/ IPR008980/ IPR013828/ IPR000149/ IPR001364,1,7WVD,Wildtype,L7YN49,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
7WVG,1,,,,,,7WVG,Structural basis for a human broadly neutralizing influenza A hemagglutinin stem-specific antibody including H17/18 subtypes.,Crystal structure of H18 complexed with SIA28,VIRUS,HA,,GO:0016324/ GO:0020002/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0075512/ GO:0039654/ GO:0019064/ GO:0046761/ GO:0019062/ IPR008980/ IPR013828/ IPR000149/ IPR001364,1,7WVG,Wildtype,A0A1W5II89,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,8
7XBF,1,,,,,,7XBF,Host range and structural analysis of bat-origin RshSTT182/200 coronavirus binding to human ACE2 and its animal orthologs.,The complex structure of RshSTT182/200 RBD-insert2 bound to human ACE2,VIRAL PROTEIN,ACE2/ UNQ868/PRO1885,3.4.17.23/ 3.4.17,GO:0016324/ GO:0031526/ GO:0009986/ GO:0005929/ GO:0030666/ GO:0005788/ GO:0070062/ GO:0005576/ GO:0005615/ GO:0016020/ GO:0045121/ GO:0005886/ GO:0004180/ GO:0004175/ GO:0042802/ GO:0004181/ GO:0008237/ GO:0008241/ GO:0001618/ GO:0008270/ GO:0002003/ GO:0003051/ GO:0097746/ GO:0060135/ GO:0061025/ GO:0070373/ GO:2000272/ GO:0048662/ GO:0051957/ GO:0060452/ GO:1903598/ GO:1905737/ GO:2000379/ GO:0019065/ GO:0046813/ GO:1903779/ GO:0042127/ GO:0001817/ GO:0050727/ GO:0003081/ GO:0022898/ GO:0019229/ GO:0015827/ GO:0046718/ GO:0019058/ IPR031588/ IPR001548/ Q9BYF1,1,7XBF,Wildtype,Q9BYF1,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,3
7XBG,1,,,,,,7XBG,Host range and structural analysis of bat-origin RshSTT182/200 coronavirus binding to human ACE2 and its animal orthologs.,The crystal structure of RshSTT182/200 RBD-insert2-T346R-Y496G mutant in complex with human ACE2,VIRAL PROTEIN,ACE2/ UNQ868/PRO1885,3.4.17.23/ 3.4.17,GO:0016324/ GO:0031526/ GO:0009986/ GO:0005929/ GO:0030666/ GO:0005788/ GO:0070062/ GO:0005576/ GO:0005615/ GO:0016020/ GO:0045121/ GO:0005886/ GO:0004180/ GO:0004175/ GO:0042802/ GO:0004181/ GO:0008237/ GO:0008241/ GO:0001618/ GO:0008270/ GO:0002003/ GO:0003051/ GO:0097746/ GO:0060135/ GO:0061025/ GO:0070373/ GO:2000272/ GO:0048662/ GO:0051957/ GO:0060452/ GO:1903598/ GO:1905737/ GO:2000379/ GO:0019065/ GO:0046813/ GO:1903779/ GO:0042127/ GO:0001817/ GO:0050727/ GO:0003081/ GO:0022898/ GO:0019229/ GO:0015827/ GO:0046718/ GO:0019058/ IPR031588/ IPR001548/ Q9BYF1,1,7XBG,Wildtype,Q9BYF1,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7XBH,1,,,,,,7XBH,Host range and structural analysis of bat-origin RshSTT182/200 coronavirus binding to human ACE2 and its animal orthologs.,The complex structure of RshSTT182/200 RBD bound to human ACE2,VIRAL PROTEIN,ACE2/ UNQ868/PRO1885,3.4.17.23/ 3.4.17,GO:0016324/ GO:0031526/ GO:0009986/ GO:0005929/ GO:0030666/ GO:0005788/ GO:0070062/ GO:0005576/ GO:0005615/ GO:0016020/ GO:0045121/ GO:0005886/ GO:0004180/ GO:0004175/ GO:0042802/ GO:0004181/ GO:0008237/ GO:0008241/ GO:0001618/ GO:0008270/ GO:0002003/ GO:0003051/ GO:0097746/ GO:0060135/ GO:0061025/ GO:0070373/ GO:2000272/ GO:0048662/ GO:0051957/ GO:0060452/ GO:1903598/ GO:1905737/ GO:2000379/ GO:0019065/ GO:0046813/ GO:1903779/ GO:0042127/ GO:0001817/ GO:0050727/ GO:0003081/ GO:0022898/ GO:0019229/ GO:0015827/ GO:0046718/ GO:0019058/ IPR031588/ IPR001548/ Q9BYF1,1,7XBH,Wildtype,Q9BYF1,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,3
7XBK,1,,,,,,7XBK,Comprehensive structural characterization of the human AAA+ disaggregase CLPB in the apo- and substrate-bound states reveals a unique mode of action driven by oligomerization.,Structure and mechanism of a mitochondrial AAA+ disaggregase CLPB,CHAPERONE,CLPB/ HSP78/ SKD3,3.6.1,GO:0005737/ GO:0005758/ GO:0005739/ GO:0005524/ GO:0016887/ GO:0140374/ GO:0034605/ GO:0039529/ IPR003593/ IPR002110/ IPR036770/ IPR003959/ IPR019489/ IPR001270/ IPR027417/ Q9H078,1,7XBK,mutant,Q9H078,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,3
7XQG,1,,,,,,7XQG,Conformational changes in the human Cx43/GJA1 gap junction channel visualized using cryo-EM.,Hemichannel-focused structure of C-terminal truncated connexin43/Cx43/GJA1 gap junction intercellular channel in POPE nanodiscs (GCN conformation),MEMBRANE PROTEIN,GJA1/ GJAL,,GO:0016324/ GO:0030054/ GO:0044291/ GO:0005922/ GO:0005737/ GO:0005789/ GO:0005925/ GO:0005921/ GO:0005794/ GO:0000139/ GO:0030660/ GO:0014704/ GO:0043231/ GO:0045121/ GO:0005739/ GO:0005654/ GO:0005634/ GO:0005886/ GO:0070160/ GO:0043014/ GO:0008013/ GO:0015562/ GO:0005243/ GO:0086075/ GO:1903763/ GO:0055077/ GO:0034634/ GO:0015075/ GO:0015631/ GO:0086014/ GO:0060348/ GO:0046849/ GO:0003161/ GO:0010644/ GO:0086064/ GO:0007267/ GO:1904646/ GO:0000132/ GO:0140115/ GO:0016264/ GO:0014047/ GO:0034220/ GO:0035633/ GO:0099111/ GO:0030308/ GO:0032277/ GO:1901164/ GO:0120162/ GO:0010628/ GO:0043123/ GO:1905772/ GO:1905332/ GO:2000648/ GO:1904707/ GO:0008104/ GO:0007165/ GO:0007283/ GO:0042908/ IPR035091/ IPR000500/ IPR002261/ IPR013124/ IPR034634/ IPR019570/ IPR017990/ IPR013092/ IPR038359/ P17302/ Transmembrane.Alpha-helical polytopic.Tetraspan junctional complexes.Connexin/ Generic PDBTM,1,7XQG,Wildtype,P17302,UniProt,C31 H50 O4,486.726,Y01,CHOLESTEROL HEMISUCCINATE,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC(=O)CCC(=O)O)C)C,3
7Y5N,1,,,,,,7Y5N,Structural insights into the covalent regulation of PAPP-A activity by proMBP and STC3.,Structure of 1:2 PAPP-A.ProMBP complex(half map),METAL BINDING PROTEIN/HYDROLASE,PAPPA,3.4.24.79,GO:0005576/ GO:0005615/ GO:0004222/ GO:0008237/ GO:0008270/ GO:0007166/ GO:0007565/ GO:0030163/ GO:0006508/ GO:0071548/ GO:0032354/ IPR013320/ IPR006558/ IPR024079/ IPR011936/ IPR000800/ IPR030433/ IPR043543/ IPR008754/ IPR035976/ IPR000436/ Q13219,2,7Y5N,Wildtype,Q13219,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7Y76,1,,,,,,7Y76,Structures of ACE2-SIT1 recognized by Omicron variants of SARS-CoV-2.,SIT1-ACE2-BA.5 RBD,VIRAL PROTEIN/HYDROLASE,SLC6A20/ SIT1/ XT3/ XTRP3,,GO:0016324/ GO:0005886/ GO:0015171/ GO:0015199/ GO:0015188/ GO:0015193/ GO:0015175/ GO:0005298/ GO:0015370/ GO:0089718/ GO:0006865/ GO:0015838/ GO:1903804/ GO:0015816/ GO:1903806/ GO:1904271/ GO:1905647/ GO:0015824/ GO:0035725/ GO:0150104/ IPR000175/ IPR002438/ IPR037272/ Q9NP91/ Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Neurotransmitter: sodium symporter,1,7Y76,mutant,Q9NP91,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
7Y76,1,,,,,,7Y76,Structures of ACE2-SIT1 recognized by Omicron variants of SARS-CoV-3.,SIT1-ACE2-BA.6 RBD,VIRAL PROTEIN/HYDROLASE,ACE2/ UNQ868/PRO1885,3.4.17.23/ 3.4.17,GO:0016324/ GO:0031526/ GO:0009986/ GO:0005929/ GO:0030666/ GO:0005788/ GO:0070062/ GO:0005576/ GO:0005615/ GO:0016020/ GO:0045121/ GO:0005886/ GO:0004180/ GO:0004175/ GO:0042802/ GO:0004181/ GO:0008237/ GO:0008241/ GO:0001618/ GO:0008270/ GO:0002003/ GO:0003051/ GO:0097746/ GO:0060135/ GO:0061025/ GO:0070373/ GO:2000272/ GO:0048662/ GO:0051957/ GO:0060452/ GO:1903598/ GO:1905737/ GO:2000379/ GO:0019065/ GO:0046813/ GO:1903779/ GO:0042127/ GO:0001817/ GO:0050727/ GO:0003081/ GO:0022898/ GO:0019229/ GO:0015827/ GO:0046718/ GO:0019058/ IPR031588/ IPR001548/ Q9BYF1/ Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Neurotransmitter: sodium symporter,2,7Y76,mutant,Q9BYF1,UniProt,C39 H77 O8 P,704.998,3PH,1/2-DIACYL-GLYCEROL-3-SN-PHOSPHATE,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)O)OC(=O)CCCCCCCCCCCCCCCCC,6
7Z87,1,,,,,,7Z87,Human DNA-dependent protein kinase activation mechanism.,DNA-PK in the active state,DNA BINDING PROTEIN,PRKDC/ HYRC/ HYRC1,2.7.11.1,GO:0000781/ GO:0005829/ GO:0070418/ GO:0005958/ GO:0016020/ GO:0070419/ GO:0005730/ GO:0005654/ GO:0005634/ GO:0032991/ GO:0032993/ GO:0032040/ GO:0005667/ GO:0005524/ GO:0004677/ GO:0003690/ GO:0019899/ GO:0019904/ GO:0004672/ GO:0106310/ GO:0004674/ GO:0003723/ GO:0061629/ GO:0034511/ GO:0002218/ GO:0002326/ GO:0007420/ GO:0006974/ GO:0032869/ GO:0006302/ GO:0097681/ GO:0006303/ GO:0035234/ GO:0007507/ GO:0002327/ GO:0033152/ GO:0045087/ GO:0008630/ GO:0000460/ GO:0031571/ GO:0043066/ GO:0001933/ GO:0018105/ GO:0018107/ GO:0043065/ GO:2001034/ GO:0045648/ GO:0045621/ GO:1905221/ GO:0045944/ GO:0045727/ GO:0002328/ GO:0031648/ GO:0036211/ GO:0006468/ GO:0042752/ GO:0050678/ GO:1902036/ GO:0048660/ GO:0010332/ GO:0048511/ GO:0034462/ GO:0001756/ GO:0033077/ GO:0002360/ GO:0033153/ GO:0016233/ GO:0000723/ IPR011989/ IPR016024/ IPR037706/ IPR012582/ IPR045581/ IPR003152/ IPR011009/ IPR000403/ IPR036940/ IPR018936/ IPR003151/ IPR014009/ P78527,1,7Z87,Wildtype,P78527,UniProt,C24 H21 Cl F N5 O3,481.907,1IX,(~{S})-[2-chloranyl-4-fluoranyl-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol,COc1ccc(nn1)C(c2cc(c(cc2Cl)F)c3c4ccc(cc4ncn3)N5CCOCC5)O,6
7Z88,1,,,,,,7Z88,Human DNA-dependent protein kinase activation mechanism.,DNA-PK in the intermediate state,DNA BINDING PROTEIN,PRKDC/ HYRC/ HYRC1,2.7.11.1,GO:0000781/ GO:0005829/ GO:0070418/ GO:0005958/ GO:0016020/ GO:0070419/ GO:0005730/ GO:0005654/ GO:0005634/ GO:0032991/ GO:0032993/ GO:0032040/ GO:0005667/ GO:0005524/ GO:0004677/ GO:0003690/ GO:0019899/ GO:0019904/ GO:0004672/ GO:0106310/ GO:0004674/ GO:0003723/ GO:0061629/ GO:0034511/ GO:0002218/ GO:0002326/ GO:0007420/ GO:0006974/ GO:0032869/ GO:0006302/ GO:0097681/ GO:0006303/ GO:0035234/ GO:0007507/ GO:0002327/ GO:0033152/ GO:0045087/ GO:0008630/ GO:0000460/ GO:0031571/ GO:0043066/ GO:0001933/ GO:0018105/ GO:0018107/ GO:0043065/ GO:2001034/ GO:0045648/ GO:0045621/ GO:1905221/ GO:0045944/ GO:0045727/ GO:0002328/ GO:0031648/ GO:0036211/ GO:0006468/ GO:0042752/ GO:0050678/ GO:1902036/ GO:0048660/ GO:0010332/ GO:0048511/ GO:0034462/ GO:0001756/ GO:0033077/ GO:0002360/ GO:0033153/ GO:0016233/ GO:0000723/ IPR011989/ IPR016024/ IPR037706/ IPR012582/ IPR045581/ IPR003152/ IPR011009/ IPR000403/ IPR036940/ IPR018936/ IPR003151/ IPR014009/ P78527,1,7Z88,Wildtype,P78527,UniProt,C24 H21 Cl F N5 O3,481.907,1IX,(~{S})-[2-chloranyl-4-fluoranyl-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol,COc1ccc(nn1)C(c2cc(c(cc2Cl)F)c3c4ccc(cc4ncn3)N5CCOCC5)O,6
7ZTC,1,,,,,,7ZTC,Structural basis underlying specific biochemical activities of non-muscle tropomyosin isoforms.,Non-muscle F-actin decorated with non-muscle tropomyosin 1.6,CYTOSOLIC PROTEIN,,,IPR004000/ IPR020902/ IPR004001/ IPR043129,1,7ZTC,Wildtype,A0A6I9HGD1,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,3
7ZTD,1,,,,,,7ZTD,Structural basis underlying specific biochemical activities of non-muscle tropomyosin isoforms.,Non-muscle F-actin decorated with non-muscle tropomyosin 3.2,CYTOSOLIC PROTEIN,,,IPR004000/ IPR020902/ IPR004001/ IPR043129,1,7ZTD,Wildtype,A0A6I9HGD1,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,3
8BYN,1,,,,,,8BYN,Cryo-EM structures of chronic traumatic encephalopathy tau filaments with PET ligand flortaucipir,Chronic traumatic encephalopathy tau filaments with PET ligand flortaucipir,PROTEIN FIBRIL,MAPT/ MAPTL/ MTBT1/ TAU,,GO:0030673/ GO:0030424/ GO:1904115/ GO:0044297/ GO:0005737/ GO:0036464/ GO:0005829/ GO:0030425/ GO:0043197/ GO:0005576/ GO:0097386/ GO:0030426/ GO:0044304/ GO:0045121/ GO:0005874/ GO:0015630/ GO:0005739/ GO:0097418/ GO:0043005/ GO:0043025/ GO:0034399/ GO:0016607/ GO:0005634/ GO:0005886/ GO:0036477/ GO:0045298/ GO:0003779/ GO:0034185/ GO:0051087/ GO:0003677/ GO:0003690/ GO:0034452/ GO:0019899/ GO:0099077/ GO:0051879/ GO:0042802/ GO:0071813/ GO:0008017/ GO:0099609/ GO:0003680/ GO:0035091/ GO:1902936/ GO:0019901/ GO:0051721/ GO:0030674/ GO:0003723/ GO:0043565/ GO:0017124/ GO:0003697/ GO:0006919/ GO:1990000/ GO:0048143/ GO:0061564/ GO:0098930/ GO:0019896/ GO:0007267/ GO:1990416/ GO:0034605/ GO:1990090/ GO:0034614/ GO:0021954/ GO:0031122/ GO:0048699/ GO:0006475/ GO:0048312/ GO:0007611/ GO:0007613/ GO:0001774/ GO:0000226/ GO:0046785/ GO:1903748/ GO:0010629/ GO:0033673/ GO:0090258/ GO:0010917/ GO:1904428/ GO:1902988/ GO:0031175/ GO:0072386/ GO:0045773/ GO:1905689/ GO:0031116/ GO:1901216/ GO:1903829/ GO:1902474/ GO:0032930/ GO:0051260/ GO:0051258/ GO:0010506/ GO:0050848/ GO:1900034/ GO:0033044/ GO:1900452/ GO:0070507/ GO:0031113/ GO:0031110/ GO:0090140/ GO:0048167/ GO:0010288/ GO:0016072/ GO:0034063/ GO:0097435/ GO:0007416/ GO:0050808/ IPR001084/ IPR002955/ P10636,1,8BYN,Wildtype,P10636,UniProt,C16 H10 F N3,263.269,S9C,7-(6-fluoranylpyridin-3-yl)-5~{H}-pyrido[4/3-b]indole,c1cc2c(cc1c3ccc(nc3)F)[nH]c4c2cncc4,2
8CZK,1,,,,,,8CZK,The mechanism of thia-Michael addition catalyzed by LanC enzymes.,Human LanCL1 bound to GSH and Dhb-Erk peptide,SIGNALING PROTEIN,LANCL1/ GPR69A,2.5.1.18,GO:0005737/ GO:0005886/ GO:0004930/ GO:0043295/ GO:0004364/ GO:0050750/ GO:0017124/ GO:0008270/ GO:0005975/ GO:0007186/ GO:0043523/ IPR012341/ IPR007822/ IPR020464/ O43813,2,8CZK,Wildtype,O43813,UniProt,C10 H17 N3 O6 S,307.323,GSH,GLUTATHIONE,C(CC(=O)NC(CS)C(=O)NCC(=O)O)C(C(=O)O)N,4
8CZL,1,,,,,,8CZL,The mechanism of thia-Michael addition catalyzed by LanC enzymes.,Human LanCL1 bound to methyl glutathione (MeGSH),SIGNALING PROTEIN,LANCL1/ GPR69A,2.5.1.18,GO:0005737/ GO:0005886/ GO:0004930/ GO:0043295/ GO:0004364/ GO:0050750/ GO:0017124/ GO:0008270/ GO:0005975/ GO:0007186/ GO:0043523/ IPR012341/ IPR007822/ IPR020464/ O43813,1,8CZL,Wildtype,O43813,UniProt,C11 H19 N3 O6 S,321.35,GSM,L-GAMMA-GLUTAMYL-S-METHYLCYSTEINYLGLYCINE,CSCC(C(=O)NCC(=O)O)NC(=O)CCC(C(=O)O)N,3
8D0V,1,,,,,,8D0V,The mechanism of thia-Michael addition catalyzed by LanC enzymes.,Human LanCL1 C264A mutant bound to GSH,SIGNALING PROTEIN,LANCL1/ GPR69A,2.5.1.18,GO:0005737/ GO:0005886/ GO:0004930/ GO:0043295/ GO:0004364/ GO:0050750/ GO:0017124/ GO:0008270/ GO:0005975/ GO:0007186/ GO:0043523/ IPR012341/ IPR007822/ IPR020464/ O43813,1,8D0V,mutant,O43813,UniProt,C10 H17 N3 O6 S,307.323,GSH,GLUTATHIONE,C(CC(=O)NC(CS)C(=O)NCC(=O)O)C(C(=O)O)N,3
8D19,1,,,,,,8D19,The mechanism of thia-Michael addition catalyzed by LanC enzymes.,Human LanCL1 bound to GSH,SIGNALING PROTEIN,LANCL1/ GPR69A,2.5.1.18,GO:0005737/ GO:0005886/ GO:0004930/ GO:0043295/ GO:0004364/ GO:0050750/ GO:0017124/ GO:0008270/ GO:0005975/ GO:0007186/ GO:0043523/ IPR012341/ IPR007822/ IPR020464/ O43813,1,8D19,Wildtype,O43813,UniProt,C10 H17 N3 O6 S,307.323,GSH,GLUTATHIONE,C(CC(=O)NC(CS)C(=O)NCC(=O)O)C(C(=O)O)N,3
8D59,1,,,,,,8D59,Structures and mechanisms of tRNA methylation by METTL1-WDR4.,Crystal structure of human METTL1 in complex with SAM,TRANSFERASE,METTL1/ C12orf1,2.1.1.33/ 2.1.1,GO:0005829/ GO:0005730/ GO:0005654/ GO:0005634/ GO:0043527/ GO:0008176/ GO:0000049/ GO:0036265/ GO:0030488/ GO:0006400/ IPR029063/ IPR025763/ IPR003358/ Q9UBP6,1,8D59,Wildtype,Q9UBP6,UniProt,C15 H22 N6 O5 S,398.437,SAM,S-ADENOSYLMETHIONINE,C[S+](CCC(C(=O)[O-])N)CC1C(C(C(O1)n2cnc3c2ncnc3N)O)O,2
8D5B,1,,,,,,8D5B,Structures and mechanisms of tRNA methylation by METTL1-WDR4.,Crystal structure of human METTL1 in complex with SAH,TRANSFERASE,METTL1/ C12orf1,2.1.1.33/ 2.1.1,GO:0005829/ GO:0005730/ GO:0005654/ GO:0005634/ GO:0043527/ GO:0008176/ GO:0000049/ GO:0036265/ GO:0030488/ GO:0006400/ IPR029063/ IPR025763/ IPR003358/ Q9UBP6,1,8D5B,Wildtype,Q9UBP6,UniProt,C14 H20 N6 O5 S,384.411,SAH,S-ADENOSYL-L-HOMOCYSTEINE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)CSCCC(C(=O)O)N)O)O)N,2
8D9L,1,,,,,,8D9L,Structures and mechanisms of tRNA methylation by METTL1-WDR4.,CryoEM structure of human METTL1-WDR4 in complex with Lys-tRNA and SAM,TRANSFERASE/RNA,WDR4,,GO:0005694/ GO:0005829/ GO:0005654/ GO:0005634/ GO:0043527/ GO:0006974/ GO:0106004/ GO:0006400/ IPR028884/ IPR015943/ IPR001680/ IPR036322/ P57081,1,8D9L,mutant,P57081,UniProt,C15 H22 N6 O5 S,398.437,SAM,S-ADENOSYLMETHIONINE,C[S+](CCC(C(=O)[O-])N)CC1C(C(C(O1)n2cnc3c2ncnc3N)O)O,4
8DKB,1,,,,,,8DKB,Discovery of High-Affinity Small-Molecule Binders of the Epigenetic Reader YEATS4.,Crystal Structure of human YEATS4 in complex with Pfizer small molecule compound 3b,PROTEIN BINDING,YEATS4/ GAS41,,GO:0035267/ GO:0016363/ GO:0031965/ GO:0005654/ GO:0000786/ GO:0005634/ GO:0042393/ GO:0070577/ GO:0140030/ GO:0005200/ GO:0006338/ GO:0016573/ GO:0043968/ GO:0043967/ GO:0000278/ GO:1905168/ GO:0045893/ GO:0042981/ GO:0051726/ GO:2000779/ GO:0040008/ GO:0006357/ GO:0006355/ IPR038704/ IPR005033/ O95619,1,8DKB,Wildtype,O95619,UniProt,C24 H36 N4 O2,412.568,SJI,N-ethyl-1-{(3S/4S)-1-[(1-hydroxycyclohexyl)methyl]-3-methylpiperidin-4-yl}-2-methyl-1H-benzimidazole-5-carboxamide,CCNC(=O)c1ccc2c(c1)nc(n2C3CCN(CC3C)CC4(CCCCC4)O)C,2
8DOV,1,,,,,,8DOV,The Shr receptor from Streptococcus pyogenes uses a cap and release mechanism to acquire heme-iron from human hemoglobin.,Crystal structure of the Shr Hemoglobin Interacting Domain 2 (HID2) in complex with Hemoglobin,TRANSPORT PROTEIN,HBA1/ HBA2,,GO:0072562/ GO:0005829/ GO:0022627/ GO:0071682/ GO:0070062/ GO:0005576/ GO:0005615/ GO:0031838/ GO:0005833/ GO:0016020/ GO:0001664/ GO:0020037/ GO:0005506/ GO:0043177/ GO:0019825/ GO:0005344/ GO:0015670/ GO:0098869/ GO:0042744/ GO:0030185/ GO:0015671/ GO:0042542/ IPR000971/ IPR009050/ IPR012292/ IPR002338/ IPR002339/ P69905,1,8DOV,Wildtype,P69905,UniProt,C34 H32 Fe N4 O4,616.487,HEM,PROTOPORPHYRIN IX CONTAINING FE,Cc1c2n3c(c1CCC(=O)O)C=C4C(=C(C5=[N]4[Fe]36[N]7=C(C=C8N6C(=C5)C(=C8C)C=C)C(=C(C7=C2)C)C=C)C)CCC(=O)O,4
8E9F,1,,,,,,8E9F,Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models.,WD repeat-containing protein 5 complexed with 4-(7-((1H-imidazol-1-yl)methyl)-5-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-1-oxo-3/4-dihydroisoquinolin-2(1H)-yl)-6-ethyl-N-methylquinoline-8-carboxamide (compound 10),TRANSCRIPTION,WDR5/ BIG3,,GO:0140672/ GO:0000123/ GO:0035097/ GO:0072686/ GO:0071339/ GO:0044665/ GO:0044666/ GO:0044545/ GO:0005654/ GO:0005634/ GO:0048188/ GO:0042393/ GO:0035064/ GO:0006325/ GO:0006094/ GO:0043966/ GO:0044154/ GO:0051568/ GO:0043984/ GO:0043981/ GO:0043982/ GO:0051572/ GO:0031175/ GO:0045722/ GO:0051571/ GO:0045893/ GO:0051726/ GO:0051302/ GO:1900095/ GO:0045995/ GO:0031063/ GO:0006357/ GO:0006355/ GO:0090043/ GO:0001501/ IPR020472/ IPR015943/ IPR001680/ IPR019775/ IPR036322/ P61964,1,8E9F,Wildtype,P61964,UniProt,C31 H28 F3 N7 O2,587.595,UY9,6-ethyl-4-[(5P)-7-[(1H-imidazol-1-yl)methyl]-5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]-1-oxo-3/4-dihydroisoquinolin-2(1H)-yl]-N-methylquinoline-8-carboxamide,CCc1cc2c(ccnc2c(c1)C(=O)NC)N3CCc4c(cc(cc4C3=O)Cn5ccnc5)c6cn(nc6C(F)(F)F)C,3
8EFE,1,,,,,,8EFE,Conformational changes linked to ADP release from human cardiac myosin bound to actin-tropomyosin.,Human beta-cardiac myosin II bound to ADP-MG2+ and the associated essential light chain,CONTRACTILE PROTEIN,Myl1/ Mylf,,GO:0043292/ GO:0030016/ GO:0016460/ GO:0005509/ GO:0008307/ GO:0060048/ GO:0006936/ IPR011992/ IPR002048/ P05977,2,8EFE,Wildtype,P05977,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,4
8EFH,1,,,,,,8EFH,Conformational changes linked to ADP release from human cardiac myosin bound to actin-tropomyosin.,Helical reconstruction of the human cardiac actin-tropomyosin-myosin complex in complex with ADP-Mg2+,MOTOR PROTEIN,ACTC1,,GO:0005884/ GO:0044297/ GO:0005737/ GO:0005869/ GO:0030175/ GO:0030027/ GO:0030017/ GO:0017022/ GO:0007015/ GO:0033275/ GO:0060047/ GO:0090131/ GO:0010628/ IPR004000/ IPR020902/ IPR004001/ IPR043129,2,8EFH,Wildtype,B6VNT8,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,5
8EG0,1,,,,,,8EG0,Structures and mechanisms of tRNA methylation by METTL1-WDR4.,CryoEM structure of human METTL1-WDR4 in complex with Lys-tRNA and SAH,TRANSFERASE/RNA,WDR4,,GO:0005694/ GO:0005829/ GO:0005654/ GO:0005634/ GO:0043527/ GO:0006974/ GO:0106004/ GO:0006400/ IPR028884/ IPR015943/ IPR001680/ IPR036322/ P57081,1,8EG0,Wildtype,P57081,UniProt,C14 H20 N6 O5 S,384.411,SAH,S-ADENOSYL-L-HOMOCYSTEINE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)CSCCC(C(=O)O)N)O)O)N,4
8F1G,1,,,,,,8F1G,Discovery of Potent Small-Molecule Inhibitors of WDR5-MYC Interaction.,Crystal structure of human WDR5 in complex with compound WM662,ONCOPROTEIN,WDR5/ BIG3,,GO:0140672/ GO:0000123/ GO:0035097/ GO:0072686/ GO:0071339/ GO:0044665/ GO:0044666/ GO:0044545/ GO:0005654/ GO:0005634/ GO:0048188/ GO:0042393/ GO:0035064/ GO:0006325/ GO:0006094/ GO:0043966/ GO:0044154/ GO:0051568/ GO:0043984/ GO:0043981/ GO:0043982/ GO:0051572/ GO:0031175/ GO:0045722/ GO:0051571/ GO:0045893/ GO:0051726/ GO:0051302/ GO:1900095/ GO:0045995/ GO:0031063/ GO:0006357/ GO:0006355/ GO:0090043/ GO:0001501/ IPR020472/ IPR015943/ IPR001680/ IPR019775/ IPR036322/ P61964,1,8F1G,Wildtype,P61964,UniProt,C19 H18 Cl N5 O4,415.83,X8N,(2S)-2-({(2S)-3-(3'-chloro[1/1'-biphenyl]-4-yl)-1-oxo-1-[(1H-tetrazol-5-yl)amino]propan-2-yl}oxy)propanoic acid,CC(C(=O)O)OC(Cc1ccc(cc1)c2cccc(c2)Cl)C(=O)Nc3[nH]nnn3,2
8F9Z,1,,,,,,8F9Z,Antiviral Activity and Crystal Structures of HIV-1 gp120 Antagonists.,Crystal structure of clade A/E 93TH057 HIV-1 gp120 core in complex with NBD-14204/ an HIV-1 gp120 antagonist,VIRAL PROTEIN/INHIBITOR,HIV-1 Env,,IPR036377/ IPR000777,1,8F9Z,Wildtype,A0A0M3KKW8,UniProt,C17 H16 F3 N5 O2 S,411.401,XKW,(5M)-N-{(1S)-2-amino-1-[5-(hydroxymethyl)-1/3-thiazol-2-yl]ethyl}-5-[5-(trifluoromethyl)pyridin-2-yl]-1H-pyrrole-2-carboxamide,c1cc(ncc1C(F)(F)F)c2ccc([nH]2)C(=O)NC(CN)c3ncc(s3)CO,3
8FA0,1,,,,,,8FA0,Antiviral Activity and Crystal Structures of HIV-1 gp120 Antagonists.,Crystal structure of clade A/E 93TH057 HIV-1 gp120 core in complex with NBD-14208/ an HIV-1 gp120 antagonist,VIRAL PROTEIN,HIV-1 Env,,IPR036377/ IPR000777,1,8FA0,mutant,A0A0M3KKW8,UniProt,C18 H17 Cl F2 N4 O3 S,442.867,XKR,N-{(1S)-2-amino-1-[4/5-bis(hydroxymethyl)-1/3-thiazol-2-yl]ethyl}-5-(4-chloro-3/5-difluorophenyl)-1H-pyrrole-2-carboxamide,c1cc([nH]c1c2cc(c(c(c2)F)Cl)F)C(=O)NC(CN)c3nc(c(s3)CO)CO,3
8GXB,1,,,,,,8GXB,Structure-based investigations of the NAD+-II riboswitch.,Crystal structure of NAD+ -II riboswitch in complex with NAD+,PROTEIN/RNA,SNRPA,,GO:0005654/ GO:0005634/ GO:0005681/ GO:0005685/ GO:0046540/ GO:0042802/ GO:0003723/ GO:0030619/ GO:1990446/ GO:0000398/ IPR012677/ IPR035979/ IPR000504/ IPR034407/ IPR034409/ P09012,2,8GXB,mutant,P09012,UniProt,C21 H27 N7 O14 P2,663.425,NAD,NICOTINAMIDE-ADENINE-DINUCLEOTIDE,c1cc(c[n+](c1)C2C(C(C(O2)COP(=O)([O-])OP(=O)(O)OCC3C(C(C(O3)n4cnc5c4ncnc5N)O)O)O)O)C(=O)N,3
8GXC,1,,,,,,8GXC,Structure-based investigations of the NAD+-II riboswitch.,Crystal structure of NAD+ -II riboswitch in complex with NMN,PROTEIN/RNA,SNRPA,,GO:0005654/ GO:0005634/ GO:0005681/ GO:0005685/ GO:0046540/ GO:0042802/ GO:0003723/ GO:0030619/ GO:1990446/ GO:0000398/ IPR012677/ IPR035979/ IPR000504/ IPR034407/ IPR034409/ P09012,1,8GXC,mutant,P09012,UniProt,C11 H16 N2 O8 P,335.227,NMN,BETA-NICOTINAMIDE RIBOSE MONOPHOSPHATE,c1cc(c[n+](c1)C2C(C(C(O2)COP(=O)(O)O)O)O)C(=O)N,3
8H78,1,,,,,,8H78,Discovery of TP0597850: A Selective/ Chemically Stable/ and Slow Tight-Binding Matrix Metalloproteinase-2 Inhibitor with a Phenylbenzamide-Pentapeptide Hybrid Scaffold.,Crystal structure of human MMP-2 catalytic domain in complex with inhibitor,HYDROLASE,MMP2,3.4.24.24,,1,8H78,Wildtype,,,C41 H57 N9 O13 S,916.009,L2U,(2~{R})-2-[[4-[(4-aminocarbonylphenyl)carbonylamino]phenyl]sulfonylamino]-5-[(2~{S}/4~{S})-4-azanyl-2-[[(2~{S})-1-[[(2~{S})-1-[(5-azanyl-5-oxidanylidene-pentyl)amino]-5-oxidanyl-1/5-bis(oxidanylidene)pentan-2-yl]-methyl-amino]-4-methyl-1-oxidanylidene-pentan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-oxidanylidene-pentanoic acid,CC(C)CC(C(=O)N(C)C(CCC(=O)O)C(=O)NCCCCC(=O)N)NC(=O)C1CC(CN1C(=O)CCC(C(=O)O)NS(=O)(=O)c2ccc(cc2)NC(=O)c3ccc(cc3)C(=O)N)N,5
8HC2,1,,,,,,8HC2,Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants.,SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 1 YB9-258 Fab (1 RBD up),VIRAL PROTEIN/IMMUNE SYSTEM,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,8HC2,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
8HC3,1,,,,,,8HC3,Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants.,SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 2 YB9-258 Fabs (2 RBD up),VIRAL PROTEIN/IMMUNE SYSTEM,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,8HC3,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
8HC4,1,,,,,,8HC4,Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants.,SARS-CoV-2 wildtype spike trimer (6P) in complex with 3 YB9-258 Fabs and 3 R1-32 Fabs (3 RBD up),VIRAL PROTEIN/IMMUNE SYSTEM,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,8HC4,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,7
8HC5,1,,,,,,8HC5,Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants.,SARS-CoV-2 wildtype S1 in complex with YB9-258 Fab and R1-32 Fab,VIRAL PROTEIN/IMMUNE SYSTEM,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,8HC5,Wildtype,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
8HC6,1,,,,,,8HC6,Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants.,SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with YB9-258 Fab/ focused refinement of Fab region,VIRAL PROTEIN/IMMUNE SYSTEM,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,8HC6,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
8HC7,1,,,,,,8HC7,Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants.,SARS-CoV-2 Omicron BA.1 spike trimer (6P) complex with YB9-258 Fab/ focused refinement of RBD-dimer region,VIRAL PROTEIN/IMMUNE SYSTEM,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,8HC7,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
8HC8,1,,,,,,8HC8,Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants.,SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with YB13-292 Fab/ focused refinement of Fab region,VIRAL PROTEIN/IMMUNE SYSTEM,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,8HC8,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
8HC9,1,,,,,,8HC9,Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants.,SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 3 YB13-292 Fabs (3 RBD down),VIRAL PROTEIN/IMMUNE SYSTEM,,S/ 2,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,8HC9,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
8HCA,1,,,,,,8HCA,Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants.,SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 3 YB13-292 Fabs (1 RBD up),VIRAL PROTEIN/IMMUNE SYSTEM,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,8HCA,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
8HCB,1,,,,,,8HCB,Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants.,SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 3 YB13-292 Fabs (2 RBD up),VIRAL PROTEIN/IMMUNE SYSTEM,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,8HCB,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
8HU6,1,,,,,,8HU6,The discovery of 3/3-dimethyl-1/2/3/4-tetrahydroquinoxaline-1-carboxamides as AMPD2 inhibitors with a novel mechanism of action.,AMP deaminase 2 in complex with AMP,HYDROLASE,AMPD2,3.5.4.6,GO:0005829/ GO:0003876/ GO:0042802/ GO:0046872/ GO:0046033/ GO:0052652/ GO:0097009/ GO:0006188/ GO:0032264/ IPR006650/ IPR006329/ IPR029749/ IPR032466/ Q01433,1,8HU6,Wildtype,Q01433,UniProt,C10 H14 N5 O7 P,347.221,AMP,ADENOSINE MONOPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)O)O)O)N,4
8HUB,1,,,,,,8HUB,The discovery of 3/3-dimethyl-1/2/3/4-tetrahydroquinoxaline-1-carboxamides as AMPD2 inhibitors with a novel mechanism of action.,AMP deaminase 2 in complex with an inhibitor,HYDROLASE,AMPD2,3.5.4.6,GO:0005829/ GO:0003876/ GO:0042802/ GO:0046872/ GO:0046033/ GO:0052652/ GO:0097009/ GO:0006188/ GO:0032264/ IPR006650/ IPR006329/ IPR029749/ IPR032466/ Q01433,1,8HUB,Wildtype,Q01433,UniProt,C18 H21 N3 O,295.379,N4X,3/3-dimethyl-4-(phenylmethyl)-2~{H}-quinoxaline-1-carboxamide,CC1(CN(c2ccccc2N1Cc3ccccc3)C(=O)N)C,3
7QXN,2,,,,,,7QXN,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z+A state,STRUCTURAL PROTEIN,SEM1/ C7orf76/ DSS1/ SHFDG1/ SHFM1,,GO:0005829/ GO:0005654/ GO:0000502/ GO:0008541/ GO:0032991/ GO:0000724/ GO:0006406/ GO:0043248/ GO:0043161/ IPR007834,11,7QXN,wildtype,P60896,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,34
7QXN,2,,,,,,7QXN,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z+A state,STRUCTURAL PROTEIN,PSMD2/ TRAP2,,GO:0005829/ GO:0070062/ GO:0005576/ GO:1904813/ GO:0016020/ GO:0005654/ GO:0005634/ GO:0022624/ GO:0000502/ GO:0005838/ GO:0008540/ GO:0034515/ GO:0034774/ GO:0030234/ GO:0043161/ GO:0042176/ IPR016643/ IPR011989/ IPR016024/ IPR002015/ IPR041433/ IPR040892/ Q13200,12,7QXN,wildtype,Q13200,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,36
7QXP,2,,,,,,7QXP,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z+B state,STRUCTURAL PROTEIN,PSMD8,,GO:0005829/ GO:0005654/ GO:0005634/ GO:0022624/ GO:0000502/ GO:0005838/ GO:0008541/ GO:0043161/ IPR006746/ IPR033464/ IPR000717/ P48556,10,7QXP,wildtype,P48556,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,34
7QXP,2,,,,,,7QXP,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z+B state,STRUCTURAL PROTEIN,PSMD2/ TRAP2,,GO:0005829/ GO:0070062/ GO:0005576/ GO:1904813/ GO:0016020/ GO:0005654/ GO:0005634/ GO:0022624/ GO:0000502/ GO:0005838/ GO:0008540/ GO:0034515/ GO:0034774/ GO:0030234/ GO:0043161/ GO:0042176/ IPR016643/ IPR011989/ IPR016024/ IPR002015/ IPR041433/ IPR040892/ Q13200,12,7QXP,wildtype,Q13200,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,36
7QXU,2,,,,,,7QXU,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z+C state,STRUCTURAL PROTEIN,PSMD1,,GO:0035578/ GO:0005829/ GO:0005576/ GO:0016020/ GO:0005654/ GO:0005634/ GO:0022624/ GO:0000502/ GO:0005838/ GO:0008540/ GO:0034515/ GO:0030234/ GO:0031625/ GO:0043161/ GO:0042176/ IPR016642/ IPR011989/ IPR016024/ IPR002015/ IPR035266/ IPR040623/ Q99460,1,7QXU,wildtype,Q99460,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,34
7QXU,2,,,,,,7QXU,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z+C state,STRUCTURAL PROTEIN,SEM1/ C7orf76/ DSS1/ SHFDG1/ SHFM1,,GO:0005829/ GO:0005654/ GO:0000502/ GO:0008541/ GO:0032991/ GO:0000724/ GO:0006406/ GO:0043248/ GO:0043161/ IPR007834,11,7QXU,wildtype,P60896,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,36
7QXW,2,,,,,,7QXW,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z+D state,STRUCTURAL PROTEIN,PSMD8,,GO:0005829/ GO:0005654/ GO:0005634/ GO:0022624/ GO:0000502/ GO:0005838/ GO:0008541/ GO:0043161/ IPR006746/ IPR033464/ IPR000717/ P48556,10,7QXW,wildtype,P48556,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,35
7QXW,2,,,,,,7QXW,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z+D state,STRUCTURAL PROTEIN,PSMC2/ MSS1,,GO:0005737/ GO:0036464/ GO:0005829/ GO:0005576/ GO:1904813/ GO:0016020/ GO:0005654/ GO:0005634/ GO:0000932/ GO:0022624/ GO:0000502/ GO:0008540/ GO:0034774/ GO:0005524/ GO:0016887/ GO:0036402/ GO:0001649/ GO:1901800/ GO:0043161/ GO:0006511/ IPR005937/ IPR003593/ IPR041569/ IPR003959/ IPR003960/ IPR012340/ IPR027417/ IPR035245/ P35998,12,7QXW,wildtype,P35998,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,37
7QXX,2,,,,,,7QXX,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z+E state,STRUCTURAL PROTEIN,PSMB2,3.4.25.1,GO:0005737/ GO:0005829/ GO:0070062/ GO:0016020/ GO:0005654/ GO:0005634/ GO:0000502/ GO:0005839/ GO:0019774/ GO:0010498/ GO:0043161/ GO:0014070/ GO:0010243/ IPR029055/ IPR035206/ IPR016050/ IPR001353/ IPR023333/ P49721,29,7QXX,wildtype,P49721,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,34
7QXX,2,,,,,,7QXX,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z+E state,STRUCTURAL PROTEIN,PSMD1,,GO:0035578/ GO:0005829/ GO:0005576/ GO:0016020/ GO:0005654/ GO:0005634/ GO:0022624/ GO:0000502/ GO:0005838/ GO:0008540/ GO:0034515/ GO:0030234/ GO:0031625/ GO:0043161/ GO:0042176/ IPR016642/ IPR011989/ IPR016024/ IPR002015/ IPR035266/ IPR040623/ Q99460,1,7QXX,wildtype,Q99460,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,36
7QY7,2,,,,,,7QY7,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND6,Proteasome-ZFAND6 Complex Z-A state,STRUCTURAL PROTEIN,PSMD13,,GO:0005829/ GO:0005576/ GO:1904813/ GO:0016020/ GO:0005654/ GO:0005634/ GO:0022624/ GO:0000502/ GO:0005838/ GO:0008541/ GO:0034774/ GO:0005198/ GO:0007127/ GO:0043161/ GO:0006511/ IPR000717/ IPR035298/ IPR036390/ Q9UNM6,1,7QY7,wildtype,Q9UNM6,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,34
7QYA,2,,,,,,7QYA,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z-B state,STRUCTURAL PROTEIN,PSMD11,,GO:0005829/ GO:0005576/ GO:1904813/ GO:0016020/ GO:0005654/ GO:0005634/ GO:0022624/ GO:0000502/ GO:0008541/ GO:0034774/ GO:0005198/ GO:0043248/ GO:0043161/ GO:0048863/ GO:0006511/ IPR000717/ IPR035295/ IPR040780/ IPR040773/ IPR011990/ IPR036390/ O00231,10,7QYA,wildtype,O00231,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,34
7QYB,2,,,,,,7QYB,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z-C state,STRUCTURAL PROTEIN,PSMD1,,GO:0035578/ GO:0005829/ GO:0005576/ GO:0016020/ GO:0005654/ GO:0005634/ GO:0022624/ GO:0000502/ GO:0005838/ GO:0008540/ GO:0034515/ GO:0030234/ GO:0031625/ GO:0043161/ GO:0042176/ IPR016642/ IPR011989/ IPR016024/ IPR002015/ IPR035266/ IPR040623/ Q99460,1,7QYB,wildtype,Q99460,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,34
7QYB,2,,,,,,7QYB,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z-C state,STRUCTURAL PROTEIN,PSMD8,,GO:0005829/ GO:0005654/ GO:0005634/ GO:0022624/ GO:0000502/ GO:0005838/ GO:0008541/ GO:0043161/ IPR006746/ IPR033464/ IPR000717/ P48556,10,7QYB,wildtype,P48556,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,36
7TTZ,2,,,,,,7TTZ,Engineering a pure and stable heterodimeric IgA for the development of multispecific therapeutics.,Heterodimeric IgA Fc in complex with Staphylococcus aureus protein SSL7,IMMUNE SYSTEM,DKFZp686L19235,,GO:0016020/ IPR007110/ IPR036179/ IPR013783/ IPR003006/ IPR003597/ IPR003599/ IPR003598/ IPR013106,1,7TTZ,mutant,Q6MZV6,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7TTZ,2,,,,,,7TTZ,Engineering a pure and stable heterodimeric IgA for the development of multispecific therapeutics.,Heterodimeric IgA Fc in complex with Staphylococcus aureus protein SSL7,IMMUNE SYSTEM,DKFZp686L19235,,GO:0016020/ IPR007110/ IPR036179/ IPR013783/ IPR003006/ IPR003597/ IPR003599/ IPR003598/ IPR013106,2,7TTZ,mutant,Q6MZV6,UniProt,C11 H24 O6,252.305,1PG,2-(2-{2-[2-(2-METHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHANOL,COCCOCCOCCOCCOCCO,5
7TUO,2,,,,,,7TUO,Crystal Structure Analysis of human USP28 complex with a compound,Crystal structure analysis of human USP28 complex with a compound,HYDROLASE/HYDROLASE INHIBITOR,USP28/ KIAA1515,3.4.19.12,GO:0005829/ GO:0016604/ GO:0005654/ GO:0005634/ GO:0032991/ GO:0004843/ GO:0004197/ GO:0008283/ GO:0006974/ GO:0034644/ GO:0000077/ GO:0006281/ GO:0042771/ GO:0016579/ GO:0007265/ GO:0031647/ GO:0010212/ GO:0006511/ IPR038765/ IPR001394/ IPR009060/ IPR018200/ IPR028889/ Q96RU2,1,7TUO,wildtype,Q96RU2,UniProt,C23 H27 N5 O S,421.558,KL9,7-amino-N-(2-{4-[(1R/3s/5S)-8-azabicyclo[3.2.1]octan-3-yl]phenyl}ethyl)-3-methylthieno[2/3-b]pyrazine-6-carboxamide,Cc1cnc2c(c(sc2n1)C(=O)NCCc3ccc(cc3)C4CC5CCC(C4)N5)N,2
7TVA,2,,,,,,7TVA,A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo.,Stat5a Core in complex with AK2292,TRANSCRIPTION,STAT5A/ STAT5,,GO:0000785/ GO:0005829/ GO:0005654/ GO:0090575/ GO:0003700/ GO:0000981/ GO:0140297/ GO:0000978/ GO:0019221/ GO:0006952/ GO:0060397/ GO:0007595/ GO:0043536/ GO:0001938/ GO:0045944/ GO:0007259/ GO:0038026/ GO:0042127/ GO:0040014/ GO:0006357/ GO:0043434/ GO:0019530/ IPR008967/ IPR000980/ IPR036860/ IPR001217/ IPR035858/ IPR036535/ IPR013800/ IPR015988/ IPR013801/ IPR012345/ IPR013799/ P42229,1,7TVA,wildtype,P42229,UniProt,C52 H54 F2 N7 O10 P S2,1070.127,KOO,N-{5-[difluoro(phosphono)methyl]-1-benzothiophene-2-carbonyl}-3-methyl-L-valyl-L-prolyl-N-(5-{2-[(3R)-2/6-dioxopiperidin-3-yl]-1-oxo-2/3-dihydro-1H-isoindol-4-yl}pent-4-yn-1-yl)-N-methyl-N~3~-[4-(1/3-thiazol-2-yl)phenyl]-beta-alaninamide,CC(C)(C)C(C(=O)N1CCCC1C(=O)N(CCC(=O)N(C)CCCC#Cc2cccc3c2CN(C3=O)C4CCC(=O)NC4=O)c5ccc(cc5)c6nccs6)NC(=O)c7cc8cc(ccc8s7)C(F)(F)P(=O)(O)O,2
7TVB,2,,,,,,7TVB,A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo.,Stat5A Core in Complex with AK305,TRANSCRIPTION,STAT5A/ STAT5,,GO:0000785/ GO:0005829/ GO:0005654/ GO:0090575/ GO:0003700/ GO:0000981/ GO:0140297/ GO:0000978/ GO:0019221/ GO:0006952/ GO:0060397/ GO:0007595/ GO:0043536/ GO:0001938/ GO:0045944/ GO:0007259/ GO:0038026/ GO:0042127/ GO:0040014/ GO:0006357/ GO:0043434/ GO:0019530/ IPR008967/ IPR000980/ IPR036860/ IPR001217/ IPR035858/ IPR036535/ IPR013800/ IPR015988/ IPR013801/ IPR012345/ IPR013799/ P42229,1,7TVB,wildtype,P42229,UniProt,C35 H40 F2 N5 O7 P S2,775.822,KOC,N-{5-[difluoro(phosphono)methyl]-1-benzothiophene-2-carbonyl}-3-methyl-L-valyl-L-prolyl-N/N-dimethyl-N~3~-[4-(1/3-thiazol-2-yl)phenyl]-beta-alaninamide,CC(C)(C)C(C(=O)N1CCCC1C(=O)N(CCC(=O)N(C)C)c2ccc(cc2)c3nccs3)NC(=O)c4cc5cc(ccc5s4)C(F)(F)P(=O)(O)O,2
7UBT,2,,,,,,7UBT,Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia.,Stat5a Core in complex with Compound 18,TRANSCRIPTION/INHIBITOR,STAT5A/ STAT5,,GO:0000785/ GO:0005829/ GO:0005654/ GO:0090575/ GO:0003700/ GO:0000981/ GO:0140297/ GO:0000978/ GO:0019221/ GO:0006952/ GO:0060397/ GO:0007595/ GO:0043536/ GO:0001938/ GO:0045944/ GO:0007259/ GO:0038026/ GO:0042127/ GO:0040014/ GO:0006357/ GO:0043434/ GO:0019530/ IPR008967/ IPR000980/ IPR036860/ IPR001217/ IPR035858/ IPR036535/ IPR013800/ IPR015988/ IPR013801/ IPR012345/ IPR013799/ P42229,1,7UBT,wildtype,P42229,UniProt,C33 H38 F2 N5 O7 P S2,749.785,MIW,N-{5-[difluoro(phosphono)methyl]-1-benzothiophene-2-carbonyl}-3-methyl-L-valyl-L-prolyl-N~3~-(1/3-benzothiazol-5-yl)-N/N-dimethyl-beta-alaninamide,CC(C)(C)C(C(=O)N1CCCC1C(=O)N(CCC(=O)N(C)C)c2ccc3c(c2)ncs3)NC(=O)c4cc5cc(ccc5s4)C(F)(F)P(=O)(O)O,3
7UC6,2,,,,,,7UC6,Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia.,Stat5a Core in complex with Compound 12,TRANSCRIPTION/INHIBITOR,STAT5A/ STAT5,,GO:0000785/ GO:0005829/ GO:0005654/ GO:0090575/ GO:0003700/ GO:0000981/ GO:0140297/ GO:0000978/ GO:0019221/ GO:0006952/ GO:0060397/ GO:0007595/ GO:0043536/ GO:0001938/ GO:0045944/ GO:0007259/ GO:0038026/ GO:0042127/ GO:0040014/ GO:0006357/ GO:0043434/ GO:0019530/ IPR008967/ IPR000980/ IPR036860/ IPR001217/ IPR035858/ IPR036535/ IPR013800/ IPR015988/ IPR013801/ IPR012345/ IPR013799/ P42229,1,7UC6,wildtype,P42229,UniProt,C32 H38 Br F2 N4 O7 P S,771.606,MJ6,N-{5-[difluoro(phosphono)methyl]-1-benzothiophene-2-carbonyl}-3-methyl-L-valyl-L-prolyl-N~3~-(4-bromophenyl)-N/N-dimethyl-beta-alaninamide,CC(C)(C)C(C(=O)N1CCCC1C(=O)N(CCC(=O)N(C)C)c2ccc(cc2)Br)NC(=O)c3cc4cc(ccc4s3)C(F)(F)P(=O)(O)O,2
7UC7,2,,,,,,7UC7,Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia.,Stat5a Core in complex with Compound 17,TRANSCRIPTION/INHIBITOR,STAT5A/ STAT5,,GO:0000785/ GO:0005829/ GO:0005654/ GO:0090575/ GO:0003700/ GO:0000981/ GO:0140297/ GO:0000978/ GO:0019221/ GO:0006952/ GO:0060397/ GO:0007595/ GO:0043536/ GO:0001938/ GO:0045944/ GO:0007259/ GO:0038026/ GO:0042127/ GO:0040014/ GO:0006357/ GO:0043434/ GO:0019530/ IPR008967/ IPR000980/ IPR036860/ IPR001217/ IPR035858/ IPR036535/ IPR013800/ IPR015988/ IPR013801/ IPR012345/ IPR013799/ P42229,1,7UC7,wildtype,P42229,UniProt,C34 H39 F2 N4 O8 P S,732.731,MQX,N-{5-[difluoro(phosphono)methyl]-1-benzothiophene-2-carbonyl}-3-methyl-L-valyl-L-prolyl-N~3~-(1-benzofuran-5-yl)-N/N-dimethyl-beta-alaninamide,CC(C)(C)C(C(=O)N1CCCC1C(=O)N(CCC(=O)N(C)C)c2ccc3c(c2)cco3)NC(=O)c4cc5cc(ccc5s4)C(F)(F)P(=O)(O)O,3
7UV9,2,,,,,,7UV9,Structural basis of paralog-specific KDM2A/B nucleosome recognition.,KDM2A-nucleosome structure stabilized by H3K36C-UNC8015 covalent conjugate,GENE REGULATION/DNA,H3C15/ HIST2H3A/ H3C14/ H3F2/ H3FM/ HIST2H3C/ H3C13/ HIST2H3D,,GO:0070062/ GO:0005576/ GO:0005654/ GO:0000786/ GO:0005634/ GO:0003677/ GO:0046982/ GO:0030527/ GO:0006334/ IPR009072/ IPR007125/ IPR000164/ Q71DI3,1,7UV9,mutant,Q71DI3,UniProt,C10 H19 N O4,217.262,OH0,N-heptanoyl-N-hydroxy-beta-alanine,CCCCCCC(=O)N(CCC(=O)O)O,8
7UVA,2,,,,,,7UVA,Structural basis of paralog-specific KDM2A/B nucleosome recognition.,Crystal structure of KDM2A histone demethylase catalytic domain in complex with an H3C36 peptide modified by UNC8015,GENE REGULATION,Kdm2a/ Fbl11/ Fbxl11/ Jhdm1a/ Kiaa1004,1.14.11.27,GO:0000785/ GO:0005654/ GO:0032452/ GO:0140680/ GO:0051864/ GO:0003712/ GO:0045322/ GO:0008270/ GO:0006325/ GO:0032922/ GO:0006303/ GO:0001947/ GO:0070544/ GO:0001701/ GO:0035264/ GO:0043066/ GO:0010629/ GO:0010944/ GO:0001843/ GO:0060563/ GO:0030182/ GO:0010628/ GO:0033184/ GO:0006482/ GO:0042752/ GO:0006357/ IPR001810/ IPR041070/ IPR003347/ IPR006553/ IPR032675/ IPR019786/ IPR002857/ IPR011011/ IPR001965/ IPR019787/ IPR013083/ P59997,2,7UVA,wildtype,P59997,UniProt,C10 H19 N O4,217.262,OH0,N-heptanoyl-N-hydroxy-beta-alanine,CCCCCCC(=O)N(CCC(=O)O)O,5
7UXL,2,,,,,,7UXL,Highly potent/ naturally acquired human monoclonal antibodies against Pfs48/45 block Plasmodium falciparum transmission to mosquitoes.,Crystal structure of malaria transmission-blocking antigen Pfs48/45-6C variant in complex with human antibodies RUPA-44 and RUPA-29,IMMUNE SYSTEM,,,,1,7UXL,mutant,,,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
7W41,2,,,,,,7W41,Structures of human gastrin-releasing peptide receptors bound to antagonist and agonist for cancer and itch therapy.,Crystal Structure of Human Gastrin Releasing Peptide Receptor in complex with the antagonist PD176252,MEMBRANE PROTEIN,GRPR,,GO:0005886/ GO:0008528/ GO:0004930/ GO:0042923/ GO:0008188/ GO:0007186/ GO:0007611/ GO:0061744/ GO:0007200/ GO:2000987/ GO:1903942/ GO:0036343/ GO:0042127/ GO:0043207/ GO:0035176/ IPR001556/ IPR001966/ IPR000276/ IPR017452/ GO:0004373/ GO:0000166/ IPR001296/ IPR011835/ IPR013534/ P30550/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.G Protein-Coupled Receptors: Class A.Gastrin Releasing Peptide Receptor (GRPR) - G<sub>q</sub> complex with bound agonist GRP/ Generic PDBTM,1,7W41,mutant,P30550,UniProt,C32 H36 N6 O5,584.665,8B8,(2S)-3-(1H-indol-3-yl)-N-[[1-(5-methoxypyridin-2-yl)cyclohexyl]methyl]-2-methyl-2-[(4-nitrophenyl)carbamoylamino]propanamide,CC(Cc1c[nH]c2c1cccc2)(C(=O)NCC3(CCCCC3)c4ccc(cn4)OC)NC(=O)Nc5ccc(cc5)[N+](=O)[O-],2
7WR9,2,,,,,,7WR9,Local CryoEM structure of the SARS-CoV S2P in complex with BD55-3152 Fab,Local CryoEM structure of the SARS-CoV S2P in complex with BD55-3152 Fab,VIRAL PROTEIN,,,,1,7WR9,wildtype,,,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
7WUZ,2,,,,,,7WUZ,Structural study of the complex of cblC methylmalonic aciduria and homocysteinuria-related protein MMACHC with cyanocobalamin,Structural study of the complex of cblC methylmalonic aciduria and homocysteinuria-related protein MMACHC with cyanocobalamin,OXIDOREDUCTASE,MMACHC,2.5.1.151/ 1.16.1.6,GO:0005737/ GO:0005829/ GO:0031419/ GO:0033787/ GO:0032451/ GO:0071949/ GO:0043295/ GO:0016491/ GO:0042803/ GO:0016740/ GO:0009235/ GO:0070988/ GO:0006749/ IPR032037/ Q9Y4U1,1,7WUZ,wildtype,Q9Y4U1,UniProt,C4 H6 O6,150.087,TLA,L(+)-TARTARIC ACID,C(C(C(=O)O)O)(C(=O)O)O,3
7WUZ,2,,,,,,7WUZ,Structural study of the complex of cblC methylmalonic aciduria and homocysteinuria-related protein MMACHC with cyanocobalamin,Structural study of the complex of cblC methylmalonic aciduria and homocysteinuria-related protein MMACHC with cyanocobalamin,OXIDOREDUCTASE,MMACHC,2.5.1.151/ 1.16.1.6,GO:0005737/ GO:0005829/ GO:0031419/ GO:0033787/ GO:0032451/ GO:0071949/ GO:0043295/ GO:0016491/ GO:0042803/ GO:0016740/ GO:0009235/ GO:0070988/ GO:0006749/ IPR032037/ Q9Y4U1,1,7WUZ,wildtype,Q9Y4U1,UniProt,C63 H89 Co N14 O14 P,1356.373,CNC,CYANOCOBALAMIN,Cc1cc2c(cc1C)n(cn2)C3C(C(C(O3)CO)OP(=O)(O)OC(C)CNC(=O)CCC4(C(C5C6(C(C(C7=[N]6[Co+2]89(N5C4=C(C1=[N]8C(=CC2=[N]9C(=C7C)C(C2CCC(=O)N)(C)CC(=O)N)C(C1CCC(=O)N)(C)C)C)C#N)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O,2
7WWI,2,,,,,,7WWI,SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab in the class 1 conformation,SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab in the class 1 conformation,VIRAL PROTEIN/IMMUNE SYSTEM,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,7WWI,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
7WWJ,2,,,,,,7WWJ,EM structure of SARS-CoV-2 Omicron variant spike glycoprotein and 55A8,SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab in the class 2 conformation,VIRAL PROTEIN/IMMUNE SYSTEM,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,7WWJ,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
7WZ3,2,,,,,,7WZ3,Pathway and mechanism of tubulin folding mediated by TRiC/CCT conjugated with its ATPase cycle revealed by cryo-EM,Cryo-EM structure of human TRiC-tubulin-S1 state,STRUCTURAL PROTEIN,TCP1/ CCT1/ CCTA,,GO:0001669/ GO:0044297/ GO:0005813/ GO:0005832/ GO:0005829/ GO:0070062/ GO:0005794/ GO:0000792/ GO:0005874/ GO:0000242/ GO:0002199/ GO:0005524/ GO:0016887/ GO:0140662/ GO:0044183/ GO:0003723/ GO:0031625/ GO:0051082/ GO:0007339/ GO:0061077/ GO:1904851/ GO:1904871/ GO:0051973/ GO:1904874/ GO:0032212/ GO:0006457/ GO:0050821/ GO:2000109/ GO:0090666/ GO:1901998/ GO:0044053/ GO:0007021/ IPR012715/ IPR017998/ IPR002194/ IPR002423/ IPR027409/ IPR027413/ IPR027410/ P17987,1,7WZ3,mutant,P17987,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,9
7X8P,2,,,,,,7X8P,An epitope-directed selection strategy facilitating the identification of Frizzled receptor selective antibodies.,Frizzled 2 CRD in complex with pF7_A5 Fab,SIGNALING PROTEIN,FZD2,,GO:0030669/ GO:0005737/ GO:0005925/ GO:0005886/ GO:0004930/ GO:0030165/ GO:0042813/ GO:0017147/ GO:0060070/ GO:0090103/ GO:0045446/ GO:0060022/ GO:0060119/ GO:0003149/ GO:0003150/ GO:0030182/ GO:0003151/ GO:0090179/ GO:0051091/ GO:0045893/ GO:0007608/ GO:0016055/ GO:0060071/ IPR015526/ IPR000539/ IPR020067/ IPR036790/ IPR041778/ IPR026550/ IPR017981/ Q14332,1,7X8P,wildtype,Q14332,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7X8P,2,,,,,,7X8P,An epitope-directed selection strategy facilitating the identification of Frizzled receptor selective antibodies.,Frizzled 2 CRD in complex with pF7_A5 Fab,SIGNALING PROTEIN,FZD2,,GO:0030669/ GO:0005737/ GO:0005925/ GO:0005886/ GO:0004930/ GO:0030165/ GO:0042813/ GO:0017147/ GO:0060070/ GO:0090103/ GO:0045446/ GO:0060022/ GO:0060119/ GO:0003149/ GO:0003150/ GO:0030182/ GO:0003151/ GO:0090179/ GO:0051091/ GO:0045893/ GO:0007608/ GO:0016055/ GO:0060071/ IPR015526/ IPR000539/ IPR020067/ IPR036790/ IPR041778/ IPR026550/ IPR017981/ Q14332,2,7X8P,wildtype,Q14332,UniProt,C16 H30 O2,254.408,PAM,PALMITOLEIC ACID,CCCCCCC=CCCCCCCCC(=O)O,5
7XQB,2,,,,,,7XQB,Conformational changes in the human Cx43/GJA1 gap junction channel visualized using cryo-EM.,Structure of connexin43/Cx43/GJA1 gap junction intercellular channel in POPE/CHS nanodiscs at pH ~8.0,MEMBRANE PROTEIN,GJA1/ GJAL,,GO:0016324/ GO:0030054/ GO:0044291/ GO:0005922/ GO:0005737/ GO:0005789/ GO:0005925/ GO:0005921/ GO:0005794/ GO:0000139/ GO:0030660/ GO:0014704/ GO:0043231/ GO:0045121/ GO:0005739/ GO:0005654/ GO:0005634/ GO:0005886/ GO:0070160/ GO:0043014/ GO:0008013/ GO:0015562/ GO:0005243/ GO:0086075/ GO:1903763/ GO:0055077/ GO:0034634/ GO:0015075/ GO:0015631/ GO:0086014/ GO:0060348/ GO:0046849/ GO:0003161/ GO:0010644/ GO:0086064/ GO:0007267/ GO:1904646/ GO:0000132/ GO:0140115/ GO:0016264/ GO:0014047/ GO:0034220/ GO:0035633/ GO:0099111/ GO:0030308/ GO:0032277/ GO:1901164/ GO:0120162/ GO:0010628/ GO:0043123/ GO:1905772/ GO:1905332/ GO:2000648/ GO:1904707/ GO:0008104/ GO:0007165/ GO:0007283/ GO:0042908/ IPR035091/ IPR000500/ IPR002261/ IPR013124/ IPR034634/ IPR019570/ IPR017990/ IPR013092/ IPR038359/ P17302/ Transmembrane.Alpha-helical polytopic.Tetraspan junctional complexes.Connexin/ Generic PDBTM,1,7XQB,wildtype,P17302,UniProt,C31 H50 O4,486.726,Y01,CHOLESTEROL HEMISUCCINATE,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC(=O)CCC(=O)O)C)C,3
7XQD,2,,,,,,7XQD,Conformational changes in the human Cx43/GJA1 gap junction channel visualized using cryo-EM.,Structure of C-terminal truncated connexin43/Cx43/GJA1 gap junction intercellular channel in POPE/CHS nanodiscs (C1 symmetry),MEMBRANE PROTEIN,GJA1/ GJAL,,GO:0016324/ GO:0030054/ GO:0044291/ GO:0005922/ GO:0005737/ GO:0005789/ GO:0005925/ GO:0005921/ GO:0005794/ GO:0000139/ GO:0030660/ GO:0014704/ GO:0043231/ GO:0045121/ GO:0005739/ GO:0005654/ GO:0005634/ GO:0005886/ GO:0070160/ GO:0043014/ GO:0008013/ GO:0015562/ GO:0005243/ GO:0086075/ GO:1903763/ GO:0055077/ GO:0034634/ GO:0015075/ GO:0015631/ GO:0086014/ GO:0060348/ GO:0046849/ GO:0003161/ GO:0010644/ GO:0086064/ GO:0007267/ GO:1904646/ GO:0000132/ GO:0140115/ GO:0016264/ GO:0014047/ GO:0034220/ GO:0035633/ GO:0099111/ GO:0030308/ GO:0032277/ GO:1901164/ GO:0120162/ GO:0010628/ GO:0043123/ GO:1905772/ GO:1905332/ GO:2000648/ GO:1904707/ GO:0008104/ GO:0007165/ GO:0007283/ GO:0042908/ IPR035091/ IPR000500/ IPR002261/ IPR013124/ IPR034634/ IPR019570/ IPR017990/ IPR013092/ IPR038359/ P17302/ Transmembrane.Alpha-helical polytopic.Tetraspan junctional complexes.Connexin/ Generic PDBTM,1,7XQD,wildtype,P17302,UniProt,C31 H50 O4,486.726,Y01,CHOLESTEROL HEMISUCCINATE,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC(=O)CCC(=O)O)C)C,4
7XQF,2,,,,,,7XQF,Conformational changes in the human Cx43/GJA1 gap junction channel visualized using cryo-EM.,Structure of C-terminal truncated connexin43/Cx43/GJA1 gap junction intercellular channel in POPE/CHS nanodiscs,MEMBRANE PROTEIN,GJA1/ GJAL,,GO:0016324/ GO:0030054/ GO:0044291/ GO:0005922/ GO:0005737/ GO:0005789/ GO:0005925/ GO:0005921/ GO:0005794/ GO:0000139/ GO:0030660/ GO:0014704/ GO:0043231/ GO:0045121/ GO:0005739/ GO:0005654/ GO:0005634/ GO:0005886/ GO:0070160/ GO:0043014/ GO:0008013/ GO:0015562/ GO:0005243/ GO:0086075/ GO:1903763/ GO:0055077/ GO:0034634/ GO:0015075/ GO:0015631/ GO:0086014/ GO:0060348/ GO:0046849/ GO:0003161/ GO:0010644/ GO:0086064/ GO:0007267/ GO:1904646/ GO:0000132/ GO:0140115/ GO:0016264/ GO:0014047/ GO:0034220/ GO:0035633/ GO:0099111/ GO:0030308/ GO:0032277/ GO:1901164/ GO:0120162/ GO:0010628/ GO:0043123/ GO:1905772/ GO:1905332/ GO:2000648/ GO:1904707/ GO:0008104/ GO:0007165/ GO:0007283/ GO:0042908/ IPR035091/ IPR000500/ IPR002261/ IPR013124/ IPR034634/ IPR019570/ IPR017990/ IPR013092/ IPR038359/ P17302/ Transmembrane.Alpha-helical polytopic.Tetraspan junctional complexes.Connexin/ Generic PDBTM,1,7XQF,wildtype,P17302,UniProt,C31 H50 O4,486.726,Y01,CHOLESTEROL HEMISUCCINATE,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC(=O)CCC(=O)O)C)C,4
7YCN,2,,,,,,7YCN,Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2.,Crystal structure of SARS-CoV-2 Spike RBD in complex with IY-2A Fab,VIRAL PROTEIN/IMMUNE SYSTEM,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,7YCN,wildtype,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7YSG,2,,,,,,7YSG,Immunoglobulin M perception by Fc mu R.,Cryo-EM structure of human FcmR bound to sIgM,IMMUNE SYSTEM,IGHM,,GO:0072562/ GO:0009986/ GO:0009897/ GO:0070062/ GO:0005615/ GO:0071757/ GO:0071753/ GO:0042571/ GO:0071756/ GO:0005886/ GO:0003823/ GO:0002250/ GO:0019731/ GO:0050853/ GO:0006958/ GO:0042742/ GO:0050829/ GO:0045087/ GO:0006911/ GO:0006910/ GO:0050871/ IPR007110/ IPR036179/ IPR013783/ IPR003006/ IPR003597/ P01871,1,7YSG,wildtype,P01871,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
7Z6U,2,,,,,,7Z6U,Pose/ duplicate/ then elaborate: Steps towards increased affinity for inhibitors targeting the specificity surface of the Pim-1 kinase.,Pim1 in complex with (E)-4-((6-amino-2-oxoindolin-3-ylidene)methyl)benzoic acid and Pimtide,TRANSFERASE,PIM1,2.7.11.1,GO:0005737/ GO:0005829/ GO:0005730/ GO:0005654/ GO:0005634/ GO:0005886/ GO:0005524/ GO:0030145/ GO:0106310/ GO:0043539/ GO:0004674/ GO:0043024/ GO:0008134/ GO:0006915/ GO:0007049/ GO:1990748/ GO:0043066/ GO:0043433/ GO:0090336/ GO:0060045/ GO:1905062/ GO:0045737/ GO:0045893/ GO:0071902/ GO:0046777/ GO:0006468/ GO:0050821/ GO:1902033/ GO:0022898/ GO:0070561/ IPR011009/ IPR017348/ IPR000719/ IPR017441/ IPR008271,1,7Z6U,mutant,P11309-1,UniProt,C16 H12 N2 O3,280.278,IJB,4-[(~{E})-(6-azanyl-2-oxidanylidene-1~{H}-indol-3-ylidene)methyl]benzoic acid,c1cc(ccc1C=C2c3ccc(cc3NC2=O)N)C(=O)O,4
7ZY6,2,,,,,,7ZY6,Identification of M4205?A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors.,Identification of M4205 a highly selective inhibitor of cKIT mutations for unresectable metastatic or recurrent GIST,TRANSFERASE,,,,1,7ZY6,wildtype,,,C23 H24 N6,384.477,KCI,5-imidazo[1/2-a]pyridin-3-yl-~{N}-[(1~{R})-1-(6-pyrrolidin-1-ylpyridin-3-yl)ethyl]pyridin-3-amine,CC(c1ccc(nc1)N2CCCC2)Nc3cc(cnc3)c4cnc5n4cccc5,2
8ADB,2,,,,,,8ADB,A widely distributed family of eukaryotic and bacterial deubiquitinases related to herpesviral large tegument proteins.,Viral tegument-like DUBs,HYDROLASE,wcw_1294,,GO:0016020/ IPR038765,1,8ADB,wildtype,D6YWY5,UniProt,C6 H8 O7,192.124,CIT,CITRIC ACID,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,3
8BDI,2,,,,,,8BDI,Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design.,VCB in complex with compound 32,LIGASE,ELOC/ TCEB1,,GO:0031462/ GO:0031466/ GO:0005829/ GO:0070449/ GO:0005654/ GO:0030674/ GO:0001222/ GO:0016567/ GO:0006357/ GO:0006367/ GO:0006511/ IPR039948/ IPR001232/ IPR011333/ IPR016073/ Q15369,2,8BDI,wildtype,Q15369,UniProt,C29 H38 F N5 O5 S,587.706,QF7,(2~{S}/4~{R})-1-[(2~{S})-2-[(1-fluoranylcyclopropyl)carbonylamino]-3/3-dimethyl-butanoyl]-~{N}-[(1~{S})-3-(methylamino)-1-[4-(4-methyl-1/3-thiazol-5-yl)phenyl]-3-oxidanylidene-propyl]-4-oxidanyl-pyrrolidine-2-carboxamide,Cc1c(scn1)c2ccc(cc2)C(CC(=O)NC)NC(=O)C3CC(CN3C(=O)C(C(C)(C)C)NC(=O)C4(CC4)F)O,5
8BDJ,2,,,,,,8BDJ,Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design.,VCB in complex with compound 30,LIGASE,ELOB/ TCEB2,,GO:0031462/ GO:0031466/ GO:0005829/ GO:0070449/ GO:0005654/ GO:0030891/ GO:0001222/ GO:0031625/ GO:0032436/ GO:0016567/ GO:0065003/ GO:0006368/ GO:0006367/ IPR039049/ IPR000626/ IPR029071/ Q15370,1,8BDJ,wildtype,Q15370,UniProt,C25 H34 Cl N3 O6,508.007,QE0,(2~{S}/4~{R})-~{N}-[(1~{S})-1-[4-chloranyl-2-(2-methoxyethoxy)phenyl]ethyl]-1-[(2~{R})-3-methyl-2-(3-methyl-1/2-oxazol-5-yl)butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide,Cc1cc(on1)C(C(C)C)C(=O)N2CC(CC2C(=O)NC(C)c3ccc(cc3OCCOC)Cl)O,5
8BDL,2,,,,,,8BDL,Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design.,VCB in complex with compound 27,LIGASE,ELOC/ TCEB1,,GO:0031462/ GO:0031466/ GO:0005829/ GO:0070449/ GO:0005654/ GO:0030674/ GO:0001222/ GO:0016567/ GO:0006357/ GO:0006367/ GO:0006511/ IPR039948/ IPR001232/ IPR011333/ IPR016073/ Q15369,2,8BDL,wildtype,Q15369,UniProt,C29 H38 N4 O6 S,570.7,QF3,(2~{S}/4~{R})-~{N}-[(1~{S})-1-[2-(2-methoxyethoxy)-4-(4-methyl-1/3-thiazol-5-yl)phenyl]ethyl]-1-[(2~{R})-3-methyl-2-(3-methyl-1/2-oxazol-5-yl)butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide,Cc1cc(on1)C(C(C)C)C(=O)N2CC(CC2C(=O)NC(C)c3ccc(cc3OCCOC)c4c(ncs4)C)O,4
8BDM,2,,,,,,8BDM,Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design.,VCB in complex with compound 26,LIGASE,ELOB/ TCEB2,,GO:0031462/ GO:0031466/ GO:0005829/ GO:0070449/ GO:0005654/ GO:0030891/ GO:0001222/ GO:0031625/ GO:0032436/ GO:0016567/ GO:0065003/ GO:0006368/ GO:0006367/ IPR039049/ IPR000626/ IPR029071/ Q15370,1,8BDM,wildtype,Q15370,UniProt,C28 H36 N4 O6 S,556.674,QE9,(2~{S}/4~{R})-~{N}-[[2-(2-methoxyethoxy)-4-(4-methyl-1/3-thiazol-5-yl)phenyl]methyl]-1-[(2~{R})-3-methyl-2-(3-methyl-1/2-oxazol-5-yl)butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide,Cc1cc(on1)C(C(C)C)C(=O)N2CC(CC2C(=O)NCc3ccc(cc3OCCOC)c4c(ncs4)C)O,4
8BDN,2,,,,,,8BDN,Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design.,VCB in complex with compound 23,LIGASE,ELOC/ TCEB1,,GO:0031462/ GO:0031466/ GO:0005829/ GO:0070449/ GO:0005654/ GO:0030674/ GO:0001222/ GO:0016567/ GO:0006357/ GO:0006367/ GO:0006511/ IPR039948/ IPR001232/ IPR011333/ IPR016073/ Q15369,2,8BDN,wildtype,Q15369,UniProt,C26 H31 N5 O4 S,509.62,QFR,(2~{R})-3-methyl-1-[(2~{S}/4~{R})-2-[(5~{R})-5-methyl-5-[4-(4-methyl-1/3-thiazol-5-yl)phenyl]-4~{H}-1/2/4-oxadiazol-3-yl]-4-oxidanyl-pyrrolidin-1-yl]-2-(3-methyl-1/2-oxazol-5-yl)butan-1-one,Cc1cc(on1)C(C(C)C)C(=O)N2CC(CC2C3=NOC(N3)(C)c4ccc(cc4)c5c(ncs5)C)O,4
8BDO,2,,,,,,8BDO,Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design.,VCB in complex with compound 21,LIGASE,ELOB/ TCEB2,,GO:0031462/ GO:0031466/ GO:0005829/ GO:0070449/ GO:0005654/ GO:0030891/ GO:0001222/ GO:0031625/ GO:0032436/ GO:0016567/ GO:0065003/ GO:0006368/ GO:0006367/ IPR039049/ IPR000626/ IPR029071/ Q15370,1,8BDO,wildtype,Q15370,UniProt,C24 H28 N4 O5 S,484.568,QFF,(2~{S}/4~{R})-1-[(2~{R})-3-methyl-2-(3-methyl-1/2-oxazol-5-yl)butanoyl]-~{N}-[4-(4-methyl-1/3-thiazol-5-yl)phenoxy]-4-oxidanyl-pyrrolidine-2-carboxamide,Cc1cc(on1)C(C(C)C)C(=O)N2CC(CC2C(=O)NOc3ccc(cc3)c4c(ncs4)C)O,4
8BEB,2,,,,,,8BEB,Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design.,Ternary complex between VCB/ BRD4-BD1 and PROTAC 49,LIGASE,ELOC/ TCEB1,,GO:0031462/ GO:0031466/ GO:0005829/ GO:0070449/ GO:0005654/ GO:0030674/ GO:0001222/ GO:0016567/ GO:0006357/ GO:0006367/ GO:0006511/ IPR039948/ IPR001232/ IPR011333/ IPR016073/ Q15369,2,8BEB,wildtype,Q15369,UniProt,C50 H57 Cl N10 O6 S2,993.634,QIK,(2~{S}/4~{R})-~{N}-[(1~{S})-3-[4-[2-[(9~{S})-7-(4-chlorophenyl)-4/5/13-trimethyl-3-thia-1/8/11/12-tetrazatricyclo[8.3.0.0^{2/6}]trideca-2(6)/4/7/10/12-pentaen-9-yl]ethanoylamino]butylamino]-1-[4-(4-methyl-1/3-thiazol-5-yl)phenyl]-3-oxidanylidene-propyl]-1-[(2~{R})-3-methyl-2-(3-methyl-1/2-oxazol-5-yl)butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide,Cc1cc(on1)C(C(C)C)C(=O)N2CC(CC2C(=O)NC(CC(=O)NCCCCNC(=O)CC3c4nnc(n4-c5c(c(c(s5)C)C)C(=N3)c6ccc(cc6)Cl)C)c7ccc(cc7)c8c(ncs8)C)O,6
8D0A,2,,,,,,8D0A,TBD,Crystal structure of human USP30 in complex with a covalent inhibitor 829 and a Fab,HYDROLASE,USP30,3.4.19.12,GO:0005829/ GO:0005741/ GO:0005739/ GO:0005634/ GO:0005778/ GO:0004843/ GO:0004197/ GO:0101005/ GO:0000422/ GO:0008053/ GO:1901525/ GO:0000425/ GO:0016579/ GO:0035871/ GO:0044313/ GO:0006511/ IPR038765/ IPR001394/ IPR018200/ IPR028889/ Q70CQ3,1,8D0A,mutant,Q70CQ3,UniProt,C21 H23 Cl N5 O S,428.958,PKH,~{N}-[(1~{R}/2~{R}/4~{S}/7~{E})-7-[azanyl(sulfanyl)methylidene]-7$l^{4}-azabicyclo[2.2.1]heptan-2-yl]-2-chloranyl-4-(6-cyclopropylpyrazin-2-yl)benzamide,c1cc(c(cc1c2cncc(n2)C3CC3)Cl)C(=O)NC4CC5CCC4[N+]5=C(N)S,4
8D1T,2,,,,,,8D1T,TBD,Crystal structure of human USP30 in complex with a covalent inhibitor 552 and a Fab,HYDROLASE,USP30,3.4.19.12,GO:0005829/ GO:0005741/ GO:0005739/ GO:0005634/ GO:0005778/ GO:0004843/ GO:0004197/ GO:0101005/ GO:0000422/ GO:0008053/ GO:1901525/ GO:0000425/ GO:0016579/ GO:0035871/ GO:0044313/ GO:0006511/ IPR038765/ IPR001394/ IPR018200/ IPR028889/ Q70CQ3,1,8D1T,mutant,Q70CQ3,UniProt,C24 H24 Cl N4 O S,451.992,PXW,(1R/2R/4S/7E)-7-[amino(sulfanyl)methylidene]-2-{[(1P)-3-chloro-3'-(1-cyanocyclopropyl)[1/1'-biphenyl]-4-carbonyl]amino}-7-azabicyclo[2.2.1]heptan-7-ium,c1cc(cc(c1)C2(CC2)C#N)c3ccc(c(c3)Cl)C(=O)NC4CC5CCC4[N+]5=C(N)S,4
8D6L,2,,,,,,8D6L,Light controlled reversible Michael addition of cysteine: a new tool for dynamic site-specific labeling of proteins.,Q108K:K40L:T51C:T53A:R58L:Q38F:Q4F mutant of hCRBPII bound to synthetic fluorophore CM1V,TRANSPORT PROTEIN,RBP2/ CRBP2,,GO:0005829/ GO:0005634/ GO:0005504/ GO:0016918/ GO:0005501/ GO:0019841/ GO:0008544/ GO:0015908/ GO:0006776/ IPR012674/ IPR000463/ IPR031259/ IPR000566/ P50120,1,8D6L,mutant,P50120,UniProt,C16 H19 N O2,257.328,RH6,(2E)-3-[7-(diethylamino)-2-oxo-2H-1-benzopyran-3-yl]prop-2-enal/ bound form,CCN(CC)c1ccc2c(c1)OC(=O)C(=C2)C=CC,3
8DB2,2,,,,,,8DB2,Light controlled reversible Michael addition of cysteine: a new tool for dynamic site-specific labeling of proteins.,Q108K:K40L:T51C:T53A:R58L:Q38F mutant of hCRBPII bound to synthetic fluorophore CM1V,TRANSPORT PROTEIN,RBP2/ CRBP2,,GO:0005829/ GO:0005634/ GO:0005504/ GO:0016918/ GO:0005501/ GO:0019841/ GO:0008544/ GO:0015908/ GO:0006776/ IPR012674/ IPR000463/ IPR031259/ IPR000566/ P50120,1,8DB2,mutant,P50120,UniProt,C16 H19 N O2,257.328,RH6,(2E)-3-[7-(diethylamino)-2-oxo-2H-1-benzopyran-3-yl]prop-2-enal/ bound form,CCN(CC)c1ccc2c(c1)OC(=O)C(=C2)C=CC,2
8DD7,2,,,,,,8DD7,Cryptochrome-Timeless structure reveals circadian clock timing mechanisms.,The Cryo-EM structure of Drosophila Cryptochrome in complex with Timeless,CIRCADIAN CLOCK PROTEIN,,2.1.1.63,GO:0003908/ GO:0006304/ GO:0006281/ GO:0032259/ IPR001497/ IPR014048/ IPR036217/ IPR008332/ IPR036631/ IPR036388/ GO:0005737/ GO:0005829/ GO:0005654/ GO:0005634/ GO:0048471/ GO:0009882/ GO:0003677/ GO:0071949/ GO:0050660/ GO:0008020/ GO:0009881/ GO:0009785/ GO:0071482/ GO:0048512/ GO:0032922/ GO:0007623/ GO:0050980/ GO:0009649/ GO:0043153/ GO:0042332/ GO:0045475/ GO:0050958/ GO:0045892/ GO:0007602/ GO:0042752/ GO:0045187/ GO:0009637/ GO:0009416/ GO:0071000/ GO:0009588/ IPR036134/ IPR036155/ IPR005101/ IPR002081/ IPR006050/ IPR014729,1,8DD7,wildtype,E5BBQ0,UniProt,C27 H33 N9 O15 P2,785.55,FAD,FLAVIN-ADENINE DINUCLEOTIDE,Cc1cc2c(cc1C)N(C3=NC(=O)NC(=O)C3=N2)CC(C(C(COP(=O)(O)OP(=O)(O)OCC4C(C(C(O4)n5cnc6c5ncnc6N)O)O)O)O)O,3
8DN1,2,,,,,,8DN1,Light controlled reversible Michael addition of cysteine: a new tool for dynamic site-specific labeling of proteins.,Q108K:K40L:T51C:T53A:R58L:Q38F:Q4F mutant of hCRBPII bound to synthetic fluorophore CM1V at pH 7.2,TRANSPORT PROTEIN,RBP2/ CRBP2,,GO:0005829/ GO:0005634/ GO:0005504/ GO:0016918/ GO:0005501/ GO:0019841/ GO:0008544/ GO:0015908/ GO:0006776/ IPR012674/ IPR000463/ IPR031259/ IPR000566/ P50120,1,8DN1,mutant,P50120,UniProt,C16 H19 N O2,257.328,RH6,(2E)-3-[7-(diethylamino)-2-oxo-2H-1-benzopyran-3-yl]prop-2-enal/ bound form,CCN(CC)c1ccc2c(c1)OC(=O)C(=C2)C=CC,3
8DWL,2,,,,,,8DWL,Inhibitor-3 inhibits Protein Phosphatase 1 via a metal binding dynamic protein-protein interaction.,Inhibitor-3:PP1 coexpressed complex,HYDROLASE,PPP1CA/ PPP1A,3.1.3.16,GO:0005912/ GO:0005737/ GO:0005829/ GO:0043197/ GO:0070062/ GO:0098978/ GO:0042587/ GO:0005730/ GO:0005654/ GO:0005634/ GO:0043204/ GO:0005886/ GO:0098793/ GO:0000164/ GO:0072357/ GO:0098641/ GO:0046872/ GO:0017018/ GO:0016791/ GO:0004721/ GO:0008157/ GO:0004722/ GO:0043021/ GO:1904886/ GO:0048754/ GO:0007049/ GO:0051301/ GO:0032922/ GO:0016311/ GO:0043153/ GO:0005977/ GO:0030324/ GO:0032091/ GO:0070262/ GO:0035970/ GO:2001241/ GO:0006470/ GO:0060828/ GO:0042752/ GO:0005979/ GO:0005981/ GO:0036496/ GO:0010288/ IPR004843/ IPR029052/ IPR037979/ IPR006186/ IPR031675/ P62136,1,8DWL,wildtype,P62136,UniProt,C2 H6 O2,62.068,EDO,1/2-ETHANEDIOL,C(CO)O,4
8E8O,2,,,,,,8E8O,Integrative structural and functional analysis of human malic enzyme 3: A potential therapeutic target for pancreatic cancer.,Cryo-EM structure of human ME3 in the presence of citrate,HYDROLASE,ME3,1.1.1.40,GO:0005759/ GO:0005739/ GO:0004471/ GO:0004473/ GO:0004470/ GO:0046872/ GO:0051287/ GO:0070401/ GO:0008948/ GO:0009060/ GO:0006108/ GO:0072592/ GO:0006090/ IPR046346/ IPR015884/ IPR012301/ IPR037062/ IPR012302/ IPR001891/ IPR036291/ Q16798,1,8E8O,wildtype,Q16798,UniProt,C21 H28 N7 O17 P3,743.405,NAP,NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE,c1cc(c[n+](c1)C2C(C(C(O2)COP(=O)([O-])OP(=O)(O)OCC3C(C(C(O3)n4cnc5c4ncnc5N)OP(=O)(O)O)O)O)O)C(=O)N,2
8EFG,2,,,,,,8EFG,Human and bacterial TatD enzymes exhibit apurinic/apyrimidinic (AP) endonuclease activity.,Crystal structure of human TATDN1 bound to dAMP and two zinc ions,HYDROLASE,TATDN1/ CDA11,3.1.21,GO:0005654/ GO:0008296/ GO:0046872/ IPR018228/ IPR032466/ IPR001130/ Q6P1N9,1,8EFG,wildtype,Q6P1N9,UniProt,C10 H14 N5 O6 P,331.222,DA,2'-DEOXYADENOSINE-5'-MONOPHOSPHATE,c1nc(c2c(n1)n(cn2)C3CC(C(O3)COP(=O)(O)O)O)N,5
8EQ4,2,,,,,,8EQ4,Inhibition of the proton-activated chloride channel PAC by PIP 2.,Human PAC in nanodisc at pH 4.0 with PI(4/5)P2 diC8,MEMBRANE PROTEIN,PACC1/ C1orf75/ TMEM206,,GO:0009986/ GO:0034707/ GO:0061797/ GO:0006821/ IPR029366/ Q9H813/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Channels: Other Ion Channels.proton-activated chloride (PAC/ASOR) channel/ pH 4.0 with diC<sub>8</sub>-PI(4/5)P<sub>2</sub> using full map/ Transmembrane.Alpha-helical polytopic.Proton-activated chloride channel.Proton-activated chloride channel,1,8EQ4,wildtype,Q9H813,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,2
8EQ4,2,,,,,,8EQ4,Inhibition of the proton-activated chloride channel PAC by PIP 2.,Human PAC in nanodisc at pH 4.0 with PI(4/5)P2 diC8,MEMBRANE PROTEIN,PACC1/ C1orf75/ TMEM206,,GO:0009986/ GO:0034707/ GO:0061797/ GO:0006821/ IPR029366/ Q9H813/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Channels: Other Ion Channels.proton-activated chloride (PAC/ASOR) channel/ pH 4.0 with diC<sub>8</sub>-PI(4/5)P<sub>2</sub> using full map/ Transmembrane.Alpha-helical polytopic.Proton-activated chloride channel.Proton-activated chloride channel,1,8EQ4,wildtype,Q9H813,UniProt,C25 H49 O19 P3,746.566,PIO,[(2R)-2-octanoyloxy-3-[oxidanyl-[(1R/2R/3S/4R/5R/6S)-2/3/6-tris(oxidanyl)-4/5-diphosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-propyl] octanoate,CCCCCCCC(=O)OCC(COP(=O)(O)OC1C(C(C(C(C1O)OP(=O)(O)O)OP(=O)(O)O)O)O)OC(=O)CCCCCCC,3
8EWD,2,,,,,,8EWD,Dynamic Ir(III) Photosensors for the Major Human Drug-Metabolizing Enzyme Cytochrome P450 3A4.,Crystal structure of CYP3A4 bound to an inhibitor,OXIDOREDUCTASE/INHIBITOR,CYP3A4/ CYP3A3,1.14.14.1/ 1.14.14.56/ 1.14.14.73/ 1.14.14.55,GO:0005737/ GO:0005789/ GO:0043231/ GO:0102320/ GO:0062181/ GO:0062188/ GO:0062189/ GO:0062187/ GO:0070330/ GO:0034875/ GO:0019899/ GO:0101020/ GO:0101021/ GO:0020037/ GO:0005506/ GO:0004497/ GO:0016491/ GO:0019825/ GO:0050591/ GO:0008401/ GO:0005496/ GO:0008395/ GO:0050649/ GO:0070576/ GO:0030343/ GO:0046222/ GO:0009822/ GO:0008209/ GO:0008203/ GO:0008210/ GO:0046483/ GO:0002933/ GO:0006629/ GO:0042759/ GO:0016098/ GO:0070989/ GO:0042573/ GO:0042572/ GO:0006706/ GO:0008202/ GO:0042369/ GO:0042359/ GO:0042178/ GO:0006805/ IPR001128/ IPR017972/ IPR008072/ IPR002402/ IPR036396/ P08684,1,8EWD,wildtype,P08684,UniProt,C54 H47 Ir N7 O3,1034.213,WZN,{tert-butyl [1-{[([2/2'-bipyridin]-5-yl-kappa~2~N~1~/N~1'~)methyl]amino}-1-oxo-3-(pyridin-4-yl)propan-2-yl]carbamate}bis[2-(quinolin-2-yl-kappaN)phenyl-kappaC~1~]iridium(1+),CC(C)(C)OC(=O)NC(Cc1ccncc1)C(=O)NCC2=C[N]3=C(C=C2)C4=CC=CC=[N]4[Ir+]356(c7ccccc7C8=[N]5c9ccccc9C=C8)c1ccccc1C1=CC=C2C=CC=CC2=[N]61,3
8EWE,2,,,,,,8EWE,Dynamic Ir(III) Photosensors for the Major Human Drug-Metabolizing Enzyme Cytochrome P450 3A4.,Crystal structure of CYP3A4 bound to an inhibitor,OXIDOREDUCTASE/INHIBITOR,CYP3A4/ CYP3A3,1.14.14.1/ 1.14.14.56/ 1.14.14.73/ 1.14.14.55,GO:0005737/ GO:0005789/ GO:0043231/ GO:0102320/ GO:0062181/ GO:0062188/ GO:0062189/ GO:0062187/ GO:0070330/ GO:0034875/ GO:0019899/ GO:0101020/ GO:0101021/ GO:0020037/ GO:0005506/ GO:0004497/ GO:0016491/ GO:0019825/ GO:0050591/ GO:0008401/ GO:0005496/ GO:0008395/ GO:0050649/ GO:0070576/ GO:0030343/ GO:0046222/ GO:0009822/ GO:0008209/ GO:0008203/ GO:0008210/ GO:0046483/ GO:0002933/ GO:0006629/ GO:0042759/ GO:0016098/ GO:0070989/ GO:0042573/ GO:0042572/ GO:0006706/ GO:0008202/ GO:0042369/ GO:0042359/ GO:0042178/ GO:0006805/ IPR001128/ IPR017972/ IPR008072/ IPR002402/ IPR036396/ P08684,1,8EWE,wildtype,P08684,UniProt,C54 H47 Ir N7 O3,1034.213,X0E,{tert-butyl [1-{[([2/2'-bipyridin]-5-yl-kappa~2~N~1~/N~1'~)methyl]amino}-1-oxo-3-(pyridin-4-yl)propan-2-yl]carbamate}bis[2-(quinolin-2-yl-kappaN)phenyl-kappaC~1~]iridium,CC(C)(C)OC(=O)NC(Cc1ccncc1)C(=O)NCC2=C[N]3=C(C=C2)C4=CC=CC=[N]4[Ir+]356(c7ccccc7C8=[N]5c9ccccc9C=C8)c1ccccc1C1=CC=C2C=CC=CC2=[N]61,3
8EWL,2,,,,,,8EWL,Dynamic Ir(III) Photosensors for the Major Human Drug-Metabolizing Enzyme Cytochrome P450 3A4.,Crystal structure of CYP3A4 bound to an inhibitor,OXIDOREDUCTASE/INHIBITOR,CYP3A4/ CYP3A3,1.14.14.1/ 1.14.14.56/ 1.14.14.73/ 1.14.14.55,GO:0005737/ GO:0005789/ GO:0043231/ GO:0102320/ GO:0062181/ GO:0062188/ GO:0062189/ GO:0062187/ GO:0070330/ GO:0034875/ GO:0019899/ GO:0101020/ GO:0101021/ GO:0020037/ GO:0005506/ GO:0004497/ GO:0016491/ GO:0019825/ GO:0050591/ GO:0008401/ GO:0005496/ GO:0008395/ GO:0050649/ GO:0070576/ GO:0030343/ GO:0046222/ GO:0009822/ GO:0008209/ GO:0008203/ GO:0008210/ GO:0046483/ GO:0002933/ GO:0006629/ GO:0042759/ GO:0016098/ GO:0070989/ GO:0042573/ GO:0042572/ GO:0006706/ GO:0008202/ GO:0042369/ GO:0042359/ GO:0042178/ GO:0006805/ IPR001128/ IPR017972/ IPR008072/ IPR002402/ IPR036396/ P08684,1,8EWL,wildtype,P08684,UniProt,C49 H38 Ir N6 O,919.083,X1C,{N-[([2/2'-bipyridin]-5-yl-kappa~2~N~1~/N~1'~)methyl]-3-(pyridin-4-yl)propanamide}bis[2-(quinolin-2-yl-kappaN)phenyl-kappaC~1~]iridium(1+),c1ccc2c(c1)C=CC3=[N]2[Ir+]45(c6c3cccc6)(c7ccccc7C8=CC=C9C=CC=CC9=[N]48)[N]1=C(C=CC=C1)C1=[N]5C=C(C=C1)CNC(=O)CCc1ccncc1,3
8EWM,2,,,,,,8EWM,Dynamic Ir(III) Photosensors for the Major Human Drug-Metabolizing Enzyme Cytochrome P450 3A4.,Crystal structure of CYP3A4 bound to an inhibitor,OXIDOREDUCTASE/INHIBITOR,CYP3A4/ CYP3A3,1.14.14.1/ 1.14.14.56/ 1.14.14.73/ 1.14.14.55,GO:0005737/ GO:0005789/ GO:0043231/ GO:0102320/ GO:0062181/ GO:0062188/ GO:0062189/ GO:0062187/ GO:0070330/ GO:0034875/ GO:0019899/ GO:0101020/ GO:0101021/ GO:0020037/ GO:0005506/ GO:0004497/ GO:0016491/ GO:0019825/ GO:0050591/ GO:0008401/ GO:0005496/ GO:0008395/ GO:0050649/ GO:0070576/ GO:0030343/ GO:0046222/ GO:0009822/ GO:0008209/ GO:0008203/ GO:0008210/ GO:0046483/ GO:0002933/ GO:0006629/ GO:0042759/ GO:0016098/ GO:0070989/ GO:0042573/ GO:0042572/ GO:0006706/ GO:0008202/ GO:0042369/ GO:0042359/ GO:0042178/ GO:0006805/ IPR001128/ IPR017972/ IPR008072/ IPR002402/ IPR036396/ P08684,1,8EWM,wildtype,P08684,UniProt,C46 H37 F4 Ir N7 O3,1004.042,X1I,{tert-butyl [1-{[([2/2'-bipyridin]-5-yl-kappa~2~N~1~/N~1'~)methylidene]amino}-1-oxo-3-(pyridin-4-yl)propan-2-yl]carbamate}bis[3/5-difluoro-2-(pyridin-2-yl-kappaN)phenyl-kappaC~1~]iridium(1+),CC(C)(C)OC(=O)NC(Cc1ccncc1)C(=O)N=CC2=C[N]3=C(C=C2)C4=[N]([Ir+]356(c7cc(cc(c7C8=[N]5C=CC=C8)F)F)c9cc(cc(c9C1=CC=CC=[N]61)F)F)C=CC=C4,3
8EWN,2,,,,,,8EWN,Dynamic Ir(III) Photosensors for the Major Human Drug-Metabolizing Enzyme Cytochrome P450 3A4.,Crystal structure of CYP3A4 bound to an inhibitor,OXIDOREDUCTASE/INHIBITOR,CYP3A4/ CYP3A3,1.14.14.1/ 1.14.14.56/ 1.14.14.73/ 1.14.14.55,GO:0005737/ GO:0005789/ GO:0043231/ GO:0102320/ GO:0062181/ GO:0062188/ GO:0062189/ GO:0062187/ GO:0070330/ GO:0034875/ GO:0019899/ GO:0101020/ GO:0101021/ GO:0020037/ GO:0005506/ GO:0004497/ GO:0016491/ GO:0019825/ GO:0050591/ GO:0008401/ GO:0005496/ GO:0008395/ GO:0050649/ GO:0070576/ GO:0030343/ GO:0046222/ GO:0009822/ GO:0008209/ GO:0008203/ GO:0008210/ GO:0046483/ GO:0002933/ GO:0006629/ GO:0042759/ GO:0016098/ GO:0070989/ GO:0042573/ GO:0042572/ GO:0006706/ GO:0008202/ GO:0042369/ GO:0042359/ GO:0042178/ GO:0006805/ IPR001128/ IPR017972/ IPR008072/ IPR002402/ IPR036396/ P08684,1,8EWN,wildtype,P08684,UniProt,C41 H30 F4 Ir N6 O,890.927,X1O,{N-[([2/2'-bipyridin]-5-yl-kappa~2~N~1~/N~1'~)methyl]-3-(pyridin-4-yl)propanamide}bis[3/5-difluoro-2-(pyridin-2-yl-kappaN)phenyl-kappaC~1~]iridium(1+),c1cnccc1CCC(=O)NCC2=CC=C3C4=CC=CC=[N]4[Ir+]56([N]3=C2)(c7cc(cc(c7C8=[N]5C=CC=C8)F)F)c9cc(cc(c9C1=CC=CC=[N]61)F)F,3
8EWP,2,,,,,,8EWP,Dynamic Ir(III) Photosensors for the Major Human Drug-Metabolizing Enzyme Cytochrome P450 3A4.,Crystal structure of CYP3A4 bound to an inhibitor,OXIDOREDUCTASE/INHIBITOR,CYP3A4/ CYP3A3,1.14.14.1/ 1.14.14.56/ 1.14.14.73/ 1.14.14.55,GO:0005737/ GO:0005789/ GO:0043231/ GO:0102320/ GO:0062181/ GO:0062188/ GO:0062189/ GO:0062187/ GO:0070330/ GO:0034875/ GO:0019899/ GO:0101020/ GO:0101021/ GO:0020037/ GO:0005506/ GO:0004497/ GO:0016491/ GO:0019825/ GO:0050591/ GO:0008401/ GO:0005496/ GO:0008395/ GO:0050649/ GO:0070576/ GO:0030343/ GO:0046222/ GO:0009822/ GO:0008209/ GO:0008203/ GO:0008210/ GO:0046483/ GO:0002933/ GO:0006629/ GO:0042759/ GO:0016098/ GO:0070989/ GO:0042573/ GO:0042572/ GO:0006706/ GO:0008202/ GO:0042369/ GO:0042359/ GO:0042178/ GO:0006805/ IPR001128/ IPR017972/ IPR008072/ IPR002402/ IPR036396/ P08684,1,8EWP,wildtype,P08684,UniProt,C53 H38 Ir N6 O S2,1031.255,X2Q,{N-[([2/2'-bipyridin]-5-yl-kappa~2~N~1~/N~1'~)methyl]-3-(pyridin-4-yl)propanamide}bis[2-(quinolin-2-yl-kappaN)-1-benzothiophen-3-yl-kappaC~3~]iridium(1+),c1ccc2c(c1)C=CC3=[N]2[Ir+]45(c6c3sc7c6cccc7)(c8c9ccccc9sc8C1=CC=C2C=CC=CC2=[N]41)[N]1=C(C=CC=C1)C1=[N]5C=C(C=C1)CNC(=O)CCc1ccncc1,3
8EWQ,2,,,,,,8EWQ,Dynamic Ir(III) Photosensors for the Major Human Drug-Metabolizing Enzyme Cytochrome P450 3A4.,Crystal structure of CYP3A4 bound to an inhibitor,OXIDOREDUCTASE/INHIBITOR,CYP3A4/ CYP3A3,1.14.14.1/ 1.14.14.56/ 1.14.14.73/ 1.14.14.55,GO:0005737/ GO:0005789/ GO:0043231/ GO:0102320/ GO:0062181/ GO:0062188/ GO:0062189/ GO:0062187/ GO:0070330/ GO:0034875/ GO:0019899/ GO:0101020/ GO:0101021/ GO:0020037/ GO:0005506/ GO:0004497/ GO:0016491/ GO:0019825/ GO:0050591/ GO:0008401/ GO:0005496/ GO:0008395/ GO:0050649/ GO:0070576/ GO:0030343/ GO:0046222/ GO:0009822/ GO:0008209/ GO:0008203/ GO:0008210/ GO:0046483/ GO:0002933/ GO:0006629/ GO:0042759/ GO:0016098/ GO:0070989/ GO:0042573/ GO:0042572/ GO:0006706/ GO:0008202/ GO:0042369/ GO:0042359/ GO:0042178/ GO:0006805/ IPR001128/ IPR017972/ IPR008072/ IPR002402/ IPR036396/ P08684,1,8EWQ,wildtype,P08684,UniProt,C56 H43 Ir N7 O2,1038.203,X2B,{N-[1-{[([2/2'-bipyridin]-5-yl-kappa~2~N~1~/N~1'~)methyl]amino}-1-oxo-3-(pyridin-4-yl)propan-2-yl]benzamide}bis[2-(quinolin-2-yl-kappaN)phenyl-kappaC~1~]iridium(1+),c1ccc(cc1)C(=O)NC(Cc2ccncc2)C(=O)NCC3=C[N]4=C(C=C3)C5=[N]([Ir+]467(c8ccccc8C9=[N]6c1ccccc1C=C9)c1ccccc1C1=CC=C2C=CC=CC2=[N]71)C=CC=C5,3
8EWR,2,,,,,,8EWR,Dynamic Ir(III) Photosensors for the Major Human Drug-Metabolizing Enzyme Cytochrome P450 3A4.,Crystal structure of CYP3A4 bound to an inhibitor,OXIDOREDUCTASE/INHIBITOR,CYP3A4/ CYP3A3,1.14.14.1/ 1.14.14.56/ 1.14.14.73/ 1.14.14.55,GO:0005737/ GO:0005789/ GO:0043231/ GO:0102320/ GO:0062181/ GO:0062188/ GO:0062189/ GO:0062187/ GO:0070330/ GO:0034875/ GO:0019899/ GO:0101020/ GO:0101021/ GO:0020037/ GO:0005506/ GO:0004497/ GO:0016491/ GO:0019825/ GO:0050591/ GO:0008401/ GO:0005496/ GO:0008395/ GO:0050649/ GO:0070576/ GO:0030343/ GO:0046222/ GO:0009822/ GO:0008209/ GO:0008203/ GO:0008210/ GO:0046483/ GO:0002933/ GO:0006629/ GO:0042759/ GO:0016098/ GO:0070989/ GO:0042573/ GO:0042572/ GO:0006706/ GO:0008202/ GO:0042369/ GO:0042359/ GO:0042178/ GO:0006805/ IPR001128/ IPR017972/ IPR008072/ IPR002402/ IPR036396/ P08684,1,8EWR,wildtype,P08684,UniProt,C54 H47 Ir N7 O3,1034.213,WZN,{tert-butyl [1-{[([2/2'-bipyridin]-5-yl-kappa~2~N~1~/N~1'~)methyl]amino}-1-oxo-3-(pyridin-4-yl)propan-2-yl]carbamate}bis[2-(quinolin-2-yl-kappaN)phenyl-kappaC~1~]iridium(1+),CC(C)(C)OC(=O)NC(Cc1ccncc1)C(=O)NCC2=C[N]3=C(C=C2)C4=CC=CC=[N]4[Ir+]356(c7ccccc7C8=[N]5c9ccccc9C=C8)c1ccccc1C1=CC=C2C=CC=CC2=[N]61,3
8EWS,2,,,,,,8EWS,Dynamic Ir(III) Photosensors for the Major Human Drug-Metabolizing Enzyme Cytochrome P450 3A4.,Crystal structure of CYP3A4 bound to an inhibitor,OXIDOREDUCTASE/INHIBITOR,CYP3A4/ CYP3A3,1.14.14.1/ 1.14.14.56/ 1.14.14.73/ 1.14.14.55,GO:0005737/ GO:0005789/ GO:0043231/ GO:0102320/ GO:0062181/ GO:0062188/ GO:0062189/ GO:0062187/ GO:0070330/ GO:0034875/ GO:0019899/ GO:0101020/ GO:0101021/ GO:0020037/ GO:0005506/ GO:0004497/ GO:0016491/ GO:0019825/ GO:0050591/ GO:0008401/ GO:0005496/ GO:0008395/ GO:0050649/ GO:0070576/ GO:0030343/ GO:0046222/ GO:0009822/ GO:0008209/ GO:0008203/ GO:0008210/ GO:0046483/ GO:0002933/ GO:0006629/ GO:0042759/ GO:0016098/ GO:0070989/ GO:0042573/ GO:0042572/ GO:0006706/ GO:0008202/ GO:0042369/ GO:0042359/ GO:0042178/ GO:0006805/ IPR001128/ IPR017972/ IPR008072/ IPR002402/ IPR036396/ P08684,1,8EWS,wildtype,P08684,UniProt,C53 H38 Ir N6 O S2,1031.255,X2Q,{N-[([2/2'-bipyridin]-5-yl-kappa~2~N~1~/N~1'~)methyl]-3-(pyridin-4-yl)propanamide}bis[2-(quinolin-2-yl-kappaN)-1-benzothiophen-3-yl-kappaC~3~]iridium(1+),c1ccc2c(c1)C=CC3=[N]2[Ir+]45(c6c3sc7c6cccc7)(c8c9ccccc9sc8C1=CC=C2C=CC=CC2=[N]41)[N]1=C(C=CC=C1)C1=[N]5C=C(C=C1)CNC(=O)CCc1ccncc1,3
8EXB,2,,,,,,8EXB,Dynamic Ir(III) Photosensors for the Major Human Drug-Metabolizing Enzyme Cytochrome P450 3A4.,Crystal structure of CYP3A4 bound to an inhibitor,OXIDOREDUCTASE/INHIBITOR,CYP3A4/ CYP3A3,1.14.14.1/ 1.14.14.56/ 1.14.14.73/ 1.14.14.55,GO:0005737/ GO:0005789/ GO:0043231/ GO:0102320/ GO:0062181/ GO:0062188/ GO:0062189/ GO:0062187/ GO:0070330/ GO:0034875/ GO:0019899/ GO:0101020/ GO:0101021/ GO:0020037/ GO:0005506/ GO:0004497/ GO:0016491/ GO:0019825/ GO:0050591/ GO:0008401/ GO:0005496/ GO:0008395/ GO:0050649/ GO:0070576/ GO:0030343/ GO:0046222/ GO:0009822/ GO:0008209/ GO:0008203/ GO:0008210/ GO:0046483/ GO:0002933/ GO:0006629/ GO:0042759/ GO:0016098/ GO:0070989/ GO:0042573/ GO:0042572/ GO:0006706/ GO:0008202/ GO:0042369/ GO:0042359/ GO:0042178/ GO:0006805/ IPR001128/ IPR017972/ IPR008072/ IPR002402/ IPR036396/ P08684,1,8EXB,wildtype,P08684,UniProt,C53 H38 Ir N6 O S2,1031.255,X4E,{N-[([2/2'-bipyridin]-5-yl-kappa~2~N~1~/N~1'~)methyl]-3-(pyridin-3-yl)propanamide}bis[2-(quinolin-2-yl-kappaN)-1-benzothiophen-3-yl-kappaC~3~]iridium(1+),c1ccc2c(c1)c3c(s2)C4=CC=C5C=CC=CC5=[N]4[Ir+]367(c8c9ccccc9sc8C1=CC=C2C=CC=CC2=[N]61)[N]1=CC=CC=C1C1=CC=C(C=[N]71)CNC(=O)CCc1cccnc1,3
8EYO,2,,,,,,8EYO,Integrative structural and functional analysis of human malic enzyme 3: A potential therapeutic target for pancreatic cancer.,Crystal Structure of Human Mitochondrial NADP+ Malic Enzyme 3 with NADP bound,OXIDOREDUCTASE,ME3,1.1.1.40,GO:0005759/ GO:0005739/ GO:0004471/ GO:0004473/ GO:0004470/ GO:0046872/ GO:0051287/ GO:0070401/ GO:0008948/ GO:0009060/ GO:0006108/ GO:0072592/ GO:0006090/ IPR046346/ IPR015884/ IPR012301/ IPR037062/ IPR012302/ IPR001891/ IPR036291/ Q16798,1,8EYO,wildtype,Q16798,UniProt,C21 H28 N7 O17 P3,743.405,NAP,NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE,c1cc(c[n+](c1)C2C(C(C(O2)COP(=O)([O-])OP(=O)(O)OCC3C(C(C(O3)n4cnc5c4ncnc5N)OP(=O)(O)O)O)O)O)C(=O)N,2
8F4V,2,,,,,,8F4V,Structural Elucidation of Ivermectin Binding to alpha 7nAChR and the Induced Channel Desensitization.,Alpha7 nicotinic acetylcholine receptor intracellular and transmembrane domains bound to ivermectin in a desensitized state,MEMBRANE PROTEIN,CHRNA7/ NACHRA7,,GO:0005892/ GO:0070161/ GO:0043005/ GO:0005886/ GO:0044853/ GO:0098794/ GO:0045211/ GO:0045202/ GO:0042166/ GO:0015464/ GO:0022848/ GO:0001540/ GO:0005262/ GO:0017081/ GO:0005231/ GO:0005216/ GO:0030594/ GO:0042803/ GO:0015643/ GO:1904315/ GO:0095500/ GO:0006816/ GO:0006874/ GO:0007268/ GO:0050890/ GO:0140059/ GO:0097061/ GO:0034220/ GO:0006811/ GO:0007611/ GO:0051899/ GO:0007613/ GO:0098815/ GO:1902430/ GO:0032720/ GO:0050877/ GO:1902004/ GO:0045766/ GO:0008284/ GO:1905920/ GO:0070374/ GO:2000463/ GO:1900273/ GO:0043410/ GO:0051247/ GO:0001934/ GO:1905906/ GO:1902991/ GO:0042391/ GO:1901214/ GO:0080164/ GO:1905144/ GO:1904645/ GO:0001666/ GO:0035094/ GO:0050893/ GO:0007614/ GO:0007165/ GO:0050808/ GO:0007271/ IPR006202/ IPR036734/ IPR006201/ IPR036719/ IPR038050/ IPR006029/ IPR018000/ IPR002394/ P36544/ Transmembrane.Alpha-helical polytopic.Pentameric ligand-gated ion channels.Ligand-gated ion channel of neurotransmitter receptors/ Generic PDBTM,1,8F4V,mutant,P36544,UniProt,C48 H74 O14,875.093,IVM,(2aE/4E/5'S/6S/6'R/7S/8E/11R/13R/15S/17aR/20R/20aR/20bS)-6'-[(2S)-butan-2-yl]-20/20b-dihydroxy-5'/6/8/19-tetramethyl-17-oxo-3'/4'/5'/6/6'/10/11/14/15/17/17a/20/20a/20b-tetradecahydro-2H/7H-spiro[11/15-methanofuro[4/3/2-pq][2/6]benzodioxacyclooctadecine-13/2'-pyran]-7-yl 2/6-dideoxy-4-O-(2/6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,2
8FBL,2,,,,,,8FBL,Inhibition of the proton-activated chloride channel PAC by PIP 2.,Human PAC in nanodisc at pH 4.0 with PI(4/5)P2 diC8,MEMBRANE PROTEIN,PACC1/ C1orf75/ TMEM206,,GO:0009986/ GO:0034707/ GO:0061797/ GO:0006821/ IPR029366/ Q9H813/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Channels: Other Ion Channels.proton-activated chloride (PAC/ASOR) channel/ pH 4.0 with diC<sub>8</sub>-PI(4/5)P<sub>2</sub> using full map/ Transmembrane.Alpha-helical polytopic.Proton-activated chloride channel.Proton-activated chloride channel,1,8FBL,wildtype,Q9H813,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,2
8FBL,2,,,,,,8FBL,Inhibition of the proton-activated chloride channel PAC by PIP 2.,Human PAC in nanodisc at pH 4.0 with PI(4/5)P2 diC8,MEMBRANE PROTEIN,PACC1/ C1orf75/ TMEM206,,GO:0009986/ GO:0034707/ GO:0061797/ GO:0006821/ IPR029366/ Q9H813/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Channels: Other Ion Channels.proton-activated chloride (PAC/ASOR) channel/ pH 4.0 with diC<sub>8</sub>-PI(4/5)P<sub>2</sub> using full map/ Transmembrane.Alpha-helical polytopic.Proton-activated chloride channel.Proton-activated chloride channel,1,8FBL,wildtype,Q9H813,UniProt,C25 H49 O19 P3,746.566,PIO,[(2R)-2-octanoyloxy-3-[oxidanyl-[(1R/2R/3S/4R/5R/6S)-2/3/6-tris(oxidanyl)-4/5-diphosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-propyl] octanoate,CCCCCCCC(=O)OCC(COP(=O)(O)OC1C(C(C(C(C1O)OP(=O)(O)O)OP(=O)(O)O)O)O)OC(=O)CCCCCCC,3
8FHN,2,,,,,,8FHN,Structure and thiazide inhibition mechanism of the human Na-Cl cotransporter.,Cryo-EM structure of human NCC (class 2),MEMBRANE PROTEIN,slc12a2/ nkcc1,,GO:0016324/ GO:0016323/ GO:0008519/ GO:0015377/ GO:0042802/ GO:0015379/ GO:0008511/ GO:0006884/ GO:0055064/ GO:1902476/ GO:0043583/ GO:0042472/ GO:0055075/ GO:1990573/ GO:0055078/ GO:0035725/ GO:0048798/ IPR004841/ IPR013612/ IPR002444/ IPR018491/ IPR002443/ IPR004842/ GO:0005829/ GO:0070062/ GO:0016020/ GO:0005886/ GO:0015081/ GO:0015378/ GO:0071241/ GO:0006811/ GO:0006468/ GO:1904044/ GO:0002021/ GO:0007165/ GO:0006814/ IPR002948/ P55017/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Amino Acid/Polyamine/Organocation (APC) Superfamily.NCC cation-chloride cotransporter (CCC)/ Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Cation-chloride cotransporter/ Generic PDBTM,1,8FHN,mutant,A0A0G2KTI4,UniProt,C11 H13 Cl F3 N3 O4 S3,439.882,XZF,Polythiazide,CN1C(Nc2cc(c(cc2S1(=O)=O)S(=O)(=O)N)Cl)CSCC(F)(F)F,3
8FHN,2,,,,,,8FHN,Structure and thiazide inhibition mechanism of the human Na-Cl cotransporter.,Cryo-EM structure of human NCC (class 2),MEMBRANE PROTEIN,SLC12A3/ NCC/ TSC,,GO:0016324/ GO:0016323/ GO:0008519/ GO:0015377/ GO:0042802/ GO:0015379/ GO:0008511/ GO:0006884/ GO:0055064/ GO:1902476/ GO:0043583/ GO:0042472/ GO:0055075/ GO:1990573/ GO:0055078/ GO:0035725/ GO:0048798/ IPR004841/ IPR013612/ IPR002444/ IPR018491/ IPR002443/ IPR004842/ GO:0005829/ GO:0070062/ GO:0016020/ GO:0005886/ GO:0015081/ GO:0015378/ GO:0071241/ GO:0006811/ GO:0006468/ GO:1904044/ GO:0002021/ GO:0007165/ GO:0006814/ IPR002948/ P55017/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Amino Acid/Polyamine/Organocation (APC) Superfamily.NCC cation-chloride cotransporter (CCC)/ Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Cation-chloride cotransporter/ Generic PDBTM,1,8FHN,mutant,P55017,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,2
8FHO,2,,,,,,8FHO,Structure and thiazide inhibition mechanism of the human Na-Cl cotransporter.,Cryo-EM structure of human NCC (class 1),MEMBRANE PROTEIN,slc12a2/ nkcc1,,GO:0016324/ GO:0016323/ GO:0008519/ GO:0015377/ GO:0042802/ GO:0015379/ GO:0008511/ GO:0006884/ GO:0055064/ GO:1902476/ GO:0043583/ GO:0042472/ GO:0055075/ GO:1990573/ GO:0055078/ GO:0035725/ GO:0048798/ IPR004841/ IPR013612/ IPR002444/ IPR018491/ IPR002443/ IPR004842/ GO:0005829/ GO:0070062/ GO:0016020/ GO:0005886/ GO:0015081/ GO:0015378/ GO:0071241/ GO:0006811/ GO:0006468/ GO:1904044/ GO:0002021/ GO:0007165/ GO:0006814/ IPR002948/ P55017/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Amino Acid/Polyamine/Organocation (APC) Superfamily.NCC cation-chloride cotransporter (CCC)/ Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Cation-chloride cotransporter/ Generic PDBTM,1,8FHO,mutant,A0A0G2KTI4,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,2
8FHO,2,,,,,,8FHO,Structure and thiazide inhibition mechanism of the human Na-Cl cotransporter.,Cryo-EM structure of human NCC (class 1),MEMBRANE PROTEIN,SLC12A3/ NCC/ TSC,,GO:0016324/ GO:0016323/ GO:0008519/ GO:0015377/ GO:0042802/ GO:0015379/ GO:0008511/ GO:0006884/ GO:0055064/ GO:1902476/ GO:0043583/ GO:0042472/ GO:0055075/ GO:1990573/ GO:0055078/ GO:0035725/ GO:0048798/ IPR004841/ IPR013612/ IPR002444/ IPR018491/ IPR002443/ IPR004842/ GO:0005829/ GO:0070062/ GO:0016020/ GO:0005886/ GO:0015081/ GO:0015378/ GO:0071241/ GO:0006811/ GO:0006468/ GO:1904044/ GO:0002021/ GO:0007165/ GO:0006814/ IPR002948/ P55017/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Amino Acid/Polyamine/Organocation (APC) Superfamily.NCC cation-chloride cotransporter (CCC)/ Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Cation-chloride cotransporter/ Generic PDBTM,1,8FHO,mutant,P55017,UniProt,C11 H13 Cl F3 N3 O4 S3,439.882,XZF,Polythiazide,CN1C(Nc2cc(c(cc2S1(=O)=O)S(=O)(=O)N)Cl)CSCC(F)(F)F,3
8FHP,2,,,,,,8FHP,Structure and thiazide inhibition mechanism of the human Na-Cl cotransporter.,Cryo-EM structure of human NCC (class 3-1),MEMBRANE PROTEIN,slc12a2/ nkcc1,,GO:0016324/ GO:0016323/ GO:0008519/ GO:0015377/ GO:0042802/ GO:0015379/ GO:0008511/ GO:0006884/ GO:0055064/ GO:1902476/ GO:0043583/ GO:0042472/ GO:0055075/ GO:1990573/ GO:0055078/ GO:0035725/ GO:0048798/ IPR004841/ IPR013612/ IPR002444/ IPR018491/ IPR002443/ IPR004842/ GO:0005829/ GO:0070062/ GO:0016020/ GO:0005886/ GO:0015081/ GO:0015378/ GO:0071241/ GO:0006811/ GO:0006468/ GO:1904044/ GO:0002021/ GO:0007165/ GO:0006814/ IPR002948/ P55017/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Amino Acid/Polyamine/Organocation (APC) Superfamily.NCC cation-chloride cotransporter (CCC)/ Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Cation-chloride cotransporter/ Generic PDBTM,1,8FHP,mutant,A0A0G2KTI4,UniProt,C11 H13 Cl F3 N3 O4 S3,439.882,XZF,Polythiazide,CN1C(Nc2cc(c(cc2S1(=O)=O)S(=O)(=O)N)Cl)CSCC(F)(F)F,2
8FHQ,2,,,,,,8FHQ,Structure and thiazide inhibition mechanism of the human Na-Cl cotransporter.,Cryo-EM structure of human NCC (class 3-2),MEMBRANE PROTEIN,slc12a2/ nkcc1,,GO:0016324/ GO:0016323/ GO:0008519/ GO:0015377/ GO:0042802/ GO:0015379/ GO:0008511/ GO:0006884/ GO:0055064/ GO:1902476/ GO:0043583/ GO:0042472/ GO:0055075/ GO:1990573/ GO:0055078/ GO:0035725/ GO:0048798/ IPR004841/ IPR013612/ IPR002444/ IPR018491/ IPR002443/ IPR004842/ GO:0005829/ GO:0070062/ GO:0016020/ GO:0005886/ GO:0015081/ GO:0015378/ GO:0071241/ GO:0006811/ GO:0006468/ GO:1904044/ GO:0002021/ GO:0007165/ GO:0006814/ IPR002948/ P55017/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Amino Acid/Polyamine/Organocation (APC) Superfamily.NCC cation-chloride cotransporter (CCC)/ Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Cation-chloride cotransporter/ Generic PDBTM,1,8FHQ,mutant,A0A0G2KTI4,UniProt,C11 H13 Cl F3 N3 O4 S3,439.882,XZF,Polythiazide,CN1C(Nc2cc(c(cc2S1(=O)=O)S(=O)(=O)N)Cl)CSCC(F)(F)F,2
8FHR,2,,,,,,8FHR,Structure and thiazide inhibition mechanism of the human Na-Cl cotransporter.,Cryo-EM structure of human NCC (class 3-3),MEMBRANE PROTEIN,slc12a2/ nkcc1,,GO:0016324/ GO:0016323/ GO:0008519/ GO:0015377/ GO:0042802/ GO:0015379/ GO:0008511/ GO:0006884/ GO:0055064/ GO:1902476/ GO:0043583/ GO:0042472/ GO:0055075/ GO:1990573/ GO:0055078/ GO:0035725/ GO:0048798/ IPR004841/ IPR013612/ IPR002444/ IPR018491/ IPR002443/ IPR004842/ GO:0005829/ GO:0070062/ GO:0016020/ GO:0005886/ GO:0015081/ GO:0015378/ GO:0071241/ GO:0006811/ GO:0006468/ GO:1904044/ GO:0002021/ GO:0007165/ GO:0006814/ IPR002948/ P55017/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Amino Acid/Polyamine/Organocation (APC) Superfamily.NCC cation-chloride cotransporter (CCC)/ Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Cation-chloride cotransporter/ Generic PDBTM,1,8FHR,mutant,A0A0G2KTI4,UniProt,C11 H13 Cl F3 N3 O4 S3,439.882,XZF,Polythiazide,CN1C(Nc2cc(c(cc2S1(=O)=O)S(=O)(=O)N)Cl)CSCC(F)(F)F,2
8HHY,2,,,,,,8HHY,Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2.,SARS-CoV-2 Delta Spike in complex with IS-9A,VIRAL PROTEIN/IMMUNE SYSTEM,,,,1,8HHY,mutant,,,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
7TXT,3,,,,,,7TXT,Structure of human serotonin transporter bound to small molecule '8090 in lipid nanodisc and NaCl,Structure of human serotonin transporter bound to small molecule '8090 in lipid nanodisc and NaCl,TRANSPORT PROTEIN,,,,1,7TXT,wildtype,,,C13 H14 F N3 S,263.334,KWC,1-[4-(4-fluorophenyl)-1/3-thiazol-2-yl]piperazine,c1cc(ccc1c2csc(n2)N3CCNCC3)F,4
7U0Q,3,,,,,,7U0Q,SARS-Cov2 S protein structure in complex with neutralizing monoclonal antibody 002-02,SARS-Cov2 S protein structure in complex with neutralizing monoclonal antibody 002-02,VIRAL PROTEIN/IMMUNE SYSTEM,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,7U0Q,wildtype,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
7U0X,3,,,,,,7U0X,SARS-Cov2 S protein structure in complex with neutralizing monoclonal antibody 002-13,SARS-Cov2 S protein structure in complex with neutralizing monoclonal antibody 002-13,VIRAL PROTEIN/IMMUNE SYSTEM,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,7U0X,wildtype,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
7U8F,3,,,,,,7U8F,Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy.,Ternary complex structure of Cereblon-DDB1 bound to IKZF2(ZF2) and the molecular glue DKY709,LIGASE,DDB1/ XAP1,,GO:0000781/ GO:0080008/ GO:0031464/ GO:0031465/ GO:0005737/ GO:0070062/ GO:0005615/ GO:0005654/ GO:0005634/ GO:0032991/ GO:0035861/ GO:0097602/ GO:0003684/ GO:0003677/ GO:0044877/ GO:0030674/ GO:0071987/ GO:0006915/ GO:0051702/ GO:0006974/ GO:0034644/ GO:0006281/ GO:0035234/ GO:0035518/ GO:0043066/ GO:0051093/ GO:2000242/ GO:0006289/ GO:0046726/ GO:0045722/ GO:0045732/ GO:0045070/ GO:0010498/ GO:0043161/ GO:0016567/ GO:0042752/ GO:1901990/ GO:0048511/ GO:0006511/ GO:0070914/ GO:0019076/ GO:0016055/ IPR004871/ IPR018846/ IPR031297/ IPR015943/ IPR036322/ Q16531,2,7U8F,wildtype,Q16531,UniProt,C25 H27 N3 O3,417.5,LWK,(3S)-3-[5-(1-benzylpiperidin-4-yl)-1-oxo-1/3-dihydro-2H-isoindol-2-yl]piperidine-2/6-dione,c1ccc(cc1)CN2CCC(CC2)c3ccc4c(c3)CN(C4=O)C5CCC(=O)NC5=O,5
7X0Z,3,,,,,,7X0Z,Structural insights into substrate recognition and translocation of human peroxisomal ABC transporter ALDP.,Cryo-EM structure of human ABCD1 E630Q in the presence of ATP and Magnesium in outward-facing state,STRUCTURAL PROTEIN,ABCD1/ ALD,3.1.2/ 7.6.2,GO:0005737/ GO:0005829/ GO:0005789/ GO:0005765/ GO:0016020/ GO:0031966/ GO:0048471/ GO:0005778/ GO:0005777/ GO:0015607/ GO:0047617/ GO:0043531/ GO:0005524/ GO:0016887/ GO:0042626/ GO:0019899/ GO:0042802/ GO:0005324/ GO:0046982/ GO:0042803/ GO:0036109/ GO:0006635/ GO:0030497/ GO:0055089/ GO:0043651/ GO:0042758/ GO:0015910/ GO:0043217/ GO:1900016/ GO:1903427/ GO:1990535/ GO:0015919/ GO:0007031/ GO:0032000/ GO:2001280/ GO:1900407/ GO:0031998/ GO:0051900/ GO:0002082/ GO:0055092/ GO:0042760/ GO:0000038/ GO:0036113/ IPR003593/ IPR011527/ IPR036640/ IPR003439/ IPR017871/ IPR031237/ IPR005283/ IPR027417/ P33897/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.ATP Binding Cassette (ABC) Transporters.peroxisomal fatty acid transporter ABCD1/ also known as adrenoleukodystrophy protein (ALDP)/ C26:0 bound/ Transmembrane.Alpha-helical polytopic.ABC transporters.ABC transporter D familiy (ABCD)/ Generic PDBTM,1,7X0Z,mutant,P33897,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,3
7X1W,3,,,,,,7X1W,Structural insights into substrate recognition and translocation of human peroxisomal ABC transporter ALDP.,Cryo-EM structure of human ABCD1 E630Q in the presence of ATP in inward-facing state,STRUCTURAL PROTEIN,ABCD1/ ALD,3.1.2/ 7.6.2,GO:0005737/ GO:0005829/ GO:0005789/ GO:0005765/ GO:0016020/ GO:0031966/ GO:0048471/ GO:0005778/ GO:0005777/ GO:0015607/ GO:0047617/ GO:0043531/ GO:0005524/ GO:0016887/ GO:0042626/ GO:0019899/ GO:0042802/ GO:0005324/ GO:0046982/ GO:0042803/ GO:0036109/ GO:0006635/ GO:0030497/ GO:0055089/ GO:0043651/ GO:0042758/ GO:0015910/ GO:0043217/ GO:1900016/ GO:1903427/ GO:1990535/ GO:0015919/ GO:0007031/ GO:0032000/ GO:2001280/ GO:1900407/ GO:0031998/ GO:0051900/ GO:0002082/ GO:0055092/ GO:0042760/ GO:0000038/ GO:0036113/ IPR003593/ IPR011527/ IPR036640/ IPR003439/ IPR017871/ IPR031237/ IPR005283/ IPR027417/ P33897/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.ATP Binding Cassette (ABC) Transporters.peroxisomal fatty acid transporter ABCD1/ also known as adrenoleukodystrophy protein (ALDP)/ C26:0 bound/ Transmembrane.Alpha-helical polytopic.ABC transporters.ABC transporter D familiy (ABCD)/ Generic PDBTM,1,7X1W,mutant,P33897,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,2
7X2H,3,,,,,,7X2H,Crystal structure of SARS-CoV-2 spike receptor-binding domain bound with 6-2C Fab,Crystal structure of SARS-CoV-2 spike receptor-binding domain bound with 6-2C Fab,VIRAL PROTEIN/IMMUNE SYSTEM,,,,1,7X2H,wildtype,,,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7X3N,3,,,,,,7X3N,Structural determination of an antibody that specifically recognizes polyethylene glycol with a terminal methoxy group,Crystal structure of anti-mPEG h15-2b Fab,IMMUNE SYSTEM,,,,1,7X3N,wildtype,,,C13 H28 O7,296.357,P15,2/5/8/11/14/17-HEXAOXANONADECAN-19-OL,COCCOCCOCCOCCOCCOCCO,3
7X93,3,,,,,,7X93,Intentional generation of sars-cov-2 therapeutic antibodies with broad spectrum,The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab765,VIRAL PROTEIN,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,7X93,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
7XDB,3,,,,,,7XDB,Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5.,Cryo-EM structure of SARS-CoV-2 Omicron Spike protein in complex with BA7208 fab,VIRAL PROTEIN,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,2,7XDB,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
7XDE,3,,,,,,7XDE,Suppression of the human malic enzyme 2 modifies energy metabolism and inhibits cellular respiration,Cryo-EM structures of human mitochondrial NAD(P)+-dependent malic enzyme in apo form,HYDROLASE,ME2,1.1.1.38,GO:0043231/ GO:0005759/ GO:0005739/ GO:0009055/ GO:0004471/ GO:0004473/ GO:0004470/ GO:0046872/ GO:0051287/ GO:0008948/ GO:0006108/ GO:0006090/ GO:1902031/ IPR046346/ IPR015884/ IPR012301/ IPR037062/ IPR012302/ IPR001891/ IPR036291/ P23368,1,7XDE,wildtype,P23368,UniProt,C21 H27 N7 O14 P2,663.425,NAD,NICOTINAMIDE-ADENINE-DINUCLEOTIDE,c1cc(c[n+](c1)C2C(C(C(O2)COP(=O)([O-])OP(=O)(O)OCC3C(C(C(O3)n4cnc5c4ncnc5N)O)O)O)O)C(=O)N,2
7XDF,3,,,,,,7XDF,Suppression of the human malic enzyme 2 modifies energy metabolism and inhibits cellular respiration,Cryo-EM structures of human mitochondrial NAD(P)+-dependent malic enzyme in a ternary complex with NAD+ and allosteric inhibitor EA,HYDROLASE,ME2,1.1.1.38,GO:0043231/ GO:0005759/ GO:0005739/ GO:0009055/ GO:0004471/ GO:0004473/ GO:0004470/ GO:0046872/ GO:0051287/ GO:0008948/ GO:0006108/ GO:0006090/ GO:1902031/ IPR046346/ IPR015884/ IPR012301/ IPR037062/ IPR012302/ IPR001891/ IPR036291/ P23368,1,7XDF,wildtype,P23368,UniProt,C21 H27 N7 O14 P2,663.425,NAD,NICOTINAMIDE-ADENINE-DINUCLEOTIDE,c1cc(c[n+](c1)C2C(C(C(O2)COP(=O)([O-])OP(=O)(O)OCC3C(C(C(O3)n4cnc5c4ncnc5N)O)O)O)O)C(=O)N,2
7XDF,3,,,,,,7XDF,Suppression of the human malic enzyme 2 modifies energy metabolism and inhibits cellular respiration,Cryo-EM structures of human mitochondrial NAD(P)+-dependent malic enzyme in a ternary complex with NAD+ and allosteric inhibitor EA,HYDROLASE,ME2,1.1.1.38,GO:0043231/ GO:0005759/ GO:0005739/ GO:0009055/ GO:0004471/ GO:0004473/ GO:0004470/ GO:0046872/ GO:0051287/ GO:0008948/ GO:0006108/ GO:0006090/ GO:1902031/ IPR046346/ IPR015884/ IPR012301/ IPR037062/ IPR012302/ IPR001891/ IPR036291/ P23368,1,7XDF,wildtype,P23368,UniProt,C23 H16 O6,388.37,JBR,4-[(3-carboxy-2-oxidanyl-naphthalen-1-yl)methyl]-3-oxidanyl-naphthalene-2-carboxylic acid,c1ccc2c(c1)cc(c(c2Cc3c4ccccc4cc(c3O)C(=O)O)O)C(=O)O,3
7XDG,3,,,,,,7XDG,Suppression of the human malic enzyme 2 modifies energy metabolism and inhibits cellular respiration,Cryo-EM structures of human mitochondrial NAD(P)+-dependent malic enzyme in a ternary complex with NAD+ and allosteric inhibitor MDSA,HYDROLASE,ME2,1.1.1.38,GO:0043231/ GO:0005759/ GO:0005739/ GO:0009055/ GO:0004471/ GO:0004473/ GO:0004470/ GO:0046872/ GO:0051287/ GO:0008948/ GO:0006108/ GO:0006090/ GO:1902031/ IPR046346/ IPR015884/ IPR012301/ IPR037062/ IPR012302/ IPR001891/ IPR036291/ P23368,1,7XDG,wildtype,P23368,UniProt,C21 H27 N7 O14 P2,663.425,NAD,NICOTINAMIDE-ADENINE-DINUCLEOTIDE,c1cc(c[n+](c1)C2C(C(C(O2)COP(=O)([O-])OP(=O)(O)OCC3C(C(C(O3)n4cnc5c4ncnc5N)O)O)O)O)C(=O)N,2
7XDG,3,,,,,,7XDG,Suppression of the human malic enzyme 2 modifies energy metabolism and inhibits cellular respiration,Cryo-EM structures of human mitochondrial NAD(P)+-dependent malic enzyme in a ternary complex with NAD+ and allosteric inhibitor MDSA,HYDROLASE,ME2,1.1.1.38,GO:0043231/ GO:0005759/ GO:0005739/ GO:0009055/ GO:0004471/ GO:0004473/ GO:0004470/ GO:0046872/ GO:0051287/ GO:0008948/ GO:0006108/ GO:0006090/ GO:1902031/ IPR046346/ IPR015884/ IPR012301/ IPR037062/ IPR012302/ IPR001891/ IPR036291/ P23368,1,7XDG,wildtype,P23368,UniProt,C15 H12 O6,288.252,D5S,5-[(3-carboxy-4-oxidanyl-phenyl)methyl]-2-oxidanyl-benzoic acid,c1cc(c(cc1Cc2ccc(c(c2)C(=O)O)O)C(=O)O)O,3
7XDK,3,,,,,,7XDK,Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5.,Cryo-EM structure of SARS-CoV-2 Delta Spike protein in complex with BA7054 and BA7125 fab,VIRAL PROTEIN,,,,2,7XDK,wildtype,,,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,7
7XDL,3,,,,,,7XDL,Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5.,Cryo-EM structure of SARS-CoV-2 Delta Spike protein in complex with BA7208 and BA7125 fab,VIRAL PROTEIN,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,7XDL,wildtype,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,7
7XEC,3,,,,,,7XEC,Structural insights into substrate recognition and translocation of human peroxisomal ABC transporter ALDP.,Cryo-EM structure of human ABCD1 E630Q in the presence of ATP in inward-facing state 2,STRUCTURAL PROTEIN,ABCD1/ ALD,3.1.2/ 7.6.2,GO:0005737/ GO:0005829/ GO:0005789/ GO:0005765/ GO:0016020/ GO:0031966/ GO:0048471/ GO:0005778/ GO:0005777/ GO:0015607/ GO:0047617/ GO:0043531/ GO:0005524/ GO:0016887/ GO:0042626/ GO:0019899/ GO:0042802/ GO:0005324/ GO:0046982/ GO:0042803/ GO:0036109/ GO:0006635/ GO:0030497/ GO:0055089/ GO:0043651/ GO:0042758/ GO:0015910/ GO:0043217/ GO:1900016/ GO:1903427/ GO:1990535/ GO:0015919/ GO:0007031/ GO:0032000/ GO:2001280/ GO:1900407/ GO:0031998/ GO:0051900/ GO:0002082/ GO:0055092/ GO:0042760/ GO:0000038/ GO:0036113/ IPR003593/ IPR011527/ IPR036640/ IPR003439/ IPR017871/ IPR031237/ IPR005283/ IPR027417/ P33897/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.ATP Binding Cassette (ABC) Transporters.peroxisomal fatty acid transporter ABCD1/ also known as adrenoleukodystrophy protein (ALDP)/ C26:0 bound/ Transmembrane.Alpha-helical polytopic.ABC transporters.ABC transporter D familiy (ABCD)/ Generic PDBTM,1,7XEC,mutant,P33897,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,2
7XKI,3,,,,,,7XKI,Cryo-EM structures of human Cx36/GJD2 neuronal gap junction channel.,Human Cx36/GJD2 (N-terminal deletion BRIL-fused mutant) gap junction channel in soybean lipids (D6 symmetry),MEMBRANE PROTEIN,GJD2/ GJA9,,GO:0042597/ GO:0009055/ GO:0020037/ GO:0005506/ IPR009155/ IPR010980/ GO:0005922/ GO:0005886/ GO:0045202/ GO:0005243/ GO:0007267/ GO:0007268/ GO:0019228/ GO:0007601/ IPR000500/ IPR002260/ IPR019570/ IPR017990/ IPR013092/ IPR038359/ Q9UKL4/ Transmembrane.Alpha-helical polytopic.Tetraspan junctional complexes.Connexin/ Generic PDBTM,1,7XKI,mutant,Q9UKL4,UniProt,C36 H72 N O8 P,677.933,MC3,1/2-DIMYRISTOYL-RAC-GLYCERO-3-PHOSPHOCHOLINE,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC,2
7XKT,3,,,,,,7XKT,Cryo-EM structures of human Cx36/GJD2 neuronal gap junction channel.,Human Cx36/GJD2 (BRIL-fused mutant) gap junction channel in detergents at 2.2 Angstroms resolution,MEMBRANE PROTEIN,GJD2/ GJA9,,GO:0042597/ GO:0009055/ GO:0020037/ GO:0005506/ IPR009155/ IPR010980/ GO:0005922/ GO:0005886/ GO:0045202/ GO:0005243/ GO:0007267/ GO:0007268/ GO:0019228/ GO:0007601/ IPR000500/ IPR002260/ IPR019570/ IPR017990/ IPR013092/ IPR038359/ Q9UKL4/ Transmembrane.Alpha-helical polytopic.Tetraspan junctional complexes.Connexin/ Generic PDBTM,1,7XKT,mutant,Q9UKL4,UniProt,C36 H72 N O8 P,677.933,MC3,1/2-DIMYRISTOYL-RAC-GLYCERO-3-PHOSPHOCHOLINE,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC,2
7XKT,3,,,,,,7XKT,Cryo-EM structures of human Cx36/GJD2 neuronal gap junction channel.,Human Cx36/GJD2 (BRIL-fused mutant) gap junction channel in detergents at 2.2 Angstroms resolution,MEMBRANE PROTEIN,cybC,,GO:0042597/ GO:0009055/ GO:0020037/ GO:0005506/ IPR009155/ IPR010980/ GO:0005922/ GO:0005886/ GO:0045202/ GO:0005243/ GO:0007267/ GO:0007268/ GO:0019228/ GO:0007601/ IPR000500/ IPR002260/ IPR019570/ IPR017990/ IPR013092/ IPR038359/ Q9UKL4/ Transmembrane.Alpha-helical polytopic.Tetraspan junctional complexes.Connexin/ Generic PDBTM,1,7XKT,mutant,P0ABE7,UniProt,C31 H50 O4,486.726,Y01,CHOLESTEROL HEMISUCCINATE,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC(=O)CCC(=O)O)C)C,3
7XKT,3,,,,,,7XKT,Cryo-EM structures of human Cx36/GJD2 neuronal gap junction channel.,Human Cx36/GJD2 (BRIL-fused mutant) gap junction channel in detergents at 2.2 Angstroms resolution,MEMBRANE PROTEIN,GJD2/ GJA9,,GO:0042597/ GO:0009055/ GO:0020037/ GO:0005506/ IPR009155/ IPR010980/ GO:0005922/ GO:0005886/ GO:0045202/ GO:0005243/ GO:0007267/ GO:0007268/ GO:0019228/ GO:0007601/ IPR000500/ IPR002260/ IPR019570/ IPR017990/ IPR013092/ IPR038359/ Q9UKL4/ Transmembrane.Alpha-helical polytopic.Tetraspan junctional complexes.Connexin/ Generic PDBTM,1,7XKT,mutant,P0ABE7,,C38 H75 O10 P,722.97,LHG,1/2-DIPALMITOYL-PHOSPHATIDYL-GLYCEROLE,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCC(CO)O)OC(=O)CCCCCCCCCCCCCCC,4
7XNH,3,,,,,,7XNH,Cryo-EM structures of human Cx36/GJD2 neuronal gap junction channel.,Human Cx36/GJD2 gap junction channel with pore-lining N-terminal helices in soybean lipids,MEMBRANE PROTEIN,GJD2/ GJA9,,GO:0005922/ GO:0005886/ GO:0045202/ GO:0005243/ GO:0007267/ GO:0007268/ GO:0019228/ GO:0007601/ IPR000500/ IPR002260/ IPR019570/ IPR017990/ IPR013092/ IPR038359/ Q9UKL4/ Transmembrane.Alpha-helical polytopic.Tetraspan junctional complexes.Connexin/ Generic PDBTM,1,7XNH,wildtype,Q9UKL4,UniProt,C36 H72 N O8 P,677.933,MC3,1/2-DIMYRISTOYL-RAC-GLYCERO-3-PHOSPHOCHOLINE,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC,2
7XNV,3,,,,,,7XNV,Cryo-EM structures of human Cx36/GJD2 neuronal gap junction channel.,Structurally hetero-junctional human Cx36/GJD2 gap junction channel in soybean lipids (C6 symmetry),MEMBRANE PROTEIN,GJD2/ GJA9,,GO:0005922/ GO:0005886/ GO:0045202/ GO:0005243/ GO:0007267/ GO:0007268/ GO:0019228/ GO:0007601/ IPR000500/ IPR002260/ IPR019570/ IPR017990/ IPR013092/ IPR038359/ Q9UKL4/ Transmembrane.Alpha-helical polytopic.Tetraspan junctional complexes.Connexin/ Generic PDBTM,1,7XNV,wildtype,Q9UKL4,UniProt,C36 H72 N O8 P,677.933,MC3,1/2-DIMYRISTOYL-RAC-GLYCERO-3-PHOSPHOCHOLINE,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC,2
7Y09,3,,,,,,7Y09,Cryo-EM structure of human IgM-Fc in complex with the J chain and the DBL domain of DBLMSP,Cryo-EM structure of human IgM-Fc in complex with the J chain and the DBL domain of DBLMSP,IMMUNE SYSTEM,,,GO:0016020/ GO:0046789/ IPR042202/ IPR008602/ IPR010784,1,7Y09,wildtype,C5HX06,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
7Y4A,3,,,,,,7Y4A,Targeting Ras-binding domain of ELMO3 by computational nanobody design.,Crystal structure of human ELMO3 RBD-RhoG complex,SIGNALING PROTEIN,ELMO1/ KIAA0281,,GO:0005737/ GO:0005829/ GO:0032045/ GO:0016020/ GO:0005886/ GO:0017124/ GO:0030036/ GO:0007015/ GO:0030029/ GO:0006915/ GO:0016477/ GO:0048870/ GO:0006911/ GO:0016601/ GO:0050790/ IPR011989/ IPR016024/ IPR030715/ IPR024574/ IPR006816/ IPR011993/ IPR001849/ Q92556,2,7Y4A,wildtype,Q92556,UniProt,C10 H15 N5 O11 P2,443.201,GDP,GUANOSINE-5'-DIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,5
7YAG,3,,,,,,7YAG,Cryo-EM structures of human SPCA1a reveal the mechanism of Ca 2+ /Mn 2+ transport into the Golgi apparatus.,CryoEM structure of SPCA1a in E1-Ca-AMPPCP state subclass 1,TRANSPORT PROTEIN,ATP2C1/ KIAA1347/ PMR1L/ HUSSY-28,7.2.2.10,GO:0033106/ GO:0005783/ GO:0005794/ GO:0032580/ GO:0000139/ GO:0016020/ GO:0005886/ GO:0005802/ GO:0005524/ GO:0016887/ GO:0005509/ GO:0030145/ GO:0046872/ GO:0005388/ GO:0015662/ GO:0140613/ GO:0070588/ GO:0006816/ GO:0016339/ GO:0006874/ GO:0030026/ GO:0008544/ GO:0032468/ GO:0032472/ GO:0034220/ GO:0006828/ GO:0042998/ GO:0043123/ GO:0098629/ IPR006068/ IPR004014/ IPR023299/ IPR018303/ IPR023298/ IPR008250/ IPR036412/ IPR023214/ IPR006413/ IPR001757/ IPR044492/ P98194/ Transmembrane.Alpha-helical polytopic.P-type ATPase (P-ATPase).P-ATPase/ Generic PDBTM,1,7YAG,wildtype,P98194,UniProt,C11 H18 N5 O12 P3,505.208,ACP,PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(CP(=O)(O)O)O)O)O)N,3
7YAH,3,,,,,,7YAH,Cryo-EM structures of human SPCA1a reveal the mechanism of Ca 2+ /Mn 2+ transport into the Golgi apparatus.,CryoEM structure of SPCA1a in E1-Ca-AMPPCP state subclass 2,TRANSPORT PROTEIN,ATP2C1/ KIAA1347/ PMR1L/ HUSSY-28,7.2.2.10,GO:0033106/ GO:0005783/ GO:0005794/ GO:0032580/ GO:0000139/ GO:0016020/ GO:0005886/ GO:0005802/ GO:0005524/ GO:0016887/ GO:0005509/ GO:0030145/ GO:0046872/ GO:0005388/ GO:0015662/ GO:0140613/ GO:0070588/ GO:0006816/ GO:0016339/ GO:0006874/ GO:0030026/ GO:0008544/ GO:0032468/ GO:0032472/ GO:0034220/ GO:0006828/ GO:0042998/ GO:0043123/ GO:0098629/ IPR006068/ IPR004014/ IPR023299/ IPR018303/ IPR023298/ IPR008250/ IPR036412/ IPR023214/ IPR006413/ IPR001757/ IPR044492/ P98194/ Transmembrane.Alpha-helical polytopic.P-type ATPase (P-ATPase).P-ATPase/ Generic PDBTM,1,7YAH,wildtype,P98194,UniProt,C11 H18 N5 O12 P3,505.208,ACP,PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(CP(=O)(O)O)O)O)O)N,3
7YAI,3,,,,,,7YAI,Cryo-EM structures of human SPCA1a reveal the mechanism of Ca 2+ /Mn 2+ transport into the Golgi apparatus.,CryoEM structure of SPCA1a in E1-Ca-AMPPCP state subclass 3,TRANSPORT PROTEIN,ATP2C1/ KIAA1347/ PMR1L/ HUSSY-28,7.2.2.10,GO:0033106/ GO:0005783/ GO:0005794/ GO:0032580/ GO:0000139/ GO:0016020/ GO:0005886/ GO:0005802/ GO:0005524/ GO:0016887/ GO:0005509/ GO:0030145/ GO:0046872/ GO:0005388/ GO:0015662/ GO:0140613/ GO:0070588/ GO:0006816/ GO:0016339/ GO:0006874/ GO:0030026/ GO:0008544/ GO:0032468/ GO:0032472/ GO:0034220/ GO:0006828/ GO:0042998/ GO:0043123/ GO:0098629/ IPR006068/ IPR004014/ IPR023299/ IPR018303/ IPR023298/ IPR008250/ IPR036412/ IPR023214/ IPR006413/ IPR001757/ IPR044492/ P98194/ Transmembrane.Alpha-helical polytopic.P-type ATPase (P-ATPase).P-ATPase/ Generic PDBTM,1,7YAI,wildtype,P98194,UniProt,C11 H18 N5 O12 P3,505.208,ACP,PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(CP(=O)(O)O)O)O)O)N,3
7YAJ,3,,,,,,7YAJ,Cryo-EM structures of human SPCA1a reveal the mechanism of Ca 2+ /Mn 2+ transport into the Golgi apparatus.,CryoEM structure of SPCA1a in E1-Mn-AMPPCP state subclass 1,TRANSPORT PROTEIN,ATP2C1/ KIAA1347/ PMR1L/ HUSSY-28,7.2.2.10,GO:0033106/ GO:0005783/ GO:0005794/ GO:0032580/ GO:0000139/ GO:0016020/ GO:0005886/ GO:0005802/ GO:0005524/ GO:0016887/ GO:0005509/ GO:0030145/ GO:0046872/ GO:0005388/ GO:0015662/ GO:0140613/ GO:0070588/ GO:0006816/ GO:0016339/ GO:0006874/ GO:0030026/ GO:0008544/ GO:0032468/ GO:0032472/ GO:0034220/ GO:0006828/ GO:0042998/ GO:0043123/ GO:0098629/ IPR006068/ IPR004014/ IPR023299/ IPR018303/ IPR023298/ IPR008250/ IPR036412/ IPR023214/ IPR006413/ IPR001757/ IPR044492/ P98194/ Transmembrane.Alpha-helical polytopic.P-type ATPase (P-ATPase).P-ATPase/ Generic PDBTM,1,7YAJ,wildtype,P98194,UniProt,C11 H18 N5 O12 P3,505.208,ACP,PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(CP(=O)(O)O)O)O)O)N,3
7YG2,3,,,,,,7YG2,Cryo-EM structure of human IgM-Fc in complex with the J chain and the DBL domain of DBLMSP2,Cryo-EM structure of human IgM-Fc in complex with the J chain and the DBL domain of DBLMSP2,IMMUNE SYSTEM,DBLMSP2,,GO:0016020/ GO:0046789/ IPR042202/ IPR008602,1,7YG2,wildtype,A0A0A7MCY3,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
7YK7,3,,,,,,7YK7,Ligand recognition mechanism of the human relaxin family peptide receptor 4 (RXFP4).,Cryo-EM structure of the DC591053-bound human relaxin family peptide receptor 4 (RXFP4)-Gi complex,STRUCTURAL PROTEIN,GNG2,,GO:0005834/ GO:0016020/ GO:0005886/ GO:0031681/ GO:0003924/ GO:0007191/ GO:0071870/ GO:0071380/ GO:0007186/ IPR015898/ IPR036284/ IPR001770/ Transmembrane.Alpha-helical polytopic.Rhodopsin-like receptors and pumps.G-protein coupled receptors/ family A/ Generic PDBTM,1,7YK7,mutant,P63212,UniProt,C28 H35 N3 O5,493.595,IYM,[(1S)-7-ethoxy-6-methoxy-1-[2-(5-methoxy-1H-indol-3-yl)ethyl]-3/4-dihydro-1H-isoquinolin-2-yl]-morpholin-4-yl-methanone,CCOc1cc2c(cc1OC)CCN(C2CCc3c[nH]c4c3cc(cc4)OC)C(=O)N5CCOCC5,6
7YS6,3,,,,,,7YS6,Structural insights into constitutive activity of 5-HT6 receptor,Cryo-EM structure of the Serotonin 6 (5-HT6) receptor-DNGs-scFv16 complex,MEMBRANE PROTEIN,HTR6,,GO:0005929/ GO:0030425/ GO:0005886/ GO:0045202/ GO:0004993/ GO:0004969/ GO:0030594/ GO:0021795/ GO:0007268/ GO:0007187/ GO:0032008/ IPR002232/ IPR000276/ IPR017452/ P50406/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.G Protein-Coupled Receptors: Class A.5-HT<sub>6</sub> serotonin receptor G<sub>s</sub>-scFv16 complex/ Transmembrane.Alpha-helical polytopic.Rhodopsin-like receptors and pumps.G-protein coupled receptors/ family A/ Generic PDBTM,1,7YS6,wildtype,P50406,UniProt,C10 H12 N2 O,176.215,SRO,SEROTONIN,c1cc2c(cc1O)c(c[nH]2)CCN,6
8A5V,3,,,,,,8A5V,L-serine biosynthesis in the human central nervous system: Structure and function of phosphoserine aminotransferase.,Crystal structure of the human phosposerine aminotransferase (PSAT),TRANSFERASE,PSAT1/ PSA,2.6.1.52,GO:0005737/ GO:0005829/ GO:0070062/ GO:0042802/ GO:0004648/ GO:0030170/ GO:0006564/ GO:0008615/ IPR000192/ IPR020578/ IPR022278/ IPR015424/ IPR015421/ IPR015422/ Q9Y617,2,8A5V,wildtype,Q9Y617,UniProt,C8 H13 N2 O5 P,248.173,PMP,4'-DEOXY-4'-AMINOPYRIDOXAL-5'-PHOSPHATE,Cc1c(c(c(cn1)COP(=O)(O)O)CN)O,4
8A5W,3,,,,,,8A5W,L-serine biosynthesis in the human central nervous system: Structure and function of phosphoserine aminotransferase.,Crystal structure of the human phosphoserine aminotransferase (PSAT) in complex with O-phosphoserine,TRANSFERASE,PSAT1/ PSA,2.6.1.52,GO:0005737/ GO:0005829/ GO:0070062/ GO:0042802/ GO:0004648/ GO:0030170/ GO:0006564/ GO:0008615/ IPR000192/ IPR020578/ IPR022278/ IPR015424/ IPR015421/ IPR015422/ Q9Y617,1,8A5W,wildtype,Q9Y617,UniProt,C8 H13 N2 O5 P,248.173,PMP,4'-DEOXY-4'-AMINOPYRIDOXAL-5'-PHOSPHATE,Cc1c(c(c(cn1)COP(=O)(O)O)CN)O,7
8A5W,3,,,,,,8A5W,L-serine biosynthesis in the human central nervous system: Structure and function of phosphoserine aminotransferase.,Crystal structure of the human phosphoserine aminotransferase (PSAT) in complex with O-phosphoserine,TRANSFERASE,PSAT1/ PSA,2.6.1.52,GO:0005737/ GO:0005829/ GO:0070062/ GO:0042802/ GO:0004648/ GO:0030170/ GO:0006564/ GO:0008615/ IPR000192/ IPR020578/ IPR022278/ IPR015424/ IPR015421/ IPR015422/ Q9Y617,2,8A5W,wildtype,Q9Y617,UniProt,C11 H16 N2 O11 P2,414.199,E1U,(2S)-2-[(E)-[2-methyl-3-oxidanyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]-3-phosphonooxy-propanoic acid,Cc1c(c(c(cn1)COP(=O)(O)O)C=NC(COP(=O)(O)O)C(=O)O)O,4
8A5W,3,,,,,,8A5W,L-serine biosynthesis in the human central nervous system: Structure and function of phosphoserine aminotransferase.,Crystal structure of the human phosphoserine aminotransferase (PSAT) in complex with O-phosphoserine,TRANSFERASE,PSAT1/ PSA,2.6.1.52,GO:0005737/ GO:0005829/ GO:0070062/ GO:0042802/ GO:0004648/ GO:0030170/ GO:0006564/ GO:0008615/ IPR000192/ IPR020578/ IPR022278/ IPR015424/ IPR015421/ IPR015422/ Q9Y617,3,8A5W,wildtype,Q9Y617,UniProt,C17 H30 N4 O12 P2,544.387,U93,(2~{S})-2-[[(~{R})-[[(5~{S})-5-azanyl-6-oxidanylidene-hexyl]amino]-[2-methyl-3-oxidanyl-5-(phosphonooxymethyl)pyridin-4-yl]methyl]amino]-3-phosphonooxy-propanoic acid,Cc1c(c(c(cn1)COP(=O)(O)O)C(NCCCCC(C=O)N)NC(COP(=O)(O)O)C(=O)O)O,5
8A5W,3,,,,,,8A5W,L-serine biosynthesis in the human central nervous system: Structure and function of phosphoserine aminotransferase.,Crystal structure of the human phosphoserine aminotransferase (PSAT) in complex with O-phosphoserine,TRANSFERASE,PSAT1/ PSA,2.6.1.52,GO:0005737/ GO:0005829/ GO:0070062/ GO:0042802/ GO:0004648/ GO:0030170/ GO:0006564/ GO:0008615/ IPR000192/ IPR020578/ IPR022278/ IPR015424/ IPR015421/ IPR015422/ Q9Y617,3,8A5W,wildtype,Q9Y617,UniProt,C3 H8 N O6 P,185.072,SEP,PHOSPHOSERINE,C(C(C(=O)O)N)OP(=O)(O)O,6
8AFO,3,,,,,,8AFO,X-ray structure and function of fibronectin domains two and three of the neural cell adhesion molecule L1.,Structure of fibronectin 2 and 3 of L1CAM at 2.0 Angstrom,CELL ADHESION,L1CAM/ CAML1/ MIC5,,GO:0030424/ GO:0044295/ GO:0009986/ GO:0062023/ GO:0030425/ GO:0005925/ GO:0043025/ GO:0005886/ GO:0008046/ GO:0019904/ GO:0061564/ GO:0007411/ GO:0007155/ GO:0016477/ GO:0007160/ GO:0006935/ GO:0007156/ GO:0007399/ GO:0031175/ GO:0045773/ GO:0050808/ IPR003961/ IPR036116/ IPR007110/ IPR036179/ IPR013783/ IPR013098/ IPR003599/ IPR003598/ IPR026966/ P32004,1,8AFO,wildtype,P32004,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,3
8AFP,3,,,,,,8AFP,X-ray structure and function of fibronectin domains two and three of the neural cell adhesion molecule L1.,Structure of fibronectin 2 and 3 of L1CAM at 3.0 Angstrom,CELL ADHESION,L1CAM/ CAML1/ MIC5,,GO:0030424/ GO:0044295/ GO:0009986/ GO:0062023/ GO:0030425/ GO:0005925/ GO:0043025/ GO:0005886/ GO:0008046/ GO:0019904/ GO:0061564/ GO:0007411/ GO:0007155/ GO:0016477/ GO:0007160/ GO:0006935/ GO:0007156/ GO:0007399/ GO:0031175/ GO:0045773/ GO:0050808/ IPR003961/ IPR036116/ IPR007110/ IPR036179/ IPR013783/ IPR013098/ IPR003599/ IPR003598/ IPR026966/ P32004,1,8AFP,wildtype,P32004,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,2
8BC8,3,,,,,,8BC8,Conformation-dependent ligand hot spots in the spliceosomal RNA helicase BRR2.,Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 18,HYDROLASE,SNRNP200/ ASCC3L1/ HELIC2/ KIAA0788,3.6.4.13,GO:0071013/ GO:0016020/ GO:0005654/ GO:0005634/ GO:0005681/ GO:0071006/ GO:0071005/ GO:0046540/ GO:0005682/ GO:0005524/ GO:0016887/ GO:0004386/ GO:0042802/ GO:0003723/ GO:0003724/ GO:0000354/ GO:0000398/ GO:0001649/ GO:0000388/ IPR041094/ IPR035892/ IPR011545/ IPR014001/ IPR001650/ IPR014756/ IPR027417/ IPR004179/ IPR036388/ IPR036390/ O75643,1,8BC8,wildtype,O75643,UniProt,C6 H8 N2 O3 S,188.204,QB6,3-azanyl-4-oxidanyl-benzenesulfonamide,c1cc(c(cc1S(=O)(=O)N)N)O,3
8BC9,3,,,,,,8BC9,Conformation-dependent ligand hot spots in the spliceosomal RNA helicase BRR2.,Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 24,HYDROLASE,SNRNP200/ ASCC3L1/ HELIC2/ KIAA0788,3.6.4.13,GO:0071013/ GO:0016020/ GO:0005654/ GO:0005634/ GO:0005681/ GO:0071006/ GO:0071005/ GO:0046540/ GO:0005682/ GO:0005524/ GO:0016887/ GO:0004386/ GO:0042802/ GO:0003723/ GO:0003724/ GO:0000354/ GO:0000398/ GO:0001649/ GO:0000388/ IPR041094/ IPR035892/ IPR011545/ IPR014001/ IPR001650/ IPR014756/ IPR027417/ IPR004179/ IPR036388/ IPR036390/ O75643,1,8BC9,wildtype,O75643,UniProt,C6 H7 N O3 S,173.19,A09,N-hydroxybenzenesulfonamide,c1ccc(cc1)S(=O)(=O)NO,3
8BCA,3,,,,,,8BCA,Conformation-dependent ligand hot spots in the spliceosomal RNA helicase BRR2.,Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 26,HYDROLASE,PRPF8/ PRPC8,,GO:0071013/ GO:0016020/ GO:0016607/ GO:0005654/ GO:0005634/ GO:0071006/ GO:0071007/ GO:0071005/ GO:0046540/ GO:0005682/ GO:0070530/ GO:0097157/ GO:0003723/ GO:0030619/ GO:0030620/ GO:0030623/ GO:0017070/ GO:0071222/ GO:0071356/ GO:0006397/ GO:0000398/ GO:0008380/ GO:0000375/ GO:0000244/ IPR000555/ IPR037518/ IPR012591/ IPR012592/ IPR012984/ IPR027652/ IPR021983/ IPR043173/ IPR043172/ IPR019581/ IPR042516/ IPR019580/ IPR012337/ IPR019582/ Q6P2Q9,2,8BCA,wildtype,Q6P2Q9,UniProt,C8 H13 N3 O2 S,215.273,Q96,3-azanyl-~{N}-methyl-4-(methylamino)benzenesulfonamide,CNc1ccc(cc1N)S(=O)(=O)NC,3
8BCB,3,,,,,,8BCB,Conformation-dependent ligand hot spots in the spliceosomal RNA helicase BRR2.,Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 34,HYDROLASE,SNRNP200/ ASCC3L1/ HELIC2/ KIAA0788,3.6.4.13,GO:0071013/ GO:0016020/ GO:0005654/ GO:0005634/ GO:0005681/ GO:0071006/ GO:0071005/ GO:0046540/ GO:0005682/ GO:0005524/ GO:0016887/ GO:0004386/ GO:0042802/ GO:0003723/ GO:0003724/ GO:0000354/ GO:0000398/ GO:0001649/ GO:0000388/ IPR041094/ IPR035892/ IPR011545/ IPR014001/ IPR001650/ IPR014756/ IPR027417/ IPR004179/ IPR036388/ IPR036390/ O75643,1,8BCB,wildtype,O75643,UniProt,C6 H8 N2 O2 S,172.205,SAN,SULFANILAMIDE,c1cc(ccc1N)S(=O)(=O)N,4
8BCC,3,,,,,,8BCC,Conformation-dependent ligand hot spots in the spliceosomal RNA helicase BRR2.,Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 39,HYDROLASE,SNRNP200/ ASCC3L1/ HELIC2/ KIAA0788,3.6.4.13,GO:0071013/ GO:0016020/ GO:0005654/ GO:0005634/ GO:0005681/ GO:0071006/ GO:0071005/ GO:0046540/ GO:0005682/ GO:0005524/ GO:0016887/ GO:0004386/ GO:0042802/ GO:0003723/ GO:0003724/ GO:0000354/ GO:0000398/ GO:0001649/ GO:0000388/ IPR041094/ IPR035892/ IPR011545/ IPR014001/ IPR001650/ IPR014756/ IPR027417/ IPR004179/ IPR036388/ IPR036390/ O75643,1,8BCC,wildtype,O75643,UniProt,C6 H7 N O3 S,173.19,QAU,3-oxidanylbenzenesulfonamide,c1cc(cc(c1)S(=O)(=O)N)O,3
8BCD,3,,,,,,8BCD,Conformation-dependent ligand hot spots in the spliceosomal RNA helicase BRR2.,Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 50,HYDROLASE,SNRNP200/ ASCC3L1/ HELIC2/ KIAA0788,3.6.4.13,GO:0071013/ GO:0016020/ GO:0005654/ GO:0005634/ GO:0005681/ GO:0071006/ GO:0071005/ GO:0046540/ GO:0005682/ GO:0005524/ GO:0016887/ GO:0004386/ GO:0042802/ GO:0003723/ GO:0003724/ GO:0000354/ GO:0000398/ GO:0001649/ GO:0000388/ IPR041094/ IPR035892/ IPR011545/ IPR014001/ IPR001650/ IPR014756/ IPR027417/ IPR004179/ IPR036388/ IPR036390/ O75643,1,8BCD,wildtype,O75643,UniProt,C7 H7 N O2 S3,233.331,QB0,phenylsulfonylcarbamodithioic acid,c1ccc(cc1)S(=O)(=O)NC(=S)S,3
8BCE,3,,,,,,8BCE,Conformation-dependent ligand hot spots in the spliceosomal RNA helicase BRR2.,Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 76,HYDROLASE,SNRNP200/ ASCC3L1/ HELIC2/ KIAA0788,3.6.4.13,GO:0071013/ GO:0016020/ GO:0005654/ GO:0005634/ GO:0005681/ GO:0071006/ GO:0071005/ GO:0046540/ GO:0005682/ GO:0005524/ GO:0016887/ GO:0004386/ GO:0042802/ GO:0003723/ GO:0003724/ GO:0000354/ GO:0000398/ GO:0001649/ GO:0000388/ IPR041094/ IPR035892/ IPR011545/ IPR014001/ IPR001650/ IPR014756/ IPR027417/ IPR004179/ IPR036388/ IPR036390/ O75643,1,8BCE,wildtype,O75643,UniProt,C7 H9 N O3 S,187.216,B09,N-methoxybenzenesulfonamide,CONS(=O)(=O)c1ccccc1,3
8BCF,3,,,,,,8BCF,Conformation-dependent ligand hot spots in the spliceosomal RNA helicase BRR2.,Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 78,HYDROLASE,PRPF8/ PRPC8,,GO:0071013/ GO:0016020/ GO:0016607/ GO:0005654/ GO:0005634/ GO:0071006/ GO:0071007/ GO:0071005/ GO:0046540/ GO:0005682/ GO:0070530/ GO:0097157/ GO:0003723/ GO:0030619/ GO:0030620/ GO:0030623/ GO:0017070/ GO:0071222/ GO:0071356/ GO:0006397/ GO:0000398/ GO:0008380/ GO:0000375/ GO:0000244/ IPR000555/ IPR037518/ IPR012591/ IPR012592/ IPR012984/ IPR027652/ IPR021983/ IPR043173/ IPR043172/ IPR019581/ IPR042516/ IPR019580/ IPR012337/ IPR019582/ Q6P2Q9,2,8BCF,wildtype,Q6P2Q9,UniProt,C8 H11 N O3 S,201.243,Q8Z,~{N}-methoxy-~{N}-methyl-benzenesulfonamide,CN(OC)S(=O)(=O)c1ccccc1,4
8BCG,3,,,,,,8BCG,Conformation-dependent ligand hot spots in the spliceosomal RNA helicase BRR2.,Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 86,HYDROLASE,SNRNP200/ ASCC3L1/ HELIC2/ KIAA0788,3.6.4.13,GO:0071013/ GO:0016020/ GO:0005654/ GO:0005634/ GO:0005681/ GO:0071006/ GO:0071005/ GO:0046540/ GO:0005682/ GO:0005524/ GO:0016887/ GO:0004386/ GO:0042802/ GO:0003723/ GO:0003724/ GO:0000354/ GO:0000398/ GO:0001649/ GO:0000388/ IPR041094/ IPR035892/ IPR011545/ IPR014001/ IPR001650/ IPR014756/ IPR027417/ IPR004179/ IPR036388/ IPR036390/ O75643,1,8BCG,wildtype,O75643,UniProt,C8 H10 Cl N O3 S,235.688,Q9I,4-chloranyl-~{N}-methoxy-~{N}-methyl-benzenesulfonamide,CN(OC)S(=O)(=O)c1ccc(cc1)Cl,3
8BCH,3,,,,,,8BCH,Conformation-dependent ligand hot spots in the spliceosomal RNA helicase BRR2.,Human Brr2 Helicase Region in complex with Sulfaguanidine,HYDROLASE,SNRNP200/ ASCC3L1/ HELIC2/ KIAA0788,3.6.4.13,GO:0071013/ GO:0016020/ GO:0005654/ GO:0005634/ GO:0005681/ GO:0071006/ GO:0071005/ GO:0046540/ GO:0005682/ GO:0005524/ GO:0016887/ GO:0004386/ GO:0042802/ GO:0003723/ GO:0003724/ GO:0000354/ GO:0000398/ GO:0001649/ GO:0000388/ IPR041094/ IPR035892/ IPR011545/ IPR014001/ IPR001650/ IPR014756/ IPR027417/ IPR004179/ IPR036388/ IPR036390/ O75643,1,8BCH,wildtype,O75643,UniProt,C7 H10 N4 O2 S,214.245,QA9,1-(4-aminophenyl)sulfonylguanidine,c1cc(ccc1N)S(=O)(=O)NC(=N)N,2
8BZY,3,,,,,,8BZY,Structures of ferroportin in complex with its specific inhibitor vamifeport.,Structure of SLC40/ferroportin in complex with vamifeport and synthetic nanobody Sy3 in occluded conformation,TRANSPORT PROTEIN,SLC40A1/ FPN1/ IREG1/ SLC11A3/ MSTP079,,GO:0016323/ GO:0005737/ GO:0005829/ GO:0005654/ GO:0005886/ GO:0008021/ GO:0015093/ GO:0042802/ GO:0005381/ GO:0046872/ GO:0017046/ GO:0006915/ GO:0006879/ GO:0003158/ GO:0051649/ GO:1903988/ GO:0034755/ GO:0002260/ GO:0060586/ GO:0043066/ GO:0045944/ GO:0034395/ GO:0060345/ GO:0006366/ IPR009716/ IPR036259/ Q9NP59/ Transmembrane.Alpha-helical polytopic.Major Facilitator Superfamily (MFS).Ferroportin/ Generic PDBTM,2,8BZY,wildtype,Q9NP59,UniProt,C21 H21 F N6 O2,408.429,SZU,2-[2-[2-(1~{H}-benzimidazol-2-yl)ethylamino]ethyl]-~{N}-[(3-fluoranylpyridin-2-yl)methyl]-1/3-oxazole-4-carboxamide,c1ccc2c(c1)[nH]c(n2)CCNCCc3nc(co3)C(=O)NCc4c(cccn4)F,4
8C03,3,,,,,,8C03,Structures of ferroportin in complex with its specific inhibitor vamifeport.,Structure of SLC40/ferroportin in complex with vamifeport and synthetic nanobody Sy12 in outward-facing conformation,TRANSPORT PROTEIN,SLC40A1/ FPN1/ IREG1/ SLC11A3/ MSTP079,,GO:0016323/ GO:0005737/ GO:0005829/ GO:0005654/ GO:0005886/ GO:0008021/ GO:0015093/ GO:0042802/ GO:0005381/ GO:0046872/ GO:0017046/ GO:0006915/ GO:0006879/ GO:0003158/ GO:0051649/ GO:1903988/ GO:0034755/ GO:0002260/ GO:0060586/ GO:0043066/ GO:0045944/ GO:0034395/ GO:0060345/ GO:0006366/ IPR009716/ IPR036259/ Q9NP59/ Transmembrane.Alpha-helical polytopic.Major Facilitator Superfamily (MFS).Ferroportin/ Generic PDBTM,1,8C03,wildtype,Q9NP59,UniProt,C21 H21 F N6 O2,408.429,SZU,2-[2-[2-(1~{H}-benzimidazol-2-yl)ethylamino]ethyl]-~{N}-[(3-fluoranylpyridin-2-yl)methyl]-1/3-oxazole-4-carboxamide,c1ccc2c(c1)[nH]c(n2)CCNCCc3nc(co3)C(=O)NCc4c(cccn4)F,2
8C3N,3,,,,,,8C3N,A Recombinant Approach For Stapled Peptide Discovery Yields Inhibitors of the RAD51 Recombinase,Stapled peptide SP30 in complex with humanised RadA mutant HumRadA22,RECOMBINATION,radA/ PF1926,,GO:0005524/ GO:0140664/ GO:0003684/ GO:0006310/ GO:0006281/ IPR003593/ IPR013632/ IPR011938/ IPR016467/ IPR010995/ IPR003583/ IPR027417/ IPR033925/ IPR020588/ IPR020587,1,8C3N,mutant,O74036,UniProt,C8 H13 N3,151.209,RF6,4/6-diethylpyrimidin-2-amine,CCc1cc(nc(n1)N)CC,5
8DBB,3,,,,,,8DBB,2/5-Pyridinedicarboxylic acid is a bioactive and highly selective inhibitor of D-dopachrome tautomerase.,Crystal structure of DDT with the selective inhibitor 2/5-Pyridinedicarboxylic Acid,LYASE/INHIBITOR,DDT,4.1.1.84,GO:0005737/ GO:0070062/ GO:0005615/ GO:0005126/ GO:0033981/ GO:0004167/ GO:0050178/ GO:0042438/ GO:0010760/ GO:0070374/ GO:0050729/ GO:0032760/ IPR001398/ IPR019829/ IPR014347/ P30046,1,8DBB,wildtype,P30046,UniProt,C7 H5 N O4,167.119,R3K,pyridine-2/5-dicarboxylic acid,c1cc(ncc1C(=O)O)C(=O)O,2
8DEY,3,,,,,,8DEY,Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy.,Ternary complex structure of Cereblon-DDB1 bound to IKZF2(ZF2/3) and the molecular glue DKY709,LIGASE,IKZF2/ HELIOS/ ZNFN1A2,,GO:0005634/ GO:0003700/ GO:0046872/ GO:0000978/ GO:0006357/ IPR036236/ IPR013087/ Q9UKS7,3,8DEY,wildtype,Q9UKS7,UniProt,C25 H27 N3 O3,417.5,LWK,(3S)-3-[5-(1-benzylpiperidin-4-yl)-1-oxo-1/3-dihydro-2H-isoindol-2-yl]piperidine-2/6-dione,c1ccc(cc1)CN2CCC(CC2)c3ccc4c(c3)CN(C4=O)C5CCC(=O)NC5=O,5
8F8E,3,,,,,,8F8E,Crystal structure of the WDR domain of human DCAF1 in complex with OICR-8268 compound,Crystal structure of the WDR domain of human DCAF1 in complex with OICR-8268 compound,TRANSFERASE/INHIBITOR,DCAF1/ KIAA0800/ RIP/ VPRBP,2.7.11.1,GO:0080008/ GO:0005737/ GO:0001650/ GO:0005654/ GO:0005634/ GO:0005524/ GO:1990244/ GO:0030331/ GO:0106310/ GO:0030183/ GO:0035212/ GO:0006325/ GO:0000122/ GO:0043687/ GO:0016567/ GO:0033151/ IPR011989/ IPR016024/ IPR006594/ IPR033270/ IPR015943/ IPR036322/ Q9Y4B6,1,8F8E,mutant,Q9Y4B6,UniProt,C19 H14 Cl2 F2 N4 O2,439.243,XJI,(3P)-N-[(1S)-3-amino-1-(3-chloro-4-fluorophenyl)-3-oxopropyl]-3-(4-chloro-2-fluorophenyl)-1H-pyrazole-4-carboxamide,c1cc(c(cc1C(CC(=O)N)NC(=O)c2c[nH]nc2c3ccc(cc3F)Cl)Cl)F,2
8FN0,3,,,,,,8FN0,Neurotensin Receptor Allosterism Revealed in Complex with a Biased Allosteric Modulator.,CryoEM structure of Go-coupled NTSR1 with a biased allosteric modulator,MEMBRANE PROTEIN,Ntsr1/ Ntsr,,GO:0030424/ GO:0043679/ GO:0009986/ GO:0005737/ GO:0009898/ GO:0030425/ GO:0043198/ GO:0043197/ GO:0005783/ GO:0005794/ GO:0045121/ GO:0005739/ GO:0044309/ GO:0043025/ GO:0043204/ GO:0005886/ GO:0032280/ GO:0045202/ GO:0043195/ GO:0016492/ GO:0004930/ GO:0042802/ GO:0044877/ GO:0008344/ GO:0070779/ GO:0050965/ GO:0007186/ GO:0071545/ GO:0098712/ GO:0007612/ GO:0043066/ GO:0051280/ GO:0003085/ GO:0007218/ GO:0043065/ GO:0090238/ GO:2001259/ GO:0014054/ GO:0010628/ GO:0014049/ GO:0097151/ GO:0060732/ GO:0051092/ GO:0051281/ GO:0098900/ GO:0003254/ GO:0043576/ GO:0051930/ GO:0033993/ GO:0001659/ IPR000276/ IPR017452/ IPR003985/ IPR003984/ P20789/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.G Protein-Coupled Receptors: Class A.NTSR1 neurotensin receptor - G<sub>oA</sub> complex/ Transmembrane.Alpha-helical polytopic.Rhodopsin-like receptors and pumps.G-protein coupled receptors/ family A/ Generic PDBTM,1,8FN0,mutant,P20789,UniProt,C26 H31 F N4 O2,450.548,SRW,2-[{2-(1-fluorocyclopropyl)-4-[4-(2-methoxyphenyl)piperidin-1-yl]quinazolin-6-yl}(methyl)amino]ethan-1-ol,CN(CCO)c1ccc2c(c1)c(nc(n2)C3(CC3)F)N4CCC(CC4)c5ccccc5OC,7
8FT6,3,,,,,,8FT6,Decreasing the flexibility of the TELSAM-target protein linker and omitting the cleavable fusion tag improves crystal order and diffraction limits.,The von Willebrand factor A domain of human capillary morphogenesis gene II/ flexibly fused to the 1TEL crystallization chaperone/ Ala-Ala linker variant/ SUMO tag-free preparation.,PEPTIDE BINDING PROTEIN,ANTXR2/ CMG2,,GO:0009986/ GO:0005789/ GO:0010008/ GO:0005576/ GO:0005886/ GO:0046872/ GO:0004888/ GO:1901998/ IPR017360/ IPR008399/ IPR008400/ IPR002035/ IPR036465/ GO:0000785/ GO:0005829/ GO:0005730/ GO:0005634/ GO:0001228/ GO:0003700/ GO:0000981/ GO:0001227/ GO:0019904/ GO:0000978/ GO:0000977/ GO:0030154/ GO:0071425/ GO:0097152/ GO:0000122/ GO:0022008/ GO:0006357/ GO:0007296/ IPR000418/ IPR046328/ IPR003118/ IPR013761/ IPR036388/ IPR036390/ P58335/ P41212,1,8FT6,mutant,P58335,UniProt,I,126.904,IOD,IODIDE ION,[I-],3
8G46,3,,,,,,8G46,Template-assisted covalent modification of DCAF16 underlies activity of BRD4 molecular glue degraders.,Cryo-EM structure of DDB1deltaB-DDA1-DCAF16-BRD4(BD2)-MMH2,LIGASE,DDB1/ XAP1,,GO:0000781/ GO:0080008/ GO:0031464/ GO:0031465/ GO:0005737/ GO:0070062/ GO:0005615/ GO:0005654/ GO:0005634/ GO:0032991/ GO:0035861/ GO:0097602/ GO:0003684/ GO:0003677/ GO:0044877/ GO:0030674/ GO:0071987/ GO:0006915/ GO:0051702/ GO:0006974/ GO:0034644/ GO:0006281/ GO:0035234/ GO:0035518/ GO:0043066/ GO:0051093/ GO:2000242/ GO:0006289/ GO:0046726/ GO:0045722/ GO:0045732/ GO:0045070/ GO:0010498/ GO:0043161/ GO:0016567/ GO:0042752/ GO:1901990/ GO:0048511/ GO:0006511/ GO:0070914/ GO:0019076/ GO:0016055/ IPR004871/ IPR018846/ IPR031297/ IPR015943/ IPR036322/ Q16531,1,8G46,wildtype,Q16531,UniProt,C25 H31 N5 O4 S2,529.675,YK3,tert-butyl [(6S/10P)-4-{4-[(ethanesulfonyl)amino]phenyl}-2/3/9-trimethyl-6H-thieno[3/2-f][1/2/4]triazolo[4/3-a][1/4]diazepin-6-yl]acetate,CCS(=O)(=O)Nc1ccc(cc1)C2=NC(c3nnc(n3-c4c2c(c(s4)C)C)C)CC(=O)OC(C)(C)C,6
8G59,3,,,,,,8G59,Unsaturated bond recognition leads to biased signal in a fatty acid receptor.,Cryo-EM structure of the TUG891 bound GPR120-Giq complex,MEMBRANE PROTEIN,GNB1,,GO:0005737/ GO:0005829/ GO:0070062/ GO:1903561/ GO:0005834/ GO:0005765/ GO:0016020/ GO:0097381/ GO:0005886/ GO:0045202/ GO:0003924/ GO:0051020/ GO:0044877/ GO:0030159/ GO:0007191/ GO:0008283/ GO:0071870/ GO:0071380/ GO:0007213/ GO:0007186/ GO:0007200/ GO:0007265/ GO:0060041/ GO:0050909/ GO:0007165/ IPR020472/ IPR001632/ IPR016346/ IPR015943/ IPR001680/ IPR019775/ IPR036322/ P62873,1,8G59,mutant,P62873,UniProt,C23 H21 F O3,364.409,YN9,3-{4-[(4-fluoro-4'-methyl[1/1'-biphenyl]-2-yl)methoxy]phenyl}propanoic acid,Cc1ccc(cc1)c2ccc(cc2COc3ccc(cc3)CCC(=O)O)F,6
8GCY,3,,,,,,8GCY,Co-crystal structure of CBL-B in complex with N-Aryl isoindolin-1-one inhibitor,Co-crystal structure of CBL-B in complex with N-Aryl isoindolin-1-one inhibitor,LIGASE/LIGASE INHIBITOR,CBLB/ RNF56/ Nbla00127,2.3.2.27,GO:0005829/ GO:0045121/ GO:0005654/ GO:0005886/ GO:0005509/ GO:0001784/ GO:0030971/ GO:0017124/ GO:0061630/ GO:0008270/ GO:0035739/ GO:0006955/ GO:0035556/ GO:2000562/ GO:0007175/ GO:0050860/ GO:0006607/ GO:0018193/ GO:0045732/ GO:0031398/ GO:0002669/ GO:0030163/ GO:0043087/ GO:2000583/ GO:0043393/ GO:0007165/ GO:0002870/ GO:0050852/ IPR024162/ IPR014741/ IPR036537/ IPR003153/ IPR014742/ IPR039520/ IPR024159/ IPR011992/ IPR036860/ IPR015940/ IPR001841/ IPR013083/ IPR017907/ Q13191,1,8GCY,wildtype,Q13191,UniProt,C30 H34 F3 N5 O,537.619,Z3N,2-{3-[(1s/3R)-3-methyl-1-(4-methyl-4H-1/2/4-triazol-3-yl)cyclobutyl]phenyl}-6-{[(3S)-3-methylpiperidin-1-yl]methyl}-4-(trifluoromethyl)-2/3-dihydro-1H-isoindol-1-one,CC1CCCN(C1)Cc2cc3c(c(c2)C(F)(F)F)CN(C3=O)c4cccc(c4)C5(CC(C5)C)c6nncn6C,3
8GSU,3,,,,,,8GSU,Mutagenic analysis of actin reveals the mechanism of His161 flipping that triggers ATP hydrolysis.,Crystal structure of human cardiac alpha actin (WT_ADP-Pi) in complex with fragmin F1 domain,CONTRACTILE PROTEIN,ACTC1/ ACTC,3.6.4,GO:0005884/ GO:0072562/ GO:0044297/ GO:0005737/ GO:0005829/ GO:0005869/ GO:0070062/ GO:0005615/ GO:0030175/ GO:0005925/ GO:0098978/ GO:0031674/ GO:0030027/ GO:0016020/ GO:0030017/ GO:0005524/ GO:0016787/ GO:0000146/ GO:0017022/ GO:0007015/ GO:0030048/ GO:0033275/ GO:0031032/ GO:0055008/ GO:0055003/ GO:0060047/ GO:0090131/ GO:0043066/ GO:0010628/ GO:0030240/ IPR004000/ IPR020902/ IPR004001/ IPR043129/ P68032,1,8GSU,wildtype,P68032,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,3
8GSW,3,,,,,,8GSW,Mutagenic analysis of actin reveals the mechanism of His161 flipping that triggers ATP hydrolysis.,Crystal structure of human cardiac alpha actin A108G mutant (AMPPNP state) in complex with fragmin F1 domain,CONTRACTILE PROTEIN,ACTC1/ ACTC,3.6.4,GO:0005884/ GO:0072562/ GO:0044297/ GO:0005737/ GO:0005829/ GO:0005869/ GO:0070062/ GO:0005615/ GO:0030175/ GO:0005925/ GO:0098978/ GO:0031674/ GO:0030027/ GO:0016020/ GO:0030017/ GO:0005524/ GO:0016787/ GO:0000146/ GO:0017022/ GO:0007015/ GO:0030048/ GO:0033275/ GO:0031032/ GO:0055008/ GO:0055003/ GO:0060047/ GO:0090131/ GO:0043066/ GO:0010628/ GO:0030240/ IPR004000/ IPR020902/ IPR004001/ IPR043129/ P68032,1,8GSW,mutant,P68032,UniProt,C10 H17 N6 O12 P3,506.196,ANP,PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(NP(=O)(O)O)O)O)O)N,3
8GT1,3,,,,,,8GT1,Mutagenic analysis of actin reveals the mechanism of His161 flipping that triggers ATP hydrolysis.,Crystal structure of human cardiac alpha actin A108G mutant (ADP-Pi state) in complex with fragmin F1 domain,CONTRACTILE PROTEIN,,,GO:0051015/ IPR029006/ IPR007123/ IPR007122,2,8GT1,mutant,Q94707,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,3
8GT2,3,,,,,,8GT2,Mutagenic analysis of actin reveals the mechanism of His161 flipping that triggers ATP hydrolysis.,Crystal structure of human cardiac alpha actin P109A mutant (AMPPNP state) in complex with fragmin F1 domain,CONTRACTILE PROTEIN,ACTC1/ ACTC,3.6.4,GO:0051015/ IPR029006/ IPR007123/ IPR007122,2,8GT2,mutant,Q94707,UniProt,C10 H17 N6 O12 P3,506.196,ANP,PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(NP(=O)(O)O)O)O)O)N,3
8GT3,3,,,,,,8GT3,Mutagenic analysis of actin reveals the mechanism of His161 flipping that triggers ATP hydrolysis.,Crystal structure of human cardiac alpha actin P109A mutant (ADP-Pi state) in complex with fragmin F1 domain,CONTRACTILE PROTEIN,ACTC1/ ACTC,3.6.4,GO:0051015/ IPR029006/ IPR007123/ IPR007122,2,8GT3,mutant,Q94707,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,3
8GT4,3,,,,,,8GT4,Mutagenic analysis of actin reveals the mechanism of His161 flipping that triggers ATP hydrolysis.,Crystal structure of human cardiac alpha actin Q137A mutant (AMPPNP state) in complex with fragmin F1 domain,CONTRACTILE PROTEIN,ACTC1/ ACTC,3.6.4,GO:0051015/ IPR029006/ IPR007123/ IPR007122,2,8GT4,mutant,Q94707,UniProt,C10 H17 N6 O12 P3,506.196,ANP,PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(NP(=O)(O)O)O)O)O)N,3
8GT5,3,,,,,,8GT5,Mutagenic analysis of actin reveals the mechanism of His161 flipping that triggers ATP hydrolysis.,Crystal structure of human cardiac alpha actin Q137A mutant (ADP-Pi state) in complex with fragmin F1 domain,CONTRACTILE PROTEIN,ACTC1/ ACTC,3.6.4,GO:0005884/ GO:0072562/ GO:0044297/ GO:0005737/ GO:0005829/ GO:0005869/ GO:0070062/ GO:0005615/ GO:0030175/ GO:0005925/ GO:0098978/ GO:0031674/ GO:0030027/ GO:0016020/ GO:0030017/ GO:0005524/ GO:0016787/ GO:0000146/ GO:0017022/ GO:0007015/ GO:0030048/ GO:0033275/ GO:0031032/ GO:0055008/ GO:0055003/ GO:0060047/ GO:0090131/ GO:0043066/ GO:0010628/ GO:0030240/ IPR004000/ IPR020902/ IPR004001/ IPR043129/ P68032,1,8GT5,mutant,P68032,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,3
8GYW,3,,,,,,8GYW,Making membranes: Structure of human choline/ethanolamine phosphotransferase 1,Cryo-EM structure of human CEPT1 complexed with CDP-choline,LIPID BINDING PROTEIN,CEPT1/ PRO1101,2.7.8.1/ 2.7.8.2/ 2.7.8.22,GO:0005789/ GO:0005794/ GO:0016020/ GO:0031965/ GO:0047359/ GO:0004142/ GO:0004307/ GO:0046872/ GO:0006629/ GO:0006646/ IPR000462/ IPR043130/ IPR014472/ Q9Y6K0/ Transmembrane.Alpha-helical polytopic.Choline/ethanolamine phosphotransferase.Choline/ethanolamine phosphotransferase 1/ Generic PDBTM,1,8GYW,wildtype,Q9Y6K0,UniProt,C14 H26 N4 O11 P2,488.324,CDC,[2-CYTIDYLATE-O'-PHOSPHONYLOXYL]-ETHYL-TRIMETHYL-AMMONIUM,C[N+](C)(C)CCOP(=O)([O-])OP(=O)(O)OCC1C(C(C(O1)N2C=CC(=NC2=O)N)O)O,3
8GYX,3,,,,,,8GYX,Making membranes: Structure of human choline/ethanolamine phosphotransferase 1,Cryo-EM structure of human CEPT1,LIPID BINDING PROTEIN,CEPT1/ PRO1101,2.7.8.1/ 2.7.8.2/ 2.7.8.22,GO:0005789/ GO:0005794/ GO:0016020/ GO:0031965/ GO:0047359/ GO:0004142/ GO:0004307/ GO:0046872/ GO:0006629/ GO:0006646/ IPR000462/ IPR043130/ IPR014472/ Q9Y6K0/ Transmembrane.Alpha-helical polytopic.Choline/ethanolamine phosphotransferase.Choline/ethanolamine phosphotransferase 1/ Generic PDBTM,1,8GYX,wildtype,Q9Y6K0,UniProt,C42 H82 N O8 P,760.076,POV,(2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC,2
8GZ1,3,,,,,,8GZ1,Structure of human Na V 1.6 channel reveals Na + selectivity and pore blockade by 4/9-anhydro-tetrodotoxin.,Cryo-EM structure of human NaV1.6/beta1/beta2/apo state,MEMBRANE PROTEIN,SCN1B,,GO:0005576/ GO:0014704/ GO:0033268/ GO:0043204/ GO:0005886/ GO:0030315/ GO:0001518/ GO:0019871/ GO:0017080/ GO:0044325/ GO:0005244/ GO:0005248/ GO:0086006/ GO:0086062/ GO:0007411/ GO:0061337/ GO:0086002/ GO:0060048/ GO:0007155/ GO:0021966/ GO:0040011/ GO:0051899/ GO:0086012/ GO:0086047/ GO:0019227/ GO:0010976/ GO:0010765/ GO:0060371/ GO:0086091/ GO:2000649/ GO:0060307/ GO:0035725/ IPR036179/ IPR013783/ IPR013106/ IPR027098/ IPR044568/ Q07699/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Channels: Potassium/ Sodium/ & Proton Ion-Selective.Na<sub>V</sub>1.6 with 棺1 and 棺2 subunits/ apo state/ Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Voltage-gated calcium and sodium channels/ Generic PDBTM,1,8GZ1,wildtype,Q07699,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
8GZ2,3,,,,,,8GZ2,Structure of human Na V 1.6 channel reveals Na + selectivity and pore blockade by 4/9-anhydro-tetrodotoxin.,Cryo-EM structure of human NaV1.6/beta1/beta2-4/9-anhydro-tetrodotoxin,MEMBRANE PROTEIN,SCN8A/ MED,,GO:0030424/ GO:0043194/ GO:0030054/ GO:0031410/ GO:0016020/ GO:0033268/ GO:0005886/ GO:0001518/ GO:0030018/ GO:0005524/ GO:0005244/ GO:0005248/ GO:0086010/ GO:0042552/ GO:0007399/ GO:0019228/ GO:0007422/ GO:0034765/ GO:0035725/ GO:0006814/ IPR005821/ IPR000048/ IPR008054/ IPR001696/ IPR044564/ IPR010526/ IPR024583/ IPR043203/ IPR027359/ Q9UQD0/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Channels: Potassium/ Sodium/ & Proton Ion-Selective.Na<sub>V</sub>1.6 with 棺1 and 棺2 subunits/ apo state/ Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Voltage-gated calcium and sodium channels/ Generic PDBTM,2,8GZ2,wildtype,Q9UQD0,UniProt,C11 H15 N3 O7,301.253,WMK,(1R/2S/3S/4R/5R/9S/11S/12S/14R)-7-amino-2/4/12-trihydroxy-2-(hydroxymethyl)-10/13/15-trioxa-6/8-diazapentacyclo[7.4.1.1~3/12~.0~5/11~.0~5/14~]pentadec-7-en-8-ium (non-preferred name),C(C1(C2C3C4N=C(NC35C(C1OC(C5O4)(O2)O)O)N)O)O,6
8HKP,3,,,,,,8HKP,Cryo-EM structures of human Cx36/GJD2 neuronal gap junction channel.,Structurally hetero-junctional human Cx36/GJD2 gap junction channel in detergents (C6 symmetry),MEMBRANE PROTEIN,GJD2/ GJA9,,GO:0005922/ GO:0005886/ GO:0045202/ GO:0005243/ GO:0007267/ GO:0007268/ GO:0019228/ GO:0007601/ IPR000500/ IPR002260/ IPR019570/ IPR017990/ IPR013092/ IPR038359/ Q9UKL4/ Transmembrane.Alpha-helical polytopic.Tetraspan junctional complexes.Connexin/ Generic PDBTM,1,8HKP,wildtype,Q9UKL4,UniProt,C47 H88 O22,1005.188,AV0,2-decyl-2-{[(4-O-alpha-D-glucopyranosyl-beta-D-glucopyranosyl)oxy]methyl}dodecyl4-O-alpha-D-glucopyranosyl-beta-D-glucopyranoside,CCCCCCCCCCC(CCCCCCCCCC)(COC1C(C(C(C(O1)CO)OC2C(C(C(C(O2)CO)O)O)O)O)O)COC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)CO)O)O)O)O)O,2
8ID4,3,,,,,,8ID4,Unsaturated bond recognition leads to biased signal in a fatty acid receptor.,Cryo-EM structure of the linoleic acid bound GPR120-Gi complex,MEMBRANE PROTEIN,FFAR4/ GPR120/ GPR129/ O3FAR1/ PGR4,,GO:0060170/ GO:0005929/ GO:0030139/ GO:0010008/ GO:0005765/ GO:0005886/ GO:1990763/ GO:0005504/ GO:0004930/ GO:0008527/ GO:0050873/ GO:0007186/ GO:0036321/ GO:0046879/ GO:0006954/ GO:0043066/ GO:0001818/ GO:0050728/ GO:0032691/ GO:0090275/ GO:0007200/ GO:0090336/ GO:0043950/ GO:0120162/ GO:0007204/ GO:0070374/ GO:0070094/ GO:0045669/ GO:0010827/ GO:0050872/ IPR000276/ IPR017452/ Q5NUL3/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.G Protein-Coupled Receptors: Class A.GPR120 free fatty-acid receptor 4 (FFAR4) - G<sub>iq</sub> complex/ with bound TUG891/ Transmembrane.Alpha-helical polytopic.Rhodopsin-like receptors and pumps.G-protein coupled receptors/ family A/ Generic PDBTM,1,8ID4,wildtype,Q5NUL3,UniProt,C18 H32 O2,280.445,EIC,LINOLEIC ACID,CCCCCC=CCC=CCCCCCCCC(=O)O,6
8ID9,3,,,,,,8ID9,Unsaturated bond recognition leads to biased signal in a fatty acid receptor.,Cryo-EM structure of the eicosapentaenoic acid bound GPR120-Gi complex,MEMBRANE PROTEIN,GNB1,,GO:0005737/ GO:0005829/ GO:0070062/ GO:1903561/ GO:0005834/ GO:0005765/ GO:0016020/ GO:0097381/ GO:0005886/ GO:0045202/ GO:0003924/ GO:0051020/ GO:0044877/ GO:0030159/ GO:0007191/ GO:0008283/ GO:0071870/ GO:0071380/ GO:0007213/ GO:0007186/ GO:0007200/ GO:0007265/ GO:0060041/ GO:0050909/ GO:0007165/ IPR020472/ IPR001632/ IPR016346/ IPR015943/ IPR001680/ IPR019775/ IPR036322/ P62873,1,8ID9,wildtype,P62873,UniProt,C20 H30 O2,302.451,EPA,5/8/11/14/17-EICOSAPENTAENOIC ACID,CCC=CCC=CCC=CCC=CCC=CCCCC(=O)O,6
7PSC,4,,,,,,7PSC,Crystal structure of the disease-causing I358T mutant of the human dihydrolipoamide dehydrogenase,Crystal structure of the disease-causing I358T mutant of the human dihydrolipoamide dehydrogenase,OXIDOREDUCTASE,DLD/ GCSL/ LAD/ PHE3,1.8.1.4,GO:0043159/ GO:0005947/ GO:0005759/ GO:0005967/ GO:0005739/ GO:0031514/ GO:0005634/ GO:0045252/ GO:0045254/ GO:0004148/ GO:0050660/ GO:0006086/ GO:0009083/ GO:0045454/ GO:0007369/ GO:0106077/ GO:0006120/ GO:0006508/ GO:0042391/ GO:0048240/ IPR036188/ IPR023753/ IPR016156/ IPR006258/ IPR001100/ IPR004099/ IPR012999/ P09622,1,7PSC,Mutant,P09622,UniProt,C27 H33 N9 O15 P2,785.55,FAD,FLAVIN-ADENINE DINUCLEOTIDE,Cc1cc2c(cc1C)N(C3=NC(=O)NC(=O)C3=N2)CC(C(C(COP(=O)(O)OP(=O)(O)OCC4C(C(C(O4)n5cnc6c5ncnc6N)O)O)O)O)O,2
7UGE,4,,,,,,7UGE,Structural basis of CBP and EP300 interaction with kinase inhibitors,Bromodomain of CBP liganded with BMS-536924,TRANSCRIPTION,CREBBP,2.3.1.48,GO:0016604/ GO:0005654/ GO:0004402/ GO:0003712/ GO:0016573/ GO:0045944/ IPR001487/ IPR036427/ IPR018359/ IPR031162/ IPR013178/ IPR003101/ IPR036529/ IPR010303/ IPR038547/ IPR013083,1,7UGE,wildtype,I3L466,UniProt,C25 H26 Cl N5 O3,479.959,N6I,(3M)-4-{[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}-3-[4-methyl-6-(morpholin-4-yl)-1H-benzimidazol-2-yl]pyridin-2(1H)-one,Cc1cc(cc2c1nc([nH]2)C3=C(C=CNC3=O)NCC(c4cccc(c4)Cl)O)N5CCOCC5,2
7UGL,4,,,,,,7UGL,Structural basis of CBP and EP300 interaction with kinase inhibitors,Bromodomain of CBP liganded with BMS-536924 and SGC-CBP30,TRANSCRIPTION,CREBBP,2.3.1.48,GO:0016604/ GO:0005654/ GO:0004402/ GO:0003712/ GO:0016573/ GO:0045944/ IPR001487/ IPR036427/ IPR018359/ IPR031162/ IPR013178/ IPR003101/ IPR036529/ IPR010303/ IPR038547/ IPR013083,1,7UGL,wildtype,I3L466,UniProt,C25 H26 Cl N5 O3,479.959,N6I,(3M)-4-{[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}-3-[4-methyl-6-(morpholin-4-yl)-1H-benzimidazol-2-yl]pyridin-2(1H)-one,Cc1cc(cc2c1nc([nH]2)C3=C(C=CNC3=O)NCC(c4cccc(c4)Cl)O)N5CCOCC5,2
7UGL,4,,,,,,7UGL,Structural basis of CBP and EP300 interaction with kinase inhibitors,Bromodomain of CBP liganded with BMS-536924 and SGC-CBP30,TRANSCRIPTION,CREBBP,2.3.1.48,GO:0016604/ GO:0005654/ GO:0004402/ GO:0003712/ GO:0016573/ GO:0045944/ IPR001487/ IPR036427/ IPR018359/ IPR031162/ IPR013178/ IPR003101/ IPR036529/ IPR010303/ IPR038547/ IPR013083,1,7UGL,wildtype,I3L466,UniProt,C28 H33 Cl N4 O3,509.04,2LO,2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(3/5-dimethyl-1/2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-benzimidazole,Cc1c(c(on1)C)c2ccc3c(c2)nc(n3CC(C)N4CCOCC4)CCc5ccc(c(c5)Cl)OC,3
7UIA,4,,,,,,7UIA,Structural basis for botulinum neurotoxin E recognition of synaptic vesicle protein 2.,Crystal structure of BoNT/E receptor binding domain in complex with SV2 and VHH,TOXIN,,,GO:0005576/ GO:0008237/ GO:0046929/ GO:0006508/ IPR013320/ IPR011065/ IPR013104/ IPR012928,3,7UIA,wildtype,A5H0J8,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
7UOW,4,,,,,,7UOW,SARS-Cov2 S protein structure in complex with neutralizing monoclonal antibody 034_32,SARS-Cov2 S protein structure in complex with neutralizing monoclonal antibody 034_32,VIRAL PROTEIN,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,7UOW,wildtype,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
7US2,4,,,,,,7US2,PARL-cleaved Skd3 (human ClpB) E455Q Nucleotide Binding Domain hexamer bound to ATPgammaS/ open conformation,PARL-cleaved Skd3 (human ClpB) E455Q Nucleotide Binding Domain hexamer bound to ATPgammaS/ open conformation,CHAPERONE,CLPB/ HSP78/ SKD3,3.6.1,GO:0005737/ GO:0005758/ GO:0005739/ GO:0005524/ GO:0016887/ GO:0140374/ GO:0034605/ GO:0039529/ IPR003593/ IPR002110/ IPR036770/ IPR003959/ IPR019489/ IPR001270/ IPR027417/ Q9H078,1,7US2,wildtype,Q9H078,UniProt,C10 H16 N5 O12 P3 S,523.247,AGS,PHOSPHOTHIOPHOSPHORIC ACID-ADENYLATE ESTER,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=S)(O)O)O)O)N,3
7X0S,4,,,,,,7X0S,Pathway and mechanism of tubulin folding mediated by TRiC/CCT conjugated with its ATPase cycle revealed by cryo-EM,Human TRiC-tubulin-S3,STRUCTURAL PROTEIN,CCT6A/ CCT6/ CCTZ,,GO:0005832/ GO:0005737/ GO:0005829/ GO:0070062/ GO:0005874/ GO:0005524/ GO:0016887/ GO:0140662/ GO:0044183/ GO:0003723/ GO:0051082/ GO:0071987/ GO:0061077/ GO:1904851/ GO:1904871/ GO:1904874/ GO:0032212/ GO:0006457/ GO:0050821/ IPR012722/ IPR017998/ IPR002194/ IPR002423/ IPR027409/ IPR027413/ IPR027410/ P40227,1,7X0S,Mutant,P40227,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,10
7X0V,4,,,,,,7X0V,Pathway and mechanism of tubulin folding mediated by TRiC/CCT conjugated with its ATPase cycle revealed by cryo-EM,cryo-EM structure of human TRiC-ADP-AlFx,STRUCTURAL PROTEIN,CCT7/ CCTH/ NIP7-1,,GO:0044297/ GO:0005832/ GO:0005737/ GO:0005829/ GO:0070062/ GO:0005874/ GO:0005524/ GO:0016887/ GO:0140662/ GO:0044183/ GO:0051082/ GO:0007339/ GO:0061077/ GO:1904851/ GO:1904871/ GO:1904874/ GO:0032212/ GO:0006457/ GO:0050821/ GO:1901998/ IPR012720/ IPR017998/ IPR002194/ IPR002423/ IPR027409/ IPR027413/ IPR027410/ Q99832,3,7X0V,Mutant,Q99832,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,9
7XJ6,4,,,,,,7XJ6,SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab and 58G6 Fab in the class 1 conformation,SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab and 58G6 Fab in the class 1 conformation,VIRAL PROTEIN/IMMUNE SYSTEM,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,7XJ6,Mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,7
7XJ8,4,,,,,,7XJ8,SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab and 58G6 Fab in the class 2 conformation,SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab and 58G6 Fab in the class 2 conformation,VIRAL PROTEIN/IMMUNE SYSTEM,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,7XJ8,Mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,7
7XK9,4,,,,,,7XK9,Structure of human beta2 adrenergic receptor bound to constrained isoproterenol,Structure of human beta2 adrenergic receptor bound to constrained isoproterenol,MEMBRANE PROTEIN,E,3.2.1.17,GO:0016324/ GO:0030669/ GO:0005769/ GO:0005768/ GO:0010008/ GO:0005794/ GO:0005764/ GO:0016020/ GO:0005634/ GO:0005886/ GO:0043235/ GO:0008179/ GO:0001540/ GO:0004941/ GO:0004930/ GO:0042802/ GO:0051380/ GO:0015459/ GO:0042803/ GO:0044877/ GO:0007190/ GO:0007171/ GO:0071880/ GO:0007188/ GO:0071875/ GO:0045453/ GO:0050873/ GO:0007166/ GO:1904646/ GO:0002032/ GO:0002024/ GO:0008333/ GO:0031649/ GO:0040015/ GO:0045986/ GO:0002025/ GO:2000969/ GO:1901098/ GO:0030501/ GO:2000481/ GO:0120162/ GO:1904504/ GO:0043410/ GO:0061885/ GO:0010739/ GO:0071902/ GO:0045944/ GO:0006898/ GO:0002028/ GO:0009409/ GO:1990911/ GO:0006939/ GO:0006366/ IPR002233/ IPR000332/ IPR000276/ IPR017452/ GO:0030430/ GO:0003796/ GO:0016998/ GO:0019835/ GO:0042742/ GO:0009253/ GO:0044659/ IPR034690/ IPR002196/ IPR023346/ IPR023347/ IPR001165/ P07550/ Transmembrane.Alpha-helical polytopic.Rhodopsin-like receptors and pumps.G-protein coupled receptors/ family A,1,7XK9,Mutant,P00720,UniProt,C13 H19 N O3,237.295,GJ6,(5R/6R)-6-(propan-2-ylamino)-5/6/7/8-tetrahydronaphthalene-1/2/5-triol,CC(C)NC1CCc2c(ccc(c2O)O)C1O,3
7XKA,4,,,,,,7XKA,Structure of human beta2 adrenergic receptor bound to constrained epinephrine,Structure of human beta2 adrenergic receptor bound to constrained epinephrine,MEMBRANE PROTEIN,E,3.2.1.17,GO:0016324/ GO:0030669/ GO:0005769/ GO:0005768/ GO:0010008/ GO:0005794/ GO:0005764/ GO:0016020/ GO:0005634/ GO:0005886/ GO:0043235/ GO:0008179/ GO:0001540/ GO:0004941/ GO:0004930/ GO:0042802/ GO:0051380/ GO:0015459/ GO:0042803/ GO:0044877/ GO:0007190/ GO:0007171/ GO:0071880/ GO:0007188/ GO:0071875/ GO:0045453/ GO:0050873/ GO:0007166/ GO:1904646/ GO:0002032/ GO:0002024/ GO:0008333/ GO:0031649/ GO:0040015/ GO:0045986/ GO:0002025/ GO:2000969/ GO:1901098/ GO:0030501/ GO:2000481/ GO:0120162/ GO:1904504/ GO:0043410/ GO:0061885/ GO:0010739/ GO:0071902/ GO:0045944/ GO:0006898/ GO:0002028/ GO:0009409/ GO:1990911/ GO:0006939/ GO:0006366/ IPR002233/ IPR000332/ IPR000276/ IPR017452/ GO:0030430/ GO:0003796/ GO:0016998/ GO:0019835/ GO:0042742/ GO:0009253/ GO:0044659/ IPR034690/ IPR002196/ IPR023346/ IPR023347/ IPR001165/ P07550/ Transmembrane.Alpha-helical polytopic.Rhodopsin-like receptors and pumps.G-protein coupled receptors/ family A,1,7XKA,Mutant,P00720,UniProt,C11 H15 N O3,209.242,G1I,(5R/6R)-6-(methylamino)-5/6/7/8-tetrahydronaphthalene-1/2/5-triol,CNC1CCc2c(ccc(c2O)O)C1O,3
7XS8,4,,,,,,7XS8,Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants.,Crystal structure of SARS-CoV-2 spike receptor binding domain bound with P5S-1H1 Fab,VIRAL PROTEIN/IMMUNE SYSTEM,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,2,7XS8,wildtype,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7XUO,4,,,,,,7XUO,Structures of the human Wilson disease copper transporter ATP7B.,Structure of ATP7B C983S/C985S/D1027A mutant with cisplatin in presence of ATOX1,TRANSLOCATE/METAL TRANSPORT,ATP7B/ PWD/ WC1/ WND,7.2.2.8,GO:0005794/ GO:0000139/ GO:0005770/ GO:0016020/ GO:0005739/ GO:0005886/ GO:0032588/ GO:0005524/ GO:0016887/ GO:0005507/ GO:0005375/ GO:0043682/ GO:0140581/ GO:0006878/ GO:0006882/ GO:0060003/ GO:0055070/ GO:0015677/ GO:0006825/ GO:0051649/ GO:0034220/ GO:0007595/ GO:0015680/ GO:0046688/ GO:0051208/ GO:1990961/ IPR023299/ IPR018303/ IPR023298/ IPR008250/ IPR036412/ IPR023214/ IPR017969/ IPR006122/ IPR006121/ IPR036163/ IPR027256/ IPR001757/ IPR044492/ P35670/ Transmembrane.Alpha-helical polytopic.P-type ATPase (P-ATPase).Copper-transporting P-type ATPase/ Generic PDBTM,1,7XUO,Mutant,P35670,UniProt,Pt,195.078,PT,PLATINUM (II) ION,[Pt+2],2
7Y0H,4,,,,,,7Y0H,Cryo-EM structure of human IgM-Fc in complex with the J chain and the P. falciparum VAR2CSA FCR3,Cryo-EM structure of human IgM-Fc in complex with the J chain and the P. falciparum VAR2CSA FCR3,IMMUNE SYSTEM,IGHM,,GO:0072562/ GO:0009986/ GO:0009897/ GO:0070062/ GO:0005615/ GO:0071757/ GO:0071753/ GO:0042571/ GO:0071756/ GO:0005886/ GO:0003823/ GO:0002250/ GO:0019731/ GO:0050853/ GO:0006958/ GO:0042742/ GO:0050829/ GO:0045087/ GO:0006911/ GO:0006910/ GO:0050871/ IPR007110/ IPR036179/ IPR013783/ IPR003006/ IPR003597/ P01871,1,7Y0H,wildtype,P01871,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
7Y7W,4,,,,,,7Y7W,Structural investigation of the GABA transporter GAT1,Cryo-EM structure of human GABA transporter GAT1 bound with GABA in NaCl solution in an inward-occluded state at 2.4 angstrom,TRANSPORT PROTEIN,SLC6A1/ GABATR/ GABT1/ GAT1,,GO:0070161/ GO:0030424/ GO:0009986/ GO:0098982/ GO:0016020/ GO:0043005/ GO:0043025/ GO:0005886/ GO:0015185/ GO:0005332/ GO:0042802/ GO:0046872/ GO:0015378/ GO:0008306/ GO:0007268/ GO:1902476/ GO:0051939/ GO:0051936/ GO:0098658/ GO:0007613/ GO:0032229/ GO:0014054/ GO:0051592/ GO:0042220/ GO:0032355/ GO:0010035/ GO:0010288/ GO:0014074/ GO:0009744/ GO:0009636/ GO:0098719/ GO:0035725/ GO:0050808/ GO:0150104/ IPR000175/ IPR002980/ IPR037272/ P30531/ Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Neurotransmitter: sodium symporter/ Generic PDBTM,1,7Y7W,wildtype,P30531,UniProt,C4 H9 N O2,103.12,ABU,GAMMA-AMINO-BUTANOIC ACID,C(CC(=O)O)CN,2
7Y7Y,4,,,,,,7Y7Y,Structural investigation of the GABA transporter GAT1,Cryo-EM structure of human GABA transporter GAT1 bound with nipecotic acid in NaCl solution in an inward-occluded state at 2.4 angstrom,TRANSPORT PROTEIN,SLC6A1/ GABATR/ GABT1/ GAT1,,GO:0070161/ GO:0030424/ GO:0009986/ GO:0098982/ GO:0016020/ GO:0043005/ GO:0043025/ GO:0005886/ GO:0015185/ GO:0005332/ GO:0042802/ GO:0046872/ GO:0015378/ GO:0008306/ GO:0007268/ GO:1902476/ GO:0051939/ GO:0051936/ GO:0098658/ GO:0007613/ GO:0032229/ GO:0014054/ GO:0051592/ GO:0042220/ GO:0032355/ GO:0010035/ GO:0010288/ GO:0014074/ GO:0009744/ GO:0009636/ GO:0098719/ GO:0035725/ GO:0050808/ GO:0150104/ IPR000175/ IPR002980/ IPR037272/ P30531/ Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Neurotransmitter: sodium symporter/ Generic PDBTM,1,7Y7Y,wildtype,P30531,UniProt,C6 H11 N O2,129.157,ID7,(3R)-piperidine-3-carboxylic acid,C1CC(CNC1)C(=O)O,2
7Y7Z,4,,,,,,7Y7Z,Structural investigation of the GABA transporter GAT1,Cryo-EM structure of human GABA transporter GAT1 bound with tiagabine in NaCl solution in an inward-open state at 3.2 angstrom,TRANSPORT PROTEIN,SLC6A1/ GABATR/ GABT1/ GAT1,,GO:0070161/ GO:0030424/ GO:0009986/ GO:0098982/ GO:0016020/ GO:0043005/ GO:0043025/ GO:0005886/ GO:0015185/ GO:0005332/ GO:0042802/ GO:0046872/ GO:0015378/ GO:0008306/ GO:0007268/ GO:1902476/ GO:0051939/ GO:0051936/ GO:0098658/ GO:0007613/ GO:0032229/ GO:0014054/ GO:0051592/ GO:0042220/ GO:0032355/ GO:0010035/ GO:0010288/ GO:0014074/ GO:0009744/ GO:0009636/ GO:0098719/ GO:0035725/ GO:0050808/ GO:0150104/ IPR000175/ IPR002980/ IPR037272/ P30531/ Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Neurotransmitter: sodium symporter/ Generic PDBTM,1,7Y7Z,wildtype,P30531,UniProt,C20 H25 N O2 S2,375.548,TGI,Tiagabine,Cc1ccsc1C(=CCCN2CCCC(C2)C(=O)O)c3c(ccs3)C,2
7YF2,4,,,,,,7YF2,Molecular basis for METTL9-mediated N1-histidine methylation,Crystal structure of METTL9 in complex with unmethylated SLC39A5 peptide and SAH,TRANSFERASE,METTL9/ DREV/ CGI-81,2.1.1,GO:0005783/ GO:0005739/ GO:0106370/ IPR007884/ IPR029063/ Q9H1A3,1,7YF2,Mutant,Q9H1A3,UniProt,C14 H20 N6 O5 S,384.411,SAH,S-ADENOSYL-L-HOMOCYSTEINE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)CSCCC(C(=O)O)N)O)O)N,3
7YF3,4,,,,,,7YF3,Molecular basis for METTL9-mediated N1-histidine methylation,Crystal structure of METTL9 in complex with unmethylated S100A9 peptide and SAH,TRANSFERASE,METTL9/ DREV/ CGI-81,2.1.1,GO:0005783/ GO:0005739/ GO:0106370/ IPR007884/ IPR029063/ Q9H1A3,1,7YF3,Mutant,Q9H1A3,UniProt,C14 H20 N6 O5 S,384.411,SAH,S-ADENOSYL-L-HOMOCYSTEINE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)CSCCC(C(=O)O)N)O)O)N,3
7YF4,4,,,,,,7YF4,Molecular basis for METTL9-mediated N1-histidine methylation,Crystal structure of METTL9 in complex with SLC39A5 mutant peptide and SAH,TRANSFERASE,METTL9/ DREV/ CGI-81,2.1.1,GO:0005783/ GO:0005739/ GO:0106370/ IPR007884/ IPR029063/ Q9H1A3,1,7YF4,Mutant,Q9H1A3,UniProt,C14 H20 N6 O5 S,384.411,SAH,S-ADENOSYL-L-HOMOCYSTEINE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)CSCCC(C(=O)O)N)O)O)N,3
7YFF,4,,,,,,7YFF,Distinct structure and gating mechanism in diverse NMDA receptors with GluN2C and GluN2D subunits.,Structure of GluN1a-GluN2D NMDA receptor in complex with agonist glycine and competitive antagonist CPP.,ELECTRON TRANSPORT,GRIN2D/ GluN2D/ NMDAR2D,,GO:0070161/ GO:0005789/ GO:0098978/ GO:0098686/ GO:0017146/ GO:0005886/ GO:0098839/ GO:0045211/ GO:0016595/ GO:0022849/ GO:0004970/ GO:0015276/ GO:0042165/ GO:0004972/ GO:0038023/ GO:1904315/ GO:0008344/ GO:0007420/ GO:0097553/ GO:0098976/ GO:0060079/ GO:0060291/ GO:2000463/ GO:0051968/ GO:1904062/ GO:0048168/ GO:0051930/ GO:0048167/ GO:0001964/ GO:0035249/ IPR001828/ IPR019594/ IPR001508/ IPR001320/ IPR028082/ O15399/ Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Glutamate-gated Ion Channel (GIC) family/ Generic PDBTM,2,7YFF,wildtype,O15399,UniProt,C8 H17 N2 O5 P,252.205,7RC,(2R)-4-(3-phosphonopropyl)piperazine-2-carboxylic acid,C1CN(CC(N1)C(=O)O)CCCP(=O)(O)O,6
7YFL,4,,,,,,7YFL,Distinct structure and gating mechanism in diverse NMDA receptors with GluN2C and GluN2D subunits.,Structure of GluN1a-GluN2D NMDA receptor in complex with agonists glycine and glutamate.,ELECTRON TRANSPORT,GRIN2D/ GluN2D/ NMDAR2D,,GO:0070161/ GO:0005789/ GO:0098978/ GO:0098686/ GO:0017146/ GO:0005886/ GO:0098839/ GO:0045211/ GO:0016595/ GO:0022849/ GO:0004970/ GO:0015276/ GO:0042165/ GO:0004972/ GO:0038023/ GO:1904315/ GO:0008344/ GO:0007420/ GO:0097553/ GO:0098976/ GO:0060079/ GO:0060291/ GO:2000463/ GO:0051968/ GO:1904062/ GO:0048168/ GO:0051930/ GO:0048167/ GO:0001964/ GO:0035249/ IPR001828/ IPR019594/ IPR001508/ IPR001320/ IPR028082/ O15399/ Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Glutamate-gated Ion Channel (GIC) family/ Generic PDBTM,2,7YFL,wildtype,O15399,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
7YFR,4,,,,,,7YFR,Distinct structure and gating mechanism in diverse NMDA receptors with GluN2C and GluN2D subunits.,Structure of GluN1a E698C-GluN2D NMDA receptor in cystines non-crosslinked state.,ELECTRON TRANSPORT,GRIN2D/ GluN2D/ NMDAR2D,,GO:0070161/ GO:0005789/ GO:0098978/ GO:0098686/ GO:0017146/ GO:0005886/ GO:0098839/ GO:0045211/ GO:0016595/ GO:0022849/ GO:0004970/ GO:0015276/ GO:0042165/ GO:0004972/ GO:0038023/ GO:1904315/ GO:0008344/ GO:0007420/ GO:0097553/ GO:0098976/ GO:0060079/ GO:0060291/ GO:2000463/ GO:0051968/ GO:1904062/ GO:0048168/ GO:0051930/ GO:0048167/ GO:0001964/ GO:0035249/ IPR001828/ IPR019594/ IPR001508/ IPR001320/ IPR028082/ O15399/ Generic PDBTM,2,7YFR,Mutant,O15399,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
7YKD,4,,,,,,7YKD,Cryo-EM structure of the human chemerin receptor 1-Gi protein complex bound to the C-terminal nonapeptide of chemerin.,Cryo-EM structure of the human chemerin receptor 1 complex with the C-terminal nonapeptide of chemerin,PEPTIDE BINDING PROTEIN,GNG2,,GO:0070062/ GO:0005834/ GO:0016020/ GO:0005886/ GO:0031681/ GO:0007191/ GO:0071870/ GO:0071380/ GO:0048144/ GO:0007186/ IPR015898/ IPR036284/ IPR001770/ P59768/ Transmembrane.Alpha-helical polytopic.Rhodopsin-like receptors and pumps.G-protein coupled receptors/ family A/ Generic PDBTM,5,7YKD,Mutant,P59768,UniProt,C27 H46 O,386.654,CLR,CHOLESTEROL,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C,7
7YV4,4,,,,,,7YV4,Farrerol directly activates the deubiqutinase UCHL3 to promote DNA repair and reprogramming when mediated by somatic cell nuclear transfer.,Crystal structure of human UCHL3 in complex with Farrerol,HYDROLASE,UCHL3,3.4.19.12,GO:0005737/ GO:0005829/ GO:0005654/ GO:0004843/ GO:0019784/ GO:0008233/ GO:0043130/ GO:0043687/ GO:0030163/ GO:0016579/ GO:0016567/ GO:0006511/ IPR038765/ IPR001578/ IPR036959/ P15374,1,7YV4,wildtype,P15374,UniProt,C17 H16 O5,300.306,JXY,(2~{S})-2-(4-hydroxyphenyl)-6/8-dimethyl-5/7-bis(oxidanyl)-2/3-dihydrochromen-4-one,Cc1c(c(c2c(c1O)C(=O)CC(O2)c3ccc(cc3)O)C)O,2
7ZI4,4,,,,,,7ZI4,Cryo-EM structure of the human INO80 complex bound to a WT nucleosome,Cryo-EM structure of the human INO80 complex bound to a WT nucleosome,DNA BINDING PROTEIN,HIST1H2BJ/ H2BFR/ H2BC11,,GO:0043505/ GO:0005829/ GO:0005615/ GO:0005654/ GO:0000786/ GO:0005634/ GO:0003677/ GO:0001530/ GO:0046982/ GO:0030527/ GO:0019731/ GO:0061844/ GO:0050829/ GO:0050830/ GO:0002227/ GO:0031640/ GO:0010804/ GO:0006334/ GO:0061644/ IPR009072/ IPR007125/ IPR000558/ P06899,11,7ZI4,wildtype,P06899,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,13
7ZLM,4,,,,,,7ZLM,Structure-based design of a phosphotyrosine-masked/ cell-penetrant small molecule covalently targeting Cys111 on the E3 ligase SOCS2,Crystal structure of SOCS2:ElonginB:ElonginC in complex with compound MN551,LIGASE,SOCS2/ CIS2/ SSI2/ STATI2,,GO:0005737/ GO:0005829/ GO:0005942/ GO:0046935/ GO:0005131/ GO:0005159/ GO:0008269/ GO:0032870/ GO:0060396/ GO:0035556/ GO:0007595/ GO:0060749/ GO:0043066/ GO:0040015/ GO:0046426/ GO:0046854/ GO:0045666/ GO:0016567/ GO:0007259/ GO:0001558/ GO:0009966/ GO:0032355/ IPR000980/ IPR036860/ IPR028410/ IPR035862/ IPR001496/ IPR036036/ O14508,1,7ZLM,wildtype,O14508,UniProt,C26 H26 Cl F N3 O7 P,577.926,JIH,[4-[(2~{S})-3-[[3-(2-chloranylethanoylamino)phenyl]methylamino]-2-[2-(4-fluorophenyl)ethanoylamino]-3-oxidanylidene-propyl]phenyl] dihydrogen phosphate,c1cc(cc(c1)NC(=O)CCl)CNC(=O)C(Cc2ccc(cc2)OP(=O)(O)O)NC(=O)Cc3ccc(cc3)F,4
7ZLN,4,,,,,,7ZLN,Structure-based design of a phosphotyrosine-masked/ cell-penetrant small molecule covalently targeting Cys111 on the E3 ligase SOCS2,Crystal structure of SOCS2:ElonginB:ElonginC in complex with compound 11,LIGASE,SOCS2/ CIS2/ SSI2/ STATI2,,GO:0005737/ GO:0005829/ GO:0005942/ GO:0046935/ GO:0005131/ GO:0005159/ GO:0008269/ GO:0032870/ GO:0060396/ GO:0035556/ GO:0007595/ GO:0060749/ GO:0043066/ GO:0040015/ GO:0046426/ GO:0046854/ GO:0045666/ GO:0016567/ GO:0007259/ GO:0001558/ GO:0009966/ GO:0032355/ IPR000980/ IPR036860/ IPR028410/ IPR035862/ IPR001496/ IPR036036/ O14508,1,7ZLN,wildtype,O14508,UniProt,C25 H25 F2 N2 O6 P,518.446,JI9,[4-[(2~{S})-3-[(4-fluoranyl-3-methyl-phenyl)methylamino]-2-[2-(4-fluorophenyl)ethanoylamino]-3-oxidanylidene-propyl]phenyl] dihydrogen phosphate,Cc1cc(ccc1F)CNC(=O)C(Cc2ccc(cc2)OP(=O)(O)O)NC(=O)Cc3ccc(cc3)F,4
7ZLO,4,,,,,,7ZLO,Structure-based design of a phosphotyrosine-masked/ cell-penetrant small molecule covalently targeting Cys111 on the E3 ligase SOCS2,Crystal structure of SOCS2:ElonginB:ElonginC in complex with compound 12,LIGASE,SOCS2/ CIS2/ SSI2/ STATI2,,GO:0005737/ GO:0005829/ GO:0005942/ GO:0046935/ GO:0005131/ GO:0005159/ GO:0008269/ GO:0032870/ GO:0060396/ GO:0035556/ GO:0007595/ GO:0060749/ GO:0043066/ GO:0040015/ GO:0046426/ GO:0046854/ GO:0045666/ GO:0016567/ GO:0007259/ GO:0001558/ GO:0009966/ GO:0032355/ IPR000980/ IPR036860/ IPR028410/ IPR035862/ IPR001496/ IPR036036/ O14508,1,7ZLO,wildtype,O14508,UniProt,C26 H27 F2 N2 O6 P,532.473,JI0,[4-[(2~{S})-3-[(3-ethyl-4-fluoranyl-phenyl)methylamino]-2-[2-(4-fluorophenyl)ethanoylamino]-3-oxidanylidene-propyl]phenyl] dihydrogen phosphate,CCc1cc(ccc1F)CNC(=O)C(Cc2ccc(cc2)OP(=O)(O)O)NC(=O)Cc3ccc(cc3)F,4
7ZLP,4,,,,,,7ZLP,Structure-based design of a phosphotyrosine-masked/ cell-penetrant small molecule covalently targeting Cys111 on the E3 ligase SOCS2,Crystal structure of SOCS2:ElonginB:ElonginC in complex with compound 9,LIGASE,SOCS2/ CIS2/ SSI2/ STATI2,,GO:0005737/ GO:0005829/ GO:0005942/ GO:0046935/ GO:0005131/ GO:0005159/ GO:0008269/ GO:0032870/ GO:0060396/ GO:0035556/ GO:0007595/ GO:0060749/ GO:0043066/ GO:0040015/ GO:0046426/ GO:0046854/ GO:0045666/ GO:0016567/ GO:0007259/ GO:0001558/ GO:0009966/ GO:0032355/ IPR000980/ IPR036860/ IPR028410/ IPR035862/ IPR001496/ IPR036036/ O14508,1,7ZLP,wildtype,O14508,UniProt,C24 H23 F2 N2 O6 P,504.42,JHR,[4-[(2~{S})-2-[2-(4-fluorophenyl)ethanoylamino]-3-[(4-fluorophenyl)methylamino]-3-oxidanylidene-propyl]phenyl] dihydrogen phosphate,c1cc(ccc1CC(C(=O)NCc2ccc(cc2)F)NC(=O)Cc3ccc(cc3)F)OP(=O)(O)O,4
7ZLR,4,,,,,,7ZLR,Structure-based design of a phosphotyrosine-masked/ cell-penetrant small molecule covalently targeting Cys111 on the E3 ligase SOCS2,Crystal structure of SOCS2:ElonginB:ElonginC in complex with compound 13,LIGASE,SOCS2/ CIS2/ SSI2/ STATI2,,GO:0005737/ GO:0005829/ GO:0005942/ GO:0046935/ GO:0005131/ GO:0005159/ GO:0008269/ GO:0032870/ GO:0060396/ GO:0035556/ GO:0007595/ GO:0060749/ GO:0043066/ GO:0040015/ GO:0046426/ GO:0046854/ GO:0045666/ GO:0016567/ GO:0007259/ GO:0001558/ GO:0009966/ GO:0032355/ IPR000980/ IPR036860/ IPR028410/ IPR035862/ IPR001496/ IPR036036/ O14508,1,7ZLR,wildtype,O14508,UniProt,C27 H27 F2 N2 O6 P,544.484,JH9,[4-[(2~{S})-3-[(4-fluoranyl-3-prop-2-enyl-phenyl)methylamino]-2-[2-(4-fluorophenyl)ethanoylamino]-3-oxidanylidene-propyl]phenyl] dihydrogen phosphate,C=CCc1cc(ccc1F)CNC(=O)C(Cc2ccc(cc2)OP(=O)(O)O)NC(=O)Cc3ccc(cc3)F,4
7ZLS,4,,,,,,7ZLS,Structure-based design of a phosphotyrosine-masked/ cell-penetrant small molecule covalently targeting Cys111 on the E3 ligase SOCS2,co-crystal structure of SOCS2:ElonginB:ElonginC in complex with compound 13,LIGASE,ELOB/ TCEB2,,GO:0031462/ GO:0031466/ GO:0005829/ GO:0070449/ GO:0005654/ GO:0030891/ GO:0001222/ GO:0031625/ GO:0032436/ GO:0016567/ GO:0065003/ GO:0006368/ GO:0006367/ IPR039049/ IPR000626/ IPR029071/ Q15370,2,7ZLS,wildtype,Q15370,UniProt,C27 H27 F2 N2 O6 P,544.484,JH9,[4-[(2~{S})-3-[(4-fluoranyl-3-prop-2-enyl-phenyl)methylamino]-2-[2-(4-fluorophenyl)ethanoylamino]-3-oxidanylidene-propyl]phenyl] dihydrogen phosphate,C=CCc1cc(ccc1F)CNC(=O)C(Cc2ccc(cc2)OP(=O)(O)O)NC(=O)Cc3ccc(cc3)F,5
7ZLY,4,,,,,,7ZLY,Structural insights into the human niacin receptor HCA2-G i signalling complex.,Crystal structure of human GPCR Niacin receptor (HCA2) expressed from Spodoptera frugiperda,MEMBRANE PROTEIN,HCAR2/ GPR109A/ HCA2/ HM74A/ NIACR1,,GO:0042597/ GO:0009055/ GO:0020037/ GO:0005506/ IPR009155/ IPR010980/ GO:0030054/ GO:0005886/ GO:0004930/ GO:0070553/ GO:0007186/ GO:0050995/ GO:0001781/ GO:0070165/ GO:0033031/ IPR000276/ IPR017452/ IPR028017/ Q8TDS4/ Transmembrane.Alpha-helical polytopic.Rhodopsin-like receptors and pumps.G-protein coupled receptors/ family A/ Generic PDBTM,1,7ZLY,wildtype,Q8TDS4,UniProt,C18 H34 O2,282.461,OLA,OLEIC ACID,CCCCCCCCC=CCCCCCCCC(=O)O,2
7ZLY,4,,,,,,7ZLY,Structural insights into the human niacin receptor HCA2-G i signalling complex.,Crystal structure of human GPCR Niacin receptor (HCA2) expressed from Spodoptera frugiperda,MEMBRANE PROTEIN,cybC,,GO:0042597/ GO:0009055/ GO:0020037/ GO:0005506/ IPR009155/ IPR010980/ GO:0030054/ GO:0005886/ GO:0004930/ GO:0070553/ GO:0007186/ GO:0050995/ GO:0001781/ GO:0070165/ GO:0033031/ IPR000276/ IPR017452/ IPR028017/ Q8TDS4/ Transmembrane.Alpha-helical polytopic.Rhodopsin-like receptors and pumps.G-protein coupled receptors/ family A/ Generic PDBTM,1,7ZLY,wildtype,P0ABE7,UniProt,C21 H40 O4,356.54,OLC,(2R)-2/3-dihydroxypropyl (9Z)-octadec-9-enoate,CCCCCCCCC=CCCCCCCCC(=O)OCC(CO)O,3
8A62,4,,,,,,8A62,A Systematic Approach to the Discovery of Protein-Protein Interaction Stabilizers.,Small molecule stabilizer (compound 2) for FOXO1 and 14-3-3,STRUCTURAL PROTEIN,FOXO1/ FKHR/ FOXO1A,,GO:0000785/ GO:0005737/ GO:0005829/ GO:0005739/ GO:0005654/ GO:0005634/ GO:0008013/ GO:0003682/ GO:0031490/ GO:0001228/ GO:0003700/ GO:0000981/ GO:0001227/ GO:1990841/ GO:0051721/ GO:0000978/ GO:0043565/ GO:0031625/ GO:0006915/ GO:0006914/ GO:0001568/ GO:0060070/ GO:0001678/ GO:0070417/ GO:0006974/ GO:0071455/ GO:0032869/ GO:0071732/ GO:0034599/ GO:0009267/ GO:0097009/ GO:0045444/ GO:0008286/ GO:0043066/ GO:0090090/ GO:1903243/ GO:0045599/ GO:0046676/ GO:0032873/ GO:0045892/ GO:0097150/ GO:0043065/ GO:0010508/ GO:0045722/ GO:0045732/ GO:0045944/ GO:0045893/ GO:0006473/ GO:2000177/ GO:2000377/ GO:0006357/ GO:0070542/ GO:0001659/ IPR001766/ IPR032067/ IPR032068/ IPR030456/ IPR036388/ IPR036390/ Q12778,2,8A62,Mutant,Q12778,UniProt,C19 H27 Cl2 N3 O3 S2,480.472,L7L,(3~{S})-1-[3/5-bis(chloranyl)-4-oxidanyl-phenyl]carbonyl-~{N}-[2-[2-(dimethylamino)ethyldisulfanyl]ethyl]piperidine-3-carboxamide,CN(C)CCSSCCNC(=O)C1CCCN(C1)C(=O)c2cc(c(c(c2)Cl)O)Cl,4
8A65,4,,,,,,8A65,A Systematic Approach to the Discovery of Protein-Protein Interaction Stabilizers.,Small molecule stabilizer (compound 3) for FOXO1 and 14-3-3,STRUCTURAL PROTEIN,FOXO1/ FKHR/ FOXO1A,,GO:0000785/ GO:0005737/ GO:0005829/ GO:0005739/ GO:0005654/ GO:0005634/ GO:0008013/ GO:0003682/ GO:0031490/ GO:0001228/ GO:0003700/ GO:0000981/ GO:0001227/ GO:1990841/ GO:0051721/ GO:0000978/ GO:0043565/ GO:0031625/ GO:0006915/ GO:0006914/ GO:0001568/ GO:0060070/ GO:0001678/ GO:0070417/ GO:0006974/ GO:0071455/ GO:0032869/ GO:0071732/ GO:0034599/ GO:0009267/ GO:0097009/ GO:0045444/ GO:0008286/ GO:0043066/ GO:0090090/ GO:1903243/ GO:0045599/ GO:0046676/ GO:0032873/ GO:0045892/ GO:0097150/ GO:0043065/ GO:0010508/ GO:0045722/ GO:0045732/ GO:0045944/ GO:0045893/ GO:0006473/ GO:2000177/ GO:2000377/ GO:0006357/ GO:0070542/ GO:0001659/ IPR001766/ IPR032067/ IPR032068/ IPR030456/ IPR036388/ IPR036390/ Q12778,2,8A65,wildtype,Q12778,UniProt,C19 H28 Cl2 N4 O2 S2,479.487,L70,(3~{S})-1-[2-azanyl-3/5-bis(chloranyl)phenyl]carbonyl-~{N}-[2-[2-(dimethylamino)ethyldisulfanyl]ethyl]piperidine-3-carboxamide,CN(C)CCSSCCNC(=O)C1CCCN(C1)C(=O)c2cc(cc(c2N)Cl)Cl,4
8ALK,4,,,,,,8ALK,Dephosphocholination by Legionella effector Lem3 functions through remodelling of the switch II region of Rab1b.,Structure of the Legionella phosphocholine hydrolase Lem3 in complex with its substrate Rab1,HYDROLASE,lem3/ lpg0696,3.1.3,GO:0005576/ GO:0030430/ GO:0044606/ GO:0043087/ IPR036457,1,8ALK,Mutant,Q5ZXN5,UniProt,C18 H33 Cl N5 O12 P2,608.881,OJU,2-[[[5-(4-azanyl-2-oxidanylidene-pyrimidin-1-yl)-3/4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]oxy-oxidanyl-phosphoryl]oxyethyl-[3-(2-chloranylethanoylamino)propyl]-dimethyl-azanium,C[N+](C)(CCCNC(=O)CCl)CCOP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)N2C=CC(=NC2=O)N)O)O,5
8BPE,4,,,,,,8BPE,Structural basis for Fc receptor recognition of immunoglobulin M.,8:1 binding of FcMR on IgM pentameric core,IMMUNE SYSTEM,FCMR/ FAIM3/ TOSO,,GO:0005576/ GO:0005886/ GO:0004888/ GO:0006968/ GO:0002376/ GO:0043066/ IPR036179/ IPR013783/ IPR003599/ IPR013106/ O60667,1,8BPE,wildtype,O60667,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
8BPF,4,,,,,,8BPF,Structural basis for Fc receptor recognition of immunoglobulin M.,FcMR binding at subunit Fcu1 of IgM pentamer,IMMUNE SYSTEM,FCMR/ FAIM3/ TOSO,,GO:0005576/ GO:0005886/ GO:0004888/ GO:0006968/ GO:0002376/ GO:0043066/ IPR036179/ IPR013783/ IPR003599/ IPR013106/ O60667,1,8BPF,wildtype,O60667,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
8BPG,4,,,,,,8BPG,Structural basis for Fc receptor recognition of immunoglobulin M.,FcMR binding at subunit Fcu3 of IgM pentamer,IMMUNE SYSTEM,FCMR/ FAIM3/ TOSO,,GO:0005576/ GO:0005886/ GO:0004888/ GO:0006968/ GO:0002376/ GO:0043066/ IPR036179/ IPR013783/ IPR003599/ IPR013106/ O60667,1,8BPG,wildtype,O60667,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
8CAA,4,,,,,,8CAA,Optimization of a Class of Dihydrobenzofurane Analogs toward Orally Efficacious YAP-TEAD Protein-Protein Interaction Inhibitors.,Crystal structure of TEAD4 in complex with YTP-13,TRANSCRIPTION,TEAD4/ RTEF1/ TCF13L1/ TEF3,,GO:0000785/ GO:0005737/ GO:0005654/ GO:0005634/ GO:0032993/ GO:0005667/ GO:0001228/ GO:0003700/ GO:0000981/ GO:0000978/ GO:0001708/ GO:0007566/ GO:0048568/ GO:0035329/ GO:0007517/ GO:1902459/ GO:0006357/ GO:0001501/ GO:0006351/ GO:0001830/ IPR000818/ IPR038096/ IPR027255/ IPR016361/ IPR041086/ Q15561,1,8CAA,wildtype,Q15561,UniProt,C29 H27 Cl F4 N2 O4,578.982,U3F,4-[bis(fluoranyl)methoxy]-2-[(2~{S})-5-chloranyl-6-fluoranyl-2-[[(4-oxidanylcyclohexyl)amino]methyl]-2-phenyl-3~{H}-1-benzofuran-4-yl]-3-fluoranyl-benzamide,c1ccc(cc1)C2(Cc3c(cc(c(c3c4c(ccc(c4F)OC(F)F)C(=O)N)Cl)F)O2)CNC5CCC(CC5)O,2
8DNF,4,,,,,,8DNF,Structural insights into actin isoforms.,Cryo-EM structure of nonmuscle gamma-actin,STRUCTURAL PROTEIN,ACTG1/ ACTG,,GO:0005884/ GO:0043296/ GO:0120220/ GO:0072562/ GO:0044305/ GO:0005911/ GO:0005856/ GO:0005829/ GO:0097433/ GO:0070062/ GO:0005615/ GO:0031941/ GO:0005925/ GO:0016020/ GO:0030016/ GO:0005634/ GO:0045335/ GO:0005886/ GO:0098871/ GO:0099143/ GO:0098685/ GO:0005524/ GO:0042802/ GO:0005522/ GO:0005200/ GO:0098973/ GO:0031625/ GO:0001525/ GO:0071346/ GO:0035633/ GO:0001738/ GO:0070527/ GO:0030335/ GO:0010628/ GO:0090303/ GO:1902396/ GO:0051893/ GO:0051492/ GO:0150111/ GO:0051592/ GO:0009612/ GO:0001895/ GO:0045214/ GO:0048488/ GO:0120192/ IPR004000/ IPR020902/ IPR004001/ IPR043129/ P63261,1,8DNF,Mutant,P63261,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,3
8DV3,4,,,,,,8DV3,alpha beta T-cell receptor recognition of self-phosphatidylinositol presented by CD1b.,Crystal structure of human CD1b presenting Phosphatidylinositol C34:1,IMMUNE SYSTEM,CD1B,,GO:0009986/ GO:0005829/ GO:0010008/ GO:0009897/ GO:0005615/ GO:0005794/ GO:0043231/ GO:0005765/ GO:0005886/ GO:0030883/ GO:0030884/ GO:0071723/ GO:0002250/ GO:0048006/ GO:0048007/ GO:0001916/ IPR007110/ IPR036179/ IPR013783/ IPR003597/ IPR011161/ IPR037055/ IPR011162/ P29016,1,8DV3,wildtype,P29016,UniProt,C43 H80 O13 P,836.061,PIE,1/2-DIACYL-SN-GLYCERO-3-PHOSPHOINOSITOL,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OC1C(C(C(C(C1O)O)O)O)O)OC(=O)CCCCCCCC=CCCCCCCCC,10
8DV3,4,,,,,,8DV3,alpha beta T-cell receptor recognition of self-phosphatidylinositol presented by CD1b.,Crystal structure of human CD1b presenting Phosphatidylinositol C34:1,IMMUNE SYSTEM,B2M/ CDABP0092/ HDCMA22P,,GO:0005829/ GO:0031905/ GO:0031901/ GO:0005788/ GO:0012507/ GO:0009897/ GO:0070062/ GO:0005576/ GO:0005615/ GO:0005925/ GO:0005794/ GO:0000139/ GO:1990712/ GO:0016020/ GO:0042824/ GO:0042612/ GO:0042613/ GO:0030670/ GO:0005886/ GO:0055038/ GO:0035580/ GO:1904724/ GO:0042802/ GO:0023026/ GO:0042803/ GO:1990000/ GO:0019731/ GO:0019885/ GO:0019886/ GO:0002481/ GO:0061844/ GO:0071281/ GO:0071283/ GO:0071222/ GO:0071316/ GO:0050829/ GO:0050830/ GO:0045087/ GO:0006826/ GO:0007611/ GO:0050680/ GO:2000978/ GO:0050768/ GO:0010977/ GO:1900121/ GO:0002503/ GO:2000774/ GO:1904434/ GO:0032092/ GO:1900122/ GO:0048260/ GO:0050870/ GO:0002726/ GO:0001916/ GO:1904437/ GO:0051289/ GO:0042026/ GO:0045646/ GO:0034756/ GO:0003254/ GO:0002237/ GO:0001895/ GO:0007608/ GO:0033077/ GO:0001913/ IPR015707/ IPR007110/ IPR036179/ IPR013783/ IPR003006/ IPR003597/ P61769,2,8DV3,wildtype,P61769,UniProt,C40 H80 O2,593.062,6UL,TETRACOSYL PALMITATE,CCCCCCCCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC,8
8DV4,4,,,,,,8DV4,alpha beta T-cell receptor recognition of self-phosphatidylinositol presented by CD1b.,Crystal structure of the BC8B TCR-CD1b-PI complex,IMMUNE SYSTEM,B2M/ CDABP0092/ HDCMA22P,,GO:0005829/ GO:0031905/ GO:0031901/ GO:0005788/ GO:0012507/ GO:0009897/ GO:0070062/ GO:0005576/ GO:0005615/ GO:0005925/ GO:0005794/ GO:0000139/ GO:1990712/ GO:0016020/ GO:0042824/ GO:0042612/ GO:0042613/ GO:0030670/ GO:0005886/ GO:0055038/ GO:0035580/ GO:1904724/ GO:0042802/ GO:0023026/ GO:0042803/ GO:1990000/ GO:0019731/ GO:0019885/ GO:0019886/ GO:0002481/ GO:0061844/ GO:0071281/ GO:0071283/ GO:0071222/ GO:0071316/ GO:0050829/ GO:0050830/ GO:0045087/ GO:0006826/ GO:0007611/ GO:0050680/ GO:2000978/ GO:0050768/ GO:0010977/ GO:1900121/ GO:0002503/ GO:2000774/ GO:1904434/ GO:0032092/ GO:1900122/ GO:0048260/ GO:0050870/ GO:0002726/ GO:0001916/ GO:1904437/ GO:0051289/ GO:0042026/ GO:0045646/ GO:0034756/ GO:0003254/ GO:0002237/ GO:0001895/ GO:0007608/ GO:0033077/ GO:0001913/ IPR015707/ IPR007110/ IPR036179/ IPR013783/ IPR003006/ IPR003597/ P61769,2,8DV4,wildtype,P61769,UniProt,C43 H80 O13 P,836.061,PIE,1/2-DIACYL-SN-GLYCERO-3-PHOSPHOINOSITOL,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OC1C(C(C(C(C1O)O)O)O)O)OC(=O)CCCCCCCC=CCCCCCCCC,14
8DV4,4,,,,,,8DV4,alpha beta T-cell receptor recognition of self-phosphatidylinositol presented by CD1b.,Crystal structure of the BC8B TCR-CD1b-PI complex,IMMUNE SYSTEM,B2M/ CDABP0092/ HDCMA22P,,GO:0005829/ GO:0031905/ GO:0031901/ GO:0005788/ GO:0012507/ GO:0009897/ GO:0070062/ GO:0005576/ GO:0005615/ GO:0005925/ GO:0005794/ GO:0000139/ GO:1990712/ GO:0016020/ GO:0042824/ GO:0042612/ GO:0042613/ GO:0030670/ GO:0005886/ GO:0055038/ GO:0035580/ GO:1904724/ GO:0042802/ GO:0023026/ GO:0042803/ GO:1990000/ GO:0019731/ GO:0019885/ GO:0019886/ GO:0002481/ GO:0061844/ GO:0071281/ GO:0071283/ GO:0071222/ GO:0071316/ GO:0050829/ GO:0050830/ GO:0045087/ GO:0006826/ GO:0007611/ GO:0050680/ GO:2000978/ GO:0050768/ GO:0010977/ GO:1900121/ GO:0002503/ GO:2000774/ GO:1904434/ GO:0032092/ GO:1900122/ GO:0048260/ GO:0050870/ GO:0002726/ GO:0001916/ GO:1904437/ GO:0051289/ GO:0042026/ GO:0045646/ GO:0034756/ GO:0003254/ GO:0002237/ GO:0001895/ GO:0007608/ GO:0033077/ GO:0001913/ IPR015707/ IPR007110/ IPR036179/ IPR013783/ IPR003006/ IPR003597/ P61769,4,8DV4,wildtype,P61769,UniProt,C42 H84 O2,621.115,CUY,tetracosyl octadecanoate,CCCCCCCCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC,11
8F0P,4,,,,,,8F0P,Cryo-EM reveals an unprecedented binding site for Na V 1.7 inhibitors enabling rational design of potent hybrid inhibitors.,Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the hybrid inhibitor GNE-1305,MEMBRANE PROTEIN/INHIBITOR,SCN9A,,GO:0030424/ GO:0001518/ GO:0031402/ GO:0005244/ GO:0005248/ GO:0061368/ GO:0006954/ GO:0086010/ GO:0045759/ GO:0019228/ GO:0009791/ GO:0034765/ GO:0009409/ GO:0009408/ GO:0009636/ GO:0019233/ GO:0035725/ GO:0006814/ IPR005821/ IPR000048/ IPR001696/ IPR044564/ IPR010526/ IPR024583/ IPR028803/ IPR043203/ IPR027359/ IPR031649/ Q15858/ Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Voltage-gated calcium and sodium channels/ Generic PDBTM,1,8F0P,wildtype,Q15858,UniProt,C27 H35 F N4 O3 S2,546.72,X7L,N-[6-(cyclopentylmethoxy)-1/3-benzothiazol-2-yl]-4-{[(1S/2S)-2-(dimethylamino)cyclohexyl]amino}-2-fluorobenzene-1-sulfonamide,CN(C)C1CCCCC1Nc2ccc(c(c2)F)S(=O)(=O)Nc3nc4ccc(cc4s3)OCC5CCCC5,6
8F0Q,4,,,,,,8F0Q,Cryo-EM reveals an unprecedented binding site for Na V 1.7 inhibitors enabling rational design of potent hybrid inhibitors.,Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the acylsulfonamide inhibitor GDC-0310,MEMBRANE PROTEIN/INHIBITOR,SCN9A,,GO:0030424/ GO:0001518/ GO:0031402/ GO:0005244/ GO:0005248/ GO:0061368/ GO:0006954/ GO:0086010/ GO:0045759/ GO:0019228/ GO:0009791/ GO:0034765/ GO:0009409/ GO:0009408/ GO:0009636/ GO:0019233/ GO:0035725/ GO:0006814/ IPR005821/ IPR000048/ IPR001696/ IPR044564/ IPR010526/ IPR024583/ IPR028803/ IPR043203/ IPR027359/ IPR031649/ Q15858/ Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Voltage-gated calcium and sodium channels/ Generic PDBTM,1,8F0Q,wildtype,D0E0C2,UniProt,C25 H29 Cl2 F N2 O4 S,543.478,X7R,5-cyclopropyl-4-({1-[(1S)-1-(3/5-dichlorophenyl)ethyl]piperidin-4-yl}methoxy)-2-fluoro-N-(methanesulfonyl)benzamide,CC(c1cc(cc(c1)Cl)Cl)N2CCC(CC2)COc3cc(c(cc3C4CC4)C(=O)NS(=O)(=O)C)F,5
8F0R,4,,,,,,8F0R,Cryo-EM reveals an unprecedented binding site for Na V 1.7 inhibitors enabling rational design of potent hybrid inhibitors.,Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the arylsulfonamide inhibitor GNE-3565,MEMBRANE PROTEIN/INHIBITOR,SCN9A,,GO:0030424/ GO:0001518/ GO:0031402/ GO:0005244/ GO:0005248/ GO:0061368/ GO:0006954/ GO:0086010/ GO:0045759/ GO:0019228/ GO:0009791/ GO:0034765/ GO:0009409/ GO:0009408/ GO:0009636/ GO:0019233/ GO:0035725/ GO:0006814/ IPR005821/ IPR000048/ IPR001696/ IPR044564/ IPR010526/ IPR024583/ IPR028803/ IPR043203/ IPR027359/ IPR031649/ Q15858/ Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Voltage-gated calcium and sodium channels/ Generic PDBTM,1,8F0R,wildtype,D0E0C2,UniProt,C25 H26 Cl F4 N5 O2 S,572.018,X7W,5-chloro-4-({(1S/2S/4S)-2-(dimethylamino)-4-[3-(trifluoromethyl)phenyl]cyclohexyl}amino)-2-fluoro-N-(pyrimidin-4-yl)benzene-1-sulfonamide,CN(C)C1CC(CCC1Nc2cc(c(cc2Cl)S(=O)(=O)Nc3ccncn3)F)c4cccc(c4)C(F)(F)F,4
8F0S,4,,,,,,8F0S,Cryo-EM reveals an unprecedented binding site for Na V 1.7 inhibitors enabling rational design of potent hybrid inhibitors.,Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the hybrid inhibitor GNE-9296,MEMBRANE PROTEIN/INHIBITOR,SCN9A/ NENA,,GO:0030424/ GO:0001518/ GO:0031402/ GO:0005244/ GO:0005248/ GO:0061368/ GO:0006954/ GO:0086010/ GO:0045759/ GO:0019228/ GO:0009791/ GO:0034765/ GO:0009409/ GO:0009408/ GO:0009636/ GO:0019233/ GO:0035725/ GO:0006814/ IPR005821/ IPR000048/ IPR001696/ IPR044564/ IPR010526/ IPR024583/ IPR028803/ IPR043203/ IPR027359/ IPR031649/ Q15858/ Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Voltage-gated calcium and sodium channels/ Generic PDBTM,1,8F0S,wildtype,Q15858,UniProt,C27 H34 Cl F2 N3 O4 S,570.091,X80,5-chloro-4-(cyclopentylmethoxy)-N-(4-{[(1S/2S)-2-(dimethylamino)cyclohexyl]amino}-2-fluorobenzene-1-sulfonyl)-2-fluorobenzamide,CN(C)C1CCCCC1Nc2ccc(c(c2)F)S(=O)(=O)NC(=O)c3cc(c(cc3F)OCC4CCCC4)Cl,6
8G5Y,4,,,,,,8G5Y,mRNA decoding in human is kinetically and structurally distinct from bacteria.,mRNA decoding in human is kinetically and structurally distinct from bacteria (IC state),RIBOSOME,RPS4X/ CCG2/ RPS4/ SCAR,,GO:0036464/ GO:0005829/ GO:0022626/ GO:0022627/ GO:0070062/ GO:0005925/ GO:0016020/ GO:0005654/ GO:0005844/ GO:1990904/ GO:0005840/ GO:0015935/ GO:0003723/ GO:0019843/ GO:0003735/ GO:0002181/ GO:0008284/ GO:0045727/ GO:0045471/ GO:0006412/ IPR032277/ IPR005824/ IPR041982/ IPR014722/ IPR000876/ IPR013845/ IPR038237/ IPR013843/ IPR018199/ IPR002942/ IPR036986/ P62701,9,8G5Y,wildtype,P62701,UniProt,C26 H35 N O6,457.559,3H3,4-{(2R/5S/6E)-2-hydroxy-5-methyl-7-[(2R/3S/4E/6Z/10E)-3-methyl-12-oxooxacyclododeca-4/6/10-trien-2-yl]-4-oxooct-6-en-1-yl}piperidine-2/6-dione,CC1C=CC=CCCC=CC(=O)OC1C(=CC(C)C(=O)CC(CC2CC(=O)NC(=O)C2)O)C,89
8G5Z,4,,,,,,8G5Z,mRNA decoding in human is kinetically and structurally distinct from bacteria.,mRNA decoding in human is kinetically and structurally distinct from bacteria (GA state),RIBOSOME,,,,3,8G5Z,wildtype,555853,GenBank,C14 H19 N O4,265.305,ANM,ANISOMYCIN,CC(=O)OC1C(CNC1Cc2ccc(cc2)OC)O,91
8G5Z,4,,,,,,8G5Z,mRNA decoding in human is kinetically and structurally distinct from bacteria.,mRNA decoding in human is kinetically and structurally distinct from bacteria (GA state),RIBOSOME,RPS3A/ FTE1/ MFTL,,GO:0005737/ GO:0005829/ GO:0022626/ GO:0022627/ GO:0005783/ GO:0070062/ GO:0005925/ GO:0005730/ GO:0005654/ GO:0005634/ GO:1990904/ GO:0045202/ GO:0048027/ GO:0003723/ GO:0003735/ GO:0030154/ GO:0002181/ GO:0043066/ GO:0006412/ GO:0006413/ IPR027500/ IPR001593/ IPR018281/ P61247,5,8G5Z,wildtype,P61247,UniProt,C26 H35 N O6,457.559,3H3,4-{(2R/5S/6E)-2-hydroxy-5-methyl-7-[(2R/3S/4E/6Z/10E)-3-methyl-12-oxooxacyclododeca-4/6/10-trien-2-yl]-4-oxooct-6-en-1-yl}piperidine-2/6-dione,CC1C=CC=CCCC=CC(=O)OC1C(=CC(C)C(=O)CC(CC2CC(=O)NC(=O)C2)O)C,93
8G5Z,4,,,,,,8G5Z,mRNA decoding in human is kinetically and structurally distinct from bacteria.,mRNA decoding in human is kinetically and structurally distinct from bacteria (GA state),RIBOSOME,RPS2/ RPS4,,GO:0005737/ GO:0005829/ GO:0022626/ GO:0022627/ GO:0070062/ GO:0005925/ GO:0016020/ GO:0005654/ GO:0005634/ GO:0045296/ GO:0019899/ GO:0017134/ GO:0003729/ GO:0003723/ GO:0003735/ GO:0002181/ GO:0051443/ GO:0006412/ IPR000851/ IPR005324/ IPR020568/ IPR014721/ IPR005711/ IPR013810/ IPR018192/ P15880,10,8G5Z,wildtype,P15880,UniProt,C57 H87 N7 O15,1110.339,ZIY,plitidepsin,CCC(C)C1C(CC(=O)OC(C(=O)C(C(=O)NC(C(=O)N2CCCC2C(=O)N(C(C(=O)OC(C(C(=O)N1)NC(=O)C(CC(C)C)N(C)C(=O)C3CCCN3C(=O)C(=O)C)C)Cc4ccc(cc4)OC)C)CC(C)C)C)C(C)C)O,98
8G60,4,,,,,,8G60,mRNA decoding in human is kinetically and structurally distinct from bacteria.,mRNA decoding in human is kinetically and structurally distinct from bacteria (CR state),RIBOSOME,RPS29,,GO:0005737/ GO:0098556/ GO:0005829/ GO:0022627/ GO:0070062/ GO:0005925/ GO:0005654/ GO:0042788/ GO:0015935/ GO:0003735/ GO:0008270/ GO:0002181/ GO:0006412/ IPR039744/ IPR001209/ IPR043140/ IPR018271/ P62273,23,8G60,wildtype,P62273,UniProt,C57 H87 N7 O15,1110.339,ZIY,plitidepsin,CCC(C)C1C(CC(=O)OC(C(=O)C(C(=O)NC(C(=O)N2CCCC2C(=O)N(C(C(=O)OC(C(C(=O)N1)NC(=O)C(CC(C)C)N(C)C(=O)C3CCCN3C(=O)C(=O)C)C)Cc4ccc(cc4)OC)C)CC(C)C)C)C(C)C)O,97
8G61,4,,,,,,8G61,mRNA decoding in human is kinetically and structurally distinct from bacteria.,mRNA decoding in human is kinetically and structurally distinct from bacteria (AC state),RIBOSOME,RPS9,,GO:0005737/ GO:0005829/ GO:0022626/ GO:0022627/ GO:0070062/ GO:0005925/ GO:0016020/ GO:0005730/ GO:0005654/ GO:0005634/ GO:1990904/ GO:0005840/ GO:0015935/ GO:0045202/ GO:0003723/ GO:0019843/ GO:0003735/ GO:0045182/ GO:0002181/ GO:0008284/ GO:0045903/ GO:0006412/ IPR022801/ IPR005710/ IPR001912/ IPR018079/ IPR002942/ IPR036986/ P46781,8,8G61,wildtype,P46781,UniProt,C14 H19 N O4,265.305,ANM,ANISOMYCIN,CC(=O)OC1C(CNC1Cc2ccc(cc2)OC)O,88
8G61,4,,,,,,8G61,mRNA decoding in human is kinetically and structurally distinct from bacteria.,mRNA decoding in human is kinetically and structurally distinct from bacteria (AC state),RIBOSOME,RPS5,,GO:0005737/ GO:0005829/ GO:0022626/ GO:0022627/ GO:0070062/ GO:0005925/ GO:0016020/ GO:0005654/ GO:1990904/ GO:0005840/ GO:0003729/ GO:0003723/ GO:0019843/ GO:0003735/ GO:0002181/ GO:0006450/ GO:0000028/ GO:0006412/ GO:0006413/ IPR000235/ IPR005716/ IPR020606/ IPR023798/ IPR036823/ P46782,12,8G61,wildtype,P46782,UniProt,C26 H35 N O6,457.559,3H3,4-{(2R/5S/6E)-2-hydroxy-5-methyl-7-[(2R/3S/4E/6Z/10E)-3-methyl-12-oxooxacyclododeca-4/6/10-trien-2-yl]-4-oxooct-6-en-1-yl}piperidine-2/6-dione,CC1C=CC=CCCC=CC(=O)OC1C(=CC(C)C(=O)CC(CC2CC(=O)NC(=O)C2)O)C,90
8G6J,4,,,,,,8G6J,mRNA decoding in human is kinetically and structurally distinct from bacteria.,mRNA decoding in human is kinetically and structurally distinct from bacteria (GA state 2),RIBOSOME,RPS6/ OK/SW-cl.2,,GO:0044297/ GO:0005737/ GO:0036464/ GO:0005829/ GO:0022626/ GO:0022627/ GO:0030425/ GO:0005783/ GO:0016020/ GO:0005730/ GO:0005654/ GO:0005634/ GO:0048471/ GO:0005844/ GO:1990904/ GO:0015935/ GO:0019901/ GO:0003723/ GO:0003735/ GO:0006924/ GO:0002181/ GO:0048821/ GO:0000082/ GO:0007369/ GO:0042593/ GO:0022605/ GO:0043066/ GO:0001890/ GO:0043065/ GO:0008284/ GO:0042274/ GO:0006364/ GO:0033077/ GO:0002309/ GO:0031929/ GO:0006412/ IPR014401/ IPR001377/ IPR018282/ P62753,11,8G6J,wildtype,P62753,UniProt,C40 H71 N7 O9,794.033,YRB,(3R/6R/9S/12S/15S/18S/20R/24aR)-6-[(2S)-butan-2-yl]-3/12-bis[(1R)-1-hydroxy-2-methylpropyl]-8/9/11/17/18-pentamethyl-15-[(2S)-2-methylbutyl]hexadecahydropyrido[1/2-a][1/4/7/10/13/16/19]heptaazacyclohenicosine-1/4/7/10/13/16/19(21H)-heptone,CCC(C)CC1C(=O)N(C(C(=O)N2CCCCC2C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)C)O)C)C)C)C(C)CC)C(C(C)C)O)C)C,97
8GAE,4,,,,,,8GAE,Hsp90 provides a platform for kinase dephosphorylation by PP5.,Hsp90 provides platform for CRaf dephosphorylation by PP5,CHAPERONE,CDC37/ CDC37A,,GO:0101031/ GO:0005737/ GO:0005829/ GO:0070062/ GO:1990565/ GO:0051087/ GO:0031072/ GO:0051879/ GO:0019900/ GO:0019901/ GO:0019887/ GO:0097110/ GO:0051082/ GO:0098779/ GO:0010608/ GO:0006457/ GO:0050821/ GO:0006605/ GO:0000079/ GO:0060334/ GO:0060338/ IPR004918/ IPR013873/ IPR013874/ IPR038189/ IPR013855/ Q16543,2,8GAE,Mutant,Q16543,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,7
8GLP,4,,,,,,8GLP,mRNA decoding in human is kinetically and structurally distinct from bacteria.,mRNA decoding in human is kinetically and structurally distinct from bacteria (Consensus LSU focused refined structure),RIBOSOME,RPS6/ OK/SW-cl.2,,GO:0044297/ GO:0005737/ GO:0036464/ GO:0005829/ GO:0022626/ GO:0022627/ GO:0030425/ GO:0005783/ GO:0016020/ GO:0005730/ GO:0005654/ GO:0005634/ GO:0048471/ GO:0005844/ GO:1990904/ GO:0015935/ GO:0019901/ GO:0003723/ GO:0003735/ GO:0006924/ GO:0002181/ GO:0048821/ GO:0000082/ GO:0007369/ GO:0042593/ GO:0022605/ GO:0043066/ GO:0001890/ GO:0043065/ GO:0008284/ GO:0042274/ GO:0006364/ GO:0033077/ GO:0002309/ GO:0031929/ GO:0006412/ IPR014401/ IPR001377/ IPR018282/ P62753,11,8GLP,wildtype,P62753,UniProt,C26 H35 N O6,457.559,3H3,4-{(2R/5S/6E)-2-hydroxy-5-methyl-7-[(2R/3S/4E/6Z/10E)-3-methyl-12-oxooxacyclododeca-4/6/10-trien-2-yl]-4-oxooct-6-en-1-yl}piperidine-2/6-dione,CC1C=CC=CCCC=CC(=O)OC1C(=CC(C)C(=O)CC(CC2CC(=O)NC(=O)C2)O)C,87
8GV8,4,,,,,,8GV8,The structural basis of the pH-homeostasis mediated by the Cl - /HCO 3 - exchanger/ AE2.,The cryo-EM structure of hAE2 with DIDS,TRANSPORT PROTEIN,SLC4A2/ AE2/ EPB3L1/ HKB3/ MPB3L,,GO:0016324/ GO:0016323/ GO:0005925/ GO:0016020/ GO:0005886/ GO:0008509/ GO:0140900/ GO:0019899/ GO:0005452/ GO:0022857/ GO:0097186/ GO:0006820/ GO:0015701/ GO:0048565/ GO:0050801/ GO:0043377/ GO:2000565/ GO:0030316/ GO:0070175/ GO:0032956/ GO:0045124/ GO:0051453/ GO:0007283/ GO:0055085/ IPR001717/ IPR002978/ IPR018241/ IPR013769/ IPR011531/ IPR003020/ IPR016152/ P04920/ Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Anion exchanger family/ Generic PDBTM,1,8GV8,wildtype,P04920,UniProt,C16 H20 N2 O6 S4,464.6,4KU,2/2'-ethane-1/2-diylbis{5-[(sulfanylmethyl)amino]benzenesulfonic acid},c1cc(c(cc1NCS)S(=O)(=O)O)CCc2ccc(cc2S(=O)(=O)O)NCS,2
8HBF,4,,,,,,8HBF,NO binds to the distal site of haem in the fully activated soluble guanylate cyclase.,Structure of human soluble guanylate cyclase in the NO+Rio state at 3.1 angstrom,SIGNALING PROTEIN,GUCY1B1/ GUC1B3/ GUCSB3/ GUCY1B3,4.6.1.2,GO:0098978/ GO:0008074/ GO:0098831/ GO:0004016/ GO:0047805/ GO:0005525/ GO:0004383/ GO:0020037/ GO:0051879/ GO:0046872/ GO:0044877/ GO:0038023/ GO:0008015/ GO:0071732/ GO:0006182/ GO:0019934/ GO:0007263/ GO:0038060/ GO:0070482/ GO:0099555/ IPR001054/ IPR018297/ IPR038158/ IPR011644/ IPR011645/ IPR042463/ IPR024096/ IPR029787/ Q02153,2,8HBF,Mutant,Q02153,UniProt,C20 H19 F N8 O2,422.416,GZO,methyl ~{N}-[4/6-bis(azanyl)-2-[1-[(2-fluorophenyl)methyl]pyrazolo[3/4-b]pyridin-3-yl]pyrimidin-5-yl]-~{N}-methyl-carbamate,CN(c1c(nc(nc1N)c2c3cccnc3n(n2)Cc4ccccc4F)N)C(=O)OC,6
8IBU,4,,,,,,8IBU,Structural basis for motilin and erythromycin recognition by motilin receptor.,Cryo-EM structure of the erythromycin-bound motilin receptor-Gq protein complex,SIGNALING PROTEIN,,,,1,8IBU,wildtype,,,C37 H67 N O13,733.927,ERY,ERYTHROMYCIN A,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,6
8IF3,4,,,,,,8IF3,Recognition Mechanism of a Novel Gabapentinoid Drug/ Mirogabalin/ for Recombinant Human alpha 2 delta 1/ a Voltage-Gated Calcium Channel Subunit.,Structure of human alpha-2/delta-1 with mirogabalin,MEMBRANE PROTEIN,CACNA2D1/ CACNL2A/ CCHL2A/ MHS3,,GO:0070062/ GO:1990454/ GO:0016529/ GO:0005891/ GO:0046872/ GO:0005245/ GO:0098703/ GO:0070588/ GO:0061577/ GO:0006816/ GO:0060402/ GO:0086002/ GO:1904646/ GO:0086048/ GO:1901843/ GO:0045933/ GO:1902514/ GO:0051924/ GO:0086091/ GO:0098903/ GO:0060307/ IPR013680/ IPR013608/ IPR002035/ IPR036465/ P54289/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Channels: Calcium Ion-Selective.Ca<sub>v</sub> voltage-gated calcium channel 慣<sub>2</sub>灌1 subunit alone,1,8IF3,wildtype,P54289,UniProt,C12 H19 N O2,209.285,8X9,2-[(1R/5S/6S)-6-(aminomethyl)-3-ethyl-6-bicyclo[3.2.0]hept-3-enyl]acetic acid,CCC1=CC2C(C1)CC2(CC(=O)O)CN,4
8IOY,4,,,,,,8IOY,Structures of the human Wilson disease copper transporter ATP7B.,Structure of ATP7B C983S/C985S/D1027A mutant with AMP-PNP,TRANSLOCASE,ATP7B/ PWD/ WC1/ WND,7.2.2.8,GO:0005794/ GO:0000139/ GO:0005770/ GO:0016020/ GO:0005739/ GO:0005886/ GO:0032588/ GO:0005524/ GO:0016887/ GO:0005507/ GO:0005375/ GO:0043682/ GO:0140581/ GO:0006878/ GO:0006882/ GO:0060003/ GO:0055070/ GO:0015677/ GO:0006825/ GO:0051649/ GO:0034220/ GO:0007595/ GO:0015680/ GO:0046688/ GO:0051208/ GO:1990961/ IPR023299/ IPR018303/ IPR023298/ IPR008250/ IPR036412/ IPR023214/ IPR017969/ IPR006122/ IPR006121/ IPR036163/ IPR027256/ IPR001757/ IPR044492/ P35670/ Transmembrane.Alpha-helical polytopic.P-type ATPase (P-ATPase).Copper-transporting P-type ATPase/ Generic PDBTM,1,8IOY,Mutant,P35670,UniProt,C10 H17 N6 O12 P3,506.196,ANP,PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(NP(=O)(O)O)O)O)O)N,2
8SAQ,4,,,,,,8SAQ,Structural basis for breadth development in the HIV-1 V3-glycan targeting DH270 antibody clonal lineage.,CryoEM structure of DH270.6-CH848.0526.25,VIRAL PROTEIN/IMMUNE SYSTEM,,,GO:0044175/ GO:0020002/ GO:0005886/ GO:0019031/ GO:0055036/ GO:0005198/ GO:0075512/ GO:0039654/ GO:0019064/ GO:0019049/ GO:1903905/ GO:1903908/ GO:1903911/ GO:0019082/ GO:0019062/ IPR036377/ IPR037527/ IPR000328/ IPR000777,1,8SAQ,wildtype,A0A1W6IHA4,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,7
8SAR,4,,,,,,8SAR,Structural basis for breadth development in the HIV-1 V3-glycan targeting DH270 antibody clonal lineage.,CryoEM structure of DH270.6-CH848.10.17,VIRAL PROTEIN/IMMUNE SYSTEM,,,GO:0044175/ GO:0020002/ GO:0005886/ GO:0019031/ GO:0055036/ GO:0005198/ GO:0075512/ GO:0039654/ GO:0019064/ GO:1903905/ GO:1903908/ GO:1903911/ GO:0019082/ GO:0019062/ IPR036377/ IPR037527/ IPR000328/ IPR000777,1,8SAR,wildtype,A0A1W6IPB2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,10
8SAV,4,,,,,,8SAV,Structural basis for breadth development in the HIV-1 V3-glycan targeting DH270 antibody clonal lineage.,CryoEM structure of VRC01-CH848.0526.25,VIRAL PROTEIN/IMMUNE SYSTEM,,,GO:0044175/ GO:0020002/ GO:0005886/ GO:0019031/ GO:0055036/ GO:0005198/ GO:0075512/ GO:0039654/ GO:0019064/ GO:0019049/ GO:1903905/ GO:1903908/ GO:1903911/ GO:0019082/ GO:0019062/ IPR036377/ IPR037527/ IPR000328/ IPR000777,1,8SAV,wildtype,A0A1W6IHA4,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,8
7QRI,5,,,,,,7QRI,Structural characterization of human tryptophan hydroxylase 2 reveals that L-Phe is superior to L-Trp as the regulatory domain ligand.,Regulatory domain dimer of tryptophan hydroxylase 2 in complex with L-Phe,OXIDOREDUCTASE,TPH2/ NTPH,1.14.16.4,GO:0005829/ GO:0043005/ GO:0005506/ GO:0004510/ GO:0009072/ GO:0071285/ GO:0007623/ GO:0014823/ GO:0051592/ GO:0043627/ GO:0051384/ GO:0031667/ GO:0042427/ IPR045865/ IPR002912/ IPR001273/ IPR018301/ IPR036951/ IPR036329/ IPR019774/ IPR005963/ IPR041904/ IPR019773/ Q8IWU9,1,7QRI,wlidetype,Q8IWU9,UniProt,C9 H11 N O2,165.189,PHE,PHENYLALANINE,c1ccc(cc1)CC(C(=O)O)N,2
7QTT,5,,,,,,7QTT,Structural basis of catalytic activation in human splicing.,Structural organization of a late activated human spliceosome (Baqr/ core region),SPLICING,SF3B5/ SF3B10,,GO:0005654/ GO:0005634/ GO:0071011/ GO:0000124/ GO:0005681/ GO:0005689/ GO:0005686/ GO:0071005/ GO:0005684/ GO:0003723/ GO:1990935/ GO:0043966/ GO:0035521/ GO:0035522/ GO:0000398/ GO:0045893/ GO:0006282/ GO:0043484/ GO:1903241/ IPR009846/ IPR017089/ Q9BWJ5,2,7QTT,wlidetype,Q9BWJ5,UniProt,C6 H18 O24 P6,660.035,IHP,INOSITOL HEXAKISPHOSPHATE,C1(C(C(C(C(C1OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O,39
7QTT,5,,,,,,7QTT,Structural basis of catalytic activation in human splicing.,Structural organization of a late activated human spliceosome (Baqr/ core region),SPLICING,SF3B1/ SAP155,,GO:0110016/ GO:0071013/ GO:0016607/ GO:0005730/ GO:0005654/ GO:0005634/ GO:0005681/ GO:0034693/ GO:0005689/ GO:0005686/ GO:0071005/ GO:0071004/ GO:0005684/ GO:0003729/ GO:0003723/ GO:1990935/ GO:0006338/ GO:0000398/ GO:0035066/ GO:0045943/ GO:0045944/ GO:0045945/ GO:0008380/ GO:0000375/ GO:0000245/ GO:1903241/ IPR011989/ IPR016024/ IPR015016/ IPR038737/ O75533,3,7QTT,wlidetype,O75533,UniProt,C10 H16 N5 O14 P3,523.18,GTP,GUANOSINE-5'-TRIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,40
7R2M,5,,,,,,7R2M,SYNJ2BP PDZ domain in complex with a synthetic Vangl2 peptide.,SYNJ2BP complex with a synthetic Vangl2 peptide (9mer).,MEMBRANE PROTEIN,SYNJ2BP/ OMP25,,GO:0005604/ GO:0005576/ GO:0016020/ GO:0005509/ GO:0005544/ GO:0008092/ GO:0004859/ IPR001464/ IPR018502/ IPR018252/ IPR037104/ IPR002389/ GO:0016323/ GO:0030054/ GO:0005739/ GO:0031594/ GO:0043005/ GO:0098839/ GO:0098609/ GO:0007268/ GO:0045197/ GO:0016525/ GO:0010596/ GO:0001937/ GO:0070373/ GO:1903671/ GO:0006605/ GO:0043113/ GO:0097120/ GO:0030100/ GO:0008593/ GO:0007266/ IPR001478/ IPR036034/ P57105,1,7R2M,wlidetype,P57105,UniProt,C16 H34 O8,354.436,PE4,2-{2-[2-(2-{2-[2-(2-ETHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHOXY]-ETHOXY}-ETHANOL,CCOCCOCCOCCOCCOCCOCCOCCO,5
7RIG,5,,,,,,7RIG,Allosteric role of the citrate synthase homology domain of ATP citrate lyase.,Structure of ACLY-D1026A-substrates,TRANSFERASE,ACLY,2.3.3.8,GO:0035578/ GO:0005829/ GO:0070062/ GO:0005576/ GO:1904813/ GO:0016020/ GO:0005654/ GO:0005524/ GO:0003878/ GO:0046872/ GO:0006085/ GO:0006695/ GO:0006101/ GO:0015936/ GO:0006633/ GO:0008610/ GO:0006107/ IPR014608/ IPR017440/ IPR032263/ IPR016143/ IPR002020/ IPR036969/ IPR033847/ IPR003781/ IPR005811/ IPR036291/ IPR017866/ IPR016102/ P53396,1,7RIG,mutant,P53396,UniProt,C27 H42 N7 O22 P3 S,941.642,Q5B,(3S)-citryl-Coenzyme A,CC(C)(COP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)n2cnc3c2ncnc3N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CC(CC(=O)O)(C(=O)O)O)O,3
7RKZ,5,,,,,,7RKZ,Allosteric role of the citrate synthase homology domain of ATP citrate lyase.,Structure of ACLY D1026A-substrates-asym-int,TRANSFERASE,ACLY,2.3.3.8,GO:0035578/ GO:0005829/ GO:0070062/ GO:0005576/ GO:1904813/ GO:0016020/ GO:0005654/ GO:0005524/ GO:0003878/ GO:0046872/ GO:0006085/ GO:0006695/ GO:0006101/ GO:0015936/ GO:0006633/ GO:0008610/ GO:0006107/ IPR014608/ IPR017440/ IPR032263/ IPR016143/ IPR002020/ IPR036969/ IPR033847/ IPR003781/ IPR005811/ IPR036291/ IPR017866/ IPR016102/ P53396,1,7RKZ,mutant,P53396,UniProt,C27 H42 N7 O22 P3 S,941.642,Q5B,(3S)-citryl-Coenzyme A,CC(C)(COP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)n2cnc3c2ncnc3N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CC(CC(=O)O)(C(=O)O)O)O,3
7RMP,5,,,,,,7RMP,Allosteric role of the citrate synthase homology domain of ATP citrate lyase.,Structure of ACLY D1026A - substrates-asym,TRANSFERASE,ACLY,2.3.3.8,GO:0035578/ GO:0005829/ GO:0070062/ GO:0005576/ GO:1904813/ GO:0016020/ GO:0005654/ GO:0005524/ GO:0003878/ GO:0046872/ GO:0006085/ GO:0006695/ GO:0006101/ GO:0015936/ GO:0006633/ GO:0008610/ GO:0006107/ IPR014608/ IPR017440/ IPR032263/ IPR016143/ IPR002020/ IPR036969/ IPR033847/ IPR003781/ IPR005811/ IPR036291/ IPR017866/ IPR016102/ P53396,1,7RMP,mutant,P53396,UniProt,C27 H42 N7 O22 P3 S,941.642,Q5B,(3S)-citryl-Coenzyme A,CC(C)(COP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)n2cnc3c2ncnc3N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CC(CC(=O)O)(C(=O)O)O)O,3
7TRS,5,,,,,,7TRS,Structural and dynamic mechanisms of allostery at the M4 muscarinic acetylcholine receptor,Human M4 muscarinic acetylcholine receptor complex with Gi1 and the endogenous agonist acetylcholine,SIGNALING PROTEIN/IMMUNE SYSTEM,GNB1,,GO:0005737/ GO:0005829/ GO:0070062/ GO:1903561/ GO:0005834/ GO:0005765/ GO:0016020/ GO:0097381/ GO:0005886/ GO:0045202/ GO:0003924/ GO:0051020/ GO:0044877/ GO:0030159/ GO:0007191/ GO:0008283/ GO:0071870/ GO:0071380/ GO:0007213/ GO:0007186/ GO:0007200/ GO:0007265/ GO:0060041/ GO:0050909/ GO:0007165/ IPR020472/ IPR001632/ IPR016346/ IPR015943/ IPR001680/ IPR019775/ IPR036322/ P62873,1,7TRS,mutant,P62873,UniProt,C7 H16 N O2,146.207,ACH,ACETYLCHOLINE,CC(=O)OCC[N+](C)(C)C,6
7VPX,5,,,,,,7VPX,Mechanism for Branch Site Recognition and Proofreading During Prespliceosome Assembly,The cryo-EM structure of the human pre-A complex,SPLICING,SF1/ ZFM1/ ZNF162,,GO:0016604/ GO:0005654/ GO:0005634/ GO:0005840/ GO:0005681/ GO:0089701/ GO:0042802/ GO:0003729/ GO:0045131/ GO:0003723/ GO:0003714/ GO:0008270/ GO:0033327/ GO:0030238/ GO:0000389/ GO:0000398/ GO:0048662/ GO:0030575/ GO:0048024/ GO:0050810/ GO:0000245/ IPR045071/ IPR031150/ IPR004087/ IPR004088/ IPR036612/ IPR032570/ IPR001878/ Q15637,2,7VPX,wlidetype,Q15637,UniProt,C28 H45 N O8,523.659,SJT,spliceostatin A (form II),CC1CC(C(OC1CC=C(C)C=CC2C(C(CC(O2)(C)OC)(C)O)O)C)NC(=O)C=CC(C)OC(=O)C,30
7W1M,5,,,,,,7W1M,Cryo-EM structure of human cohesin-CTCF complex,Cryo-EM structure of human cohesin-CTCF-DNA complex,DNA BINDING PROTEIN/DNA,RAD21/ HR21/ KIAA0078/ NXP1/ SCC1,,GO:0000785/ GO:0005694/ GO:0000775/ GO:0008278/ GO:0005829/ GO:0016020/ GO:0030496/ GO:0016363/ GO:0005654/ GO:0005634/ GO:0000922/ GO:0003682/ GO:0003677/ GO:0006915/ GO:0051301/ GO:0006310/ GO:0006302/ GO:0034089/ GO:0010972/ GO:0045841/ GO:0045876/ GO:0071168/ GO:0007131/ GO:0006357/ GO:1990414/ GO:0007062/ IPR039781/ IPR006909/ IPR006910/ IPR023093/ IPR036390/ O60216,3,7W1M,mutant,O60216,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,9
7XJF,5,,,,,,7XJF,Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment.,Crystal structure of 6MW3211 Fab in complex with CD47,IMMUNE SYSTEM,,,,1,7XJF,mutant,,,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,7
7XUJ,5,,,,,,7XUJ,human SLC26A3 in complex with UK5099,Human SLC26A3 in complex with UK5099,TRANSPORT PROTEIN,SLC26A3/ DRA,,GO:0016324/ GO:0031526/ GO:0016020/ GO:0005886/ GO:0097225/ GO:0015106/ GO:0015108/ GO:0140900/ GO:0019531/ GO:0008271/ GO:0005452/ GO:0015116/ GO:0071320/ GO:0051454/ GO:0060081/ GO:0006820/ GO:0006811/ GO:0048240/ IPR018045/ IPR011547/ IPR001902/ IPR002645/ IPR036513/ P40879/ Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Sulfate permease/ Generic PDBTM,1,7XUJ,wlidetype,P40879,UniProt,C18 H12 N2 O2,288.3,I2R,(E)-2-cyano-3-(1-phenylindol-3-yl)prop-2-enoic acid,c1ccc(cc1)n2cc(c3c2cccc3)C=C(C#N)C(=O)O,2
7XUL,5,,,,,,7XUL,Structure of human SLC26A3 in complex with Tenidap,Human SLC26A3 in complex with Tenidap,PROTEIN TRANSPORT,SLC26A3/ DRA,,GO:0016324/ GO:0031526/ GO:0016020/ GO:0005886/ GO:0097225/ GO:0015106/ GO:0015108/ GO:0140900/ GO:0019531/ GO:0008271/ GO:0005452/ GO:0015116/ GO:0071320/ GO:0051454/ GO:0060081/ GO:0006820/ GO:0006811/ GO:0048240/ IPR018045/ IPR011547/ IPR001902/ IPR002645/ IPR036513/ P40879/ Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Sulfate permease/ Generic PDBTM,1,7XUL,wlidetype,P40879,UniProt,C14 H9 Cl N2 O3 S,320.751,I2U,5-chloranyl-2-oxidanyl-3-thiophen-2-ylcarbonyl-indole-1-carboxamide,c1cc(sc1)C(=O)c2c3cc(ccc3n(c2O)C(=O)N)Cl,2
7XY6,5,,,,,,7XY6,Cryo-EM structure of the human adenosine A 2B receptor-G s signaling complex.,Adenosine receptor bound to an agonist in complex with G protein obtained by cryo-EM,MEMBRANE PROTEIN,cybC,,GO:0042597/ GO:0009055/ GO:0020037/ GO:0005506/ IPR009155/ IPR010980/ GO:0098978/ GO:0005886/ GO:0098793/ GO:0098685/ GO:0001609/ GO:0004930/ GO:0007190/ GO:0007189/ GO:0031668/ GO:0019934/ GO:0007186/ GO:0043303/ GO:0010753/ GO:0032722/ GO:0002882/ GO:0031284/ GO:0032755/ GO:0043306/ GO:0010575/ GO:0099171/ GO:0060087/ GO:0042311/ IPR001435/ IPR001634/ IPR000276/ IPR017452/ P29275/ Transmembrane.Alpha-helical polytopic.Rhodopsin-like receptors and pumps.G-protein coupled receptors/ family A/ Generic PDBTM,4,7XY6,mutant,P0ABE7,UniProt,C19 H17 N5 O2 S,379.436,I5D,2-[6-azanyl-3/5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-yl]sulfanylethanamide,c1cc(ccc1c2c(c(nc(c2C#N)SCC(=O)N)N)C#N)OCC3CC3,5
7Y48,5,,,,,,7Y48,Cryo-EM structures of mitochondrial ABC transporter ABCB10 in apo and biliverdin-bound form,Cryo-EM Structure of biliverdin-bound mitochondrial ABC transporter ABCB10 from Biortus,MEMBRANE PROTEIN,ABCB10,,GO:0005743/ GO:0005739/ GO:0140359/ GO:0005524/ GO:0016887/ GO:0042803/ GO:0048821/ GO:0006783/ GO:0006839/ GO:0034514/ GO:0045648/ GO:0070455/ GO:0046985/ IPR003593/ IPR011527/ IPR036640/ IPR003439/ IPR017871/ IPR030260/ IPR027417/ IPR039421/ Q9NRK6/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.ATP Binding Cassette (ABC) Transporters.ABCB10 Mitochondrial ABC transporter with bound biliverdin/ Transmembrane.Alpha-helical polytopic.ABC transporters.Lipid exporter family/ Generic PDBTM,1,7Y48,mutant,Q9NRK6,UniProt,C27 H46 O,386.654,CLR,CHOLESTEROL,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C,2
7Y48,5,,,,,,7Y48,Cryo-EM structures of mitochondrial ABC transporter ABCB10 in apo and biliverdin-bound form,Cryo-EM Structure of biliverdin-bound mitochondrial ABC transporter ABCB10 from Biortus,MEMBRANE PROTEIN,ABCB10,,GO:0005743/ GO:0005739/ GO:0140359/ GO:0005524/ GO:0016887/ GO:0042803/ GO:0048821/ GO:0006783/ GO:0006839/ GO:0034514/ GO:0045648/ GO:0070455/ GO:0046985/ IPR003593/ IPR011527/ IPR036640/ IPR003439/ IPR017871/ IPR030260/ IPR027417/ IPR039421/ Q9NRK6/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.ATP Binding Cassette (ABC) Transporters.ABCB10 Mitochondrial ABC transporter with bound biliverdin/ Transmembrane.Alpha-helical polytopic.ABC transporters.Lipid exporter family/ Generic PDBTM,1,7Y48,mutant,Q9NRK6,UniProt,C33 H34 N4 O6,582.646,IE5,3-[5-[(3-ethenyl-4-methyl-5-oxidanylidene-pyrrol-2-ylidene)methyl]-2-[(~{Z})-[5-[(~{Z})-(4-ethenyl-3-methyl-5-oxidanylidene-pyrrol-2-ylidene)methyl]-3-(3-hydroxy-3-oxopropyl)-4-methyl-pyrrol-2-ylidene]methyl]-4-methyl-1~{H}-pyrrol-3-yl]propanoic acid,Cc1c(c([nH]c1C=C2C(=C(C(=O)N2)C)C=C)C=C3C(=C(C(=N3)C=C4C(=C(C(=O)N4)C=C)C)C)CCC(=O)O)CCC(=O)O,3
7YIR,5,,,,,,7YIR,Structural Insights Uncover the Specific Phosphoinositide Recognition by the PH1 Domain of Arap3.,Crystal structure of N-terminal PH domain of ARAP3 protein from human,CYTOSOLIC PROTEIN,ARAP3/ CENTD3,,GO:0005737/ GO:0005856/ GO:0030027/ GO:0005886/ GO:0001726/ GO:0005096/ GO:0046872/ GO:0005547/ GO:0043325/ GO:0007010/ GO:0035021/ GO:0035024/ GO:0043547/ GO:0008360/ GO:0007165/ GO:0016192/ IPR037278/ IPR001164/ IPR038508/ IPR011993/ IPR001849/ IPR000159/ IPR008936/ IPR037858/ IPR000198/ IPR001660/ IPR013761/ IPR029071/ Q8WWN8,1,7YIR,wlidetype,Q8WWN8,UniProt,C4 H10 O3,106.12,PEG,DI(HYDROXYETHYL)ETHER,C(COCCO)O,2
7YIS,5,,,,,,7YIS,Structural Insights Uncover the Specific Phosphoinositide Recognition by the PH1 Domain of Arap3.,Crystal structure of N-terminal PH domain of ARAP3 protein in complex with inositol 1/3/4/5-tetrakisphosphate,CYTOSOLIC PROTEIN,ARAP3/ CENTD3,,GO:0005737/ GO:0005856/ GO:0030027/ GO:0005886/ GO:0001726/ GO:0005096/ GO:0046872/ GO:0005547/ GO:0043325/ GO:0007010/ GO:0035021/ GO:0035024/ GO:0043547/ GO:0008360/ GO:0007165/ GO:0016192/ IPR037278/ IPR001164/ IPR038508/ IPR011993/ IPR001849/ IPR000159/ IPR008936/ IPR037858/ IPR000198/ IPR001660/ IPR013761/ IPR029071/ Q8WWN8,1,7YIS,wlidetype,Q8WWN8,UniProt,C17 H36 O22 P4,716.35,4PT,(2R)-3-{[(S)-{[(2S/3R/5S/6S)-2/6-DIHYDROXY-3/4/5-TRIS(PHOSPHONOOXY)CYCLOHEXYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-2-(1-HYDROXYBUTOXY)PROPYL BUTYRATE,CCCC(O)OC(COC(=O)CCC)COP(=O)(O)OC1C(C(C(C(C1O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)O,2
7YNI,5,,,,,,7YNI,Structures of human SGLT with substrate bound,Structure of human SGLT1-MAP17 complex bound with substrate 4D4FDG in the occluded conformation,PROTEIN TRANSPORT,SLC5A1/ NAGT/ SGLT1,,GO:0016324/ GO:0031526/ GO:0005769/ GO:0070062/ GO:0043229/ GO:0097708/ GO:0048471/ GO:0005886/ GO:0015151/ GO:0055056/ GO:0015150/ GO:0005354/ GO:0015371/ GO:0005355/ GO:0005412/ GO:0005367/ GO:0015146/ GO:0005372/ GO:0000017/ GO:0015756/ GO:0015757/ GO:0098708/ GO:1904659/ GO:0001951/ GO:0106001/ GO:0015798/ GO:0015750/ GO:0035623/ GO:0010035/ GO:0098719/ GO:0006814/ GO:0035377/ GO:0150104/ IPR038377/ IPR001734/ IPR018212/ P13866/ Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Solute:sodium symporter/ Generic PDBTM,1,7YNI,wlidetype,P13866,UniProt,C6 H11 F O5,182.147,KQC,(2R/3R/4R/5S/6R)-5-fluoranyl-6-(hydroxymethyl)oxane-2/3/4-triol,C(C1C(C(C(C(O1)O)O)O)F)O,3
7ZRB,5,,,,,,7ZRB,Crystal structure of Beta-catenin Armadillo repeats domain in complex with the inhibitor RS6452,Crystal structure of Beta-catenin Armadillo repeats domain in complex with the inhibitor RS6452,CELL ADHESION,CTNNB1,,GO:0005912/ GO:0005886/ GO:0045296/ GO:0007155/ IPR011989/ IPR016024/ IPR000225/ IPR013284,1,7ZRB,wlidetype,A0A2R8Y804,UniProt,C17 H13 Br N2 O2 S,389.266,JKI,4-bromanyl-~{N}-(3-pyridin-2-ylphenyl)benzenesulfonamide,c1ccnc(c1)c2cccc(c2)NS(=O)(=O)c3ccc(cc3)Br,2
7ZT6,5,,,,,,7ZT6,Structural and functional basis of inositol hexakisphosphate stimulation of NHEJ through its interaction with Ku70-Ku80,Cryo-EM structure of Ku 70/80 bound to inositol hexakisphosphate,DNA BINDING PROTEIN,XRCC6/ G22P1,3.6.4/ 4.2.99,GO:0000781/ GO:0005829/ GO:0070418/ GO:0005576/ GO:1904813/ GO:0043564/ GO:0016020/ GO:0070419/ GO:0000783/ GO:0005730/ GO:0005654/ GO:0005634/ GO:0032991/ GO:0032993/ GO:0034774/ GO:0005667/ GO:0051575/ GO:0005524/ GO:0008094/ GO:0030332/ GO:0003684/ GO:0003677/ GO:0003678/ GO:0003690/ GO:0016787/ GO:0044877/ GO:0003723/ GO:0097110/ GO:0042162/ GO:0000976/ GO:0002218/ GO:0071480/ GO:0071481/ GO:0006266/ GO:0097680/ GO:0006303/ GO:0045087/ GO:0045892/ GO:0045621/ GO:0045860/ GO:0045944/ GO:0045893/ GO:0000725/ GO:0048660/ GO:0000723/ IPR006165/ IPR006164/ IPR027388/ IPR005160/ IPR005161/ IPR003034/ IPR036361/ IPR016194/ IPR036465/ P12956,1,7ZT6,wlidetype,P12956,UniProt,C6 H18 O24 P6,660.035,IHP,INOSITOL HEXAKISPHOSPHATE,C1(C(C(C(C(C1OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O,3
7ZVT,5,,,,,,7ZVT,Structural and functional analysis of the interaction between PAXX and the core NHEJ machinery,CryoEM structure of Ku heterodimer bound to DNA,DNA BINDING PROTEIN,,,,1,7ZVT,wlidetype,,,C6 H18 O24 P6,660.035,IHP,INOSITOL HEXAKISPHOSPHATE,C1(C(C(C(C(C1OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O,5
7ZXN,5,,,,,,7ZXN,Structures of connexin 32 channels suggest a link between hemichannel gating and disease-associated mutations,cryo-EM structure of Connexin 32 gap junction channel,MEMBRANE PROTEIN,GJB1/ CX32,,GO:0005922/ GO:0005789/ GO:0016328/ GO:0005243/ GO:0042802/ GO:0007267/ GO:1905867/ GO:0016264/ GO:0007399/ GO:0015868/ IPR000500/ IPR002267/ IPR019570/ IPR017990/ IPR013092/ IPR038359/ P08034/ Transmembrane.Alpha-helical polytopic.Tetraspan junctional complexes.Connexin/ Generic PDBTM,1,7ZXN,wlidetype,P08034,UniProt,C27 H46 O,386.654,CLR,CHOLESTEROL,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C,2
8A99,5,,,,,,8A99,Immunoglobulin germline gene polymorphisms influence the function of SARS-CoV-2 neutralizing antibodies.,SARS Cov2 Spike in 1-up conformation complex with Fab47,VIRAL PROTEIN,S,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,8A99,wlidetype,P0DTC2,UniProt,C8 H15 N O5,205.208,RTV,2-(acetylamino)-1/5-anhydro-2-deoxy-D-mannitol,CC(=O)NC1COC(C(C1O)O)CO,6
8CH6,5,,,,,,8CH6,Structural basis of catalytic activation in human splicing.,Structure of a late-stage activated spliceosome (BAqr) arrested with a dominant-negative Aquarius mutant (state B complex).,SPLICING,SNRPF/ PBSCF,,GO:0071013/ GO:0005829/ GO:0034709/ GO:0005654/ GO:0005634/ GO:0034715/ GO:0030532/ GO:0034719/ GO:0005681/ GO:0005685/ GO:0005689/ GO:0005686/ GO:0071007/ GO:0071005/ GO:0005687/ GO:0046540/ GO:0005682/ GO:0005683/ GO:0003723/ GO:0036261/ GO:0000398/ GO:0008380/ GO:0000387/ GO:1903241/ IPR016487/ IPR001163/ IPR010920/ IPR034100/ P62306,2,8CH6,wlidetype,P62306,UniProt,C6 H18 O24 P6,660.035,IHP,INOSITOL HEXAKISPHOSPHATE,C1(C(C(C(C(C1OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O,51
8CSJ,5,,,,,,8CSJ,Cryo-EM structure of NTD-directed non-neutralizing antibody 4-33 in complex with prefusion SARS-CoV-2 spike glycoprotein,Cryo-EM structure of NTD-directed non-neutralizing antibody 4-33 in complex with prefusion SARS-CoV-2 spike glycoprotein,VIRAL PROTEIN/IMMUNE SYSTEM,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,8CSJ,wlidetype,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
8CZZ,5,,,,,,8CZZ,Cryo-EM structure of T/F100 SOSIP.664 HIV-1 Env trimer with LMHS mutations in complex with Temsavir/ 8ANC195/ and 10-1074,Cryo-EM structure of T/F100 SOSIP.664 HIV-1 Env trimer with LMHS mutations in complex with Temsavir/ 8ANC195/ and 10-1074,VIRAL PROTEIN/INHIBITOR,env,,GO:0044175/ GO:0020002/ GO:0005886/ GO:0019031/ GO:0055036/ GO:0005198/ GO:0075512/ GO:0039654/ GO:0019064/ GO:0019049/ GO:1903905/ GO:1903908/ GO:1903911/ GO:0019082/ GO:0019062/ IPR036377/ IPR037527/ IPR000328/ IPR000777,1,8CZZ,mutant,A0A6C0ZY47,UniProt,C24 H23 N7 O4,473.484,83J,1-[4-(benzenecarbonyl)piperazin-1-yl]-2-[4-methoxy-7-(3-methyl-1H-1/2/4-triazol-1-yl)-1H-pyrrolo[2/3-c]pyridin-3-yl]ethane-1/2-dione,Cc1ncn(n1)c2c3c(c(c[nH]3)C(=O)C(=O)N4CCN(CC4)C(=O)c5ccccc5)c(cn2)OC,14
8D0Q,5,,,,,,8D0Q,Structural basis for Lewis antigen synthesis by the alpha 1/3-fucosyltransferase FUT9.,Human FUT9 bound to GDP-CF3-Fucose and H-Type 2,TRANSFERASE,FUT9,2.4.1.152,GO:0005794/ GO:0000139/ GO:0005802/ GO:0032588/ GO:0017083/ GO:0046920/ GO:0008417/ GO:0005975/ GO:0036065/ GO:0006688/ GO:0042355/ GO:0036071/ GO:0030182/ GO:0009312/ GO:0000271/ GO:0010976/ GO:0006486/ GO:0006487/ GO:0006493/ GO:1903037/ GO:1903236/ IPR031481/ IPR001503/ IPR038577/ Q9Y231,1,8D0Q,mutant,Q9Y231,UniProt,C16 H22 F3 N5 O15 P2,643.313,6CK,[(2R/3S/4R/5R)-5-(2-amino-6-oxo-1/6-dihydro-9H-purin-9-yl)-3/4-dihydroxytetrahydrofuran-2-yl]methyl (2R/3S/4R/5S/6R)-3/4/5-trihydroxy-6-(trifluoromethyl)tetrahydro-2H-pyran-2-yl dihydrogen diphosphate (non-preferred name),c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OC4C(C(C(C(O4)C(F)(F)F)O)O)O)O)O)N=C(NC2=O)N,5
8D0Q,5,,,,,,8D0Q,Structural basis for Lewis antigen synthesis by the alpha 1/3-fucosyltransferase FUT9.,Human FUT9 bound to GDP-CF3-Fucose and H-Type 2,TRANSFERASE,FUT9,2.4.1.152,GO:0005794/ GO:0000139/ GO:0005802/ GO:0032588/ GO:0017083/ GO:0046920/ GO:0008417/ GO:0005975/ GO:0036065/ GO:0006688/ GO:0042355/ GO:0036071/ GO:0030182/ GO:0009312/ GO:0000271/ GO:0010976/ GO:0006486/ GO:0006487/ GO:0006493/ GO:1903037/ GO:1903236/ IPR031481/ IPR001503/ IPR038577/ Q9Y231,1,8D0Q,mutant,Q9Y231,UniProt,C10 H15 N5 O11 P2,443.201,GDP,GUANOSINE-5'-DIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,6
8D0R,5,,,,,,8D0R,Structural basis for Lewis antigen synthesis by the alpha 1/3-fucosyltransferase FUT9.,Human FUT9 bound to GDP and H-Type 2,TRANSFERASE,FUT9,2.4.1.152,GO:0005794/ GO:0000139/ GO:0005802/ GO:0032588/ GO:0017083/ GO:0046920/ GO:0008417/ GO:0005975/ GO:0036065/ GO:0006688/ GO:0042355/ GO:0036071/ GO:0030182/ GO:0009312/ GO:0000271/ GO:0010976/ GO:0006486/ GO:0006487/ GO:0006493/ GO:1903037/ GO:1903236/ IPR031481/ IPR001503/ IPR038577/ Q9Y231,1,8D0R,mutant,Q9Y231,UniProt,C10 H15 N5 O11 P2,443.201,GDP,GUANOSINE-5'-DIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,4
8D0S,5,,,,,,8D0S,Structural basis for Lewis antigen synthesis by the alpha 1/3-fucosyltransferase FUT9.,Human FUT9 bound to GDP and LNnT,TRANSFERASE,FUT9,2.4.1.152,GO:0005794/ GO:0000139/ GO:0005802/ GO:0032588/ GO:0017083/ GO:0046920/ GO:0008417/ GO:0005975/ GO:0036065/ GO:0006688/ GO:0042355/ GO:0036071/ GO:0030182/ GO:0009312/ GO:0000271/ GO:0010976/ GO:0006486/ GO:0006487/ GO:0006493/ GO:1903037/ GO:1903236/ IPR031481/ IPR001503/ IPR038577/ Q9Y231,1,8D0S,mutant,Q9Y231,UniProt,C10 H15 N5 O11 P2,443.201,GDP,GUANOSINE-5'-DIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,4
8D0U,5,,,,,,8D0U,Structural basis for Lewis antigen synthesis by the alpha 1/3-fucosyltransferase FUT9.,Human FUT9 bound to GDP,TRANSFERASE,FUT9,2.4.1.152,GO:0005794/ GO:0000139/ GO:0005802/ GO:0032588/ GO:0017083/ GO:0046920/ GO:0008417/ GO:0005975/ GO:0036065/ GO:0006688/ GO:0042355/ GO:0036071/ GO:0030182/ GO:0009312/ GO:0000271/ GO:0010976/ GO:0006486/ GO:0006487/ GO:0006493/ GO:1903037/ GO:1903236/ IPR031481/ IPR001503/ IPR038577/ Q9Y231,1,8D0U,mutant,Q9Y231,UniProt,C10 H15 N5 O11 P2,443.201,GDP,GUANOSINE-5'-DIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,3
8D33,5,,,,,,8D33,Pol gamma coordinates DNA synthesis and proofreading to ensure mitochondrial genome integrity.,Human mitochondrial DNA polymerase gamma ternary complex with GC basepair,TRANSFERASE/DNA,POLG2/ MTPOLB,,GO:0005737/ GO:0005760/ GO:0005759/ GO:0042645/ GO:0005739/ GO:0070182/ GO:0030337/ GO:0003887/ GO:0003690/ GO:0042802/ GO:0006281/ GO:0006261/ GO:0001701/ GO:0006264/ GO:0070584/ GO:1900264/ GO:0022904/ IPR045864/ IPR004154/ IPR036621/ IPR027031/ IPR027030/ IPR042064/ Q9UHN1,2,8D33,wlidetype,Q9UHN1,UniProt,C9 H16 N3 O13 P3,467.157,DCP,2'-DEOXYCYTIDINE-5'-TRIPHOSPHATE,C1C(C(OC1N2C=CC(=NC2=O)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,6
8D37,5,,,,,,8D37,Pol gamma coordinates DNA synthesis and proofreading to ensure mitochondrial genome integrity.,Human mitochondrial DNA polymerase gamma ternary complex with GT basepair in replication conformer,TRANSFERASE/DNA,POLG2/ MTPOLB,,GO:0005737/ GO:0005760/ GO:0005759/ GO:0042645/ GO:0005739/ GO:0070182/ GO:0030337/ GO:0003887/ GO:0003690/ GO:0042802/ GO:0006281/ GO:0006261/ GO:0001701/ GO:0006264/ GO:0070584/ GO:1900264/ GO:0022904/ IPR045864/ IPR004154/ IPR036621/ IPR027031/ IPR027030/ IPR042064/ Q9UHN1,2,8D37,wlidetype,Q9UHN1,UniProt,C9 H16 N3 O13 P3,467.157,DCP,2'-DEOXYCYTIDINE-5'-TRIPHOSPHATE,C1C(C(OC1N2C=CC(=NC2=O)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,6
8D3R,5,,,,,,8D3R,Pol gamma coordinates DNA synthesis and proofreading to ensure mitochondrial genome integrity.,Human mitochondrial DNA polymerase gamma ternary complex with GT basepair in intermediate conformer,TRANSFERASE/DNA,POLG/ MDP1/ POLG1/ POLGA,2.7.7.7,GO:0005760/ GO:0005759/ GO:0042645/ GO:0005739/ GO:0032991/ GO:0008408/ GO:0003682/ GO:0003677/ GO:0003887/ GO:0002020/ GO:0006287/ GO:0006259/ GO:0006261/ GO:0006264/ IPR019760/ IPR002297/ IPR001098/ IPR043502/ IPR041336/ IPR012337/ P54098,1,8D3R,wlidetype,P54098,UniProt,C9 H16 N3 O13 P3,467.157,DCP,2'-DEOXYCYTIDINE-5'-TRIPHOSPHATE,C1C(C(OC1N2C=CC(=NC2=O)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,5
8D42,5,,,,,,8D42,Pol gamma coordinates DNA synthesis and proofreading to ensure mitochondrial genome integrity.,Human mitochondrial DNA polymerase gamma ternary complex with GT basepair in editing conformer (composite),TRANSFERASE/DNA,POLG2/ MTPOLB,2.7.7.7,GO:0005737/ GO:0005760/ GO:0005759/ GO:0042645/ GO:0005739/ GO:0070182/ GO:0030337/ GO:0003887/ GO:0003690/ GO:0042802/ GO:0006281/ GO:0006261/ GO:0001701/ GO:0006264/ GO:0070584/ GO:1900264/ GO:0022904/ IPR045864/ IPR004154/ IPR036621/ IPR027031/ IPR027030/ IPR042064/ Q9UHN1,2,8D42,wlidetype,Q9UHN1,UniProt,C9 H16 N3 O13 P3,467.157,DCP,2'-DEOXYCYTIDINE-5'-TRIPHOSPHATE,C1C(C(OC1N2C=CC(=NC2=O)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,6
8DNN,5,,,,,,8DNN,Crystal structure of neutralizing antibody 80 in complex with SARS-CoV-2 receptor binding domain,Crystal structure of neutralizing antibody 80 in complex with SARS-CoV-2 receptor binding domain,IMMUNE SYSTEM/VIRAL PROTEIN,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,8DNN,wlidetype,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
8DO0,5,,,,,,8DO0,A common mechanism of Sec61 translocon inhibition by small molecules.,Cryo-EM structure of the human Sec61 complex inhibited by mycolactone,PROTEIN TRANSPORT/INHIBITOR,SEC61G,,GO:0005829/ GO:0016020/ GO:0071261/ GO:0008320/ GO:0043022/ GO:0031204/ GO:0045047/ IPR023391/ IPR008158/ IPR001901/ P60059/ Transmembrane.Alpha-helical polytopic.General secretory pathway (Sec).Protein translocase/ Generic PDBTM,1,8DO0,mutant,P60059,UniProt,C44 H70 O9,743.021,Q6B,[(6~{S}/7~{S}/9~{Z}/12~{R})-12-[(~{Z}/2~{S}/6~{R}/7~{R}/9~{R})-4/6-dimethyl-7/9-bis(oxidanyl)dec-4-en-2-yl]-7/9-dimethyl-2-oxidanylidene-1-oxacyclododec-9-en-6-yl] (2~{E}/4~{E}/6~{E}/8~{E}/10~{E}/12~{S}/13~{S}/15~{S})-4/6/10-trimethyl-12/13/15-tris(oxidanyl)hexadeca-2/4/6/8/10-pentaenoate,CC1CC(=CCC(OC(=O)CCCC1OC(=O)C=CC(=CC(=CC=CC(=CC(C(CC(C)O)O)O)C)C)C)C(C)CC(=CC(C)C(CC(C)O)O)C)C,4
8DO1,5,,,,,,8DO1,A common mechanism of Sec61 translocon inhibition by small molecules.,Cryo-EM structure of the human Sec61 complex inhibited by ipomoeassin F,PROTEIN TRANSPORT/INHIBITOR,SEC61B,,GO:0005829/ GO:0005783/ GO:0005789/ GO:0044322/ GO:0031205/ GO:0016020/ GO:0005784/ GO:0048408/ GO:0043022/ GO:0003723/ GO:0031204/ GO:0030970/ GO:0006616/ GO:0030433/ IPR030671/ IPR016482/ P60468/ Transmembrane.Alpha-helical polytopic.General secretory pathway (Sec).Protein translocase/ Generic PDBTM,3,8DO1,mutant,P60468,UniProt,C44 H62 O15,830.954,SXF,[(1~{S}/3~{R}/4~{S}/5~{R}/6~{R}/8~{R}/10~{S}/23~{R}/24~{R}/25~{R}/26~{R})-5-acetyloxy-6-methyl-4/26-bis(oxidanyl)-17/20-bis(oxidanylidene)-10-pentyl-24-[(~{E})-3-phenylprop-2-enoyl]oxy-2/7/9/21/27-pentaoxatricyclo[21.3.1.0^{3/8}]heptacosan-25-yl] (~{E})-2-methylbut-2-enoate,CCCCCC1CCCCCCC(=O)CCC(=O)OCC2C(C(C(C(O2)OC3C(C(C(OC3O1)C)OC(=O)C)O)O)OC(=O)C(=CC)C)OC(=O)C=Cc4ccccc4,4
8DO2,5,,,,,,8DO2,A common mechanism of Sec61 translocon inhibition by small molecules.,Cryo-EM structure of the human Sec61 complex inhibited by cyclotriazadisulfonamide (CADA),PROTEIN TRANSPORT/INHIBITOR,SEC61G,,GO:0005829/ GO:0016020/ GO:0071261/ GO:0008320/ GO:0043022/ GO:0031204/ GO:0045047/ IPR023391/ IPR008158/ IPR001901/ P60059/ Transmembrane.Alpha-helical polytopic.General secretory pathway (Sec).Protein translocase/ Generic PDBTM,1,8DO2,mutant,P60059,UniProt,C31 H39 N3 O4 S2,581.789,SXU,9-benzyl-1/5-bis(4-methylbenzene-1-sulfonyl)-3-methylidene-1/5/9-triazacyclododecane,Cc1ccc(cc1)S(=O)(=O)N2CCCN(CCCN(CC(=C)C2)S(=O)(=O)c3ccc(cc3)C)Cc4ccccc4,4
8DO3,5,,,,,,8DO3,A common mechanism of Sec61 translocon inhibition by small molecules.,Cryo-EM structure of the human Sec61 complex inhibited by eeyarestatin I,PROTEIN TRANSPORT/INHIBITOR,SEC61G,,GO:0005829/ GO:0016020/ GO:0071261/ GO:0008320/ GO:0043022/ GO:0031204/ GO:0045047/ IPR023391/ IPR008158/ IPR001901/ P60059/ Transmembrane.Alpha-helical polytopic.General secretory pathway (Sec).Protein translocase/ Generic PDBTM,1,8DO3,mutant,P60059,UniProt,C27 H26 Cl2 N7 O7,631.444,SWR,N'-(4-chlorophenyl)-N-[(4R)-3-(4-chlorophenyl)-5/5-dimethyl-1-(2-{(2E)-2-[(2E)-3-(5-nitrofuran-2-yl)prop-2-en-1-ylidene]hydrazinyl}-2-oxoethyl)-2-oxoimidazolidin-4-yl]-N-hydroxyurea,CC1(C(N(C(=O)N1CC(=O)NN=CC=Cc2ccc(o2)[N+](=O)[OH-])c3ccc(cc3)Cl)N(C(=O)Nc4ccc(cc4)Cl)O)C,4
8DZQ,5,,,,,,8DZQ,Ligand and G-protein selectivity in the kappa-opioid receptor.,momSalB bound Kappa Opioid Receptor in complex with GoA,MEMBRANE PROTEIN,GNB1,,GO:0005737/ GO:0005829/ GO:0070062/ GO:1903561/ GO:0005834/ GO:0005765/ GO:0016020/ GO:0097381/ GO:0005886/ GO:0045202/ GO:0003924/ GO:0051020/ GO:0044877/ GO:0030159/ GO:0007191/ GO:0008283/ GO:0071870/ GO:0071380/ GO:0007213/ GO:0007186/ GO:0007200/ GO:0007265/ GO:0060041/ GO:0050909/ GO:0007165/ IPR020472/ IPR001632/ IPR016346/ IPR015943/ IPR001680/ IPR019775/ IPR036322/ P62873,1,8DZQ,mutant,P62873,UniProt,C23 H30 O8,434.48,U99,methyl (2S/4aR/6aR/7R/9S/10aS/10bR)-2-(furan-3-yl)-9-(methoxymethoxy)-6a/10b-dimethyl-4/10-dioxododecahydro-2H-naphtho[2/1-c]pyran-7-carboxylate,CC12CCC3C(=O)OC(CC3(C1C(=O)C(CC2C(=O)OC)OCOC)C)c4ccoc4,6
8DZR,5,,,,,,8DZR,Ligand and G-protein selectivity in the kappa-opioid receptor.,GR89/696 bound Kappa Opioid Receptor in complex with gustducin,MEMBRANE PROTEIN,,,,2,8DZR,mutant,,,C19 H25 Cl2 N3 O3,414.326,U9I,methyl (3R)-4-[(3/4-dichlorophenyl)acetyl]-3-[(pyrrolidin-1-yl)methyl]piperazine-1-carboxylate,COC(=O)N1CCN(C(C1)CN2CCCC2)C(=O)Cc3ccc(c(c3)Cl)Cl,6
8EA5,5,,,,,,8EA5,Identification of small-molecule protein-protein interaction inhibitors for NKG2D.,NKG2D complexed with inhibitor 1a,IMMUNOSUPPRESSANT/INHIBITOR,KLRK1/ D12S2489E/ NKG2D,,GO:0009986/ GO:0009897/ GO:0005886/ GO:0030246/ GO:0042802/ GO:0042288/ GO:0032394/ GO:0038023/ GO:0002250/ GO:0030154/ GO:0071222/ GO:0050830/ GO:0030101/ GO:0042267/ GO:0034260/ GO:2000502/ GO:0006809/ GO:0032729/ GO:0045954/ GO:0045429/ GO:0007165/ GO:0002223/ GO:0031295/ IPR001304/ IPR016186/ IPR016187/ IPR042169/ IPR033992/ P26718,1,8EA5,mutant,P26718,UniProt,C23 H25 Cl2 N3 O2,446.37,VN8,(3S/5aS/8aR)-3-benzyl-6-[(3/5-dichlorophenyl)methyl]-1/4-dimethyloctahydropyrrolo[3/2-e][1/4]diazepine-2/5-dione,CN1C2CCN(C2C(=O)N(C(C1=O)Cc3ccccc3)C)Cc4cc(cc(c4)Cl)Cl,2
8EA6,5,,,,,,8EA6,Identification of small-molecule protein-protein interaction inhibitors for NKG2D.,NKG2D complexed with inhibitor 3e,IMMUNOSUPPRESSANT/INHIBITOR,KLRK1/ D12S2489E/ NKG2D,,GO:0009986/ GO:0009897/ GO:0005886/ GO:0030246/ GO:0042802/ GO:0042288/ GO:0032394/ GO:0038023/ GO:0002250/ GO:0030154/ GO:0071222/ GO:0050830/ GO:0030101/ GO:0042267/ GO:0034260/ GO:2000502/ GO:0006809/ GO:0032729/ GO:0045954/ GO:0045429/ GO:0007165/ GO:0002223/ GO:0031295/ IPR001304/ IPR016186/ IPR016187/ IPR042169/ IPR033992/ P26718,1,8EA6,mutant,P26718,UniProt,C25 H20 F6 N2 O2,494.429,VMB,N-{(1S)-2-(dimethylamino)-2-oxo-1-[3-(trifluoromethyl)phenyl]ethyl}-4'-(trifluoromethyl)[1/1'-biphenyl]-2-carboxamide,CN(C)C(=O)C(c1cccc(c1)C(F)(F)F)NC(=O)c2ccccc2c3ccc(cc3)C(F)(F)F,2
8EA6,5,,,,,,8EA6,Identification of small-molecule protein-protein interaction inhibitors for NKG2D.,NKG2D complexed with inhibitor 3e,IMMUNOSUPPRESSANT/INHIBITOR,KLRK1/ D12S2489E/ NKG2D,,GO:0009986/ GO:0009897/ GO:0005886/ GO:0030246/ GO:0042802/ GO:0042288/ GO:0032394/ GO:0038023/ GO:0002250/ GO:0030154/ GO:0071222/ GO:0050830/ GO:0030101/ GO:0042267/ GO:0034260/ GO:2000502/ GO:0006809/ GO:0032729/ GO:0045954/ GO:0045429/ GO:0007165/ GO:0002223/ GO:0031295/ IPR001304/ IPR016186/ IPR016187/ IPR042169/ IPR033992/ P26718,1,8EA6,mutant,P26718,UniProt,C29 H24 F6 N4 O2,574.517,VMH,(4M)-N-{(1S)-2-(dimethylamino)-2-oxo-1-[3-(trifluoromethyl)phenyl]ethyl}-4-(1-methyl-1H-pyrazol-5-yl)-4'-(trifluoromethyl)[1/1'-biphenyl]-2-carboxamide,Cn1c(ccn1)c2ccc(c(c2)C(=O)NC(c3cccc(c3)C(F)(F)F)C(=O)N(C)C)c4ccc(cc4)C(F)(F)F,3
8EA6,5,,,,,,8EA6,Identification of small-molecule protein-protein interaction inhibitors for NKG2D.,NKG2D complexed with inhibitor 3e,IMMUNOSUPPRESSANT/INHIBITOR,KLRK1/ D12S2489E/ NKG2D,,GO:0009986/ GO:0009897/ GO:0005886/ GO:0030246/ GO:0042802/ GO:0042288/ GO:0032394/ GO:0038023/ GO:0002250/ GO:0030154/ GO:0071222/ GO:0050830/ GO:0030101/ GO:0042267/ GO:0034260/ GO:2000502/ GO:0006809/ GO:0032729/ GO:0045954/ GO:0045429/ GO:0007165/ GO:0002223/ GO:0031295/ IPR001304/ IPR016186/ IPR016187/ IPR042169/ IPR033992/ P26718,1,8EA6,mutant,P26718,UniProt,C24 H19 F6 N3 O2,495.417,VML,N-{(1S)-2-(dimethylamino)-2-oxo-1-[3-(trifluoromethyl)phenyl]ethyl}-4-[4-(trifluoromethyl)phenyl]pyridine-3-carboxamide,CN(C)C(=O)C(c1cccc(c1)C(F)(F)F)NC(=O)c2cnccc2c3ccc(cc3)C(F)(F)F,4
8EA9,5,,,,,,8EA9,Identification of small-molecule protein-protein interaction inhibitors for NKG2D.,NKG2D complexed with inhibitor 4d,IMMUNOSUPPRESSANT/INHIBITOR,KLRK1/ D12S2489E/ NKG2D,,GO:0009986/ GO:0009897/ GO:0005886/ GO:0030246/ GO:0042802/ GO:0042288/ GO:0032394/ GO:0038023/ GO:0002250/ GO:0030154/ GO:0071222/ GO:0050830/ GO:0030101/ GO:0042267/ GO:0034260/ GO:2000502/ GO:0006809/ GO:0032729/ GO:0045954/ GO:0045429/ GO:0007165/ GO:0002223/ GO:0031295/ IPR001304/ IPR016186/ IPR016187/ IPR042169/ IPR033992/ P26718,1,8EA9,mutant,P26718,UniProt,C25 H18 F9 N3 O2,563.415,VMQ,N-[(1S)-1-[3/5-bis(trifluoromethyl)phenyl]-2-(dimethylamino)-2-oxoethyl]-4-[4-(trifluoromethyl)phenyl]pyridine-3-carboxamide,CN(C)C(=O)C(c1cc(cc(c1)C(F)(F)F)C(F)(F)F)NC(=O)c2cnccc2c3ccc(cc3)C(F)(F)F,3
8EAA,5,,,,,,8EAA,Identification of small-molecule protein-protein interaction inhibitors for NKG2D.,NKG2D complexed with inhibitor 4e,IMMUNOSUPPRESSANT/INHIBITOR,KLRK1/ D12S2489E/ NKG2D,,GO:0009986/ GO:0009897/ GO:0005886/ GO:0030246/ GO:0042802/ GO:0042288/ GO:0032394/ GO:0038023/ GO:0002250/ GO:0030154/ GO:0071222/ GO:0050830/ GO:0030101/ GO:0042267/ GO:0034260/ GO:2000502/ GO:0006809/ GO:0032729/ GO:0045954/ GO:0045429/ GO:0007165/ GO:0002223/ GO:0031295/ IPR001304/ IPR016186/ IPR016187/ IPR042169/ IPR033992/ P26718,1,8EAA,mutant,P26718,UniProt,C25 H21 F6 N3 O2,509.444,VMW,N-{(1S)-2-(dimethylamino)-1-[3-methyl-5-(trifluoromethyl)phenyl]-2-oxoethyl}-4-[4-(trifluoromethyl)phenyl]pyridine-3-carboxamide,Cc1cc(cc(c1)C(F)(F)F)C(C(=O)N(C)C)NC(=O)c2cnccc2c3ccc(cc3)C(F)(F)F,2
8EIT,5,,,,,,8EIT,Molecular mechanism of fatty acid activation of FFAR1.,Structure of FFAR1-Gq complex bound to DHA,MEMBRANE PROTEIN,,,,1,8EIT,wlidetype,,,C22 H32 O2,328.488,HXA,DOCOSA-4/7/10/13/16/19-HEXAENOIC ACID,CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)O,6
8EJC,5,,,,,,8EJC,Molecular mechanism of fatty acid activation of FFAR1.,Structure of FFAR1-Gq complex bound to TAK-875,MEMBRANE PROTEIN,,,,1,8EJC,wlidetype,,,C29 H32 O7 S,524.625,2YB,[(3S)-6-({2'/6'-dimethyl-4'-[3-(methylsulfonyl)propoxy]biphenyl-3-yl}methoxy)-2/3-dihydro-1-benzofuran-3-yl]acetic acid,Cc1cc(cc(c1c2cccc(c2)COc3ccc4c(c3)OCC4CC(=O)O)C)OCCCS(=O)(=O)C,6
8EJK,5,,,,,,8EJK,Molecular mechanism of fatty acid activation of FFAR1.,Structure of FFAR1-Gq complex bound to TAK-875 in a lipid nanodisc,MEMBRANE PROTEIN,,,,1,8EJK,wlidetype,,,C29 H32 O7 S,524.625,2YB,[(3S)-6-({2'/6'-dimethyl-4'-[3-(methylsulfonyl)propoxy]biphenyl-3-yl}methoxy)-2/3-dihydro-1-benzofuran-3-yl]acetic acid,Cc1cc(cc(c1c2cccc(c2)COc3ccc4c(c3)OCC4CC(=O)O)C)OCCCS(=O)(=O)C,6
8EMS,5,,,,,,8EMS,Cryo-EM structure of human liver glycogen phosphorylase,Cryo-EM structure of human liver glycogen phosphorylase,HYDROLASE,PYGL,2.4.1.1,GO:0005737/ GO:0005829/ GO:0070062/ GO:0005576/ GO:1904813/ GO:0034774/ GO:0016208/ GO:0005524/ GO:0032052/ GO:0005536/ GO:0008184/ GO:0042802/ GO:0102250/ GO:0002060/ GO:0030170/ GO:0102499/ GO:0019842/ GO:0006015/ GO:0042593/ GO:0005980/ GO:0005977/ GO:0070266/ GO:0009617/ IPR011833/ IPR000811/ IPR035090/ P06737,1,8EMS,wlidetype,P06737,UniProt,C8 H10 N O6 P,247.142,PLP,PYRIDOXAL-5'-PHOSPHATE,Cc1c(c(c(cn1)COP(=O)(O)O)C=O)O,2
8EMT,5,,,,,,8EMT,Cryo-EM analysis of the human aldehyde oxidase from liver,Cryo-EM analysis of the human aldehyde oxidase from liver,OXIDOREDUCTASE,AOX1/ AO,1.2.3.1/ 1.17.3,GO:0005829/ GO:0070062/ GO:0051537/ GO:0004031/ GO:0071949/ GO:0050660/ GO:0042802/ GO:0005506/ GO:0043546/ GO:0051287/ GO:0016491/ GO:0042803/ GO:0006629/ GO:0006805/ IPR002888/ IPR036884/ IPR036010/ IPR001041/ IPR006058/ IPR000674/ IPR036856/ IPR016208/ IPR014313/ IPR008274/ IPR037165/ IPR012675/ IPR005107/ IPR036683/ IPR016166/ IPR036318/ IPR016167/ IPR016169/ IPR002346/ IPR022407/ Q06278,1,8EMT,wlidetype,Q06278,UniProt,C27 H33 N9 O15 P2,785.55,FAD,FLAVIN-ADENINE DINUCLEOTIDE,Cc1cc2c(cc1C)N(C3=NC(=O)NC(=O)C3=N2)CC(C(C(COP(=O)(O)OP(=O)(O)OCC4C(C(C(O4)n5cnc6c5ncnc6N)O)O)O)O)O,5
8ET7,5,,,,,,8ET7,Molecular basis of polyspecific drug binding and transport by OCT1 and OCT2.,Cryo-EM structure of the organic cation transporter 1 in complex with diphenhydramine,TRANSPORT PROTEIN,,,,1,8ET7,wlidetype,,,C17 H21 N O,255.355,2PM,N-[2-(BENZHYDRYLOXY)ETHYL]-N/N-DIMETHYLAMINE,CN(C)CCOC(c1ccccc1)c2ccccc2,3
8ET8,5,,,,,,8ET8,Molecular basis of polyspecific drug binding and transport by OCT1 and OCT2.,Cryo-EM structure of the organic cation transporter 1 in complex with verapamil,TRANSPORT PROTEIN,,,,1,8ET8,wlidetype,,,C27 H38 N2 O4,454.602,4YH,(2S)-2-(3/4-dimethoxyphenyl)-5-{[2-(3/4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile,CC(C)C(CCCN(C)CCc1ccc(c(c1)OC)OC)(C#N)c2ccc(c(c2)OC)OC,3
8ET9,5,,,,,,8ET9,Molecular basis of polyspecific drug binding and transport by OCT1 and OCT2.,Cryo-EM structure of the organic cation transporter 2 in complex with 1-methyl-4-phenylpyridinium,TRANSPORT PROTEIN,,,,1,8ET9,wlidetype,,,C12 H12 N,170.23,WRF,1-methyl-4-phenylpyridin-1-ium,C[n+]1ccc(cc1)c2ccccc2,2
8EX4,5,,,,,,8EX4,Structural and functional insights into Spns2-mediated transport of sphingosine-1-phosphate.,Human S1P transporter Spns2 in an inward-facing open conformation (state 1),MEMBRANE PROTEIN,SPNS2,,GO:0010008/ GO:0016020/ GO:0005886/ GO:0046624/ GO:0022857/ GO:0001782/ GO:0060348/ GO:0006869/ GO:0048535/ GO:0072676/ GO:0048073/ GO:0002920/ GO:2000404/ GO:0007605/ GO:0030148/ GO:0003376/ GO:0043029/ IPR011701/ IPR020846/ IPR044770/ IPR036259/ Q8IVW8/ Transmembrane.Alpha-helical polytopic.Major Facilitator Superfamily (MFS).Spinster protein family/ Generic PDBTM,1,8EX4,wlidetype,Q8IVW8,UniProt,C18 H38 N O5 P,379.472,S1P,(2S/3R/4E)-2-amino-3-hydroxyoctadec-4-en-1-yl dihydrogen phosphate,CCCCCCCCCCCCCC=CC(C(COP(=O)(O)O)N)O,2
8EX6,5,,,,,,8EX6,Structural and functional insights into Spns2-mediated transport of sphingosine-1-phosphate.,Human S1P transporter Spns2 in an inward-facing open conformation (state 1*),MEMBRANE PROTEIN,SPNS2,,GO:0010008/ GO:0016020/ GO:0005886/ GO:0046624/ GO:0022857/ GO:0001782/ GO:0060348/ GO:0006869/ GO:0048535/ GO:0072676/ GO:0048073/ GO:0002920/ GO:2000404/ GO:0007605/ GO:0030148/ GO:0003376/ GO:0043029/ IPR011701/ IPR020846/ IPR044770/ IPR036259/ Q8IVW8/ Transmembrane.Alpha-helical polytopic.Major Facilitator Superfamily (MFS).Spinster protein family/ Generic PDBTM,1,8EX6,wlidetype,Q8IVW8,UniProt,C18 H38 N O5 P,379.472,S1P,(2S/3R/4E)-2-amino-3-hydroxyoctadec-4-en-1-yl dihydrogen phosphate,CCCCCCCCCCCCCC=CC(C(COP(=O)(O)O)N)O,2
8F93,5,,,,,,8F93,Direct mapping of ligandable tyrosines and lysines in cells with chiral sulfonyl fluoride probes,WDR5 covalently modified at Y228 by (R)-2-SF,GENE REGULATION/INHIBITOR,WDR5/ BIG3,,GO:0140672/ GO:0000123/ GO:0035097/ GO:0072686/ GO:0071339/ GO:0044665/ GO:0044666/ GO:0044545/ GO:0005654/ GO:0005634/ GO:0048188/ GO:0042393/ GO:0035064/ GO:0006325/ GO:0006094/ GO:0043966/ GO:0044154/ GO:0051568/ GO:0043984/ GO:0043981/ GO:0043982/ GO:0051572/ GO:0031175/ GO:0045722/ GO:0051571/ GO:0045893/ GO:0051726/ GO:0051302/ GO:1900095/ GO:0045995/ GO:0031063/ GO:0006357/ GO:0006355/ GO:0090043/ GO:0001501/ IPR020472/ IPR015943/ IPR001680/ IPR019775/ IPR036322/ P61964,1,8F93,wlidetype,P61964,UniProt,C30 H29 F N4 O4 S,560.639,XKN,3-ethynyl-5-{[(3R)-4-{1-[(2-methoxyphenyl)methyl]-1H-benzimidazole-5-carbonyl}-3-methylpiperazin-1-yl]methyl}benzene-1-sulfonyl fluoride,CC1CN(CCN1C(=O)c2ccc3c(c2)ncn3Cc4ccccc4OC)Cc5cc(cc(c5)S(=O)(=O)F)C#C,2
8FNY,5,,,,,,8FNY,ADP enhances the allosteric activation of eukaryotic elongation factor 2 kinase by calmodulin.,Nucleotide-bound structure of a functional construct of eukaryotic elongation factor 2 kinase.,TRANSLATION/Transferase,EEF2K,2.7.11.20,GO:0005737/ GO:0005829/ GO:0043197/ GO:0014069/ GO:0005524/ GO:0005509/ GO:0005516/ GO:0004686/ GO:0004672/ GO:0004674/ GO:0008135/ GO:0071454/ GO:1990416/ GO:0071277/ GO:0071320/ GO:0032869/ GO:0043066/ GO:0061003/ GO:0045807/ GO:0051965/ GO:0046777/ GO:0031952/ GO:0002931/ GO:1990637/ GO:0006414/ IPR017400/ IPR011009/ IPR004166/ IPR006597/ IPR011990/ O00418,1,8FNY,wlidetype,O00418,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,3
8FNY,5,,,,,,8FNY,ADP enhances the allosteric activation of eukaryotic elongation factor 2 kinase by calmodulin.,Nucleotide-bound structure of a functional construct of eukaryotic elongation factor 2 kinase.,TRANSLATION/Transferase,EEF2K,2.7.11.20,GO:0005737/ GO:0005829/ GO:0043197/ GO:0014069/ GO:0005524/ GO:0005509/ GO:0005516/ GO:0004686/ GO:0004672/ GO:0004674/ GO:0008135/ GO:0071454/ GO:1990416/ GO:0071277/ GO:0071320/ GO:0032869/ GO:0043066/ GO:0061003/ GO:0045807/ GO:0051965/ GO:0046777/ GO:0031952/ GO:0002931/ GO:1990637/ GO:0006414/ IPR017400/ IPR011009/ IPR004166/ IPR006597/ IPR011990/ O00418,1,8FNY,wlidetype,O00418,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,4
8FO3,5,,,,,,8FO3,Crystal Structures of Diaryl Hydrazone and Sulfone Stabilizers in Complex with an Amyloidogenic Light Chain Reveal an Alternate Ligand-Binding Cavity,Structure of full-length amyloidogenic immunoglobulin light chain H9 in complex with (E)-3-nitro-4-(2-(2-phenylpropylidene)hydrazineyl)benzenesulfonamide,IMMUNE SYSTEM,,,,1,8FO3,wlidetype,,,C15 H18 N4 O4 S,350.393,Y4K,3-nitro-4-{2-[(2S)-2-phenylpropyl]hydrazinyl}benzene-1-sulfonamide,CC(CNNc1ccc(cc1N(=O)=O)S(=O)(=O)N)c2ccccc2,2
8FO4,5,,,,,,8FO4,Crystal Structures of Diaryl Hydrazone and Sulfone Stabilizers in Complex with an Amyloidogenic Light Chain Reveal an Alternate Ligand-Binding Cavity,Structure of full-length amyloidogenic immunoglobulin light chain H9 in complex with 6-methyl-2-(2-((1E/2E)-3-(2-nitrophenyl)allylidene)hydrazineyl)pyrimidin-4-ol,IMMUNE SYSTEM,,,,1,8FO4,wlidetype,,,C14 H15 N5 O3,301.301,Y4Q,6-methyl-2-{2-[(1E)-3-(2-nitrophenyl)prop-1-en-1-yl]hydrazinyl}pyrimidin-4(5H)-one,CC1=NC(=NC(=O)C1)NNC=CCc2ccccc2N(=O)=O,2
8FO5,5,,,,,,8FO5,Crystal Structures of Diaryl Hydrazone and Sulfone Stabilizers in Complex with an Amyloidogenic Light Chain Reveal an Alternate Ligand-Binding Cavity,Structure of full-length amyloidogenic immunoglobulin light chain H9 in complex with 1-(1-(phenylsulfonyl)-1H-pyrrol-3-yl)ethan-1-one,IMMUNE SYSTEM,,,,1,8FO5,wlidetype,,,C12 H11 N O3 S,249.286,Y4U,1-[1-(benzenesulfonyl)-1H-pyrrol-3-yl]ethan-1-one,CC(=O)c1ccn(c1)S(=O)(=O)c2ccccc2,2
8G0L,5,,,,,,8G0L,Semi-synthetic CoA-alpha-Synuclein Constructs Trap N-terminal Acetyltransferase NatB for Binding Mechanism Studies.,Semi-synthetic CoA-alpha-Synuclein Constructs Trap N-terminal Acetyltransferase NatB for Binding Mechanism Studies,TRANSFERASE,NAA20/ NAT5,2.3.1.254,GO:0005737/ GO:0005829/ GO:0031416/ GO:0005634/ GO:0004596/ GO:0017196/ IPR016181/ IPR000182/ P61599,1,8G0L,wlidetype,P61599,UniProt,C23 H38 N7 O18 P3 S,825.57,CMC,CARBOXYMETHYL COENZYME *A,CC(C)(COP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)n2cnc3c2ncnc3N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSCC(=O)O)O,4
8G1E,5,,,,,,8G1E,Allosteric role of the citrate synthase homology domain of ATP citrate lyase.,Structure of ACLY-D1026A-products-asym,TRANSFERASE,ACLY,2.3.3.8,GO:0035578/ GO:0005829/ GO:0070062/ GO:0005576/ GO:1904813/ GO:0016020/ GO:0005654/ GO:0005524/ GO:0003878/ GO:0046872/ GO:0006085/ GO:0006695/ GO:0006101/ GO:0015936/ GO:0006633/ GO:0008610/ GO:0006107/ IPR014608/ IPR017440/ IPR032263/ IPR016143/ IPR002020/ IPR036969/ IPR033847/ IPR003781/ IPR005811/ IPR036291/ IPR017866/ IPR016102/ P53396,1,8G1E,mutant,P53396,UniProt,,,UNL,Unknown ligand,,4
8G1F,5,,,,,,8G1F,Allosteric role of the citrate synthase homology domain of ATP citrate lyase.,Structure of ACLY-D1026A-products,LYASE,ACLY,2.3.3.8,GO:0035578/ GO:0005829/ GO:0070062/ GO:0005576/ GO:1904813/ GO:0016020/ GO:0005654/ GO:0005524/ GO:0003878/ GO:0046872/ GO:0006085/ GO:0006695/ GO:0006101/ GO:0015936/ GO:0006633/ GO:0008610/ GO:0006107/ IPR014608/ IPR017440/ IPR032263/ IPR016143/ IPR002020/ IPR036969/ IPR033847/ IPR003781/ IPR005811/ IPR036291/ IPR017866/ IPR016102/ P53396,1,8G1F,mutant,P53396,UniProt,,,UNL,Unknown ligand,,3
8G2Y,5,,,,,,8G2Y,Tethered agonist activated ADGRF1 structure and signalling analysis reveal basis for G protein coupling.,Cryo-EM structure of ADGRF1 coupled to miniGs/q,SIGNALING PROTEIN,GNG2,,GO:0070062/ GO:0005834/ GO:0016020/ GO:0005886/ GO:0031681/ GO:0007191/ GO:0071870/ GO:0071380/ GO:0048144/ GO:0007186/ IPR015898/ IPR036284/ IPR001770/ P59768/ Transmembrane.Alpha-helical polytopic.Rhodopsin-like receptors and pumps.GPCR Secretin (B) family/ Generic PDBTM,3,8G2Y,wlidetype,P59768,UniProt,C22 H47 N O7 P,468.585,LPC,[1-MYRISTOYL-GLYCEROL-3-YL]PHOSPHONYLCHOLINE,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCC[N+](C)(C)C)O,6
8G3S,5,,,,,,8G3S,Discovery of an Oral/ Beyond-Rule-of-Five Mcl-1 Protein-Protein Interaction Modulator with the Potential of Treating Hematological Malignancies.,MBP-Mcl1 in complex with ligand 11,APOPTOSIS,malE/ JW3994,,GO:0097136/ GO:0005737/ GO:0005829/ GO:0016020/ GO:0005741/ GO:0005739/ GO:0005654/ GO:0005634/ GO:0051434/ GO:0046982/ GO:0042803/ GO:0008320/ GO:0001709/ GO:0019725/ GO:0097192/ GO:0008630/ GO:2000811/ GO:0043066/ GO:0010507/ GO:2001240/ GO:2001243/ GO:0043065/ GO:1903378/ GO:0042981/ GO:0034097/ IPR013281/ IPR036834/ IPR046371/ IPR026298/ IPR002475/ IPR020717/ IPR020726/ IPR020728/ GO:0042597/ GO:0015144/ IPR036736/ IPR006060/ IPR009081/ IPR006059/ IPR006061/ Q07820,1,8G3S,wlidetype,A0A4P1LXE0,UniProt,C33 H41 Cl N2 O6 S,629.206,YLT,(1'S/3aS/5R/16R/17S/19E/21S/21aR)-6'-chloro-21-methoxy-16/17-dimethyl-2/3/3'/3a/4'/16/17/18/21/21a-decahydro-2'H/6H/8H-15lambda~6~-spiro[10/12-etheno-15lambda~6~-furo[3/2-i][1/4]oxazepino[3/4-f][1/2/7]thiadiazacyclohexadecine-7/1'-naphthalene]-13/15/15(4H/14H)-trione,CC1CC=CC(C2C(CCO2)CN3CC4(CCCc5c4ccc(c5)Cl)COc6c3cc(cc6)C(=O)NS(=O)(=O)C1C)OC,4
8G3T,5,,,,,,8G3T,Discovery of an Oral/ Beyond-Rule-of-Five Mcl-1 Protein-Protein Interaction Modulator with the Potential of Treating Hematological Malignancies.,MBP-Mcl1 in complex with ligand 12,APOPTOSIS,malE/ JW3994,,GO:0097136/ GO:0005737/ GO:0005829/ GO:0016020/ GO:0005741/ GO:0005739/ GO:0005654/ GO:0005634/ GO:0051434/ GO:0046982/ GO:0042803/ GO:0008320/ GO:0001709/ GO:0019725/ GO:0097192/ GO:0008630/ GO:2000811/ GO:0043066/ GO:0010507/ GO:2001240/ GO:2001243/ GO:0043065/ GO:1903378/ GO:0042981/ GO:0034097/ IPR013281/ IPR036834/ IPR046371/ IPR026298/ IPR002475/ IPR020717/ IPR020726/ IPR020728/ GO:0042597/ GO:0015144/ IPR036736/ IPR006060/ IPR009081/ IPR006059/ IPR006061/ Q07820,1,8G3T,wlidetype,A0A4P1LXE0,UniProt,C33 H40 Cl F N2 O6 S,647.197,YLK,(1'S/3aS/5R/16R/17S/19Z/21R/21aR)-6'-chloro-20-fluoro-21-methoxy-16/17-dimethyl-2/3/3'/3a/4'/16/17/18/21/21a-decahydro-2'H/6H/8H-15lambda~6~-spiro[10/12-etheno-15lambda~6~-furo[3/2-i][1/4]oxazepino[3/4-f][1/2/7]thiadiazacyclohexadecine-7/1'-naphthalene]-13/15/15(4H/14H)-trione,CC1CC=C(C(C2C(CCO2)CN3CC4(CCCc5c4ccc(c5)Cl)COc6c3cc(cc6)C(=O)NS(=O)(=O)C1C)OC)F,5
8G3W,5,,,,,,8G3W,Discovery of an Oral/ Beyond-Rule-of-Five Mcl-1 Protein-Protein Interaction Modulator with the Potential of Treating Hematological Malignancies.,MBP-Mcl1 in complex with ligand 28,APOPTOSIS,malE/ JW3994,,GO:0097136/ GO:0005737/ GO:0005829/ GO:0016020/ GO:0005741/ GO:0005739/ GO:0005654/ GO:0005634/ GO:0051434/ GO:0046982/ GO:0042803/ GO:0008320/ GO:0001709/ GO:0019725/ GO:0097192/ GO:0008630/ GO:2000811/ GO:0043066/ GO:0010507/ GO:2001240/ GO:2001243/ GO:0043065/ GO:1903378/ GO:0042981/ GO:0034097/ IPR013281/ IPR036834/ IPR046371/ IPR026298/ IPR002475/ IPR020717/ IPR020726/ IPR020728/ GO:0042597/ GO:0015144/ IPR036736/ IPR006060/ IPR009081/ IPR006059/ IPR006061/ Q07820,1,8G3W,wlidetype,A0A4P1LXE0,UniProt,C38 H45 Cl F N5 O7 S,770.31,YKX,N-[(1'S/3aS/5R/15S/17S/19Z/21R/21aR)-6'-chloro-20-fluoro-21-methoxy-17-methyl-13/15-dioxo-2/3/3'/3a/4/4'/13/16/17/18/21/21a-dodecahydro-2'H/6H/8H-15lambda~6~-spiro[10/12-(ethanediylidene)-15lambda~6~-furo[3/2-i][1/4]oxazepino[3/4-f][1/2/7]thiadiazacyclohexadecine-7/1'-naphthalen]-15-yl]-3-methoxy-1-methyl-1H-pyrazole-4-carboxamide,CC1CC=C(C(C2C(CCO2)CN3CC4(CCCc5c4ccc(c5)Cl)COc6c3cc(cc6)C(=O)N=S(=O)(C1)NC(=O)c7cn(nc7OC)C)OC)F,5
8G3Y,5,,,,,,8G3Y,Discovery of an Oral/ Beyond-Rule-of-Five Mcl-1 Protein-Protein Interaction Modulator with the Potential of Treating Hematological Malignancies.,MBP-Mcl1 in complex with ligand 34,APOPTOSIS,malE/ JW3994,,GO:0097136/ GO:0005737/ GO:0005829/ GO:0016020/ GO:0005741/ GO:0005739/ GO:0005654/ GO:0005634/ GO:0051434/ GO:0046982/ GO:0042803/ GO:0008320/ GO:0001709/ GO:0019725/ GO:0097192/ GO:0008630/ GO:2000811/ GO:0043066/ GO:0010507/ GO:2001240/ GO:2001243/ GO:0043065/ GO:1903378/ GO:0042981/ GO:0034097/ IPR013281/ IPR036834/ IPR046371/ IPR026298/ IPR002475/ IPR020717/ IPR020726/ IPR020728/ GO:0042597/ GO:0015144/ IPR036736/ IPR006060/ IPR009081/ IPR006059/ IPR006061/ Q07820,1,8G3Y,wlidetype,A0A4P1LXE0,UniProt,C46 H59 Cl F N7 O8 S,924.519,YKL,N-[(1'S/3aS/5R/15S/17S/19Z/21S/21aR)-6'-chloro-20-fluoro-21-{[(5S/9aS)-hexahydropyrazino[2/1-c][1/4]oxazin-8(1H)-yl]methyl}-21-methoxy-17-methyl-13/15-dioxo-2/3/3'/3a/4/4'/13/16/17/18/21/21a-dodecahydro-2'H/6H/8H-15lambda~6~-spiro[10/12-(ethanediylidene)-15lambda~6~-furo[3/2-i][1/4]oxazepino[3/4-f][1/2/7]thiadiazacyclohexadecine-7/1'-naphthalen]-15-yl]-3-methoxy-1-methyl-1H-pyrazole-4-carboxamide,CC1CC=C(C(C2C(CCO2)CN3CC4(CCCc5c4ccc(c5)Cl)COc6c3cc(cc6)C(=O)N=S(=O)(C1)NC(=O)c7cn(nc7OC)C)(CN8CCN9CCOCC9C8)OC)F,6
8G5C,5,,,,,,8G5C,Allosteric role of the citrate synthase homology domain of ATP citrate lyase.,Structure of ACLY-D1026A-substrates/ local refinement of ASH domain,TRANSFERASE,ACLY,2.3.3.8,GO:0035578/ GO:0005829/ GO:0070062/ GO:0005576/ GO:1904813/ GO:0016020/ GO:0005654/ GO:0005524/ GO:0003878/ GO:0046872/ GO:0006085/ GO:0006695/ GO:0006101/ GO:0015936/ GO:0006633/ GO:0008610/ GO:0006107/ IPR014608/ IPR017440/ IPR032263/ IPR016143/ IPR002020/ IPR036969/ IPR033847/ IPR003781/ IPR005811/ IPR036291/ IPR017866/ IPR016102/ P53396,1,8G5C,mutant,P53396,UniProt,C27 H42 N7 O22 P3 S,941.642,Q5B,(3S)-citryl-Coenzyme A,CC(C)(COP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)n2cnc3c2ncnc3N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CC(CC(=O)O)(C(=O)O)O)O,6
8G5D,5,,,,,,8G5D,Allosteric role of the citrate synthase homology domain of ATP citrate lyase.,Structure of ACLY-D1026A-products/ local refinement of ASH domain,TRANSFERASE,ACLY,2.3.3.8,GO:0035578/ GO:0005829/ GO:0070062/ GO:0005576/ GO:1904813/ GO:0016020/ GO:0005654/ GO:0005524/ GO:0003878/ GO:0046872/ GO:0006085/ GO:0006695/ GO:0006101/ GO:0015936/ GO:0006633/ GO:0008610/ GO:0006107/ IPR014608/ IPR017440/ IPR032263/ IPR016143/ IPR002020/ IPR036969/ IPR033847/ IPR003781/ IPR005811/ IPR036291/ IPR017866/ IPR016102/ P53396,1,8G5D,mutant,P53396,UniProt,C27 H42 N7 O22 P3 S,941.642,Q5B,(3S)-citryl-Coenzyme A,CC(C)(COP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)n2cnc3c2ncnc3N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CC(CC(=O)O)(C(=O)O)O)O,4
8G92,5,,,,,,8G92,Mechanisms and Inhibition of Spns2-mediated transport of sphingosine-1-phosphate,Structure of inhibitor 16d-bound SPNS2,IMMUNE SYSTEM,SPNS2,,GO:0010008/ GO:0016020/ GO:0005886/ GO:0046624/ GO:0022857/ GO:0001782/ GO:0060348/ GO:0006869/ GO:0048535/ GO:0072676/ GO:0048073/ GO:0002920/ GO:2000404/ GO:0007605/ GO:0030148/ GO:0003376/ GO:0043029/ IPR011701/ IPR020846/ IPR044770/ IPR036259/ Q8IVW8/ Transmembrane.Alpha-helical polytopic.Major Facilitator Superfamily (MFS).Spinster protein family/ Generic PDBTM,1,8G92,wlidetype,Q8IVW8,UniProt,C21 H33 N3 O,343.506,YUX,3-[3-(4-decylphenyl)-1/2/4-oxadiazol-5-yl]propan-1-amine,CCCCCCCCCCc1ccc(cc1)c2nc(on2)CCCN,2
8GHF,5,,,,,,8GHF,Membrane protein isolation and structure determination in cell-derived membrane vesicles.,cryo-EM structure of hSlo1 in plasma membrane vesicles,TRANSPORT PROTEIN,KCNMA1,,GO:0016324/ GO:0005901/ GO:0005886/ GO:0045211/ GO:0008076/ GO:0003779/ GO:0015269/ GO:0042802/ GO:0060072/ GO:0046872/ GO:0005249/ GO:0030007/ GO:0060073/ GO:0045794/ GO:0043065/ GO:0006813/ GO:0034765/ GO:0042391/ GO:0060087/ GO:0051592/ GO:0034465/ GO:0001666/ GO:0006970/ GO:0060083/ IPR024939/ IPR005821/ IPR003929/ IPR036291/ Q12791/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Channels: Potassium/ Sodium/ & Proton Ion-Selective.Human BK (SLO1) K<sup>+</sup> channel in total membrane vesicles/ Ca<sup>2+</sup>-free and EDTA-free/ Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Slo potassium channels/ Generic PDBTM,1,8GHF,wlidetype,Q12791,UniProt,C42 H82 N O8 P,760.076,POV,(2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC,4
8GHF,5,,,,,,8GHF,Membrane protein isolation and structure determination in cell-derived membrane vesicles.,cryo-EM structure of hSlo1 in plasma membrane vesicles,TRANSPORT PROTEIN,KCNMA1,,GO:0016324/ GO:0005901/ GO:0005886/ GO:0045211/ GO:0008076/ GO:0003779/ GO:0015269/ GO:0042802/ GO:0060072/ GO:0046872/ GO:0005249/ GO:0030007/ GO:0060073/ GO:0045794/ GO:0043065/ GO:0006813/ GO:0034765/ GO:0042391/ GO:0060087/ GO:0051592/ GO:0034465/ GO:0001666/ GO:0006970/ GO:0060083/ IPR024939/ IPR005821/ IPR003929/ IPR036291/ Q12791/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Channels: Potassium/ Sodium/ & Proton Ion-Selective.Human BK (SLO1) K<sup>+</sup> channel in total membrane vesicles/ Ca<sup>2+</sup>-free and EDTA-free/ Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Slo potassium channels/ Generic PDBTM,1,8GHF,wlidetype,Q12791,UniProt,C27 H46 O,386.654,CLR,CHOLESTEROL,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C,5
8GM4,5,,,,,,8GM4,Structure of the complex between calmodulin and a functional construct of eukaryotic elongation factor 2 kinase bound to an ATP-competitive inhibitor.,Functional construct of the Eukaryotic elongation factor 2 kinase bound to an ATP-competitive inhibitor,TRANSLATION/Transferase,EEF2K,2.7.11.20,GO:0005737/ GO:0005829/ GO:0043197/ GO:0014069/ GO:0005524/ GO:0005509/ GO:0005516/ GO:0004686/ GO:0004672/ GO:0004674/ GO:0008135/ GO:0071454/ GO:1990416/ GO:0071277/ GO:0071320/ GO:0032869/ GO:0043066/ GO:0061003/ GO:0045807/ GO:0051965/ GO:0046777/ GO:0031952/ GO:0002931/ GO:1990637/ GO:0006414/ IPR017400/ IPR011009/ IPR004166/ IPR006597/ IPR011990/ O00418,1,8GM4,wlidetype,O00418,UniProt,C13 H15 N5 O3,289.29,EKI,7-amino-1-cyclopropyl-3-ethyl-2/4-dioxo-1/2/3/4-tetrahydropyrido[2/3-d]pyrimidine-6-carboxamide,CCN1C(=O)c2cc(c(nc2N(C1=O)C3CC3)N)C(=O)N,4
8GS8,5,,,,,,8GS8,Structure of the human respiratory complex II.,cryo-EM structure of the human respiratory complex II,OXIDOREDUCTASE,SDHA/ SDH2/ SDHF,1.3.5.1,GO:0005743/ GO:0005749/ GO:0005739/ GO:0005730/ GO:0009055/ GO:0050660/ GO:0008177/ GO:0006121/ GO:0007399/ GO:0042776/ GO:0022904/ GO:0006105/ GO:0006099/ IPR003953/ IPR036188/ IPR003952/ IPR037099/ IPR015939/ IPR030664/ IPR027477/ IPR011281/ IPR014006/ P31040/ Transmembrane.Alpha-helical polytopic.Electron transport chain complex II superfamily.Succinate dehydrogenase/fumarate reductase/ Generic PDBTM,1,8GS8,wlidetype,P31040,UniProt,C34 H32 Fe N4 O4,616.487,HEM,PROTOPORPHYRIN IX CONTAINING FE,Cc1c2n3c(c1CCC(=O)O)C=C4C(=C(C5=[N]4[Fe]36[N]7=C(C=C8N6C(=C5)C(=C8C)C=C)C(=C(C7=C2)C)C=C)C)CCC(=O)O,10
8GS8,5,,,,,,8GS8,Structure of the human respiratory complex II.,cryo-EM structure of the human respiratory complex II,OXIDOREDUCTASE,SDHC/ CYB560/ SDH3,,GO:0016020/ GO:0005743/ GO:0005749/ GO:0005739/ GO:0009055/ GO:0020037/ GO:0046872/ GO:0000104/ GO:0009060/ GO:0006121/ GO:0042776/ GO:0006099/ IPR034804/ IPR018495/ IPR014314/ IPR000701/ Q99643/ Transmembrane.Alpha-helical polytopic.Electron transport chain complex II superfamily.Succinate dehydrogenase/fumarate reductase/ Generic PDBTM,3,8GS8,wlidetype,Q99643,UniProt,C27 H33 N9 O15 P2,785.55,FAD,FLAVIN-ADENINE DINUCLEOTIDE,Cc1cc2c(cc1C)N(C3=NC(=O)NC(=O)C3=N2)CC(C(C(COP(=O)(O)OP(=O)(O)OCC4C(C(C(O4)n5cnc6c5ncnc6N)O)O)O)O)O,5
8GUQ,5,,,,,,8GUQ,Structural basis of selective cannabinoid CB 2 receptor activation.,Cryo-EM structure of CB2-G protein complex,STRUCTURAL PROTEIN,GNG2,,GO:0070062/ GO:0005834/ GO:0016020/ GO:0005886/ GO:0031681/ GO:0007191/ GO:0071870/ GO:0071380/ GO:0048144/ GO:0007186/ IPR015898/ IPR036284/ IPR001770/ P59768/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.G Protein-Coupled Receptors: Class A.CB<sub>2</sub>-G<sub>i</sub> cannabinoid receptor complex with bound LEI-102/ Transmembrane.Alpha-helical polytopic.Rhodopsin-like receptors and pumps.G-protein coupled receptors/ family A/ Generic PDBTM,3,8GUQ,wlidetype,P59768,UniProt,C18 H23 N5 O3,357.407,KNF,(2~{S}/4~{S})-~{N}-[(2~{S})-3/3-dimethyl-1-oxidanyl-butan-2-yl]-9-(4-oxidanylpyrazin-2-yl)-8/9-diazatricyclo[4.3.0.0^{2/4}]nona-1(6)/7-diene-7-carboxamide,CC(C)(C)C(CO)NC(=O)c1c2c(n(n1)c3c[n+](ccn3)[O-])C4CC4C2,6
8GUW,5,,,,,,8GUW,Structural basis for CEP192-mediated regulation of centrosomal AURKA.,Structure of Aurora Kinase A in complex with activator peptide,CYTOSOLIC PROTEIN,CEP192/ KIAA1569/ PP8407,2.7.11.1,GO:0005814/ GO:0005813/ GO:0005737/ GO:0005829/ GO:0000242/ GO:0120098/ GO:0120099/ GO:0019902/ GO:0019901/ GO:0007099/ GO:0090222/ GO:0090307/ GO:0071539/ GO:0009617/ IPR013783/ IPR039103/ GO:0043203/ GO:0032133/ GO:0036064/ GO:0042585/ GO:0072687/ GO:0005874/ GO:0015630/ GO:0030496/ GO:0072686/ GO:0097431/ GO:0005654/ GO:0005634/ GO:0048471/ GO:0045120/ GO:0005819/ GO:0051233/ GO:0031616/ GO:0005524/ GO:0046982/ GO:0004672/ GO:0106310/ GO:0004674/ GO:0004712/ GO:0031625/ GO:0009948/ GO:0006915/ GO:0051301/ GO:0051642/ GO:0061523/ GO:0000086/ GO:0097421/ GO:0000278/ GO:0007100/ GO:0007052/ GO:0043066/ GO:0010629/ GO:0032091/ GO:1990138/ GO:0018105/ GO:0090141/ GO:0045840/ GO:1900195/ GO:0032436/ GO:0043161/ GO:0046777/ GO:0006468/ GO:0046605/ GO:0032465/ GO:0010389/ GO:0031647/ GO:1901796/ GO:0009611/ GO:0007057/ GO:0007051/ IPR030616/ IPR030611/ IPR011009/ IPR000719/ IPR017441/ IPR008271/ Q8TEP8/ O14965,1,8GUW,mutant,Q8TEP8,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,2
8GZE,5,,,,,,8GZE,Crystal Structure of METTL9-SAH-SLC39A7 peptide,Crystal Structure of human METTL9-SAH-SLC39A7 peptide complex,TRANSFERASE,METTL9/ DREV/ CGI-81,2.1.1,GO:0005783/ GO:0005739/ GO:0106370/ IPR007884/ IPR029063/ Q9H1A3,1,8GZE,wlidetype,Q9H1A3,UniProt,C14 H20 N6 O5 S,384.411,SAH,S-ADENOSYL-L-HOMOCYSTEINE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)CSCCC(C(=O)O)N)O)O)N,3
8H07,5,,,,,,8H07,Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants.,SARS-CoV-2 BA.4 variants S ectodomain trimer in complex with neutralizing antibody 10-5B and 6-2C,VIRAL PROTEIN/IMMUNE SYSTEM,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,8H07,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
8H08,5,,,,,,8H08,Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants.,SARS-CoV-2 BA.1 variants S ectodomain trimer in complex with neutralizing antibody 10-5B and 6-2C,VIRAL PROTEIN/IMMUNE SYSTEM,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,8H08,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
8H9E,5,,,,,,8H9E,Structure of the human ATP synthase.,Human ATP synthase F1 domain/ state 1,MEMBRANE PROTEIN,ATP5F1B/ ATP5B/ ATPMB/ ATPSB,7.1.2.2,GO:0009986/ GO:0070062/ GO:0016020/ GO:0005743/ GO:0005759/ GO:0031966/ GO:0042645/ GO:0005753/ GO:0005754/ GO:0005739/ GO:0005634/ GO:0005886/ GO:0045259/ GO:0045261/ GO:0043532/ GO:0005524/ GO:0042288/ GO:0046933/ GO:0046961/ GO:0001525/ GO:0006754/ GO:0098761/ GO:0006091/ GO:0006629/ GO:0006933/ GO:0001649/ GO:0043536/ GO:0015986/ GO:0042776/ GO:1902600/ GO:0051453/ IPR003593/ IPR005722/ IPR020003/ IPR004100/ IPR036121/ IPR000194/ IPR024034/ IPR027417/ P06576,2,8H9E,wlidetype,P06576,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,8
8H9E,5,,,,,,8H9E,Structure of the human ATP synthase.,Human ATP synthase F1 domain/ state 1,MEMBRANE PROTEIN,ATP5F1C/ ATP5C/ ATP5C1/ ATP5CL1,,GO:0016020/ GO:0005743/ GO:0005759/ GO:0005753/ GO:0000275/ GO:0005739/ GO:0046933/ GO:0003723/ GO:0006754/ GO:0006119/ GO:0015986/ GO:0042776/ IPR035968/ IPR000131/ IPR023632/ P36542,3,8H9E,wlidetype,P36542,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,6
8H9I,5,,,,,,8H9I,Structure of the human ATP synthase.,Human ATP synthase F1 domain/ state2,MEMBRANE PROTEIN,ATP5F1A/ ATP5A/ ATP5A1/ ATP5AL2/ ATPM,,GO:0009986/ GO:0070062/ GO:0016020/ GO:0045121/ GO:0005743/ GO:0005759/ GO:0005753/ GO:0005754/ GO:0005739/ GO:0005634/ GO:0005886/ GO:0045259/ GO:0045261/ GO:0043531/ GO:0043532/ GO:0005524/ GO:0016887/ GO:0042288/ GO:0002020/ GO:0046933/ GO:0003723/ GO:0006915/ GO:0006754/ GO:0071549/ GO:0071732/ GO:0006629/ GO:0001937/ GO:0043536/ GO:0015986/ GO:0042776/ GO:0045471/ GO:0014850/ IPR023366/ IPR000793/ IPR038376/ IPR033732/ IPR005294/ IPR020003/ IPR004100/ IPR036121/ IPR000194/ IPR027417/ P25705,1,8H9I,wlidetype,P25705,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,5
8H9I,5,,,,,,8H9I,Structure of the human ATP synthase.,Human ATP synthase F1 domain/ state2,MEMBRANE PROTEIN,ATP5F1C/ ATP5C/ ATP5C1/ ATP5CL1,,GO:0016020/ GO:0005743/ GO:0005759/ GO:0005753/ GO:0000275/ GO:0005739/ GO:0046933/ GO:0003723/ GO:0006754/ GO:0006119/ GO:0015986/ GO:0042776/ IPR035968/ IPR000131/ IPR023632/ P36542,3,8H9I,wlidetype,P36542,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,7
8H9L,5,,,,,,8H9L,Structure of the human ATP synthase.,Human ATP synthase F1 domain/ state 3a,MEMBRANE PROTEIN,ATP5F1C/ ATP5C/ ATP5C1/ ATP5CL1,,GO:0016020/ GO:0005743/ GO:0005759/ GO:0005753/ GO:0000275/ GO:0005739/ GO:0046933/ GO:0003723/ GO:0006754/ GO:0006119/ GO:0015986/ GO:0042776/ IPR035968/ IPR000131/ IPR023632/ P36542,3,8H9L,wlidetype,P36542,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,6
8H9L,5,,,,,,8H9L,Structure of the human ATP synthase.,Human ATP synthase F1 domain/ state 3a,MEMBRANE PROTEIN,ATP5F1A/ ATP5A/ ATP5A1/ ATP5AL2/ ATPM,,GO:0009986/ GO:0070062/ GO:0016020/ GO:0045121/ GO:0005743/ GO:0005759/ GO:0005753/ GO:0005754/ GO:0005739/ GO:0005634/ GO:0005886/ GO:0045259/ GO:0045261/ GO:0043531/ GO:0043532/ GO:0005524/ GO:0016887/ GO:0042288/ GO:0002020/ GO:0046933/ GO:0003723/ GO:0006915/ GO:0006754/ GO:0071549/ GO:0071732/ GO:0006629/ GO:0001937/ GO:0043536/ GO:0015986/ GO:0042776/ GO:0045471/ GO:0014850/ IPR023366/ IPR000793/ IPR038376/ IPR033732/ IPR005294/ IPR020003/ IPR004100/ IPR036121/ IPR000194/ IPR027417/ P25705,1,8H9L,wlidetype,P25705,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,8
8H9P,5,,,,,,8H9P,Structure of the human ATP synthase.,Human ATP synthase F1 domain/ state 3b,MEMBRANE PROTEIN,ATP5F1A/ ATP5A/ ATP5A1/ ATP5AL2/ ATPM,,GO:0009986/ GO:0070062/ GO:0016020/ GO:0045121/ GO:0005743/ GO:0005759/ GO:0005753/ GO:0005754/ GO:0005739/ GO:0005634/ GO:0005886/ GO:0045259/ GO:0045261/ GO:0043531/ GO:0043532/ GO:0005524/ GO:0016887/ GO:0042288/ GO:0002020/ GO:0046933/ GO:0003723/ GO:0006915/ GO:0006754/ GO:0071549/ GO:0071732/ GO:0006629/ GO:0001937/ GO:0043536/ GO:0015986/ GO:0042776/ GO:0045471/ GO:0014850/ IPR023366/ IPR000793/ IPR038376/ IPR033732/ IPR005294/ IPR020003/ IPR004100/ IPR036121/ IPR000194/ IPR027417/ P25705,1,8H9P,wlidetype,P25705,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,5
8H9P,5,,,,,,8H9P,Structure of the human ATP synthase.,Human ATP synthase F1 domain/ state 3b,MEMBRANE PROTEIN,ATP5F1C/ ATP5C/ ATP5C1/ ATP5CL1,,GO:0016020/ GO:0005743/ GO:0005759/ GO:0005753/ GO:0000275/ GO:0005739/ GO:0046933/ GO:0003723/ GO:0006754/ GO:0006119/ GO:0015986/ GO:0042776/ IPR035968/ IPR000131/ IPR023632/ P36542,3,8H9P,wlidetype,P36542,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,7
8H9S,5,,,,,,8H9S,Structure of the human ATP synthase.,Human ATP synthase state 1 (combined),MEMBRANE PROTEIN,ATP5PF/ ATP5A/ ATP5J/ ATPM,,GO:0005743/ GO:0005753/ GO:0000276/ GO:0005739/ GO:0015078/ GO:0015986/ GO:0042776/ GO:0021762/ IPR008387/ IPR036204/ P18859/ Transmembrane.Alpha-helical polytopic.Proton or Sodium translocating F-type/ V-type and A-type ATPases.V-type and F-type ATPases,2,8H9S,wlidetype,P18859,UniProt,C81 H156 O17 P2,1464.043,CDL,CARDIOLIPIN,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC(COP(=O)([O-])OCC(COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)O)OC(=O)CCCCCCCCCCCCCCCCC,18
8H9S,5,,,,,,8H9S,Structure of the human ATP synthase.,Human ATP synthase state 1 (combined),MEMBRANE PROTEIN,ATP5MC1/ ATP5G1,,GO:0005743/ GO:0005753/ GO:0000276/ GO:0005739/ GO:0008289/ GO:0015078/ GO:0015986/ IPR000454/ IPR020537/ IPR038662/ IPR002379/ IPR035921/ P05496/ Transmembrane.Alpha-helical polytopic.Proton or Sodium translocating F-type/ V-type and A-type ATPases.V-type and F-type ATPases,9,8H9S,wlidetype,P05496,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,21
8H9S,5,,,,,,8H9S,Structure of the human ATP synthase.,Human ATP synthase state 1 (combined),MEMBRANE PROTEIN,ATP5PB/ ATP5F1,,GO:0016020/ GO:0005743/ GO:0005759/ GO:0005753/ GO:0000276/ GO:0005739/ GO:0005634/ GO:0015078/ GO:0015986/ GO:0042776/ GO:0021762/ IPR008688/ IPR013837/ P24539/ Transmembrane.Alpha-helical polytopic.Proton or Sodium translocating F-type/ V-type and A-type ATPases.V-type and F-type ATPases,1,8H9S,wlidetype,P24539,UniProt,C39 H77 O8 P,704.998,3PH,1/2-DIACYL-GLYCEROL-3-SN-PHOSPHATE,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)O)OC(=O)CCCCCCCCCCCCCCCCC,22
8H9S,5,,,,,,8H9S,Structure of the human ATP synthase.,Human ATP synthase state 1 (combined),MEMBRANE PROTEIN,ATP5F1D/ ATP5D,,GO:0005743/ GO:0005759/ GO:0005753/ GO:0000275/ GO:0005739/ GO:0046933/ GO:0009060/ GO:0033615/ GO:0015986/ GO:0042776/ GO:0046688/ IPR036794/ IPR001469/ IPR020546/ IPR036771/ P30049/ Transmembrane.Alpha-helical polytopic.Proton or Sodium translocating F-type/ V-type and A-type ATPases.V-type and F-type ATPases,10,8H9S,wlidetype,P30049,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,19
8H9T,5,,,,,,8H9T,Structure of the human ATP synthase.,Human ATP synthase state 2 (combined),MEMBRANE PROTEIN,ATP5PD/ ATP5H/ My032,,GO:0005743/ GO:0005753/ GO:0000274/ GO:0005739/ GO:0015078/ GO:0015986/ GO:0042776/ IPR008689/ IPR036228/ O75947/ Transmembrane.Alpha-helical polytopic.Proton or Sodium translocating F-type/ V-type and A-type ATPases.V-type and F-type ATPases,3,8H9T,wlidetype,O75947,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,17
8H9T,5,,,,,,8H9T,Structure of the human ATP synthase.,Human ATP synthase state 2 (combined),MEMBRANE PROTEIN,ATP5F1C/ ATP5C/ ATP5C1/ ATP5CL1,,GO:0016020/ GO:0005743/ GO:0005759/ GO:0005753/ GO:0000275/ GO:0005739/ GO:0046933/ GO:0003723/ GO:0006754/ GO:0006119/ GO:0015986/ GO:0042776/ IPR035968/ IPR000131/ IPR023632/ P36542/ Transmembrane.Alpha-helical polytopic.Proton or Sodium translocating F-type/ V-type and A-type ATPases.V-type and F-type ATPases,15,8H9T,wlidetype,P36542,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,19
8H9U,5,,,,,,8H9U,Structure of the human ATP synthase.,Human ATP synthase state 3a (combined),MEMBRANE PROTEIN,ATP5F1A/ ATP5A/ ATP5A1/ ATP5AL2/ ATPM,,GO:0009986/ GO:0070062/ GO:0016020/ GO:0045121/ GO:0005743/ GO:0005759/ GO:0005753/ GO:0005754/ GO:0005739/ GO:0005634/ GO:0005886/ GO:0045259/ GO:0045261/ GO:0043531/ GO:0043532/ GO:0005524/ GO:0016887/ GO:0042288/ GO:0002020/ GO:0046933/ GO:0003723/ GO:0006915/ GO:0006754/ GO:0071549/ GO:0071732/ GO:0006629/ GO:0001937/ GO:0043536/ GO:0015986/ GO:0042776/ GO:0045471/ GO:0014850/ IPR023366/ IPR000793/ IPR038376/ IPR033732/ IPR005294/ IPR020003/ IPR004100/ IPR036121/ IPR000194/ IPR027417/ P25705/ Transmembrane.Alpha-helical polytopic.Proton or Sodium translocating F-type/ V-type and A-type ATPases.V-type and F-type ATPases,1,8H9U,wlidetype,P25705,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,18
8H9U,5,,,,,,8H9U,Structure of the human ATP synthase.,Human ATP synthase state 3a (combined),MEMBRANE PROTEIN,MT-ATP6/ ATP6/ ATPASE6/ MTATP6,,GO:0005743/ GO:0005753/ GO:0045263/ GO:0015078/ GO:0015986/ GO:0042776/ GO:0055093/ IPR000568/ IPR023011/ IPR045083/ IPR035908/ P00846/ Transmembrane.Alpha-helical polytopic.Proton or Sodium translocating F-type/ V-type and A-type ATPases.V-type and F-type ATPases,11,8H9U,wlidetype,P00846,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,20
8H9V,5,,,,,,8H9V,Structure of the human ATP synthase.,Human ATP synthase state 3b (combined),MEMBRANE PROTEIN,ATP5F1D/ ATP5D,,GO:0005743/ GO:0005759/ GO:0005753/ GO:0000275/ GO:0005739/ GO:0046933/ GO:0009060/ GO:0033615/ GO:0015986/ GO:0042776/ GO:0046688/ IPR036794/ IPR001469/ IPR020546/ IPR036771/ P30049/ Transmembrane.Alpha-helical polytopic.Proton or Sodium translocating F-type/ V-type and A-type ATPases.V-type and F-type ATPases/ Generic PDBTM,2,8H9V,wlidetype,P30049,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,17
8H9V,5,,,,,,8H9V,Structure of the human ATP synthase.,Human ATP synthase state 3b (combined),MEMBRANE PROTEIN,ATP5MJ/ ATP5MPL/ C14orf2/ MP68/ PRO1574,,GO:0005743/ GO:0005753/ GO:0015986/ IPR012574/ P56378/ Transmembrane.Alpha-helical polytopic.Proton or Sodium translocating F-type/ V-type and A-type ATPases.V-type and F-type ATPases/ Generic PDBTM,7,8H9V,wlidetype,P56378,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,19
8HJ5,5,,,,,,8HJ5,Cryo-EM structure of Gq-coupled MRGPRX1 bound with  Compound-16,Cryo-EM structure of Gq-coupled MRGPRX1 bound with Compound-16,SIGNALING PROTEIN,,,,6,8HJ5,mutant,,,C23 H21 N3 O4 S,435.496,U2U,N-{2-[(1-aminoisoquinolin-6-yl)oxy]-4-methylphenyl}-2-methoxybenzene-1-sulfonamide,Cc1ccc(c(c1)Oc2ccc3c(c2)ccnc3N)NS(=O)(=O)c4ccccc4OC,7
8HJE,5,,,,,,8HJE,Structure-based discovery of potent USP28 inhibitors derived from Vismodegib.,Vismodegib binds to the catalytical domain of human Ubiquitin-Specific Protease 28,HYDROLASE,USP28/ KIAA1515,3.4.19.12,GO:0005829/ GO:0016604/ GO:0005654/ GO:0005634/ GO:0032991/ GO:0004843/ GO:0004197/ GO:0008283/ GO:0006974/ GO:0034644/ GO:0000077/ GO:0006281/ GO:0042771/ GO:0016579/ GO:0007265/ GO:0031647/ GO:0010212/ GO:0006511/ IPR038765/ IPR001394/ IPR009060/ IPR018200/ IPR028889/ Q96RU2,1,8HJE,wlidetype,Q96RU2,UniProt,C19 H14 Cl2 N2 O3 S,421.297,VIS,2-chloranyl-~{N}-(4-chloranyl-3-pyridin-2-yl-phenyl)-4-methylsulfonyl-benzamide,CS(=O)(=O)c1ccc(c(c1)Cl)C(=O)Nc2ccc(c(c2)c3ccccn3)Cl,2
8HN7,5,,,,,,8HN7,Characterization of RBD-specific cross-neutralizing antibodies responses against SARS-CoV-2 variants from COVID-19 convalescents.,Crystal structure of monoclonal antibody complexed with SARS-CoV-2 RBD,VIRAL PROTEIN/IMMUNE SYSTEM,,,,1,8HN7,wlidetype,,,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
8I4A,5,,,,,,8I4A,Cryo-EM structure ofABCC4,Cryo-EM structure of dipyridamole-bound ABCC4,TRANSPORT PROTEIN,ABCC4/ MOATB/ MRP4,7.6.2/ 7.6.2.2/ 7.6.2.3,GO:0016324/ GO:0016323/ GO:0098591/ GO:0005794/ GO:0016020/ GO:0005730/ GO:0005886/ GO:0031088/ GO:0016404/ GO:0015432/ GO:0015431/ GO:0140359/ GO:0008559/ GO:0005524/ GO:0016887/ GO:0043225/ GO:0042626/ GO:0015562/ GO:0034634/ GO:0001409/ GO:0015132/ GO:0015216/ GO:0015143/ GO:0042910/ GO:0015721/ GO:0070730/ GO:0060271/ GO:0140115/ GO:0071716/ GO:0002576/ GO:0032310/ GO:0015732/ GO:0055085/ GO:0150104/ GO:0015747/ GO:0006805/ GO:0006855/ IPR003593/ IPR011527/ IPR036640/ IPR003439/ IPR017871/ IPR030240/ IPR047083/ IPR027417/ O15439/ Transmembrane.Alpha-helical polytopic.ABC transporters.Drug conjugate transporter (ABC C family)/ Generic PDBTM,1,8I4A,wlidetype,O15439,UniProt,C24 H40 N8 O4,504.626,H9F,2-[[2-[bis(2-hydroxyethyl)amino]-4/8-di(piperidin-1-yl)pyrimido[5/4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol,C1CCN(CC1)c2c3c(c(nc(n3)N(CCO)CCO)N4CCCCC4)nc(n2)N(CCO)CCO,2
8I4C,5,,,,,,8I4C,Cryo-EM structure ofABCC4,Cryo-EM structure of U46619-bound ABCC4,TRANSPORT PROTEIN,ABCC4/ MOATB/ MRP4,7.6.2/ 7.6.2.2/ 7.6.2.3,GO:0016324/ GO:0016323/ GO:0098591/ GO:0005794/ GO:0016020/ GO:0005730/ GO:0005886/ GO:0031088/ GO:0016404/ GO:0015432/ GO:0015431/ GO:0140359/ GO:0008559/ GO:0005524/ GO:0016887/ GO:0043225/ GO:0042626/ GO:0015562/ GO:0034634/ GO:0001409/ GO:0015132/ GO:0015216/ GO:0015143/ GO:0042910/ GO:0015721/ GO:0070730/ GO:0060271/ GO:0140115/ GO:0071716/ GO:0002576/ GO:0032310/ GO:0015732/ GO:0055085/ GO:0150104/ GO:0015747/ GO:0006805/ GO:0006855/ IPR003593/ IPR011527/ IPR036640/ IPR003439/ IPR017871/ IPR030240/ IPR047083/ IPR027417/ O15439/ Transmembrane.Alpha-helical polytopic.ABC transporters.Drug conjugate transporter (ABC C family)/ Generic PDBTM,1,8I4C,wlidetype,O15439,UniProt,C21 H34 O4,350.492,PUC,(5Z)-7-{(1R/4S/5S/6R)-6-[(1E/3S)-3-hydroxyoct-1-en-1-yl]-2-oxabicyclo[2.2.1]hept-5-yl}hept-5-enoic acid,CCCCCC(C=CC1C2CC(C1CC=CCCCC(=O)O)CO2)O,2
8IF2,5,,,,,,8IF2,Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant.,Crystal structure of the receptor binding domain of SARS-CoV-2 Omicron BQ.1.1 variant spike protein in complex with its receptor ACE2,VIRAL PROTEIN,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,2,8IF2,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,7
8ITF,5,,,,,,8ITF,Structural basis of amine odorant perception by a mammal olfactory receptor.,Cryo-EM structure of the DMCHA-bound mTAAR9-Gs complex,MEMBRANE PROTEIN,GNB1,,GO:0005737/ GO:0005829/ GO:0070062/ GO:1903561/ GO:0005834/ GO:0005765/ GO:0016020/ GO:0097381/ GO:0005886/ GO:0045202/ GO:0003924/ GO:0051020/ GO:0044877/ GO:0030159/ GO:0007191/ GO:0008283/ GO:0071870/ GO:0071380/ GO:0007213/ GO:0007186/ GO:0007200/ GO:0007265/ GO:0060041/ GO:0050909/ GO:0007165/ IPR020472/ IPR001632/ IPR016346/ IPR015943/ IPR001680/ IPR019775/ IPR036322/ P62873,2,8ITF,wlidetype,P62873,UniProt,C8 H17 N,127.227,8IA,~{N}/~{N}-dimethylcyclohexanamine,CN(C)C1CCCCC1,7
8IW4,5,,,,,,8IW4,Structural basis of amine odorant perception by a mammal olfactory receptor.,Cryo-EM structure of the SPE-bound mTAAR9-Gs complex,MEMBRANE PROTEIN,,,,1,8IW4,wlidetype,,,C7 H19 N3,145.246,SPD,SPERMIDINE,C(CCNCCCN)CN,6
8IW7,5,,,,,,8IW7,Structural basis of amine odorant perception by a mammal olfactory receptor.,Cryo-EM structure of the PEA-bound mTAAR9-Gs complex,MEMBRANE PROTEIN,Taar9,,GO:0005886/ GO:0001594/ IPR000276/ IPR017452/ IPR009132/ Q5QD04/ Transmembrane.Alpha-helical polytopic.Rhodopsin-like receptors and pumps.G-protein coupled receptors/ family A/ Generic PDBTM,1,8IW7,wlidetype,Q5QD04,UniProt,C8 H12 N,122.188,PEA,2-PHENYLETHYLAMINE,c1ccc(cc1)CC[NH3+],6
8J3W,5,,,,,,8J3W,Cryo-EM structure ofABCC4,Cryo-EM structure of aspirin-bound ABCC4,TRANSPORT PROTEIN,ABCC4/ MOATB/ MRP4,7.6.2/ 7.6.2.2/ 7.6.2.3,GO:0016324/ GO:0016323/ GO:0098591/ GO:0005794/ GO:0016020/ GO:0005730/ GO:0005886/ GO:0031088/ GO:0016404/ GO:0015432/ GO:0015431/ GO:0140359/ GO:0008559/ GO:0005524/ GO:0016887/ GO:0043225/ GO:0042626/ GO:0015562/ GO:0034634/ GO:0001409/ GO:0015132/ GO:0015216/ GO:0015143/ GO:0042910/ GO:0015721/ GO:0070730/ GO:0060271/ GO:0140115/ GO:0071716/ GO:0002576/ GO:0032310/ GO:0015732/ GO:0055085/ GO:0150104/ GO:0015747/ GO:0006805/ GO:0006855/ IPR003593/ IPR011527/ IPR036640/ IPR003439/ IPR017871/ IPR030240/ IPR047083/ IPR027417/ O15439/ Transmembrane.Alpha-helical polytopic.ABC transporters.Drug conjugate transporter (ABC C family)/ Generic PDBTM,1,8J3W,wlidetype,O15439,UniProt,C9 H8 O4,180.157,AIN,2-(ACETYLOXY)BENZOIC ACID,CC(=O)Oc1ccccc1C(=O)O,2
8J3Z,5,,,,,,8J3Z,Cryo-EM structure ofABCC4,Cryo-EM structure of ATP-U46619-bound ABCC4,TRANSPORT PROTEIN,ABCC4/ MOATB/ MRP4,7.6.2/ 7.6.2.2/ 7.6.2.3,GO:0016324/ GO:0016323/ GO:0098591/ GO:0005794/ GO:0016020/ GO:0005730/ GO:0005886/ GO:0031088/ GO:0016404/ GO:0015432/ GO:0015431/ GO:0140359/ GO:0008559/ GO:0005524/ GO:0016887/ GO:0043225/ GO:0042626/ GO:0015562/ GO:0034634/ GO:0001409/ GO:0015132/ GO:0015216/ GO:0015143/ GO:0042910/ GO:0015721/ GO:0070730/ GO:0060271/ GO:0140115/ GO:0071716/ GO:0002576/ GO:0032310/ GO:0015732/ GO:0055085/ GO:0150104/ GO:0015747/ GO:0006805/ GO:0006855/ IPR003593/ IPR011527/ IPR036640/ IPR003439/ IPR017871/ IPR030240/ IPR047083/ IPR027417/ O15439/ Transmembrane.Alpha-helical polytopic.ABC transporters.Drug conjugate transporter (ABC C family)/ Generic PDBTM,1,8J3Z,wlidetype,O15439,UniProt,C21 H34 O4,350.492,PUC,(5Z)-7-{(1R/4S/5S/6R)-6-[(1E/3S)-3-hydroxyoct-1-en-1-yl]-2-oxabicyclo[2.2.1]hept-5-yl}hept-5-enoic acid,CCCCCC(C=CC1C2CC(C1CC=CCCCC(=O)O)CO2)O,4
8OLX,5,,,,,,8OLX,MutSbeta bound to (CAG)2 DNA (canonical form),MutSbeta bound to (CAG)2 DNA (canonical form),DNA BINDING PROTEIN,MSH3/ DUC1/ DUG,,GO:0016020/ GO:0032302/ GO:0005654/ GO:0005634/ GO:0005524/ GO:0140664/ GO:0003690/ GO:0019899/ GO:0030983/ GO:0006281/ GO:0043570/ GO:0006298/ GO:0006312/ GO:0045910/ GO:0051096/ GO:0016447/ IPR007695/ IPR000432/ IPR007696/ IPR016151/ IPR036187/ IPR007860/ IPR036678/ IPR045076/ IPR027417/ P20585,2,8OLX,mutant,P20585,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,6
8OM5,5,,,,,,8OM5,DNA-free open form of MutSbeta,DNA-free open form of MutSbeta,DNA BINDING PROTEIN,MSH2,,GO:0000781/ GO:0016020/ GO:0032301/ GO:0032302/ GO:0005654/ GO:0005634/ GO:0005524/ GO:0016887/ GO:0008094/ GO:0140664/ GO:0019237/ GO:0003682/ GO:0003684/ GO:0003677/ GO:0019899/ GO:0032137/ GO:0042803/ GO:0019901/ GO:0030183/ GO:0019724/ GO:0008340/ GO:0006281/ GO:0006302/ GO:0007281/ GO:0001701/ GO:0042771/ GO:0045190/ GO:0043570/ GO:0008584/ GO:0006298/ GO:0031573/ GO:0006312/ GO:0045910/ GO:0043524/ GO:0006119/ GO:0051096/ GO:0048298/ GO:0048304/ GO:0006301/ GO:0071168/ GO:0010224/ GO:0010165/ GO:0016446/ GO:0016447/ GO:0002204/ IPR011184/ IPR007695/ IPR000432/ IPR007861/ IPR007696/ IPR016151/ IPR036187/ IPR007860/ IPR032642/ IPR036678/ IPR045076/ IPR027417/ P43246,1,8OM5,mutant,P43246,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,3
8OM9,5,,,,,,8OM9,MutSbeta bound to (CAG)2 DNA (open form),MutSbeta bound to (CAG)2 DNA (open form),DNA BINDING PROTEIN,MSH2,,GO:0000781/ GO:0016020/ GO:0032301/ GO:0032302/ GO:0005654/ GO:0005634/ GO:0005524/ GO:0016887/ GO:0008094/ GO:0140664/ GO:0019237/ GO:0003682/ GO:0003684/ GO:0003677/ GO:0019899/ GO:0032137/ GO:0042803/ GO:0019901/ GO:0030183/ GO:0019724/ GO:0008340/ GO:0006281/ GO:0006302/ GO:0007281/ GO:0001701/ GO:0042771/ GO:0045190/ GO:0043570/ GO:0008584/ GO:0006298/ GO:0031573/ GO:0006312/ GO:0045910/ GO:0043524/ GO:0006119/ GO:0051096/ GO:0048298/ GO:0048304/ GO:0006301/ GO:0071168/ GO:0010224/ GO:0010165/ GO:0016446/ GO:0016447/ GO:0002204/ IPR011184/ IPR007695/ IPR000432/ IPR007861/ IPR007696/ IPR016151/ IPR036187/ IPR007860/ IPR032642/ IPR036678/ IPR045076/ IPR027417/ P43246,1,8OM9,mutant,P43246,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,5
8OMA,5,,,,,,8OMA,MutSbeta bound to 61bp homoduplex DNA,MutSbeta bound to 61bp homoduplex DNA,DNA BINDING PROTEIN,,,,1,8OMA,mutant,,,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,5
8OMO,5,,,,,,8OMO,DNA-unbound MutSbeta-ATP complex (bent clamp form),DNA-unbound MutSbeta-ATP complex (bent clamp form),DNA BINDING PROTEIN,MSH2,,GO:0000781/ GO:0016020/ GO:0032301/ GO:0032302/ GO:0005654/ GO:0005634/ GO:0005524/ GO:0016887/ GO:0008094/ GO:0140664/ GO:0019237/ GO:0003682/ GO:0003684/ GO:0003677/ GO:0019899/ GO:0032137/ GO:0042803/ GO:0019901/ GO:0030183/ GO:0019724/ GO:0008340/ GO:0006281/ GO:0006302/ GO:0007281/ GO:0001701/ GO:0042771/ GO:0045190/ GO:0043570/ GO:0008584/ GO:0006298/ GO:0031573/ GO:0006312/ GO:0045910/ GO:0043524/ GO:0006119/ GO:0051096/ GO:0048298/ GO:0048304/ GO:0006301/ GO:0071168/ GO:0010224/ GO:0010165/ GO:0016446/ GO:0016447/ GO:0002204/ IPR011184/ IPR007695/ IPR000432/ IPR007861/ IPR007696/ IPR016151/ IPR036187/ IPR007860/ IPR032642/ IPR036678/ IPR045076/ IPR027417/ P43246,1,8OMO,mutant,P43246,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,3
8OMQ,5,,,,,,8OMQ,DNA-unbound MutSbeta-ATP complex (straight clamp form),DNA-unbound MutSbeta-ATP complex (straight clamp form),DNA BINDING PROTEIN,MSH3/ DUC1/ DUG,,GO:0016020/ GO:0032302/ GO:0005654/ GO:0005634/ GO:0005524/ GO:0140664/ GO:0003690/ GO:0019899/ GO:0030983/ GO:0006281/ GO:0043570/ GO:0006298/ GO:0006312/ GO:0045910/ GO:0051096/ GO:0016447/ IPR007695/ IPR000432/ IPR007696/ IPR016151/ IPR036187/ IPR007860/ IPR036678/ IPR045076/ IPR027417/ P20585,1,8OMQ,mutant,P20585,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,3
8OO5,5,,,,,,8OO5,Reinstating targeted protein degradation with DCAF1 PROTACs in CRBN PROTAC resistant settings,Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 13,TRANSFERASE,DCAF1/ KIAA0800/ RIP/ VPRBP,2.7.11.1,GO:0080008/ GO:0005737/ GO:0001650/ GO:0005654/ GO:0005634/ GO:0005524/ GO:1990244/ GO:0030331/ GO:0106310/ GO:0030183/ GO:0035212/ GO:0006325/ GO:0000122/ GO:0043687/ GO:0016567/ GO:0033151/ IPR011989/ IPR016024/ IPR006594/ IPR033270/ IPR015943/ IPR036322/ Q9Y4B6,1,8OO5,mutant,Q9Y4B6,UniProt,C28 H35 Cl N6 O,507.07,VUF,1-[4-[4-(2-azanylethylamino)-2-[1-(4-chlorophenyl)cyclohexyl]quinazolin-7-yl]piperazin-1-yl]ethanone,CC(=O)N1CCN(CC1)c2ccc3c(c2)nc(nc3NCCN)C4(CCCCC4)c5ccc(cc5)Cl,2
8OOD,5,,,,,,8OOD,Reinstating targeted protein degradation with DCAF1 PROTACs in CRBN PROTAC resistant settings,Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 15,TRANSFERASE,DCAF1/ KIAA0800/ RIP/ VPRBP,2.7.11.1,GO:0080008/ GO:0005737/ GO:0001650/ GO:0005654/ GO:0005634/ GO:0005524/ GO:1990244/ GO:0030331/ GO:0106310/ GO:0030183/ GO:0035212/ GO:0006325/ GO:0000122/ GO:0043687/ GO:0016567/ GO:0033151/ IPR011989/ IPR016024/ IPR006594/ IPR033270/ IPR015943/ IPR036322/ Q9Y4B6,1,8OOD,mutant,Q9Y4B6,UniProt,C42 H62 Cl N7 O8,828.437,VY3,~{N}-[2-[2-[2-[2-[2-[2-[3-[4-[4-(2-azanylethylamino)-2-[1-(4-chlorophenyl)cyclopentyl]quinazolin-7-yl]piperazin-1-yl]-3-oxidanylidene-propoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]ethanamide,CC(=O)NCCOCCOCCOCCOCCOCCOCCC(=O)N1CCN(CC1)c2ccc3c(c2)nc(nc3NCCN)C4(CCCC4)c5ccc(cc5)Cl,5
8P0F,5,,,,,,8P0F,Drugit: Crowd-sourcing molecular design of non-peptidic VHL binders,Crystal structure of the VCB complex with compound 1.,LIGASE,VHL,,GO:0005829/ GO:0005783/ GO:0016020/ GO:0005739/ GO:0005654/ GO:0005634/ GO:0140297/ GO:0019899/ GO:0003711/ GO:1990756/ GO:0004842/ GO:0000902/ GO:0043066/ GO:0008285/ GO:0010629/ GO:0046426/ GO:0034244/ GO:0061428/ GO:0045597/ GO:0045893/ GO:0050821/ GO:0016567/ GO:0006508/ GO:0061418/ GO:0006355/ IPR002714/ IPR024048/ IPR037139/ IPR024053/ IPR037140/ IPR036208/ IPR022772/ P40337,1,8P0F,wlidetype,P40337,UniProt,C22 H22 N4 O3 S,422.5,WBN,(3~{R}/5~{R})-~{N}-[[4-(4-methyl-1/3-thiazol-5-yl)phenyl]methyl]-5-oxidanyl-2-oxidanylidene-1-pyridin-2-yl-piperidine-3-carboxamide,Cc1c(scn1)c2ccc(cc2)CNC(=O)C3CC(CN(C3=O)c4ccccn4)O,4
8SEO,5,,,,,,8SEO,Allosteric modulation of ryanodine receptor RyR1 by nucleotide derivatives.,Cryo-EM Structure of RyR1 + ATP-gamma-S,TRANSPORT PROTEIN,RYR1,,GO:0016020/ GO:1990425/ GO:0016529/ GO:0033017/ GO:0014802/ GO:0005524/ GO:0035381/ GO:0005262/ GO:0005509/ GO:0015278/ GO:0005516/ GO:0097718/ GO:0042802/ GO:0005219/ GO:0015643/ GO:0044325/ GO:0005245/ GO:0070588/ GO:0006874/ GO:0071313/ GO:0071277/ GO:0006936/ GO:0043931/ GO:0003151/ GO:0051289/ GO:0051209/ GO:0014808/ GO:0048741/ GO:0043588/ IPR001870/ IPR043136/ IPR013320/ IPR011992/ IPR014821/ IPR005821/ IPR036300/ IPR016093/ IPR013662/ IPR000699/ IPR013333/ IPR003032/ IPR009460/ IPR035910/ IPR033215/ IPR035761/ IPR035764/ IPR035762/ IPR003877/ Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Ryanodine receptor,1,8SEO,wlidetype,P11716,UniProt,C10 H16 N5 O12 P3 S,523.247,AGS,PHOSPHOTHIOPHOSPHORIC ACID-ADENYLATE ESTER,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=S)(O)O)O)O)N,3
45177,5,,,,,,45177,Allosteric modulation of ryanodine receptor RyR1 by nucleotide derivatives.,Cryo-EM Structure of RyR1 + ADP,TRANSPORT PROTEIN,FKBP1B,2.5.1.18/ 5.2.1.8,GO:0004364/ GO:0006749/ IPR010987/ IPR036282/ IPR040079/ IPR004045/ IPR004046/ IPR036249/ GO:0034704/ GO:0005737/ GO:0005829/ GO:0016020/ GO:0033017/ GO:0030018/ GO:0019855/ GO:0030551/ GO:0005528/ GO:0003755/ GO:0005102/ GO:0044325/ GO:0006458/ GO:0035584/ GO:0086064/ GO:0061077/ GO:0035773/ GO:0010459/ GO:0061179/ GO:0032515/ GO:0051280/ GO:0060315/ GO:0019227/ GO:0048680/ GO:0007204/ GO:0051284/ GO:0022417/ GO:0000413/ GO:0042026/ GO:0010881/ GO:0051480/ GO:0010880/ GO:0060314/ GO:0051209/ GO:0042542/ GO:0051775/ GO:0033197/ GO:0006939/ GO:0042098/ IPR046357/ IPR001179/ P68106,2,08-Sep,,P08515,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,3
8SEQ,5,,,,,,8SEQ,Allosteric modulation of ryanodine receptor RyR1 by nucleotide derivatives.,Cryo-EM Structure of RyR1 + AMP,TRANSPORT PROTEIN,RYR1,,GO:0016020/ GO:1990425/ GO:0016529/ GO:0033017/ GO:0014802/ GO:0005524/ GO:0035381/ GO:0005262/ GO:0005509/ GO:0015278/ GO:0005516/ GO:0097718/ GO:0042802/ GO:0005219/ GO:0015643/ GO:0044325/ GO:0005245/ GO:0070588/ GO:0006874/ GO:0071313/ GO:0071277/ GO:0006936/ GO:0043931/ GO:0003151/ GO:0051289/ GO:0051209/ GO:0014808/ GO:0048741/ GO:0043588/ IPR001870/ IPR043136/ IPR013320/ IPR011992/ IPR014821/ IPR005821/ IPR036300/ IPR016093/ IPR013662/ IPR000699/ IPR013333/ IPR003032/ IPR009460/ IPR035910/ IPR033215/ IPR035761/ IPR035764/ IPR035762/ IPR003877/ Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Ryanodine receptor,1,8SEQ,wlidetype,P11716,UniProt,C10 H14 N5 O7 P,347.221,AMP,ADENOSINE MONOPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)O)O)O)N,3
8SER,5,,,,,,8SER,Allosteric modulation of ryanodine receptor RyR1 by nucleotide derivatives.,Cryo-EM Structure of RyR1 + Adenosine,TRANSPORT PROTEIN,RYR1,,GO:0016020/ GO:1990425/ GO:0016529/ GO:0033017/ GO:0014802/ GO:0005524/ GO:0035381/ GO:0005262/ GO:0005509/ GO:0015278/ GO:0005516/ GO:0097718/ GO:0042802/ GO:0005219/ GO:0015643/ GO:0044325/ GO:0005245/ GO:0070588/ GO:0006874/ GO:0071313/ GO:0071277/ GO:0006936/ GO:0043931/ GO:0003151/ GO:0051289/ GO:0051209/ GO:0014808/ GO:0048741/ GO:0043588/ IPR001870/ IPR043136/ IPR013320/ IPR011992/ IPR014821/ IPR005821/ IPR036300/ IPR016093/ IPR013662/ IPR000699/ IPR013333/ IPR003032/ IPR009460/ IPR035910/ IPR033215/ IPR035761/ IPR035764/ IPR035762/ IPR003877/ Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Ryanodine receptor,1,8SER,wlidetype,P11716,UniProt,C10 H13 N5 O4,267.241,ADN,ADENOSINE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)CO)O)O)N,3
8SES,5,,,,,,8SES,Allosteric modulation of ryanodine receptor RyR1 by nucleotide derivatives.,Cryo-EM Structure of RyR1 + Adenine,TRANSPORT PROTEIN,FKBP1B,2.5.1.18/ 5.2.1.8,GO:0004364/ GO:0006749/ IPR010987/ IPR036282/ IPR040079/ IPR004045/ IPR004046/ IPR036249/ GO:0034704/ GO:0005737/ GO:0005829/ GO:0016020/ GO:0033017/ GO:0030018/ GO:0019855/ GO:0030551/ GO:0005528/ GO:0003755/ GO:0005102/ GO:0044325/ GO:0006458/ GO:0035584/ GO:0086064/ GO:0061077/ GO:0035773/ GO:0010459/ GO:0061179/ GO:0032515/ GO:0051280/ GO:0060315/ GO:0019227/ GO:0048680/ GO:0007204/ GO:0051284/ GO:0022417/ GO:0000413/ GO:0042026/ GO:0010881/ GO:0051480/ GO:0010880/ GO:0060314/ GO:0051209/ GO:0042542/ GO:0051775/ GO:0033197/ GO:0006939/ GO:0042098/ IPR046357/ IPR001179/ P68106,2,8SES,wlidetype,P08515,UniProt,C5 H5 N5,135.127,ADE,ADENINE,c1[nH]c2c(n1)c(ncn2)N,4
8SET,5,,,,,,8SET,Allosteric modulation of ryanodine receptor RyR1 by nucleotide derivatives.,Cryo-EM Structure of RyR1 + cAMP,TRANSPORT PROTEIN,RYR1,,GO:0016020/ GO:1990425/ GO:0016529/ GO:0033017/ GO:0014802/ GO:0005524/ GO:0035381/ GO:0005262/ GO:0005509/ GO:0015278/ GO:0005516/ GO:0097718/ GO:0042802/ GO:0005219/ GO:0015643/ GO:0044325/ GO:0005245/ GO:0070588/ GO:0006874/ GO:0071313/ GO:0071277/ GO:0006936/ GO:0043931/ GO:0003151/ GO:0051289/ GO:0051209/ GO:0014808/ GO:0048741/ GO:0043588/ IPR001870/ IPR043136/ IPR013320/ IPR011992/ IPR014821/ IPR005821/ IPR036300/ IPR016093/ IPR013662/ IPR000699/ IPR013333/ IPR003032/ IPR009460/ IPR035910/ IPR033215/ IPR035761/ IPR035764/ IPR035762/ IPR003877/ Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Ryanodine receptor,1,8SET,wlidetype,P11716,UniProt,C10 H12 N5 O6 P,329.206,CMP,ADENOSINE-3'/5'-CYCLIC-MONOPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C4C(O3)COP(=O)(O4)O)O)N,3
8STE,5,,,,,,8STE,Inhibition mechanism of NKCC1 involves the carboxyl terminus and long-range conformational coupling.,Cryo-EM structure of NKCC1 Fu_CTD,TRANSPORT PROTEIN,SLC12A2,,GO:0005886/ GO:0015377/ GO:0006814/ IPR004841/ IPR013612/ IPR002444/ IPR018491/ IPR002443/ IPR004842,1,8STE,wlidetype,A0A8C9GPS0,UniProt,C12 H11 Cl N2 O5 S,330.744,FUN,5-(AMINOSULFONYL)-4-CHLORO-2-[(2-FURYLMETHYL)AMINO]BENZOIC ACID,c1cc(oc1)CNc2cc(c(cc2C(=O)O)S(=O)(=O)N)Cl,2
7SXF,6,,,,,,7SXF,Elucidation of the GSK3 alpha Structure Informs the Design of Novel/ Paralog-Selective Inhibitors.,BIO-2895 (BRD0705) bound GSK3alpha-axin complex,HYDROLASE,GSK3A,2.7.11.26/ 2.7.11.1,GO:0097440/ GO:0030424/ GO:0030877/ GO:0005737/ GO:0005829/ GO:0005874/ GO:0005739/ GO:0043025/ GO:0005634/ GO:0098794/ GO:1990635/ GO:0005524/ GO:0034236/ GO:0106310/ GO:0004674/ GO:0120283/ GO:0005102/ GO:0048156/ GO:0050321/ GO:0003214/ GO:0016477/ GO:0071385/ GO:0032869/ GO:0036016/ GO:0071285/ GO:0007212/ GO:0060079/ GO:0097191/ GO:0097192/ GO:0005977/ GO:0008286/ GO:0090090/ GO:0061052/ GO:2000171/ GO:0044027/ GO:0046325/ GO:2000466/ GO:0045719/ GO:1904227/ GO:0046627/ GO:0032007/ GO:2000077/ GO:0010905/ GO:0007399/ GO:0018105/ GO:0018107/ GO:0071879/ GO:0106071/ GO:1902004/ GO:0010508/ GO:0010628/ GO:2000467/ GO:0045823/ GO:1901030/ GO:0043525/ GO:0033138/ GO:0010800/ GO:0032436/ GO:0045732/ GO:1903955/ GO:0031398/ GO:0045944/ GO:0043161/ GO:0006468/ GO:1903146/ GO:0006349/ GO:0010975/ GO:0003073/ GO:0019082/ GO:0016055/ IPR011009/ IPR000719/ IPR017441/ IPR008271/ IPR039192/ P49840,1,7SXF,wildtype,P49840,UniProt,C20 H23 N3 O,321.416,6VL,(4~{S})-4-ethyl-7/7-dimethyl-4-phenyl-2/6/8/9-tetrahydropyrazolo[3/4-b]quinolin-5-one,CCC1(c2c[nH]nc2NC3=C1C(=O)CC(C3)(C)C)c4ccccc4,3
7SXG,6,,,,,,7SXG,Elucidation of the GSK3 alpha Structure Informs the Design of Novel/ Paralog-Selective Inhibitors.,BIO-8546 bound GSK3alpha-axin complex,HYDROLASE,GSK3A,2.7.11.26/ 2.7.11.1,GO:0097440/ GO:0030424/ GO:0030877/ GO:0005737/ GO:0005829/ GO:0005874/ GO:0005739/ GO:0043025/ GO:0005634/ GO:0098794/ GO:1990635/ GO:0005524/ GO:0034236/ GO:0106310/ GO:0004674/ GO:0120283/ GO:0005102/ GO:0048156/ GO:0050321/ GO:0003214/ GO:0016477/ GO:0071385/ GO:0032869/ GO:0036016/ GO:0071285/ GO:0007212/ GO:0060079/ GO:0097191/ GO:0097192/ GO:0005977/ GO:0008286/ GO:0090090/ GO:0061052/ GO:2000171/ GO:0044027/ GO:0046325/ GO:2000466/ GO:0045719/ GO:1904227/ GO:0046627/ GO:0032007/ GO:2000077/ GO:0010905/ GO:0007399/ GO:0018105/ GO:0018107/ GO:0071879/ GO:0106071/ GO:1902004/ GO:0010508/ GO:0010628/ GO:2000467/ GO:0045823/ GO:1901030/ GO:0043525/ GO:0033138/ GO:0010800/ GO:0032436/ GO:0045732/ GO:1903955/ GO:0031398/ GO:0045944/ GO:0043161/ GO:0006468/ GO:1903146/ GO:0006349/ GO:0010975/ GO:0003073/ GO:0019082/ GO:0016055/ IPR011009/ IPR000719/ IPR017441/ IPR008271/ IPR039192/ P49840,1,7SXG,wildtype,P49840,UniProt,C26 H28 F2 N4 O2,466.523,D1E,(4S/5R/8R)-4-ethyl-8-fluoro-4-[3-(3-fluoro-5-methoxypyridin-4-yl)phenyl]-7/7-dimethyl-4/5/6/7/8/9-hexahydro-2H-pyrazolo[3/4-b]quinolin-5-ol,CCC1(c2c[nH]nc2NC3=C1C(CC(C3F)(C)C)O)c4cccc(c4)c5c(cncc5F)OC,3
7X3J,6,,,,,,7X3J,Pathway and mechanism of tubulin folding mediated by TRiC/CCT conjugated with its ATPase cycle revealed by cryo-EM,Cryo-EM structure of human TRiC-tubulin-S2,STRUCTURAL PROTEIN,TCP1/ CCT1/ CCTA,,GO:0001669/ GO:0044297/ GO:0005813/ GO:0005832/ GO:0005829/ GO:0070062/ GO:0005794/ GO:0000792/ GO:0005874/ GO:0000242/ GO:0002199/ GO:0005524/ GO:0016887/ GO:0140662/ GO:0044183/ GO:0003723/ GO:0031625/ GO:0051082/ GO:0007339/ GO:0061077/ GO:1904851/ GO:1904871/ GO:0051973/ GO:1904874/ GO:0032212/ GO:0006457/ GO:0050821/ GO:2000109/ GO:0090666/ GO:1901998/ GO:0044053/ GO:0007021/ IPR012715/ IPR017998/ IPR002194/ IPR002423/ IPR027409/ IPR027413/ IPR027410/ P17987,1,7X3J,Mutant,P17987,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,9
7X3U,6,,,,,,7X3U,Pathway and mechanism of tubulin folding mediated by TRiC/CCT conjugated with its ATPase cycle revealed by cryo-EM,cryo-EM structure of human TRiC-ADP,STRUCTURAL PROTEIN,TCP1/ CCT1/ CCTA,,GO:0001669/ GO:0044297/ GO:0005813/ GO:0005832/ GO:0005829/ GO:0070062/ GO:0005794/ GO:0000792/ GO:0005874/ GO:0000242/ GO:0002199/ GO:0005524/ GO:0016887/ GO:0140662/ GO:0044183/ GO:0003723/ GO:0031625/ GO:0051082/ GO:0007339/ GO:0061077/ GO:1904851/ GO:1904871/ GO:0051973/ GO:1904874/ GO:0032212/ GO:0006457/ GO:0050821/ GO:2000109/ GO:0090666/ GO:1901998/ GO:0044053/ GO:0007021/ IPR012715/ IPR017998/ IPR002194/ IPR002423/ IPR027409/ IPR027413/ IPR027410/ P17987,1,7X3U,Mutant,P17987,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,9
7XZH,6,,,,,,7XZH,cryo-EM structure of human LRRC8A,Cryo-EM structure of human LRRC8A,MEMBRANE PROTEIN,LRRC8A/ KIAA1437/ LRRC8/ SWELL1/ UNQ221/PRO247,,GO:0009986/ GO:0034702/ GO:0016020/ GO:0005886/ GO:0140360/ GO:0042802/ GO:0005225/ GO:0098656/ GO:0006820/ GO:0015810/ GO:0006884/ GO:0001678/ GO:1902476/ GO:0140361/ GO:0032024/ GO:0045663/ GO:0002329/ GO:0034214/ GO:0006970/ GO:0007283/ GO:0015734/ IPR001611/ IPR003591/ IPR032675/ IPR021040/ Q8IWT6/ Generic PDBTM,1,7XZH,wildtype,Q8IWT6,UniProt,C42 H82 N O10 P,792.075,P5S,O-[(R)-{[(2R)-2/3-bis(octadecanoyloxy)propyl]oxy}(hydroxy)phosphoryl]-L-serine,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCC(C(=O)O)N)OC(=O)CCCCCCCCCCCCCCCCC,2
7XZH,6,,,,,,7XZH,cryo-EM structure of human LRRC8A,Cryo-EM structure of human LRRC8A,MEMBRANE PROTEIN,LRRC8A/ KIAA1437/ LRRC8/ SWELL1/ UNQ221/PRO247,,GO:0009986/ GO:0034702/ GO:0016020/ GO:0005886/ GO:0140360/ GO:0042802/ GO:0005225/ GO:0098656/ GO:0006820/ GO:0015810/ GO:0006884/ GO:0001678/ GO:1902476/ GO:0140361/ GO:0032024/ GO:0045663/ GO:0002329/ GO:0034214/ GO:0006970/ GO:0007283/ GO:0015734/ IPR001611/ IPR003591/ IPR032675/ IPR021040/ Q8IWT6/ Generic PDBTM,1,7XZH,wildtype,Q8IWT6,UniProt,C27 H46 O,386.654,CLR,CHOLESTEROL,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C,4
7Y63,6,,,,,,7Y63,Structure of human SID1 family,ApoSIDT2-pH7.4,MEMBRANE PROTEIN,SIDT2/ CGI-40/ PSEC0072/ UNQ685/PRO1325,,GO:0005765/ GO:0005764/ GO:0005886/ GO:0035650/ GO:0035612/ GO:0003677/ GO:0003725/ GO:0051032/ GO:0051033/ GO:0000902/ GO:0042593/ GO:0061178/ GO:0009749/ GO:0006401/ GO:0050658/ GO:0003323/ GO:0044342/ IPR025958/ Q8NBJ9,1,7Y63,wildtype,Q8NBJ9,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7Y68,6,,,,,,7Y68,Structure of human SID1 family,SIDT2-pH5.5 plus miRNA,MEMBRANE PROTEIN,SIDT2/ CGI-40/ PSEC0072/ UNQ685/PRO1325,,GO:0005765/ GO:0005764/ GO:0005886/ GO:0035650/ GO:0035612/ GO:0003677/ GO:0003725/ GO:0051032/ GO:0051033/ GO:0000902/ GO:0042593/ GO:0061178/ GO:0009749/ GO:0006401/ GO:0050658/ GO:0003323/ GO:0044342/ IPR025958/ Q8NBJ9,1,7Y68,wildtype,Q8NBJ9,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7Y69,6,,,,,,7Y69,Structure of SID1 family,ApoSIDT2-pH5.5,MEMBRANE PROTEIN,SIDT2/ CGI-40/ PSEC0072/ UNQ685/PRO1325,,GO:0005765/ GO:0005764/ GO:0005886/ GO:0035650/ GO:0035612/ GO:0003677/ GO:0003725/ GO:0051032/ GO:0051033/ GO:0000902/ GO:0042593/ GO:0061178/ GO:0009749/ GO:0006401/ GO:0050658/ GO:0003323/ GO:0044342/ IPR025958/ Q8NBJ9,1,7Y69,wildtype,Q8NBJ9,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7YVE,6,,,,,,7YVE,Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection.,Omicron BA.4/5 SARS-CoV-2 S in complex with TH027 Fab,VIRAL PROTEIN/ANTIVIRAL PROTEIN,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,7YVE,Mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7YVG,6,,,,,,7YVG,Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection.,Omicron BA.4/5 SARS-CoV-2 S in complex with TH132 Fab,VIRAL PROTEIN/ANTIVIRAL PROTEIN,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,7YVG,Mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7YVI,6,,,,,,7YVI,Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection.,Omicron BA.4/5 SARS-CoV-2 S in complex with TH236 Fab,VIRAL PROTEIN/ANTIVIRAL PROTEIN,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,7YVI,Mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7YVK,6,,,,,,7YVK,Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection.,Omicron BA.4/5 SARS-CoV-2 S in complex with TH272 Fab,VIRAL PROTEIN/ANTIVIRAL PROTEIN,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,7YVK,Mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7YVN,6,,,,,,7YVN,Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection.,Omicron BA.4/5 SARS-CoV-2 S in complex with TH281 Fab,VIRAL PROTEIN/ANTIVIRAL PROTEIN,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,7YVN,Mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7YVO,6,,,,,,7YVO,Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection.,Omicron BA.4/5 SARS-CoV-2 S in complex with TH027/132 Fab,VIRAL PROTEIN/ANTIVIRAL PROTEIN,,,,2,7YVO,Mutant,,,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
7YVP,6,,,,,,7YVP,Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection.,Omicron BA.4/5 SARS-CoV-2 S in complex with TH272/281 Fab,ANTIVIRAL PROTEIN/VIRAL PROTEIN,,,,1,7YVP,Mutant,,,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
7ZT2,6,,,,,,7ZT2,Promiscuous recognition of MR1 drives self-reactive Mucosal-Associated Invariant T cell responses,Structure of E8 TCR in complex with human MR1 bound to 5-OP-RU,IMMUNE SYSTEM,MR1,,GO:0031901/ GO:0005783/ GO:0005789/ GO:0009897/ GO:0005615/ GO:0000139/ GO:0031902/ GO:0042612/ GO:0005886/ GO:0030881/ GO:0032393/ GO:0042608/ GO:0019884/ GO:0002474/ GO:0050829/ GO:0050830/ GO:0006955/ GO:0045087/ GO:0002854/ GO:0033077/ IPR007110/ IPR036179/ IPR013783/ IPR003006/ IPR003597/ IPR011161/ IPR037055/ IPR011162/ IPR001039/ Q95460,1,7ZT2,wildtype,Q95460,UniProt,C12 H20 N4 O6,316.31,2LJ,1-deoxy-1-({2/6-dioxo-5-[(E)-propylideneamino]-1/2/3/6-tetrahydropyrimidin-4-yl}amino)-D-ribitol,CCC=NC1=C(NC(=O)NC1=O)NCC(C(C(CO)O)O)O,5
7ZT4,6,,,,,,7ZT4,Promiscuous recognition of MR1 drives self-reactive Mucosal-Associated Invariant T cell responses,Structure of E8 TCR in complex with human MR1 bound to 6FP,IMMUNE SYSTEM,MR1,,GO:0031901/ GO:0005783/ GO:0005789/ GO:0009897/ GO:0005615/ GO:0000139/ GO:0031902/ GO:0042612/ GO:0005886/ GO:0030881/ GO:0032393/ GO:0042608/ GO:0019884/ GO:0002474/ GO:0050829/ GO:0050830/ GO:0006955/ GO:0045087/ GO:0002854/ GO:0033077/ IPR007110/ IPR036179/ IPR013783/ IPR003006/ IPR003597/ IPR011161/ IPR037055/ IPR011162/ IPR001039/ Q95460,1,7ZT4,wildtype,Q95460,UniProt,C7 H7 N5 O,177.163,JSO,2-azanyl-6-methyl-3~{H}-pteridin-4-one,Cc1cnc2c(n1)C(=O)NC(=N2)N,5
7ZT5,6,,,,,,7ZT5,Promiscuous recognition of MR1 drives self-reactive Mucosal-Associated Invariant T cell responses,Structure of E8 TCR in complex in human MR1 bound to 3FSA,IMMUNE SYSTEM,MR1,,GO:0031901/ GO:0005783/ GO:0005789/ GO:0009897/ GO:0005615/ GO:0000139/ GO:0031902/ GO:0042612/ GO:0005886/ GO:0030881/ GO:0032393/ GO:0042608/ GO:0019884/ GO:0002474/ GO:0050829/ GO:0050830/ GO:0006955/ GO:0045087/ GO:0002854/ GO:0033077/ IPR007110/ IPR036179/ IPR013783/ IPR003006/ IPR003597/ IPR011161/ IPR037055/ IPR011162/ IPR001039/ Q95460,1,7ZT5,wildtype,Q95460,UniProt,C8 H6 O4,166.131,7ZS,3-methanoyl-2-oxidanyl-benzoic acid,c1cc(c(c(c1)C(=O)O)O)C=O,5
7ZT7,6,,,,,,7ZT7,Promiscuous recognition of MR1 drives self-reactive Mucosal-Associated Invariant T cell responses,Structure of E8 TCR in complex in human MR1 bound to 5FSA,IMMUNE SYSTEM,MR1,,GO:0031901/ GO:0005783/ GO:0005789/ GO:0009897/ GO:0005615/ GO:0000139/ GO:0031902/ GO:0042612/ GO:0005886/ GO:0030881/ GO:0032393/ GO:0042608/ GO:0019884/ GO:0002474/ GO:0050829/ GO:0050830/ GO:0006955/ GO:0045087/ GO:0002854/ GO:0033077/ IPR007110/ IPR036179/ IPR013783/ IPR003006/ IPR003597/ IPR011161/ IPR037055/ IPR011162/ IPR001039/ Q95460,1,7ZT7,wildtype,Q95460,UniProt,C8 H8 O3,152.147,54G,2-hydroxy-5-methylbenzoic acid,Cc1ccc(c(c1)C(=O)O)O,5
7ZT8,6,,,,,,7ZT8,Promiscuous recognition of MR1 drives self-reactive Mucosal-Associated Invariant T cell responses,Structure of E8 TCR in complex in human MR1 bound to 3FBA,IMMUNE SYSTEM,MR1,,GO:0031901/ GO:0005783/ GO:0005789/ GO:0009897/ GO:0005615/ GO:0000139/ GO:0031902/ GO:0042612/ GO:0005886/ GO:0030881/ GO:0032393/ GO:0042608/ GO:0019884/ GO:0002474/ GO:0050829/ GO:0050830/ GO:0006955/ GO:0045087/ GO:0002854/ GO:0033077/ IPR007110/ IPR036179/ IPR013783/ IPR003006/ IPR003597/ IPR011161/ IPR037055/ IPR011162/ IPR001039/ Q95460,1,7ZT8,wildtype,Q95460,UniProt,C8 H8 O2,136.148,OVV,3-methylbenzoic acid,Cc1cccc(c1)C(=O)O,5
7ZT9,6,,,,,,7ZT9,Promiscuous recognition of MR1 drives self-reactive Mucosal-Associated Invariant T cell responses,Structure of E8 TCR in complex in human MR1 bound to 4FBA,IMMUNE SYSTEM,MR1,,GO:0031901/ GO:0005783/ GO:0005789/ GO:0009897/ GO:0005615/ GO:0000139/ GO:0031902/ GO:0042612/ GO:0005886/ GO:0030881/ GO:0032393/ GO:0042608/ GO:0019884/ GO:0002474/ GO:0050829/ GO:0050830/ GO:0006955/ GO:0045087/ GO:0002854/ GO:0033077/ IPR007110/ IPR036179/ IPR013783/ IPR003006/ IPR003597/ IPR011161/ IPR037055/ IPR011162/ IPR001039/ Q95460,1,7ZT9,wildtype,Q95460,UniProt,C8 H8 O2,136.148,4MA,4-METHYLBENZOIC ACID,Cc1ccc(cc1)C(=O)O,5
7ZYT,6,,,,,,7ZYT,Structural and biochemical investigation of selected pathogenic mutants of the human dihydrolipoamide dehydrogenase,Crystal structure of the I318T pathogenic variant of the human dihydrolipoamide dehydrogenase,OXIDOREDUCTASE,DLD/ GCSL/ LAD/ PHE3,1.8.1.4,GO:0043159/ GO:0005947/ GO:0005759/ GO:0005967/ GO:0005739/ GO:0031514/ GO:0005634/ GO:0045252/ GO:0045254/ GO:0004148/ GO:0050660/ GO:0006086/ GO:0009083/ GO:0045454/ GO:0007369/ GO:0106077/ GO:0006120/ GO:0006508/ GO:0042391/ GO:0048240/ IPR036188/ IPR023753/ IPR016156/ IPR006258/ IPR001100/ IPR004099/ IPR012999/ P09622,1,7ZYT,Mutant,P09622,UniProt,C27 H33 N9 O15 P2,785.55,FAD,FLAVIN-ADENINE DINUCLEOTIDE,Cc1cc2c(cc1C)N(C3=NC(=O)NC(=O)C3=N2)CC(C(C(COP(=O)(O)OP(=O)(O)OCC4C(C(C(O4)n5cnc6c5ncnc6N)O)O)O)O)O,2
8ACT,6,,,,,,8ACT,Cryo-EM structure of the folded-back state of human beta-cardiac myosin.,structure of the human beta-cardiac myosin folded-back off state,CONTRACTILE PROTEIN,MYH7/ MYHCB,,GO:0005859/ GO:0030016/ GO:0016459/ GO:0032982/ GO:0016460/ GO:0030017/ GO:0001725/ GO:0030018/ GO:0051015/ GO:0005524/ GO:0005516/ GO:0000146/ GO:0007512/ GO:0046034/ GO:0060048/ GO:0014898/ GO:0006936/ GO:0030049/ GO:0002027/ GO:0031449/ GO:0002026/ GO:0014728/ GO:0045214/ GO:0003009/ GO:0006941/ GO:0014883/ GO:0055010/ IPR000048/ IPR036961/ IPR001609/ IPR004009/ IPR008989/ IPR002928/ IPR027417/ IPR014751/ P12883,1,8ACT,wildtype,P12883,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,4
8D4F,6,,,,,,8D4F,Self-assembly and structure of a clathrin-independent AP-1:Arf1 tubular membrane coat.,beta-Arf1 mediated dimeric assembly of AP-1/ Arf1/ Nef complex within lattice on MHC-I lipopeptide incorporated wide(r) membrane tubes,PROTEIN TRANSPORT,AP1B1/ ADTB1/ BAM22/ CLAPB2,,GO:0030121/ GO:0030659/ GO:0005829/ GO:0005769/ GO:0005794/ GO:0000139/ GO:0043231/ GO:0005765/ GO:0032588/ GO:0030276/ GO:0019901/ GO:0110010/ GO:0007368/ GO:0007507/ GO:0006886/ GO:0001822/ GO:1903232/ GO:0060155/ GO:0016192/ IPR026739/ IPR016342/ IPR011989/ IPR016024/ IPR000225/ IPR015151/ IPR002553/ IPR008152/ IPR013041/ IPR013037/ IPR009028/ IPR012295/ Q10567,1,8D4F,Mutant,Q10567,UniProt,C10 H16 N5 O14 P3,523.18,GTP,GUANOSINE-5'-TRIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,8
8D4G,6,,,,,,8D4G,Self-assembly and structure of a clathrin-independent AP-1:Arf1 tubular membrane coat.,gamma-Arf1 mediated dimeric assembly of AP-1/ Arf1/ Nef complex within lattice on MHC-I lipopeptide incorporated wide(r) membrane tubes,PROTEIN TRANSPORT,AP1B1/ ADTB1/ BAM22/ CLAPB2,,GO:0030121/ GO:0030659/ GO:0005829/ GO:0005769/ GO:0005794/ GO:0000139/ GO:0043231/ GO:0005765/ GO:0032588/ GO:0030276/ GO:0019901/ GO:0110010/ GO:0007368/ GO:0007507/ GO:0006886/ GO:0001822/ GO:1903232/ GO:0060155/ GO:0016192/ IPR026739/ IPR016342/ IPR011989/ IPR016024/ IPR000225/ IPR015151/ IPR002553/ IPR008152/ IPR013041/ IPR013037/ IPR009028/ IPR012295/ Q10567,1,8D4G,Mutant,Q10567,UniProt,C10 H16 N5 O14 P3,523.18,GTP,GUANOSINE-5'-TRIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,8
8DIS,6,,,,,,8DIS,CryoEM structure of Influenza A virus  A/Melbourne/1/1946 (H1N1) hemagglutinin bound to CR6261 Fab,CryoEM structure of Influenza A virus A/Melbourne/1/1946 (H1N1) hemagglutinin bound to CR6261 Fab,VIRAL PROTEIN/IMMUNE SYSTEM,HA,,,1,8DIS,wildtype,,,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,7
8E1P,6,,,,,,8E1P,Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions.,Crystal structure of BG505 SOSIP.v4.1-GT1.2 trimer in complex with gl-PGV20 and PGT124 Fabs,VIRAL PROTEIN/IMMUNE SYSTEM,,,,1,8E1P,wildtype,,,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,14
8E8R,6,,,,,,8E8R,High resolution cryo EM structures show a human monoclonal antibody binds into the canyon to neutralize all three serotypes of poliovirus,9H2 Fab-Sabin poliovirus 3 complex,VIRUS/IMMUNE SYSTEM,,,GO:0005198/ GO:0046718/ GO:0019062/ IPR001676/ IPR033703/ IPR029053,1,8E8R,wildtype,B2X7G7,UniProt,C16 H32 O2,256.424,PLM,PALMITIC ACID,CCCCCCCCCCCCCCCC(=O)O,7
8E8S,6,,,,,,8E8S,High resolution cryo EM structures show a human monoclonal antibody binds into the canyon to neutralize all three serotypes of poliovirus,9H2 Fab-poliovirus 2 complex,VIRUS/IMMUNE SYSTEM,,,GO:0005198/ GO:0046718/ GO:0019062/ IPR001676/ IPR033703/ IPR029053,1,8E8S,wildtype,Q8QNU4,UniProt,C16 H32 O2,256.424,PLM,PALMITIC ACID,CCCCCCCCCCCCCCCC(=O)O,7
8E8X,6,,,,,,8E8X,High resolution cryo EM structures show a human monoclonal antibody binds into the canyon to neutralize all three serotypes of poliovirus,9H2 Fab-Sabin poliovirus 3 complex,VIRUS/IMMUNE SYSTEM,,,GO:0005198/ GO:0046718/ GO:0019062/ IPR001676/ IPR033703/ IPR029053,1,8E8X,wildtype,B2X7G8,UniProt,C16 H32 O2,256.424,PLM,PALMITIC ACID,CCCCCCCCCCCCCCCC(=O)O,7
8E8Y,6,,,,,,8E8Y,High resolution cryo EM structures show a human monoclonal antibody binds into the canyon to neutralize all three serotypes of poliovirus,9H2 Fab-Sabin poliovirus 2 complex,VIRUS/IMMUNE SYSTEM,,3.4.22.29/ 3.6.1.15/ 3.4.22.28/ 2.7.7.48,GO:0030659/ GO:0044162/ GO:0042025/ GO:0039618/ GO:0005524/ GO:0004197/ GO:0046872/ GO:0005216/ GO:0017111/ GO:0003723/ GO:0003724/ GO:0003968/ GO:0005198/ GO:0006351/ GO:0075509/ GO:0039520/ GO:0039707/ GO:0044694/ GO:0051259/ GO:0006508/ GO:0018144/ GO:0039657/ GO:0039503/ GO:0039522/ GO:0039694/ GO:0019062/ IPR043502/ IPR000605/ IPR014759/ IPR027417/ IPR014838/ IPR036203/ IPR044067/ IPR000081/ IPR000199/ IPR009003/ IPR043504/ IPR003138/ IPR002527/ IPR001676/ IPR043128/ IPR033703/ IPR001205/ IPR007094/ IPR029053,1,8E8Y,wildtype,Q8B3S1,UniProt,C16 H32 O2,256.424,PLM,PALMITIC ACID,CCCCCCCCCCCCCCCC(=O)O,7
8EBZ,6,,,,,,8EBZ,Reduced dynamic complexity allows structure elucidation of an excited state of KRAS G13D .,Crystal Structure of GMPPNP-bound KRAS-G13D mutant at 1.2 Ang resolution,ONCOPROTEIN,KRAS/ KRAS2/ RASK2,3.6.5.2,GO:0005737/ GO:0005829/ GO:0005789/ GO:0031234/ GO:0005925/ GO:0000139/ GO:0016020/ GO:0005741/ GO:0005886/ GO:0003925/ GO:0019003/ GO:0005525/ GO:0003924/ GO:0042802/ GO:0044877/ GO:0030036/ GO:0038002/ GO:0060441/ GO:0021897/ GO:0014009/ GO:0048873/ GO:0000165/ GO:0030857/ GO:0043524/ GO:0051402/ GO:0008284/ GO:0010628/ GO:0060252/ GO:0001934/ GO:0035022/ GO:0016601/ GO:0007265/ GO:0048169/ GO:0031647/ GO:0032228/ GO:0035914/ GO:0051146/ GO:0060509/ GO:0008542/ IPR027417/ IPR005225/ IPR001806/ IPR020849,1,8EBZ,Mutant,P01116-2,UniProt,C10 H17 N6 O13 P3,522.196,GNP,PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(NP(=O)(O)O)O)O)O)N=C(NC2=O)N,2
8EEW,6,,,,,,8EEW,Opa1 helical structures give perspective to mitochondrial dysfunction,CryoEM of the soluble OPA1 dimer from the GDP-AlFx bound helical assembly on a lipid membrane,LIPID BINDING PROTEIN,OPA1/ KIAA0567,3.6.5.5,GO:1904115/ GO:0005737/ GO:0005829/ GO:0030425/ GO:0016020/ GO:0005874/ GO:0030061/ GO:0005743/ GO:0005758/ GO:0031966/ GO:0005741/ GO:0005739/ GO:0005654/ GO:1901612/ GO:0005525/ GO:0003924/ GO:0000287/ GO:0008017/ GO:0070300/ GO:0006915/ GO:0019896/ GO:0090398/ GO:0046039/ GO:0007007/ GO:0097749/ GO:0000266/ GO:0008053/ GO:0000002/ GO:0007005/ GO:0043066/ GO:1902236/ GO:0090201/ GO:0001843/ GO:0051259/ GO:0007601/ IPR022812/ IPR001401/ IPR045063/ IPR030381/ IPR033047/ IPR045817/ IPR027417/ O60313,1,8EEW,wildtype,O60313,UniProt,C10 H15 N5 O11 P2,443.201,GDP,GUANOSINE-5'-DIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,2
8EFF,6,,,,,,8EFF,Opa1 helical structures give perspective to mitochondrial dysfunction,CryoEM of the soluble OPA1 tetramer from the GDP-AlFx bound helical assembly on a lipid membrane,LIPID BINDING PROTEIN,OPA1/ KIAA0567,3.6.5.5,GO:1904115/ GO:0005737/ GO:0005829/ GO:0030425/ GO:0016020/ GO:0005874/ GO:0030061/ GO:0005743/ GO:0005758/ GO:0031966/ GO:0005741/ GO:0005739/ GO:0005654/ GO:1901612/ GO:0005525/ GO:0003924/ GO:0000287/ GO:0008017/ GO:0070300/ GO:0006915/ GO:0019896/ GO:0090398/ GO:0046039/ GO:0007007/ GO:0097749/ GO:0000266/ GO:0008053/ GO:0000002/ GO:0007005/ GO:0043066/ GO:1902236/ GO:0090201/ GO:0001843/ GO:0051259/ GO:0007601/ IPR022812/ IPR001401/ IPR045063/ IPR030381/ IPR033047/ IPR045817/ IPR027417/ O60313,1,8EFF,wildtype,O60313,UniProt,C10 H15 N5 O11 P2,443.201,GDP,GUANOSINE-5'-DIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,2
8EFR,6,,,,,,8EFR,Opa1 helical structures give perspective to mitochondrial dysfunction,CryoEM of the soluble OPA1 interfaces with GDP-AlFx bound from the helical assembly on a lipid membrane,LIPID BINDING PROTEIN,OPA1/ KIAA0567,3.6.5.5,GO:1904115/ GO:0005737/ GO:0005829/ GO:0030425/ GO:0016020/ GO:0005874/ GO:0030061/ GO:0005743/ GO:0005758/ GO:0031966/ GO:0005741/ GO:0005739/ GO:0005654/ GO:1901612/ GO:0005525/ GO:0003924/ GO:0000287/ GO:0008017/ GO:0070300/ GO:0006915/ GO:0019896/ GO:0090398/ GO:0046039/ GO:0007007/ GO:0097749/ GO:0000266/ GO:0008053/ GO:0000002/ GO:0007005/ GO:0043066/ GO:1902236/ GO:0090201/ GO:0001843/ GO:0051259/ GO:0007601/ IPR022812/ IPR001401/ IPR045063/ IPR030381/ IPR033047/ IPR045817/ IPR027417/ O60313,1,8EFR,wildtype,O60313,UniProt,C10 H15 N5 O11 P2,443.201,GDP,GUANOSINE-5'-DIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,2
8ESM,6,,,,,,8ESM,Mechanism of action for small-molecule inhibitors of triacylglycerol synthesis.,Human triacylglycerol synthesizing enzyme DGAT1 in complex with T863 inhibitor,TRANSFERASE/TRANSFERASE INHIBITOR,DGAT1/ AGRP1/ DGAT,2.3.1.20/ 2.3.1.76,GO:0005789/ GO:0005886/ GO:0035579/ GO:0003846/ GO:0016746/ GO:0004144/ GO:0042802/ GO:0008374/ GO:0050252/ GO:0046339/ GO:0055089/ GO:0019915/ GO:0035336/ GO:0006640/ GO:0019432/ GO:0006641/ GO:0034379/ IPR027251/ IPR004299/ IPR014371/ O75907/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.<em>O</em>-acyltransferases.diacylglycerol O-acyltransferase 1 (DGAT1) with bound T863 inhibitor,1,8ESM,wildtype,O75907,UniProt,C22 H26 N4 O3,394.467,WS0,{(1r/4r)-4-[4-(4-amino-7/7-dimethyl-7H-pyrimido[4/5-b][1/4]oxazin-6-yl)phenyl]cyclohexyl}acetic acid,CC1(C(=Nc2c(ncnc2O1)N)c3ccc(cc3)C4CCC(CC4)CC(=O)O)C,2
8ETM,6,,,,,,8ETM,Mechanism of action for small-molecule inhibitors of triacylglycerol synthesis.,Human triacylglycerol synthesizing enzyme DGAT1 in complex with DGAT1IN1 inhibitor,TRANSFERASE/TRANSFERASE INHIBITOR,DGAT1/ AGRP1/ DGAT,2.3.1.20/ 2.3.1.76,GO:0005789/ GO:0005886/ GO:0035579/ GO:0003846/ GO:0016746/ GO:0004144/ GO:0042802/ GO:0008374/ GO:0050252/ GO:0046339/ GO:0055089/ GO:0019915/ GO:0035336/ GO:0006640/ GO:0019432/ GO:0006641/ GO:0034379/ IPR027251/ IPR004299/ IPR014371/ O75907/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.<em>O</em>-acyltransferases.diacylglycerol O-acyltransferase 1 (DGAT1) with bound T863 inhibitor/ Generic PDBTM,1,8ETM,wildtype,O75907,UniProt,C30 H28 F3 N3 O4,551.556,WTT,[(1S/4r)-4-{4-[(4S)-2-({[4-(trifluoromethoxy)phenyl]methyl}carbamoyl)imidazo[1/2-a]pyridin-6-yl]phenyl}cyclohexyl]acetic acid,c1cc(ccc1CNC(=O)c2cn3cc(ccc3n2)c4ccc(cc4)C5CCC(CC5)CC(=O)O)OC(F)(F)F,2
8EZA,6,,,,,,8EZA,Cryo-EM visualization of DNA-PKcs structural intermediates in NHEJ.,NHEJ Long-range complex with PAXX,DNA BINDING PROTEIN/DNA,PAXX/ C9orf142/ XLS,,GO:0005737/ GO:0070419/ GO:0005654/ GO:0005634/ GO:0035861/ GO:0070182/ GO:0042802/ GO:0060090/ GO:0042803/ GO:0006974/ GO:0006303/ IPR027873/ Q9BUH6,1,8EZA,wildtype,Q9BUH6,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,11
8EZB,6,,,,,,8EZB,Cryo-EM visualization of DNA-PKcs structural intermediates in NHEJ.,NHEJ Long-range complex with ATP,DNA BINDING PROTEIN/DNA,XRCC5/ G22P2,3.6.4,GO:0000781/ GO:0005829/ GO:0070418/ GO:0005576/ GO:0043564/ GO:0016020/ GO:0070419/ GO:0000783/ GO:0005730/ GO:0005654/ GO:0005634/ GO:0005886/ GO:0032991/ GO:0032993/ GO:1990904/ GO:0034774/ GO:0090734/ GO:0032040/ GO:0005524/ GO:0008094/ GO:0003684/ GO:0003677/ GO:0045027/ GO:0003678/ GO:0003690/ GO:0008047/ GO:0016787/ GO:0044877/ GO:0003723/ GO:0042162/ GO:0000976/ GO:0034511/ GO:0031625/ GO:0002218/ GO:0007420/ GO:0071475/ GO:0006974/ GO:0071398/ GO:0071480/ GO:1990830/ GO:0071481/ GO:0006310/ GO:0006302/ GO:0006303/ GO:0060218/ GO:0071425/ GO:0045087/ GO:1904430/ GO:0045892/ GO:0022008/ GO:0043085/ GO:0050769/ GO:0045860/ GO:0051973/ GO:0032212/ GO:0070198/ GO:0000725/ GO:0048660/ GO:0032204/ GO:0009410/ GO:0034462/ GO:0000723/ IPR006164/ IPR024193/ IPR005160/ IPR036494/ IPR005161/ IPR014893/ IPR016194/ IPR002035/ IPR036465/ P13010,2,8EZB,wildtype,P13010,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,11
8FAZ,6,,,,,,8FAZ,Structural insights into BCDX2 complex function in homologous recombination,Cryo-EM structure of the human BCDX2 complex,RECOMBINATION,RAD51B/ RAD51L1/ REC2,,GO:0005654/ GO:0005634/ GO:0033063/ GO:0005657/ GO:0005524/ GO:0008094/ GO:0140664/ GO:0003677/ GO:0003690/ GO:0003697/ GO:0001832/ GO:0006310/ GO:0006281/ GO:0000724/ GO:0008284/ GO:0010971/ GO:0007131/ GO:0061053/ IPR003593/ IPR013632/ IPR016467/ IPR027417/ IPR030548/ IPR020588/ O15315,1,8FAZ,wildtype,O15315,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,5
8FAZ,6,,,,,,8FAZ,Structural insights into BCDX2 complex function in homologous recombination,Cryo-EM structure of the human BCDX2 complex,RECOMBINATION,RAD51C/ RAD51L2,,GO:0030054/ GO:0005737/ GO:0005829/ GO:0043231/ GO:0005739/ GO:0005654/ GO:0005634/ GO:0048471/ GO:0033063/ GO:0033065/ GO:0005657/ GO:0005524/ GO:0140664/ GO:0008821/ GO:0003677/ GO:0006310/ GO:0006281/ GO:0000724/ GO:0007066/ GO:0007141/ GO:0000707/ GO:0010971/ GO:0007131/ GO:0007062/ GO:0007283/ GO:0000722/ IPR013632/ IPR016467/ IPR027417/ IPR020588/ O43502,2,8FAZ,,O43502,UniProt,C10 H17 N6 O12 P3,506.196,ANP,PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(NP(=O)(O)O)O)O)O)N,6
8FCN,6,,,,,,8FCN,The p97/VCP adapter UBXD1 drives AAA+ remodeling and ring opening through multi-domain tethered interactions.,Cryo-EM structure of p97:UBXD1 VIM-only state,CHAPERONE/ HYDROLASE,UBXN6/ UBXD1/ UBXDC2,,GO:0005737/ GO:0005829/ GO:0031901/ GO:0005768/ GO:0070062/ GO:0019898/ GO:0031902/ GO:0005765/ GO:0005815/ GO:0005634/ GO:0032991/ GO:0032510/ GO:0036503/ GO:0016236/ IPR036339/ IPR018997/ IPR029071/ IPR001012/ IPR042774/ Q9BZV1,1,8FCN,wildtype,Q9BZV1,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,3
8FCY,6,,,,,,8FCY,Microtubule-binding-induced allostery triggers LIS1 dissociation from dynein prior to cargo transport.,Engineered human dynein motor domain in microtubule-bound state,MOTOR PROTEIN,DYNC1H1/ DHC1/ DNCH1/ DNCL/ DNECL/ DYHC/ KIAA0325,,GO:1904115/ GO:0035578/ GO:0005938/ GO:0005813/ GO:0005868/ GO:0005881/ GO:0005829/ GO:0030286/ GO:0070062/ GO:0005576/ GO:0030175/ GO:0016020/ GO:0005874/ GO:0005524/ GO:0045505/ GO:0051959/ GO:0008569/ GO:0003723/ GO:0051301/ GO:0031122/ GO:0051293/ GO:0007018/ GO:0072382/ GO:0000278/ GO:0007052/ GO:0007097/ GO:0033962/ GO:0120162/ GO:0032388/ GO:1905832/ GO:0090235/ GO:0060236/ GO:0008090/ GO:0034063/ IPR003593/ IPR035699/ IPR035706/ IPR041658/ IPR042219/ IPR042222/ IPR043157/ IPR041466/ IPR041228/ IPR043160/ IPR024743/ IPR024317/ IPR004273/ IPR013602/ IPR013594/ IPR042228/ IPR027417/ Q14204,1,8FCY,wildtype,Q14204,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,2
8FCY,6,,,,,,8FCY,Microtubule-binding-induced allostery triggers LIS1 dissociation from dynein prior to cargo transport.,Engineered human dynein motor domain in microtubule-bound state,MOTOR PROTEIN,DYNC1H1/ DHC1/ DNCH1/ DNCL/ DNECL/ DYHC/ KIAA0325,,,1,8FCY,wildtype,Q14204,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,3
8FD6,6,,,,,,8FD6,Microtubule-binding-induced allostery triggers LIS1 dissociation from dynein prior to cargo transport.,Engineered human dynein motor domain in the microtubule-unbound state in the buffer containing ATP-Vi,MOTOR PROTEIN,DYNC1H1/ DHC1/ DNCH1/ DNCL/ DNECL/ DYHC/ KIAA0325,,GO:1904115/ GO:0035578/ GO:0005938/ GO:0005813/ GO:0005868/ GO:0005881/ GO:0005829/ GO:0030286/ GO:0070062/ GO:0005576/ GO:0030175/ GO:0016020/ GO:0005874/ GO:0005524/ GO:0045505/ GO:0051959/ GO:0008569/ GO:0003723/ GO:0051301/ GO:0031122/ GO:0051293/ GO:0007018/ GO:0072382/ GO:0000278/ GO:0007052/ GO:0007097/ GO:0033962/ GO:0120162/ GO:0032388/ GO:1905832/ GO:0090235/ GO:0060236/ GO:0008090/ GO:0034063/ IPR003593/ IPR035699/ IPR035706/ IPR041658/ IPR042219/ IPR042222/ IPR043157/ IPR041466/ IPR041228/ IPR043160/ IPR024743/ IPR024317/ IPR004273/ IPR013602/ IPR013594/ IPR042228/ IPR027417/ Q14204,1,8FD6,wildtype,Q14204,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,2
8FD6,6,,,,,,8FD6,Microtubule-binding-induced allostery triggers LIS1 dissociation from dynein prior to cargo transport.,Engineered human dynein motor domain in the microtubule-unbound state in the buffer containing ATP-Vi,MOTOR PROTEIN,DYNC1H1/ DHC1/ DNCH1/ DNCL/ DNECL/ DYHC/ KIAA0325,,GO:1904115/ GO:0035578/ GO:0005938/ GO:0005813/ GO:0005868/ GO:0005881/ GO:0005829/ GO:0030286/ GO:0070062/ GO:0005576/ GO:0030175/ GO:0016020/ GO:0005874/ GO:0005524/ GO:0045505/ GO:0051959/ GO:0008569/ GO:0003723/ GO:0051301/ GO:0031122/ GO:0051293/ GO:0007018/ GO:0072382/ GO:0000278/ GO:0007052/ GO:0007097/ GO:0033962/ GO:0120162/ GO:0032388/ GO:1905832/ GO:0090235/ GO:0060236/ GO:0008090/ GO:0034063/ IPR003593/ IPR035699/ IPR035706/ IPR041658/ IPR042219/ IPR042222/ IPR043157/ IPR041466/ IPR041228/ IPR043160/ IPR024743/ IPR024317/ IPR004273/ IPR013602/ IPR013594/ IPR042228/ IPR027417/ Q14204,1,8FD6,wildtype,Q14204,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,3
8FD6,6,,,,,,8FD6,Microtubule-binding-induced allostery triggers LIS1 dissociation from dynein prior to cargo transport.,Engineered human dynein motor domain in the microtubule-unbound state in the buffer containing ATP-Vi,MOTOR PROTEIN,DYNC1H1/ DHC1/ DNCH1/ DNCL/ DNECL/ DYHC/ KIAA0325,,GO:1904115/ GO:0035578/ GO:0005938/ GO:0005813/ GO:0005868/ GO:0005881/ GO:0005829/ GO:0030286/ GO:0070062/ GO:0005576/ GO:0030175/ GO:0016020/ GO:0005874/ GO:0005524/ GO:0045505/ GO:0051959/ GO:0008569/ GO:0003723/ GO:0051301/ GO:0031122/ GO:0051293/ GO:0007018/ GO:0072382/ GO:0000278/ GO:0007052/ GO:0007097/ GO:0033962/ GO:0120162/ GO:0032388/ GO:1905832/ GO:0090235/ GO:0060236/ GO:0008090/ GO:0034063/ IPR003593/ IPR035699/ IPR035706/ IPR041658/ IPR042219/ IPR042222/ IPR043157/ IPR041466/ IPR041228/ IPR043160/ IPR024743/ IPR024317/ IPR004273/ IPR013602/ IPR013594/ IPR042228/ IPR027417/ Q14204,1,8FD6,wildtype,Q14204,UniProt,O4 V,114.939,VO4,VANADATE ION,[O-][V](=O)([O-])[O-],4
8FDT,6,,,,,,8FDT,Microtubule-binding-induced allostery triggers LIS1 dissociation from dynein prior to cargo transport.,Engineered human dynein motor domain in the microtubule-unbound state with LIS1 complex in the buffer containing ATP-Vi,MOTOR PROTEIN,DYNC1H1/ DHC1/ DNCH1/ DNCL/ DNECL/ DYHC/ KIAA0325,,GO:1904115/ GO:0035578/ GO:0005938/ GO:0005813/ GO:0005868/ GO:0005881/ GO:0005829/ GO:0030286/ GO:0070062/ GO:0005576/ GO:0030175/ GO:0016020/ GO:0005874/ GO:0005524/ GO:0045505/ GO:0051959/ GO:0008569/ GO:0003723/ GO:0051301/ GO:0031122/ GO:0051293/ GO:0007018/ GO:0072382/ GO:0000278/ GO:0007052/ GO:0007097/ GO:0033962/ GO:0120162/ GO:0032388/ GO:1905832/ GO:0090235/ GO:0060236/ GO:0008090/ GO:0034063/ IPR003593/ IPR035699/ IPR035706/ IPR041658/ IPR042219/ IPR042222/ IPR043157/ IPR041466/ IPR041228/ IPR043160/ IPR024743/ IPR024317/ IPR004273/ IPR013602/ IPR013594/ IPR042228/ IPR027417/ Q14204,1,8FDT,wildtype,Q14204,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,3
8FDT,6,,,,,,8FDT,Microtubule-binding-induced allostery triggers LIS1 dissociation from dynein prior to cargo transport.,Engineered human dynein motor domain in the microtubule-unbound state with LIS1 complex in the buffer containing ATP-Vi,MOTOR PROTEIN,DYNC1H1/ DHC1/ DNCH1/ DNCL/ DNECL/ DYHC/ KIAA0325,,,1,8FDT,wildtype,Q14204,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,4
8FDU,6,,,,,,8FDU,Microtubule-binding-induced allostery triggers LIS1 dissociation from dynein prior to cargo transport.,Engineered human dynein motor domain in the microtubule-unbound state with LIS1 complex in the buffer containing ATP-Vi (local refined on AAA3-AAA5 and LIS1),MOTOR PROTEIN,DYNC1H1/ DHC1/ DNCH1/ DNCL/ DNECL/ DYHC/ KIAA0325,,GO:1904115/ GO:0035578/ GO:0005938/ GO:0005813/ GO:0005868/ GO:0005881/ GO:0005829/ GO:0030286/ GO:0070062/ GO:0005576/ GO:0030175/ GO:0016020/ GO:0005874/ GO:0005524/ GO:0045505/ GO:0051959/ GO:0008569/ GO:0003723/ GO:0051301/ GO:0031122/ GO:0051293/ GO:0007018/ GO:0072382/ GO:0000278/ GO:0007052/ GO:0007097/ GO:0033962/ GO:0120162/ GO:0032388/ GO:1905832/ GO:0090235/ GO:0060236/ GO:0008090/ GO:0034063/ IPR003593/ IPR035699/ IPR035706/ IPR041658/ IPR042219/ IPR042222/ IPR043157/ IPR041466/ IPR041228/ IPR043160/ IPR024743/ IPR024317/ IPR004273/ IPR013602/ IPR013594/ IPR042228/ IPR027417/ Q14204,1,8FDU,wildtype,Q14204,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,3
8FUG,6,,,,,,8FUG,Stacked binding of a PET ligand to Alzheimer's tau paired helical filaments.,Alzheimer's disease paired-helical filament in complex with PET tracer GTP-1,PROTEIN FIBRIL,MAPT/ MAPTL/ MTBT1/ TAU,,GO:0030673/ GO:0030424/ GO:1904115/ GO:0044297/ GO:0005737/ GO:0036464/ GO:0005829/ GO:0030425/ GO:0043197/ GO:0005576/ GO:0097386/ GO:0030426/ GO:0044304/ GO:0045121/ GO:0005874/ GO:0015630/ GO:0005739/ GO:0097418/ GO:0043005/ GO:0043025/ GO:0034399/ GO:0016607/ GO:0005634/ GO:0005886/ GO:0036477/ GO:0045298/ GO:0003779/ GO:0034185/ GO:0051087/ GO:0003677/ GO:0003690/ GO:0034452/ GO:0019899/ GO:0099077/ GO:0051879/ GO:0042802/ GO:0071813/ GO:0008017/ GO:0099609/ GO:0003680/ GO:0035091/ GO:1902936/ GO:0019901/ GO:0051721/ GO:0030674/ GO:0003723/ GO:0043565/ GO:0017124/ GO:0003697/ GO:0006919/ GO:1990000/ GO:0048143/ GO:0061564/ GO:0098930/ GO:0019896/ GO:0007267/ GO:1990416/ GO:0034605/ GO:1990090/ GO:0034614/ GO:0021954/ GO:0031122/ GO:0048699/ GO:0006475/ GO:0048312/ GO:0007611/ GO:0007613/ GO:0001774/ GO:0000226/ GO:0046785/ GO:1903748/ GO:0010629/ GO:0033673/ GO:0090258/ GO:0010917/ GO:1904428/ GO:1902988/ GO:0031175/ GO:0072386/ GO:0045773/ GO:1905689/ GO:0031116/ GO:1901216/ GO:1903829/ GO:1902474/ GO:0032930/ GO:0051260/ GO:0051258/ GO:0010506/ GO:0050848/ GO:1900034/ GO:0033044/ GO:1900452/ GO:0070507/ GO:0031113/ GO:0031110/ GO:0090140/ GO:0048167/ GO:0010288/ GO:0016072/ GO:0034063/ GO:0097435/ GO:0007416/ GO:0050808/ IPR001084/ IPR002955/ P10636,1,8FUG,wildtype,P10636,UniProt,C17 H19 F N4,298.358,Y9H,(5S)-2-[4-(2-fluoroethyl)piperidin-1-yl]pyrimido[1/2-a]benzimidazole,c1ccc2c(c1)nc3n2ccc(n3)N4CCC(CC4)CCF,2
8FZB,6,,,,,,8FZB,The FAM86 domain of FAM86A confers substrate specificity to promote EEF2-Lys525 methylation.,Crystal structure of human FAM86A,TRANSFERASE,EEF2KMT/ FAM86A/ SB153,2.1.1,GO:0005737/ GO:0005829/ GO:0032991/ GO:0042054/ GO:0016279/ GO:0018023/ GO:0006479/ IPR029426/ IPR019410/ IPR029063/ Q96G04,1,8FZB,wildtype,Q96G04,UniProt,C14 H20 N6 O5 S,384.411,SAH,S-ADENOSYL-L-HOMOCYSTEINE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)CSCCC(C(=O)O)N)O)O)N,2
8G3C,6,,,,,,8G3C,Discovery and Structure-Based Design of Inhibitors of the WD Repeat-Containing Protein 5 (WDR5)-MYC Interaction.,Crystal structure of human WDR5 in complex with N-[(2'-cyano[1/1'-biphenyl]-4-yl)methyl]-3-hydroxy-6-methyl-4-oxo-4H-pyran-2-carboxamide (compound 1/ WDR5-MYC PPI inhibitor),ONCOPROTEIN/INHIBITOR,WDR5/ BIG3,,GO:0140672/ GO:0000123/ GO:0035097/ GO:0072686/ GO:0071339/ GO:0044665/ GO:0044666/ GO:0044545/ GO:0005654/ GO:0005634/ GO:0048188/ GO:0042393/ GO:0035064/ GO:0006325/ GO:0006094/ GO:0043966/ GO:0044154/ GO:0051568/ GO:0043984/ GO:0043981/ GO:0043982/ GO:0051572/ GO:0031175/ GO:0045722/ GO:0051571/ GO:0045893/ GO:0051726/ GO:0051302/ GO:1900095/ GO:0045995/ GO:0031063/ GO:0006357/ GO:0006355/ GO:0090043/ GO:0001501/ IPR020472/ IPR015943/ IPR001680/ IPR019775/ IPR036322/ P61964,1,8G3C,wildtype,P61964,UniProt,C21 H16 N2 O4,360.363,YJN,N-[(2'-cyano[1/1'-biphenyl]-4-yl)methyl]-3-hydroxy-6-methyl-4-oxo-4H-pyran-2-carboxamide,CC1=CC(=O)C(=C(O1)C(=O)NCc2ccc(cc2)c3ccccc3C#N)O,2
8G3E,6,,,,,,8G3E,Discovery and Structure-Based Design of Inhibitors of the WD Repeat-Containing Protein 5 (WDR5)-MYC Interaction.,Crystal structure of human WDR5 in complex with (1M)-N-[(3/5-difluoro[1/1'-biphenyl]-4-yl)methyl]-6-methyl-4-oxo-1-(pyridin-3-yl)-1/4-dihydropyridazine-3-carboxamide (compound 2/ WDR5-MYC inhibitor),ONCOPROTEIN/INHIBITOR,WDR5/ BIG3,,GO:0140672/ GO:0000123/ GO:0035097/ GO:0072686/ GO:0071339/ GO:0044665/ GO:0044666/ GO:0044545/ GO:0005654/ GO:0005634/ GO:0048188/ GO:0042393/ GO:0035064/ GO:0006325/ GO:0006094/ GO:0043966/ GO:0044154/ GO:0051568/ GO:0043984/ GO:0043981/ GO:0043982/ GO:0051572/ GO:0031175/ GO:0045722/ GO:0051571/ GO:0045893/ GO:0051726/ GO:0051302/ GO:1900095/ GO:0045995/ GO:0031063/ GO:0006357/ GO:0006355/ GO:0090043/ GO:0001501/ IPR020472/ IPR015943/ IPR001680/ IPR019775/ IPR036322/ P61964,1,8G3E,wildtype,P61964,UniProt,C24 H18 F2 N4 O2,432.422,YJR,(1M)-N-[(3/5-difluoro[1/1'-biphenyl]-4-yl)methyl]-6-methyl-4-oxo-1-(pyridin-3-yl)-1/4-dihydropyridazine-3-carboxamide,CC1=CC(=O)C(=NN1c2cccnc2)C(=O)NCc3c(cc(cc3F)c4ccccc4)F,2
8G8W,6,,,,,,8G8W,Structural basis of purine nucleotide inhibition of human uncoupling protein 1.,Molecular mechanism of nucleotide inhibition of human uncoupling protein 1,MEMBRANE PROTEIN,UCP1/ SLC25A7/ UCP,,GO:0005743/ GO:0005739/ GO:1901612/ GO:0019003/ GO:0005525/ GO:0036041/ GO:0017077/ GO:0032555/ GO:0022857/ GO:1990845/ GO:0050873/ GO:0070417/ GO:1903495/ GO:0071398/ GO:0032870/ GO:0034614/ GO:0002024/ GO:1990542/ GO:0120162/ GO:1902600/ GO:1903426/ GO:0006357/ GO:0009409/ GO:0031667/ GO:0009266/ IPR002030/ IPR018108/ IPR023395/ P25874/ TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Antiporters.UCP1 mitochondrial uncoupling protein 1/ Generic PDBTM,1,8G8W,wildtype,P25874,UniProt,C10 H16 N5 O14 P3,523.18,GTP,GUANOSINE-5'-TRIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,5
8GBJ,6,,,,,,8GBJ,Structural insights into BCDX2 complex function in homologous recombination,Cryo-EM structure of a human BCDX2/ssDNA complex,RECOMBINATION,RAD51B/ RAD51L1/ REC2,,GO:0005654/ GO:0005634/ GO:0033063/ GO:0005657/ GO:0005524/ GO:0008094/ GO:0140664/ GO:0003677/ GO:0003690/ GO:0003697/ GO:0001832/ GO:0006310/ GO:0006281/ GO:0000724/ GO:0008284/ GO:0010971/ GO:0007131/ GO:0061053/ IPR003593/ IPR013632/ IPR016467/ IPR027417/ IPR030548/ IPR020588/ O15315,1,8GBJ,wildtype,O15315,UniProt,C10 H17 N6 O12 P3,506.196,ANP,PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(NP(=O)(O)O)O)O)O)N,6
8GOU,6,,,,,,8GOU,Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection.,Omicron BA.4/5 SARS-CoV-2 S in complex with TH003 Fab,VIRAL PROTEIN/ANTIVIRAL PROTEIN,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,8GOU,Mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
8GRS,6,,,,,,8GRS,human TMEM63A,human TMEM63A,MEMBRANE PROTEIN,TMEM63A/ KIAA0489/ KIAA0792,,GO:0034451/ GO:0070062/ GO:0043231/ GO:0005765/ GO:0005886/ GO:0035579/ GO:0070821/ GO:0005227/ GO:0008381/ GO:0003676/ GO:1990760/ IPR045122/ IPR003864/ IPR027815/ IPR032880/ IPR012677/ IPR035979/ O94886/ Generic PDBTM,1,8GRS,wildtype,O94886,UniProt,C42 H82 N O8 P,760.076,POV,(2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC,2
8GSQ,6,,,,,,8GSQ,Structure-based discovery of an antipsychotic drug/ paliperidone/ as a modulator of human superoxide dismutase 1: a potential therapeutic target in amyotrophic lateral sclerosis.,Structure based studies reveal an atypical antipsychotic drug candidate - Paliperidone as a potent hSOD1 modulator with implications in ALS treatment.,OXIDOREDUCTASE,HEL-S-44,1.15.1.1,GO:1904115/ GO:0005829/ GO:0031045/ GO:0005615/ GO:0005764/ GO:0005758/ GO:0043025/ GO:0005654/ GO:0005777/ GO:0032991/ GO:0005507/ GO:0030346/ GO:0004784/ GO:0008089/ GO:0006915/ GO:0060088/ GO:0071318/ GO:0071276/ GO:0035865/ GO:0035234/ GO:0007566/ GO:0006749/ GO:0060047/ GO:0050665/ GO:0006879/ GO:0007626/ GO:0046716/ GO:0002262/ GO:0051093/ GO:0050728/ GO:0043524/ GO:2000242/ GO:0060052/ GO:0001541/ GO:0032287/ GO:0043085/ GO:0043410/ GO:0050766/ GO:0008217/ GO:0040014/ GO:0060087/ GO:0001975/ GO:0046677/ GO:0097332/ GO:0048678/ GO:0034465/ GO:0046688/ GO:0045471/ GO:0009408/ GO:0042542/ GO:0031667/ GO:0009410/ GO:0001895/ GO:0008090/ GO:0007605/ GO:0007283/ GO:0042554/ GO:0019226/ IPR036423/ IPR024134/ IPR018152/ IPR001424,3,8GSQ,wildtype,V9HWC9,UniProt,C23 H27 F N4 O3,426.484,K4I,(9~{R})-3-[2-[4-(6-fluoranyl-1/2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-9-oxidanyl-6/7/8/9-tetrahydropyrido[1/2-a]pyrimidin-4-one,CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)c4c5ccc(cc5on4)F,7
8HBV,6,,,,,,8HBV,Structural basis of inhibition of human UCP1 by purine nucleotides,Structure of human UCP1 in the nucleotide-free state,MEMBRANE PROTEIN,UCP1/ SLC25A7/ UCP,,GO:0005743/ GO:0005739/ GO:1901612/ GO:0019003/ GO:0005525/ GO:0036041/ GO:0017077/ GO:0032555/ GO:0022857/ GO:1990845/ GO:0050873/ GO:0070417/ GO:1903495/ GO:0071398/ GO:0032870/ GO:0034614/ GO:0002024/ GO:1990542/ GO:0120162/ GO:1902600/ GO:1903426/ GO:0006357/ GO:0009409/ GO:0031667/ GO:0009266/ IPR002030/ IPR018108/ IPR023395/ P25874,1,8HBV,wildtype,P25874,UniProt,C44 H88 N O8 P,790.145,PC1,1/2-DIACYL-SN-GLYCERO-3-PHOSPHOCHOLINE,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,4
8HBW,6,,,,,,8HBW,Structural basis of inhibition of human UCP1 by purine nucleotides,Structure of human UCP1 in the ATP-bound state,MEMBRANE PROTEIN,UCP1/ SLC25A7/ UCP,,GO:0005743/ GO:0005739/ GO:1901612/ GO:0019003/ GO:0005525/ GO:0036041/ GO:0017077/ GO:0032555/ GO:0022857/ GO:1990845/ GO:0050873/ GO:0070417/ GO:1903495/ GO:0071398/ GO:0032870/ GO:0034614/ GO:0002024/ GO:1990542/ GO:0120162/ GO:1902600/ GO:1903426/ GO:0006357/ GO:0009409/ GO:0031667/ GO:0009266/ IPR002030/ IPR018108/ IPR023395/ P25874,1,8HBW,wildtype,P25874,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,3
8HBW,6,,,,,,8HBW,Structural basis of inhibition of human UCP1 by purine nucleotides,Structure of human UCP1 in the ATP-bound state,MEMBRANE PROTEIN,UCP1/ SLC25A7/ UCP,,GO:0005743/ GO:0005739/ GO:1901612/ GO:0019003/ GO:0005525/ GO:0036041/ GO:0017077/ GO:0032555/ GO:0022857/ GO:1990845/ GO:0050873/ GO:0070417/ GO:1903495/ GO:0071398/ GO:0032870/ GO:0034614/ GO:0002024/ GO:1990542/ GO:0120162/ GO:1902600/ GO:1903426/ GO:0006357/ GO:0009409/ GO:0031667/ GO:0009266/ IPR002030/ IPR018108/ IPR023395/ P25874,1,8HBW,wildtype,P25874,UniProt,C81 H156 O17 P2,1464.043,CDL,CARDIOLIPIN,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC(COP(=O)([O-])OCC(COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)O)OC(=O)CCCCCCCCCCCCCCCCC,4
8HBW,6,,,,,,8HBW,Structural basis of inhibition of human UCP1 by purine nucleotides,Structure of human UCP1 in the ATP-bound state,MEMBRANE PROTEIN,UCP1/ SLC25A7/ UCP,,,2,8HBW,wildtype,P25874,,C44 H88 N O8 P,790.145,PC1,1/2-DIACYL-SN-GLYCERO-3-PHOSPHOCHOLINE,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,5
8HMP,6,,,,,,8HMP,Allosteric coupling between G-protein binding and extracellular ligand binding sites in GPR52 revealed by 19 F-NMR and cryo-electron microscopy.,GPR52 with Gs and c17,STRUCTURAL PROTEIN,GNB1,,GO:0005737/ GO:0005829/ GO:0070062/ GO:1903561/ GO:0005834/ GO:0005765/ GO:0016020/ GO:0097381/ GO:0005886/ GO:0045202/ GO:0003924/ GO:0051020/ GO:0044877/ GO:0030159/ GO:0007191/ GO:0008283/ GO:0071870/ GO:0071380/ GO:0007213/ GO:0007186/ GO:0007200/ GO:0007265/ GO:0060041/ GO:0050909/ GO:0007165/ IPR020472/ IPR001632/ IPR016346/ IPR015943/ IPR001680/ IPR019775/ IPR036322/ P62873,1,8HMP,Mutant,P62873,UniProt,C24 H22 F3 N3 O3 S,489.51,EN6,N-(2-hydroxyethyl)-5-(hydroxymethyl)-3-methyl-1-[2-[[3-(trifluoromethyl)phenyl]methyl]-1-benzothiophen-7-yl]pyrazole-4-carboxamide,Cc1c(c(n(n1)c2cccc3c2sc(c3)Cc4cccc(c4)C(F)(F)F)CO)C(=O)NCCO,6
8HW2,6,,,,,,8HW2,Cryo-EM structure of ABC transporter ABCC3,Cryo-EM structure of beta-estradiol 17-(beta-D-glucuronide)-bound human ABC transporter ABCC3 in nanodiscs,MEMBRANE PROTEIN,ABCC3/ CMOAT2/ MLP2/ MRP3,7.6.2/ 7.6.2.2/ 7.6.2.3,GO:0009925/ GO:0016323/ GO:0016020/ GO:0005886/ GO:0015432/ GO:0015431/ GO:0140359/ GO:0008559/ GO:0005524/ GO:0016887/ GO:0043225/ GO:0042626/ GO:0015164/ GO:0071714/ GO:0042910/ GO:0015721/ GO:0071716/ GO:0055085/ GO:0150104/ GO:0006805/ GO:0006855/ GO:0042908/ IPR003593/ IPR011527/ IPR036640/ IPR003439/ IPR017871/ IPR005292/ IPR027417/ O15438/ Generic PDBTM,1,8HW2,wildtype,O15438,UniProt,C24 H32 O8,448.506,U38,Estradiol-17beta-glucuronide,CC12CCC3c4ccc(cc4CCC3C1CCC2OC5C(C(C(C(O5)C(=O)O)O)O)O)O,2
8HW4,6,,,,,,8HW4,Cryo-EM structure of ABC transporter ABCC3,Cryo-EM structure of dehydroepiandrosterone sulfate-bound human ABC transporter ABCC3 in nanodiscs,MEMBRANE PROTEIN,ABCC3/ CMOAT2/ MLP2/ MRP3,7.6.2/ 7.6.2.2/ 7.6.2.3,GO:0009925/ GO:0016323/ GO:0016020/ GO:0005886/ GO:0015432/ GO:0015431/ GO:0140359/ GO:0008559/ GO:0005524/ GO:0016887/ GO:0043225/ GO:0042626/ GO:0015164/ GO:0071714/ GO:0042910/ GO:0015721/ GO:0071716/ GO:0055085/ GO:0150104/ GO:0006805/ GO:0006855/ GO:0042908/ IPR003593/ IPR011527/ IPR036640/ IPR003439/ IPR017871/ IPR005292/ IPR027417/ O15438/ Generic PDBTM,1,8HW4,wildtype,O15438,UniProt,C19 H28 O5 S,368.488,ZWY,17-oxo-8alpha/10alpha/13alpha/14beta-androst-5-en-3alpha-yl hydrogen sulfate,CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)OS(=O)(=O)O)C,2
8I1M,6,,,,,,8I1M,Redox switching mechanism of the adenosine 5'-phosphosulfate kinase domain (APSK2) of human PAPS synthase 2.,Crystal structure of oxidated APSK1 domain from human PAPSS1 in complex with APS and ADP,BIOSYNTHETIC PROTEIN,PAPSS1,,GO:0004020/ GO:0005524/ GO:0004781/ GO:0034033/ GO:0009152/ GO:0034030/ GO:0000103/ IPR002891/ IPR025980/ IPR027417/ IPR015947/ IPR014729/ IPR024951/ IPR002650,1,8I1M,wildtype,Q05BW9,UniProt,C10 H14 N5 O10 P S,427.284,ADX,ADENOSINE-5'-PHOSPHOSULFATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OS(=O)(=O)O)O)O)N,3
8I5B,6,,,,,,8I5B,Structural mapping of Na v 1.7 antagonists.,Structure of human Nav1.7 in complex with bupivacaine,MEMBRANE PROTEIN,SCN9A/ NENA,,GO:0030424/ GO:0001518/ GO:0031402/ GO:0005244/ GO:0005248/ GO:0061368/ GO:0006954/ GO:0086010/ GO:0045759/ GO:0019228/ GO:0009791/ GO:0034765/ GO:0009409/ GO:0009408/ GO:0009636/ GO:0019233/ GO:0035725/ GO:0006814/ IPR005821/ IPR000048/ IPR001696/ IPR044564/ IPR010526/ IPR024583/ IPR028803/ IPR043203/ IPR027359/ Q15858/ Generic PDBTM,1,8I5B,wildtype,Q15858,UniProt,C18 H28 N2 O,288.428,OJ0,(2~{S})-1-butyl-~{N}-(2/6-dimethylphenyl)piperidine-2-carboxamide,CCCCN1CCCCC1C(=O)Nc2c(cccc2C)C,10
8I5G,6,,,,,,8I5G,Structural mapping of Na v 1.7 antagonists.,Structure of human Nav1.7 in complex with PF-05089771,MEMBRANE PROTEIN,SCN1B,,GO:0005576/ GO:0014704/ GO:0033268/ GO:0043204/ GO:0005886/ GO:0030315/ GO:0001518/ GO:0019871/ GO:0017080/ GO:0044325/ GO:0005244/ GO:0005248/ GO:0086006/ GO:0086062/ GO:0007411/ GO:0061337/ GO:0086002/ GO:0060048/ GO:0007155/ GO:0021966/ GO:0040011/ GO:0051899/ GO:0086012/ GO:0086047/ GO:0019227/ GO:0010976/ GO:0010765/ GO:0060371/ GO:0086091/ GO:2000649/ GO:0060307/ GO:0035725/ IPR036179/ IPR013783/ IPR013106/ IPR027098/ IPR044568/ Q07699/ Generic PDBTM,1,8I5G,wildtype,Q07699,UniProt,C18 H12 Cl2 F N5 O3 S2,500.354,T70,4-[2-(5-azanyl-1~{H}-pyrazol-4-yl)-4-chloranyl-phenoxy]-5-chloranyl-2-fluoranyl-~{N}-(1/3-thiazol-4-yl)benzenesulfonamide,c1cc(c(cc1Cl)c2cn[nH]c2N)Oc3cc(c(cc3Cl)S(=O)(=O)Nc4cscn4)F,8
8I5X,6,,,,,,8I5X,Structural mapping of Na v 1.7 antagonists.,Structure of human Nav1.7 in complex with Vinpocetine,MEMBRANE PROTEIN,SCN9A/ NENA,,GO:0030424/ GO:0001518/ GO:0031402/ GO:0005244/ GO:0005248/ GO:0061368/ GO:0006954/ GO:0086010/ GO:0045759/ GO:0019228/ GO:0009791/ GO:0034765/ GO:0009409/ GO:0009408/ GO:0009636/ GO:0019233/ GO:0035725/ GO:0006814/ IPR005821/ IPR000048/ IPR001696/ IPR044564/ IPR010526/ IPR024583/ IPR028803/ IPR043203/ IPR027359/ Q15858/ Generic PDBTM,1,8I5X,wildtype,Q15858,UniProt,C22 H26 N2 O2,350.454,T7F,Ethyl apovincaminate,CCC12CCCN3C1c4c(c5ccccc5n4C(=C2)C(=O)OCC)CC3,9
8I5Y,6,,,,,,8I5Y,Structural mapping of Na v 1.7 antagonists.,Structure of human Nav1.7 in complex with vixotrigine,MEMBRANE PROTEIN,SCN9A/ NENA,,GO:0030424/ GO:0001518/ GO:0031402/ GO:0005244/ GO:0005248/ GO:0061368/ GO:0006954/ GO:0086010/ GO:0045759/ GO:0019228/ GO:0009791/ GO:0034765/ GO:0009409/ GO:0009408/ GO:0009636/ GO:0019233/ GO:0035725/ GO:0006814/ IPR005821/ IPR000048/ IPR001696/ IPR044564/ IPR010526/ IPR024583/ IPR028803/ IPR043203/ IPR027359/ Q15858/ Generic PDBTM,1,8I5Y,wildtype,Q15858,UniProt,C44 H85 N O8 P,787.121,PCW,1/2-DIOLEOYL-SN-GLYCERO-3-PHOSPHOCHOLINE,CCCCCCCCC=CCCCCCCCC(=O)OCC(COP(=O)(O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC,13
8IRU,6,,,,,,8IRU,Structural genomics of the human dopamine receptor system.,Dopamine Receptor D4R-Gi-Rotigotine complex,MEMBRANE PROTEIN,,,,1,8IRU,wildtype,,,C19 H25 N O S,315.473,R5F,(6~{S})-6-[propyl(2-thiophen-2-ylethyl)amino]-5/6/7/8-tetrahydronaphthalen-1-ol,CCCN(CCc1cccs1)C2CCc3c(cccc3O)C2,6
8IRV,6,,,,,,8IRV,Structural genomics of the human dopamine receptor system.,Dopamine Receptor D5R-Gs-Rotigotine complex,MEMBRANE PROTEIN,,,,1,8IRV,wildtype,,,C19 H25 N O S,315.473,R5F,(6~{S})-6-[propyl(2-thiophen-2-ylethyl)amino]-5/6/7/8-tetrahydronaphthalen-1-ol,CCCN(CCc1cccs1)C2CCc3c(cccc3O)C2,5
8ITY,6,,,,,,8ITY,Structure of the SNAPc-bound RNA polymerase III preinitiation complex.,human RNA polymerase III pre-initiation complex closed DNA 1,TRANSCRIPTION,SNAPC4/ SNAP190,,GO:0005654/ GO:0005634/ GO:0019185/ GO:0003677/ GO:0016251/ GO:0000995/ GO:0001006/ GO:0042795/ GO:0042796/ IPR009057/ IPR017930/ IPR001005/ IPR017884/ Q5SXM2,3,8ITY,Mutant,Q5SXM2,UniProt,Fe4 S4,351.64,SF4,IRON/SULFUR CLUSTER,[S]12[Fe]3[S]4[Fe]1[S]5[Fe]2[S]3[Fe]45,28
8J19,6,,,,,,8J19,Structural insights into ligand recognition and activation of the medium-chain fatty acid-sensing receptor GPR84,Cryo-EM structure of the LY237-bound GPR84 receptor-Gi complex,IMMUNE SYSTEM,GPR84/ EX33,,GO:0005886/ GO:0043235/ GO:0035579/ GO:0070821/ GO:0001604/ GO:0007218/ IPR000276/ IPR017452/ Q9NQS5,1,8J19,Mutant,Q9NQS5,UniProt,C14 H23 N O2,237.338,SWO,6-nonylpyridine-2/4-diol,CCCCCCCCCc1cc(cc(n1)O)O,6
8J1N,6,,,,,,8J1N,Structural basis for the binding of DNP and ATP onto human UCP1,Structure of human UCP1 in the DNP-bound state,MEMBRANE PROTEIN,UCP1/ SLC25A7/ UCP,,GO:0005743/ GO:0005739/ GO:1901612/ GO:0019003/ GO:0005525/ GO:0036041/ GO:0017077/ GO:0032555/ GO:0022857/ GO:1990845/ GO:0050873/ GO:0070417/ GO:1903495/ GO:0071398/ GO:0032870/ GO:0034614/ GO:0002024/ GO:1990542/ GO:0120162/ GO:1902600/ GO:1903426/ GO:0006357/ GO:0009409/ GO:0031667/ GO:0009266/ IPR002030/ IPR018108/ IPR023395/ P25874,1,8J1N,wildtype,P25874,UniProt,C6 H4 N2 O5,184.106,DNF,2/4-DINITROPHENOL,c1cc(c(cc1[N+](=O)[O-])[N+](=O)[O-])O,3
8J1N,6,,,,,,8J1N,Structural basis for the binding of DNP and ATP onto human UCP1,Structure of human UCP1 in the DNP-bound state,MEMBRANE PROTEIN,UCP1/ SLC25A7/ UCP,,GO:0005743/ GO:0005739/ GO:1901612/ GO:0019003/ GO:0005525/ GO:0036041/ GO:0017077/ GO:0032555/ GO:0022857/ GO:1990845/ GO:0050873/ GO:0070417/ GO:1903495/ GO:0071398/ GO:0032870/ GO:0034614/ GO:0002024/ GO:1990542/ GO:0120162/ GO:1902600/ GO:1903426/ GO:0006357/ GO:0009409/ GO:0031667/ GO:0009266/ IPR002030/ IPR018108/ IPR023395/ P25874,2,8J1N,wildtype,P25874,UniProt,C81 H156 O17 P2,1464.043,CDL,CARDIOLIPIN,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC(COP(=O)([O-])OCC(COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)O)OC(=O)CCCCCCCCCCCCCCCCC,4
8J1N,6,,,,,,8J1N,Structural basis for the binding of DNP and ATP onto human UCP1,Structure of human UCP1 in the DNP-bound state,MEMBRANE PROTEIN,UCP1/ SLC25A7/ UCP,,GO:0005743/ GO:0005739/ GO:1901612/ GO:0019003/ GO:0005525/ GO:0036041/ GO:0017077/ GO:0032555/ GO:0022857/ GO:1990845/ GO:0050873/ GO:0070417/ GO:1903495/ GO:0071398/ GO:0032870/ GO:0034614/ GO:0002024/ GO:1990542/ GO:0120162/ GO:1902600/ GO:1903426/ GO:0006357/ GO:0009409/ GO:0031667/ GO:0009266/ IPR002030/ IPR018108/ IPR023395/ P25874,,8J1N,wildtype,P25874,UniProt,C44 H88 N O8 P,790.145,PC1,1/2-DIACYL-SN-GLYCERO-3-PHOSPHOCHOLINE,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,5
8J1Q,6,,,,,,8J1Q,Structure-Guided Development of Bivalent Aptamers Blocking SARS-CoV-2 Infection,CryoEM structure of SARS CoV-2 RBD and Aptamer complex,VIRAL PROTEIN/IMMUNE SYSTEM/DNA,,,,1,8J1Q,wildtype,,,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
8J26,6,,,,,,8J26,Structure-Guided Development of Bivalent Aptamers Blocking SARS-CoV-2 Infection,CryoEM structure of SARS CoV-2 RBD and Aptamer complex,VIRAL PROTEIN/IMMUNE SYSTEM/DNA,,,,1,8J26,wildtype,,,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
8JD6,6,,,,,,8JD6,Structural insights into dimerization and activation of the mGlu2-mGlu3 and mGlu2-mGlu4 heterodimers.,Cryo-EM structure of Gi1-bound metabotropic glutamate receptor mGlu4,MEMBRANE PROTEIN,GRM4/ GPRC1D/ MGLUR4,,GO:0031410/ GO:0005886/ GO:0098793/ GO:0001640/ GO:0004930/ GO:0008066/ GO:0007196/ GO:0007268/ GO:0007216/ GO:0007269/ GO:0043410/ GO:0043523/ GO:0051966/ IPR001828/ IPR000337/ IPR011500/ IPR038550/ IPR017978/ IPR017979/ IPR001786/ IPR000162/ IPR028082/ Q14833,1,8JD6,wildtype,Q14833,UniProt,C12 H9 Cl N2 O,232.666,BK0,N-(3-chlorophenyl)pyridine-2-carboxamide,c1ccnc(c1)C(=O)Nc2cccc(c2)Cl,6
8JD6,6,,,,,,8JD6,Structural insights into dimerization and activation of the mGlu2-mGlu3 and mGlu2-mGlu4 heterodimers.,Cryo-EM structure of Gi1-bound metabotropic glutamate receptor mGlu4,MEMBRANE PROTEIN,GRM4/ GPRC1D/ MGLUR4,,GO:0031410/ GO:0005886/ GO:0098793/ GO:0001640/ GO:0004930/ GO:0008066/ GO:0007196/ GO:0007268/ GO:0007216/ GO:0007269/ GO:0043410/ GO:0043523/ GO:0051966/ IPR001828/ IPR000337/ IPR011500/ IPR038550/ IPR017978/ IPR017979/ IPR001786/ IPR000162/ IPR028082/ Q14833,2,8JD6,wildtype,Q14833,,C3 H8 N O6 P,185.072,SEP,PHOSPHOSERINE,C(C(C(=O)O)N)OP(=O)(O)O,7
8OG5,6,,,,,,8OG5,Discovery of New Binders for DCAF1/ an Emerging Ligase Target in the Targeted Protein Degradation Field,Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 1,TRANSFERASE,DCAF1/ KIAA0800/ RIP/ VPRBP,2.7.11.1,GO:0080008/ GO:0005737/ GO:0001650/ GO:0005654/ GO:0005634/ GO:0005524/ GO:1990244/ GO:0030331/ GO:0106310/ GO:0030183/ GO:0035212/ GO:0006325/ GO:0000122/ GO:0043687/ GO:0016567/ GO:0033151/ IPR011989/ IPR016024/ IPR006594/ IPR033270/ IPR015943/ IPR036322/ Q9Y4B6,1,8OG5,Mutant,Q9Y4B6,UniProt,C17 H13 F N2,264.297,LQH,5-(2-fluorophenyl)-2/3-dihydroimidazo[2/1-a]isoquinoline,c1ccc2c(c1)C=C(N3C2=NCC3)c4ccccc4F,4
8OG6,6,,,,,,8OG6,Discovery of New Binders for DCAF1/ an Emerging Ligase Target in the Targeted Protein Degradation Field,Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 1,TRANSFERASE,DCAF1/ KIAA0800/ RIP/ VPRBP,2.7.11.1,GO:0080008/ GO:0005737/ GO:0001650/ GO:0005654/ GO:0005634/ GO:0005524/ GO:1990244/ GO:0030331/ GO:0106310/ GO:0030183/ GO:0035212/ GO:0006325/ GO:0000122/ GO:0043687/ GO:0016567/ GO:0033151/ IPR011989/ IPR016024/ IPR006594/ IPR033270/ IPR015943/ IPR036322/ Q9Y4B6,1,8OG6,Mutant,Q9Y4B6,UniProt,C17 H13 F N2,264.297,LQH,5-(2-fluorophenyl)-2/3-dihydroimidazo[2/1-a]isoquinoline,c1ccc2c(c1)C=C(N3C2=NCC3)c4ccccc4F,2
8OG7,6,,,,,,8OG7,Discovery of New Binders for DCAF1/ an Emerging Ligase Target in the Targeted Protein Degradation Field,Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 2,TRANSFERASE,DCAF1/ KIAA0800/ RIP/ VPRBP,2.7.11.1,GO:0080008/ GO:0005737/ GO:0001650/ GO:0005654/ GO:0005634/ GO:0005524/ GO:1990244/ GO:0030331/ GO:0106310/ GO:0030183/ GO:0035212/ GO:0006325/ GO:0000122/ GO:0043687/ GO:0016567/ GO:0033151/ IPR011989/ IPR016024/ IPR006594/ IPR033270/ IPR015943/ IPR036322/ Q9Y4B6,1,8OG7,Mutant,Q9Y4B6,UniProt,C16 H15 Cl N2 O,286.756,VMR,(4~{R})-4-[3-(4-chloranylphenoxy)phenyl]pyrrolidin-2-imine,c1cc(cc(c1)Oc2ccc(cc2)Cl)C3CC(=N)NC3,4
8OG8,6,,,,,,8OG8,Discovery of New Binders for DCAF1/ an Emerging Ligase Target in the Targeted Protein Degradation Field,Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 3,TRANSFERASE,DCAF1/ KIAA0800/ RIP/ VPRBP,2.7.11.1,GO:0080008/ GO:0005737/ GO:0001650/ GO:0005654/ GO:0005634/ GO:0005524/ GO:1990244/ GO:0030331/ GO:0106310/ GO:0030183/ GO:0035212/ GO:0006325/ GO:0000122/ GO:0043687/ GO:0016567/ GO:0033151/ IPR011989/ IPR016024/ IPR006594/ IPR033270/ IPR015943/ IPR036322/ Q9Y4B6,1,8OG8,Mutant,Q9Y4B6,UniProt,C21 H20 N2,300.397,VM8,5-(2-methyl-1-phenyl-propan-2-yl)imidazo[2/1-a]isoquinoline,CC(C)(Cc1ccccc1)c2cc3ccccc3c4n2ccn4,2
8OG9,6,,,,,,8OG9,Discovery of New Binders for DCAF1/ an Emerging Ligase Target in the Targeted Protein Degradation Field,Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 4,TRANSFERASE,DCAF1/ KIAA0800/ RIP/ VPRBP,2.7.11.1,GO:0080008/ GO:0005737/ GO:0001650/ GO:0005654/ GO:0005634/ GO:0005524/ GO:1990244/ GO:0030331/ GO:0106310/ GO:0030183/ GO:0035212/ GO:0006325/ GO:0000122/ GO:0043687/ GO:0016567/ GO:0033151/ IPR011989/ IPR016024/ IPR006594/ IPR033270/ IPR015943/ IPR036322/ Q9Y4B6,1,8OG9,Mutant,Q9Y4B6,UniProt,C20 H15 Cl N2,318.8,VM3,5-[1-(4-chlorophenyl)cyclopropyl]imidazo[2/1-a]isoquinoline,c1ccc2c(c1)cc(n3c2ncc3)C4(CC4)c5ccc(cc5)Cl,2
8OGA,6,,,,,,8OGA,Discovery of New Binders for DCAF1/ an Emerging Ligase Target in the Targeted Protein Degradation Field,Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 6,TRANSFERASE,DCAF1/ KIAA0800/ RIP/ VPRBP,2.7.11.1,GO:0080008/ GO:0005737/ GO:0001650/ GO:0005654/ GO:0005634/ GO:0005524/ GO:1990244/ GO:0030331/ GO:0106310/ GO:0030183/ GO:0035212/ GO:0006325/ GO:0000122/ GO:0043687/ GO:0016567/ GO:0033151/ IPR011989/ IPR016024/ IPR006594/ IPR033270/ IPR015943/ IPR036322/ Q9Y4B6,1,8OGA,Mutant,Q9Y4B6,UniProt,C26 H31 N4 O,415.551,VLW,5-[1-(4-methoxyphenyl)cyclopropyl]-8-(4-methylpiperazin-1-yl)-2/3-dihydro-1~{H}-imidazo[2/1-a]isoquinoline,CN1CCN(CC1)c2ccc3c(c2)C=C([N]4=C3NCC4)C5(CC5)c6ccc(cc6)OC,4
8OGB,6,,,,,,8OGB,Discovery of New Binders for DCAF1/ an Emerging Ligase Target in the Targeted Protein Degradation Field,Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 8,TRANSFERASE,DCAF1/ KIAA0800/ RIP/ VPRBP,2.7.11.1,GO:0080008/ GO:0005737/ GO:0001650/ GO:0005654/ GO:0005634/ GO:0005524/ GO:1990244/ GO:0030331/ GO:0106310/ GO:0030183/ GO:0035212/ GO:0006325/ GO:0000122/ GO:0043687/ GO:0016567/ GO:0033151/ IPR011989/ IPR016024/ IPR006594/ IPR033270/ IPR015943/ IPR036322/ Q9Y4B6,1,8OGB,Mutant,Q9Y4B6,UniProt,C25 H32 N6 O,432.561,VN5,~{N}'-[2-[1-(4-methoxyphenyl)cyclopropyl]-7-(4-methylpiperazin-1-yl)quinazolin-4-yl]ethane-1/2-diamine,CN1CCN(CC1)c2ccc3c(c2)nc(nc3NCCN)C4(CC4)c5ccc(cc5)OC,3
8OGC,6,,,,,,8OGC,Discovery of New Binders for DCAF1/ an Emerging Ligase Target in the Targeted Protein Degradation Field,Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 11,TRANSFERASE,DCAF1/ KIAA0800/ RIP/ VPRBP,2.7.11.1,GO:0080008/ GO:0005737/ GO:0001650/ GO:0005654/ GO:0005634/ GO:0005524/ GO:1990244/ GO:0030331/ GO:0106310/ GO:0030183/ GO:0035212/ GO:0006325/ GO:0000122/ GO:0043687/ GO:0016567/ GO:0033151/ IPR011989/ IPR016024/ IPR006594/ IPR033270/ IPR015943/ IPR036322/ Q9Y4B6,1,8OGC,Mutant,Q9Y4B6,UniProt,C27 H33 Cl N6 O,493.044,VMZ,1-[4-[4-(2-azanylethylamino)-2-[1-(4-chlorophenyl)cyclopentyl]quinazolin-7-yl]piperazin-1-yl]ethanone,CC(=O)N1CCN(CC1)c2ccc3c(c2)nc(nc3NCCN)C4(CCCC4)c5ccc(cc5)Cl,6
8OUY,6,,,,,,8OUY,Structure and function of the RAD51B-RAD51C-RAD51D-XRCC2 tumour suppressor,Human RAD51B-RAD51C-RAD51D-XRCC2 (BCDX2) complex/ 3.4 A resolution,DNA BINDING PROTEIN,RAD51B/ RAD51L1/ REC2,,GO:0005654/ GO:0005634/ GO:0033063/ GO:0005657/ GO:0005524/ GO:0008094/ GO:0140664/ GO:0003677/ GO:0003690/ GO:0003697/ GO:0001832/ GO:0006310/ GO:0006281/ GO:0000724/ GO:0008284/ GO:0010971/ GO:0007131/ GO:0061053/ IPR003593/ IPR013632/ IPR016467/ IPR027417/ IPR030548/ IPR020588/ O15315,1,8OUY,wildtype,O15315,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,5
8OUY,6,,,,,,8OUY,Structure and function of the RAD51B-RAD51C-RAD51D-XRCC2 tumour suppressor,Human RAD51B-RAD51C-RAD51D-XRCC2 (BCDX2) complex/ 3.4 A resolution,DNA BINDING PROTEIN,RAD51D/ RAD51L3,,GO:0005813/ GO:0000781/ GO:0005737/ GO:0005654/ GO:0005634/ GO:0033063/ GO:0005657/ GO:0005524/ GO:0008094/ GO:0140664/ GO:0003677/ GO:0043015/ GO:0003697/ GO:0006281/ GO:0000724/ GO:0036297/ GO:0007131/ GO:0051726/ GO:0042148/ GO:0000723/ GO:0000722/ IPR003593/ IPR013632/ IPR016467/ IPR027417/ IPR020588/ O75771,3,8OUY,wildtype,O75771,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,7
8OUZ,6,,,,,,8OUZ,Structure and function of the RAD51B-RAD51C-RAD51D-XRCC2 tumour suppressor,Human RAD51B-RAD51C-RAD51D-XRCC2 (BCDX2) complex/ 2.2 A resolution,DNA BINDING PROTEIN,RAD51B/ RAD51L1/ REC2,,GO:0005654/ GO:0005634/ GO:0033063/ GO:0005657/ GO:0005524/ GO:0008094/ GO:0140664/ GO:0003677/ GO:0003690/ GO:0003697/ GO:0001832/ GO:0006310/ GO:0006281/ GO:0000724/ GO:0008284/ GO:0010971/ GO:0007131/ GO:0061053/ IPR003593/ IPR013632/ IPR016467/ IPR027417/ IPR030548/ IPR020588/ O15315,1,8OUZ,wildtype,O15315,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,5
8OUZ,6,,,,,,8OUZ,Structure and function of the RAD51B-RAD51C-RAD51D-XRCC2 tumour suppressor,Human RAD51B-RAD51C-RAD51D-XRCC2 (BCDX2) complex/ 2.2 A resolution,DNA BINDING PROTEIN,RAD51D/ RAD51L3,,GO:0005813/ GO:0000781/ GO:0005737/ GO:0005654/ GO:0005634/ GO:0033063/ GO:0005657/ GO:0005524/ GO:0008094/ GO:0140664/ GO:0003677/ GO:0043015/ GO:0003697/ GO:0006281/ GO:0000724/ GO:0036297/ GO:0007131/ GO:0051726/ GO:0042148/ GO:0000723/ GO:0000722/ IPR003593/ IPR013632/ IPR016467/ IPR027417/ IPR020588/ O75771,3,8OUZ,wildtype,O75771,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,7
8P06,6,,,,,,8P06,Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with 5-((2-(4H-1/2/4-triazol-4-yl)pyridin-4-yl)amino)-7-(cyclopropylamino)pyrazolo[1/5-a]pyrimidine-3-carbonitrile,Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with 5-((2-(4H-1/2/4-triazol-4-yl)pyridin-4-yl)amino)-7-(cyclopropylamino)pyrazolo[1/5-a]pyrimidine-3-carbonitrile,TRANSFERASE,CSNK2A1,,GO:0005524/ GO:0004674/ GO:0006468/ IPR045216/ IPR011009/ IPR000719/ IPR017441/ IPR008271,1,8P06,wildtype,Q5U5J2,UniProt,C17 H14 N10,358.36,WAU,7-(cyclopropylamino)-5-[[2-(1/2/4-triazol-4-yl)pyridin-4-yl]amino]pyrazolo[1/5-a]pyrimidine-3-carbonitrile,c1cnc(cc1Nc2cc(n3c(n2)c(cn3)C#N)NC4CC4)n5cnnc5,3
8S91,6,,,,,,8S91,Specificity/ Activity/ and Structure of the MCM8/9 Helicase,Structure of Walker B mutated MCM8/9 heterohexamer complex with ADP,DNA BINDING PROTEIN,MCM8/ C20orf154,3.6.4.12,GO:0005694/ GO:0042555/ GO:0097362/ GO:0005654/ GO:0005634/ GO:0005524/ GO:0016887/ GO:0003682/ GO:0003678/ GO:0019899/ GO:0032406/ GO:0032407/ GO:0032408/ GO:0003697/ GO:0007049/ GO:0006974/ GO:0032508/ GO:0000724/ GO:0007292/ GO:0048232/ GO:0070716/ GO:0071168/ GO:0050821/ GO:0036298/ IPR003593/ IPR031327/ IPR001208/ IPR041562/ IPR033762/ IPR012340/ IPR027417/ Q9UJA3,1,8S91,Mutant,Q9UJA3,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,3
8S94,6,,,,,,8S94,Specificity/ Activity/ and Structure of the MCM8/9 Helicase,Structure of C-terminal domains of Walker B mutated MCM8/9 heterohexamer complex with ADP,DNA BINDING PROTEIN,MCM8/ C20orf154,3.6.4.12,GO:0005694/ GO:0042555/ GO:0097362/ GO:0005654/ GO:0005634/ GO:0005524/ GO:0016887/ GO:0003682/ GO:0003678/ GO:0019899/ GO:0032406/ GO:0032407/ GO:0032408/ GO:0003697/ GO:0007049/ GO:0006974/ GO:0032508/ GO:0000724/ GO:0007292/ GO:0048232/ GO:0070716/ GO:0071168/ GO:0050821/ GO:0036298/ IPR003593/ IPR031327/ IPR001208/ IPR041562/ IPR033762/ IPR012340/ IPR027417/ Q9UJA3,1,8S94,Mutant,Q9UJA3,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,3
8SZA,6,,,,,,8SZA,How NINJ1 mediates plasma membrane rupture and why NINJ2 cannot,Cryo-EM Structure of NINJ1 Filament at 2.75 Angstrom Resolution,MEMBRANE PROTEIN,NINJ1,,GO:0005576/ GO:0097060/ GO:0098631/ GO:0001530/ GO:0140912/ GO:0001525/ GO:0007155/ GO:0034113/ GO:0006954/ GO:0031640/ GO:0002232/ GO:0042692/ GO:0007399/ GO:0045766/ GO:0050729/ GO:0034145/ GO:0012501/ GO:0051260/ GO:0090025/ GO:0042246/ IPR007007/ Q92982/ Generic PDBTM,1,8SZA,wildtype,Q92982,UniProt,C27 H46 O,386.654,CLR,CHOLESTEROL,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C,2
8SZB,6,,,,,,8SZB,How NINJ1 mediates plasma membrane rupture and why NINJ2 cannot,Cryo-EM Structure of NINJ2 Filament at 3.07 Angstrom Resolution,MEMBRANE PROTEIN,NINJ2,,GO:0005886/ GO:0007155/ GO:0007399/ GO:0007158/ GO:0042246/ IPR007007/ Q9NZG7/ Generic PDBTM,1,8SZB,wildtype,Q9NZG7,UniProt,C27 H46 O,386.654,CLR,CHOLESTEROL,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C,2
7UAD,7,,,,,,7UAD,PTPN2/N1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity,Crystal structure of human PTPN2 with inhibitor ABBV-CLS-484,SIGNALING PROTEIN/INHIBITOR,PTPN2/ PTPT,3.1.3.48,GO:0005737/ GO:0005829/ GO:0005783/ GO:0005793/ GO:0005654/ GO:0005634/ GO:0005886/ GO:0005178/ GO:0004726/ GO:0019901/ GO:0004725/ GO:0030971/ GO:0097677/ GO:0019905/ GO:0030183/ GO:0030218/ GO:0042593/ GO:0008286/ GO:0008285/ GO:0050922/ GO:0042059/ GO:0070373/ GO:0050728/ GO:0046627/ GO:0060336/ GO:1902206/ GO:1902215/ GO:0070104/ GO:0010888/ GO:1902227/ GO:0045650/ GO:2000587/ GO:1902233/ GO:0061099/ GO:0046426/ GO:0050860/ GO:0000122/ GO:0010804/ GO:0060339/ GO:0042532/ GO:0035335/ GO:1902237/ GO:0045722/ GO:1903899/ GO:1902202/ GO:0060334/ GO:0030217/ IPR029021/ IPR000242/ IPR012265/ IPR016130/ IPR003595/ IPR000387/ P17706,1,7UAD,wlidetype,P17706,UniProt,C17 H24 F N3 O4 S,385.454,M5R,5-{(7R)-1-fluoro-3-hydroxy-7-[(3-methylbutyl)amino]-5/6/7/8-tetrahydronaphthalen-2-yl}-1lambda~6~/2/5-thiadiazolidine-1/1/3-trione,CC(C)CCNC1CCc2cc(c(c(c2C1)F)N3CC(=O)NS3(=O)=O)O,2
7UMO,7,,,,,,7UMO,Insulin sensitization by small molecules enhancing GLUT4 translocation.,Structure of Unc119-inhibitor complex.,TRANSPORT PROTEIN,UNC119/ RG4,,GO:0005813/ GO:0005829/ GO:0045171/ GO:0051233/ GO:0000922/ GO:0045202/ GO:0008289/ GO:0007268/ GO:0006897/ GO:0042953/ GO:0000281/ GO:2001287/ GO:1900186/ GO:0007399/ GO:0007602/ GO:0061098/ GO:0007601/ IPR014756/ IPR008015/ IPR037036/ IPR032977/ Q13432,1,7UMO,wlidetype,Q13432,UniProt,C16 H18 Cl2 N2 O,325.233,NT6,(3s/5s/7s)-N-(4/5-dichloropyridin-2-yl)adamantane-1-carboxamide,c1c(c(cnc1NC(=O)C23CC4CC(C2)CC(C4)C3)Cl)Cl,2
7Y0B,7,,,,,,7Y0B,Crystal structure of human short-chain acyl-coA dehydrogenase,Crystal structure of human short-chain acyl-CoA dehydrogenase,OXIDOREDUCTASE,ACADS,1.3.8.1,GO:0005813/ GO:0005759/ GO:0005739/ GO:0005654/ GO:0005634/ GO:0003995/ GO:0004085/ GO:0050660/ GO:0046359/ GO:0006635/ GO:0033539/ IPR006089/ IPR006091/ IPR046373/ IPR036250/ IPR009075/ IPR013786/ IPR037069/ IPR009100/ P16219,1,7Y0B,wlidetype,P16219,UniProt,C23 H27 Cl O7,450.909,7R3,(2S/3R/4R/5S/6R)-2-[4-chloranyl-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3/4/5-triol,c1cc(ccc1Cc2cc(ccc2Cl)C3C(C(C(C(O3)CO)O)O)O)OC4CCOC4,3
7Y1Y,7,,,,,,7Y1Y,Structural Basis for the Enhanced Infectivity and Immune Evasion of Omicron Subvariants.,S-ECD (Omicron BA.2) in complex with PD of ACE2,VIRAL PROTEIN/HYDROLASE,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,7Y1Y,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7Y1Z,7,,,,,,7Y1Z,Structural Basis for the Enhanced Infectivity and Immune Evasion of Omicron Subvariants.,S-ECD (Omicron BA.3) in complex with three PD of ACE2,VIRAL PROTEIN/HYDROLASE,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,7Y1Z,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7YAN,7,,,,,,7YAN,UDP-glucuronosyltransferase2B17 C-terminal domain,UDP-glucuronosyltransferase2B17 C-terminal domain,TRANSFERASE,UGT2B17,2.4.1.17,GO:0005789/ GO:0016020/ GO:0015020/ GO:0052695/ GO:0008210/ GO:0008202/ GO:0006805/ IPR002213/ IPR035595/ O75795,1,7YAN,wlidetype,O75795,UniProt,C4 H6 O6,150.087,TLA,L(+)-TARTARIC ACID,C(C(C(=O)O)O)(C(=O)O)O,2
7YHW,7,,,,,,7YHW,Structural basis for receptor binding and broader interspecies receptor recognition of currently circulating Omicron sub-variants.,Cryo-EM structure of SARS-CoV-2 Omicron BA.2.12.1 RBD in complex with human ACE2 (local refinement),HYDROLASE/VIRAL PROTEIN,S/ 2,3.4.17.23/ 3.4.17,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,2,7YHW,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
7YIU,7,,,,,,7YIU,Ceramide sensing by human SPT-ORMDL complex for establishing sphingolipid homeostasis.,Cryo-EM structure of the C6-ceramide-bound SPT-ORMDL3 complex,TRANSFERASE/inhibitor,SPTSSA/ C14orf147/ SSSPTA,,GO:0005783/ GO:0005789/ GO:0017059/ GO:0004758/ GO:0046513/ GO:0008104/ GO:0030148/ GO:0046512/ IPR024512/ Q969W0/ Generic PDBTM,4,7YIU,wlidetype,Q969W0,UniProt,C24 H47 N O3,397.635,6CM,N-((E/2S/3R)-1/3-DIHYDROXYOCTADEC-4-EN-2-YL)HEXANAMIDE,CCCCCCCCCCCCCC=CC(C(CO)NC(=O)CCCCC)O,7
7YIV,7,,,,,,7YIV,The structural pathology for hypophosphatasia caused by malfunctional tissue non-specific alkaline phosphatase.,The Crystal Structure of Human Tissue Nonspecific Alkaline Phosphatase (ALPL) at Basic pH,HYDROLASE,ALPL,3.1.3.1/ 3.9.1.1,GO:0070062/ GO:0031012/ GO:0005576/ GO:0016020/ GO:0005758/ GO:0031966/ GO:0005886/ GO:0043262/ GO:0004035/ GO:0016887/ GO:0005509/ GO:0004427/ GO:0050187/ GO:0052732/ GO:0033883/ GO:0016462/ GO:0030282/ GO:0055074/ GO:0019725/ GO:0071407/ GO:0071529/ GO:0016311/ GO:0003006/ GO:0001958/ GO:0140651/ GO:0140928/ GO:0001649/ GO:0055062/ GO:0120162/ GO:0042822/ GO:0046677/ GO:0051384/ GO:0032868/ GO:0032496/ GO:0036005/ GO:1904383/ GO:0034516/ GO:0033280/ GO:0001501/ IPR001952/ IPR018299/ IPR017850/ P05186,1,7YIV,wlidetype,P05186,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,3
7YIY,7,,,,,,7YIY,Ceramide sensing by human SPT-ORMDL complex for establishing sphingolipid homeostasis.,Cryo-EM structure of SPT-ORMDL3 complex,TRANSFERASE/INHIBITOR COMPLEX,SPTLC1/ LCB1,2.3.1.50,GO:0005783/ GO:0005789/ GO:0017059/ GO:0035339/ GO:0030170/ GO:0004758/ GO:0046513/ GO:1904504/ GO:1904649/ GO:0046511/ GO:0030148/ GO:0006665/ GO:0006686/ GO:0046512/ IPR004839/ IPR015424/ IPR015421/ IPR015422/ O15269/ Generic PDBTM,5,7YIY,wlidetype,O15269,UniProt,C42 H83 N O3,650.113,Z1T,N-[(2S/3R/4E)-1/3-dihydroxyoctadec-4-en-2-yl]tetracosanamide,CCCCCCCCCCCCCCCCCCCCCCCC(=O)NC(CO)C(C=CCCCCCCCCCCCCC)O,7
7YJ3,7,,,,,,7YJ3,Structural basis for receptor binding and broader interspecies receptor recognition of currently circulating Omicron sub-variants.,Cryo-EM structure of SARS-CoV-2 Omicron BA.2 RBD in complex with human ACE2 (local refinement),HYDROLASE/VIRAL PROTEIN,ACE2/ UNQ868/PRO1885,3.4.17.23/ 3.4.17,GO:0016324/ GO:0031526/ GO:0009986/ GO:0005929/ GO:0030666/ GO:0005788/ GO:0070062/ GO:0005576/ GO:0005615/ GO:0016020/ GO:0045121/ GO:0005886/ GO:0004180/ GO:0004175/ GO:0042802/ GO:0004181/ GO:0008237/ GO:0008241/ GO:0001618/ GO:0008270/ GO:0002003/ GO:0003051/ GO:0097746/ GO:0060135/ GO:0061025/ GO:0070373/ GO:2000272/ GO:0048662/ GO:0051957/ GO:0060452/ GO:1903598/ GO:1905737/ GO:2000379/ GO:0019065/ GO:0046813/ GO:1903779/ GO:0042127/ GO:0001817/ GO:0050727/ GO:0003081/ GO:0022898/ GO:0019229/ GO:0015827/ GO:0046718/ GO:0019058/ IPR031588/ IPR001548/ Q9BYF1,1,7YJ3,mutant,Q9BYF1,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7YM8,7,,,,,,7YM8,Structural basis of alpha 1A -adrenergic receptor activation and recognition by an extracellular nanobody.,Cryo-EM structure of Nb29-alpha1AAR-miniGsq complex bound to oxymetazoline,MEMBRANE PROTEIN,,,,1,7YM8,wlidetype,,,C16 H24 N2 O,260.375,J5C,Oxymetazoline,Cc1cc(c(c(c1CC2=NCCN2)C)O)C(C)(C)C,4
7YM8,7,,,,,,7YM8,Structural basis of alpha 1A -adrenergic receptor activation and recognition by an extracellular nanobody.,Cryo-EM structure of Nb29-alpha1AAR-miniGsq complex bound to oxymetazoline,MEMBRANE PROTEIN,,,,2,7YM8,wlidetype,,,C31 H50 O4,486.726,Y01,CHOLESTEROL HEMISUCCINATE,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC(=O)CCC(=O)O)C)C,5
7YMH,7,,,,,,7YMH,Structural basis of alpha 1A -adrenergic receptor activation and recognition by an extracellular nanobody.,Cryo-EM structure of Nb29-alpha1AAR-miniGsq complex bound to noradrenaline,MEMBRANE PROTEIN,,,,1,7YMH,wlidetype,,,C8 H12 N O3,170.186,E5E,Noradrenaline,c1cc(c(cc1C(C[NH3+])O)O)O,4
7YMJ,7,,,,,,7YMJ,Structural basis of alpha 1A -adrenergic receptor activation and recognition by an extracellular nanobody.,Cryo-EM structure of alpha1AAR-Nb6 complex bound to tamsulosin,MEMBRANE PROTEIN,,,,1,7YMJ,wlidetype,,,C20 H28 N2 O5 S,408.512,JGX,Tamsulosin,CCOc1ccccc1OCCNC(C)Cc2ccc(c(c2)S(=O)(=O)N)OC,3
7YW3,7,,,,,,7YW3,Structural and biochemical insights into the molecular mechanism of TRPT1 for nucleic acid ADP-ribosylation.,Crystal structure of tRNA 2'-phosphotransferase from Homo sapiens,TRANSFERASE,TRPT1,2.7.1.160,GO:0000215/ GO:0045859/ GO:0006388/ IPR002745/ IPR042081/ IPR042080/ Q86TN4,1,7YW3,wlidetype,Q86TN4,UniProt,C15 H24 N5 O17 P3,639.296,HQG,[[(2~{R}/3~{S}/4~{R}/5~{R})-5-(6-aminopurin-9-yl)-3/4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl] [(2~{R}/3~{S}/4~{R}/5~{R})-3/4-bis(oxidanyl)-5-phosphonooxy-oxolan-2-yl]methyl hydrogen phosphate,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OCC4C(C(C(O4)OP(=O)(O)O)O)O)O)O)N,2
8DMS,7,,,,,,8DMS,Structure of Legionella pneumophila macrodomain MavL in complex with ubiquitin vinyl methyl ester soaked with ADP-ribose,Crystal structure of Legionella pneumophila macrodomain MavL in complex with ubiquitin vinyl methyl ester soaked with ADP-ribose,ANTITOXIN,,,,1,8DMS,wlidetype,Q5ZSJ1,UniProt,C15 H23 N5 O14 P2,559.316,AR6,[(2R/3S/4R/5R)-5-(6-AMINOPURIN-9-YL)-3/4-DIHYDROXY-OXOLAN-2-YL]METHYL[HYDROXY-[[(2R/3S/4R/5S)-3/4/5-TRIHYDROXYOXOLAN-2-YL]METHOXY]PHOSPHORYL] HYDROGEN PHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OCC4C(C(C(O4)O)O)O)O)O)N,3
8DYJ,7,,,,,,8DYJ,Allosteric control of metal redox state regulates coenzyme B12 repair,Crystal structure of human methylmalonyl-CoA mutase in complex with ADP and cob(II)alamin,ISOMERASE,MMUT/ MUT,5.4.99.2,GO:0005737/ GO:0005759/ GO:0005739/ GO:0031419/ GO:0003924/ GO:0042802/ GO:0046872/ GO:0004494/ GO:0072341/ GO:0042803/ GO:0050667/ GO:0043547/ GO:0009791/ GO:0019678/ IPR006159/ IPR016176/ IPR006158/ IPR036724/ IPR006099/ IPR006098/ P22033,1,8DYJ,wlidetype,P22033,UniProt,C62 H89 Co N13 O14 P,1330.356,B12,COBALAMIN,Cc1cc2c(cc1C)n(cn2)C3C(C(C(O3)CO)OP(=O)(O)OC(C)CNC(=O)CCC4(C(C5C6(C(C(C7=[N]6[Co+2]89[N]5=C4C(=C1[NH]8C(=CC2=[N]9C(=C7C)C(C2CCC(=O)N)(C)CC(=O)N)C(C1CCC(=O)N)(C)C)C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O,2
8DYJ,7,,,,,,8DYJ,Allosteric control of metal redox state regulates coenzyme B12 repair,Crystal structure of human methylmalonyl-CoA mutase in complex with ADP and cob(II)alamin,ISOMERASE,MMUT/ MUT,5.4.99.2,GO:0005737/ GO:0005759/ GO:0005739/ GO:0031419/ GO:0003924/ GO:0042802/ GO:0046872/ GO:0004494/ GO:0072341/ GO:0042803/ GO:0050667/ GO:0043547/ GO:0009791/ GO:0019678/ IPR006159/ IPR016176/ IPR006158/ IPR036724/ IPR006099/ IPR006098/ P22033,1,8DYJ,wlidetype,P22033,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,3
8DYL,7,,,,,,8DYL,Allosteric control of metal redox state regulates coenzyme B12 repair,Crystal structure of human methylmalonyl-CoA mutase bound to aquocobalamin,ISOMERASE,MMUT/ MUT,5.4.99.2,GO:0005737/ GO:0005759/ GO:0005739/ GO:0031419/ GO:0003924/ GO:0042802/ GO:0046872/ GO:0004494/ GO:0072341/ GO:0042803/ GO:0050667/ GO:0043547/ GO:0009791/ GO:0019678/ IPR006159/ IPR016176/ IPR006158/ IPR036724/ IPR006099/ IPR006098/ P22033,1,8DYL,wlidetype,P22033,UniProt,C62 H89 Co N13 O14 P,1330.356,B12,COBALAMIN,Cc1cc2c(cc1C)n(cn2)C3C(C(C(O3)CO)OP(=O)(O)OC(C)CNC(=O)CCC4(C(C5C6(C(C(C7=[N]6[Co+2]89[N]5=C4C(=C1[NH]8C(=CC2=[N]9C(=C7C)C(C2CCC(=O)N)(C)CC(=O)N)C(C1CCC(=O)N)(C)C)C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O,2
8F0M,7,,,,,,8F0M,Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors.,Monobody 12D5 bound to KRAS(G12D),SIGNALING PROTEIN/DE NOVO PROTEIN,KRAS/ KRAS2/ RASK2,3.6.5.2,GO:0005737/ GO:0005829/ GO:0005789/ GO:0031234/ GO:0005925/ GO:0000139/ GO:0016020/ GO:0005741/ GO:0005886/ GO:0003925/ GO:0019003/ GO:0005525/ GO:0003924/ GO:0042802/ GO:0044877/ GO:0030036/ GO:0038002/ GO:0060441/ GO:0021897/ GO:0014009/ GO:0048873/ GO:0000165/ GO:0030857/ GO:0043524/ GO:0051402/ GO:0008284/ GO:0010628/ GO:0060252/ GO:0001934/ GO:0035022/ GO:0016601/ GO:0007265/ GO:0048169/ GO:0031647/ GO:0032228/ GO:0035914/ GO:0051146/ GO:0060509/ GO:0008542/ IPR027417/ IPR005225/ IPR001806/ IPR020849,2,8F0M,mutant,P01116-2,UniProt,C10 H15 N5 O11 P2,443.201,GDP,GUANOSINE-5'-DIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,4
8F0M,7,,,,,,8F0M,Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors.,Monobody 12D5 bound to KRAS(G12D),SIGNALING PROTEIN/DE NOVO PROTEIN,KRAS/ KRAS2/ RASK2,3.6.5.2,GO:0005737/ GO:0005829/ GO:0005789/ GO:0031234/ GO:0005925/ GO:0000139/ GO:0016020/ GO:0005741/ GO:0005886/ GO:0003925/ GO:0019003/ GO:0005525/ GO:0003924/ GO:0042802/ GO:0044877/ GO:0030036/ GO:0038002/ GO:0060441/ GO:0021897/ GO:0014009/ GO:0048873/ GO:0000165/ GO:0030857/ GO:0043524/ GO:0051402/ GO:0008284/ GO:0010628/ GO:0060252/ GO:0001934/ GO:0035022/ GO:0016601/ GO:0007265/ GO:0048169/ GO:0031647/ GO:0032228/ GO:0035914/ GO:0051146/ GO:0060509/ GO:0008542/ IPR027417/ IPR005225/ IPR001806/ IPR020849,2,8F0M,mutant,P01116-2,UniProt,C10 H16 N5 O13 P3 S,539.246,GSP,5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=S)(O)O)O)O)N=C(NC2=O)N,6
8F5F,7,,,,,,8F5F,Discovery of branched-chain ketoacid dehydrogenase kinase (BDK) inhibitors acting as stabilizers or destabilizers,human branched chain ketoacid dehydrogenase kinase in complex with inhibitors,SIGNALING PROTEIN/TRANSFERASE/INHIBITOR,BCKDK,2.7.11.4,GO:0005947/ GO:0005759/ GO:0005739/ GO:0047323/ GO:0005524/ GO:0016301/ GO:0004674/ GO:0004740/ GO:0009063/ GO:0009083/ GO:0045763/ GO:0016310/ GO:0006468/ GO:0010906/ IPR036784/ IPR018955/ IPR039028/ IPR003594/ IPR036890/ IPR005467/ IPR004358/ O14874,1,8F5F,wlidetype,O14874,UniProt,C21 H20 N2 O3 S,380.46,XGG,(2P)-2-[(4P)-4-{6-[(1-ethylcyclopropyl)methoxy]pyridin-3-yl}-1/3-thiazol-2-yl]benzoic acid,CCC1(CC1)COc2ccc(cn2)c3csc(n3)c4ccccc4C(=O)O,4
8F5J,7,,,,,,8F5J,Discovery of branched-chain ketoacid dehydrogenase kinase (BDK) inhibitors acting as stabilizers or destabilizers,human branched chain ketoacid dehydrogenase kinase in complex with inhibitors,SIGNALING PROTEIN/TRANSFERASE/INHIBITOR,BCKDK,2.7.11.4,GO:0005947/ GO:0005759/ GO:0005739/ GO:0047323/ GO:0005524/ GO:0016301/ GO:0004674/ GO:0004740/ GO:0009063/ GO:0009083/ GO:0045763/ GO:0016310/ GO:0006468/ GO:0010906/ IPR036784/ IPR018955/ IPR039028/ IPR003594/ IPR036890/ IPR005467/ IPR004358/ O14874,1,8F5J,wlidetype,O14874,UniProt,C7 H2 Cl F O2 S2,236.671,XER,3-chloro-5-fluorothieno[3/2-b]thiophene-2-carboxylic acid,c1c2c(c(c(s2)C(=O)O)Cl)sc1F,5
8F5S,7,,,,,,8F5S,Discovery of branched-chain ketoacid dehydrogenase kinase (BDK) inhibitors acting as stabilizers or destabilizers,human branched chain ketoacid dehydrogenase kinase in complex with inhibitors,SIGNALING PROTEIN/TRANSFERASE/INHIBITOR,BCKDK,2.7.11.4,GO:0005947/ GO:0005759/ GO:0005739/ GO:0047323/ GO:0005524/ GO:0016301/ GO:0004674/ GO:0004740/ GO:0009063/ GO:0009083/ GO:0045763/ GO:0016310/ GO:0006468/ GO:0010906/ IPR036784/ IPR018955/ IPR039028/ IPR003594/ IPR036890/ IPR005467/ IPR004358/ O14874,1,8F5S,wlidetype,O14874,UniProt,C17 H13 N O2 S,295.356,XGT,(2M)-2-[2-(4-methylphenyl)-1/3-thiazol-4-yl]benzoic acid,Cc1ccc(cc1)c2nc(cs2)c3ccccc3C(=O)O,5
8F7A,7,,,,,,8F7A,Mechanism of RanGTP priming H2A-H2B release from Kap114 in an atypical RanGTP?줜ap114?줙2A-H2B complex.,Cryo-EM structure of Importin-9 bound to RanGTP,PROTEIN TRANSPORT,GSP1/ CNR1/ CST17/ YLR293C/ L8003.19,,GO:0005737/ GO:0005829/ GO:0005634/ GO:0005525/ GO:0003924/ GO:0000467/ GO:0006997/ GO:0016973/ GO:0006606/ GO:1901987/ GO:0046822/ GO:0000054/ IPR027417/ IPR002041/ IPR005225/ IPR001806,2,8F7A,wlidetype,P32835,UniProt,C10 H16 N5 O14 P3,523.18,GTP,GUANOSINE-5'-TRIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,4
8FSJ,7,,,,,,8FSJ,Structure of engineered hepatitis C virus E1E2 ectodomain in complex with neutralizing antibodies.,Cryo-EM structure of engineered hepatitis C virus E1E2 ectodomain in complex with antibodies AR4A/ HEPC74/ and IGH520,VIRAL PROTEIN,,,GO:0005737/ GO:0044167/ GO:0044186/ GO:0044191/ GO:0042025/ GO:0005811/ GO:0016020/ GO:1990904/ GO:0019031/ GO:0019013/ GO:0055036/ GO:0005198/ GO:0075512/ GO:0019049/ IPR002521/ IPR002519/ IPR002531,1,8FSJ,wlidetype,A0A2P0NE15,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,9
8FW5,7,,,,,,8FW5,Structure of the Schizosaccharomyces pombe Gtr-Lam complex reveals evolutionary divergence of mTORC1-dependent amino acid sensing.,Chimeric HsGATOR1-SpGtr-SpLam complex,SIGNALING PROTEIN,DEPDC5/ KIAA0645,,GO:0005829/ GO:1990130/ GO:0005765/ GO:0005764/ GO:0048471/ GO:0005096/ GO:0044877/ GO:0034198/ GO:0035556/ GO:0032007/ GO:1904262/ GO:0010508/ IPR000591/ IPR045838/ IPR027244/ IPR036388/ IPR036390/ O75140,1,8FW5,mutant,O75140,UniProt,C10 H15 N5 O11 P2,443.201,GDP,GUANOSINE-5'-DIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,10
8G1A,7,,,,,,8G1A,Cannabidiol inhibits Na v channels through two distinct binding sites.,Cryo-EM structure of Nav1.7 with CBD,MEMBRANE PROTEIN,SCN1B,,GO:0005576/ GO:0014704/ GO:0033268/ GO:0043204/ GO:0005886/ GO:0030315/ GO:0001518/ GO:0019871/ GO:0017080/ GO:0044325/ GO:0005244/ GO:0005248/ GO:0086006/ GO:0086062/ GO:0007411/ GO:0061337/ GO:0086002/ GO:0060048/ GO:0007155/ GO:0021966/ GO:0040011/ GO:0051899/ GO:0086012/ GO:0086047/ GO:0019227/ GO:0010976/ GO:0010765/ GO:0060371/ GO:0086091/ GO:2000649/ GO:0060307/ GO:0035725/ IPR036179/ IPR013783/ IPR013106/ IPR027098/ IPR044568/ Q07699/ Generic PDBTM,2,8G1A,wlidetype,Q07699,UniProt,C21 H30 O2,314.462,P0T,cannabidiol,CCCCCc1cc(c(c(c1)O)C2C=C(CCC2C(=C)C)C)O,6
8G1P,7,,,,,,8G1P,Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation.,Co-crystal structure of Compound 11 in complex with the bromodomain of human SMARCA2 and pVHL:ElonginC:ElonginB,GENE REGULATION,ELOC/ TCEB1,,GO:0031462/ GO:0031466/ GO:0005829/ GO:0070449/ GO:0005654/ GO:0030674/ GO:0001222/ GO:0016567/ GO:0006357/ GO:0006367/ GO:0006511/ IPR039948/ IPR001232/ IPR011333/ IPR016073/ Q15369,2,8G1P,wlidetype,Q15369,UniProt,C49 H58 F N9 O6 S,920.105,FWZ,(2~{S}/4~{R})-~{N}-[[2-[2-[4-[[4-[3-azanyl-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazin-1-yl]methyl]phenyl]ethoxy]-4-(4-methyl-1/3-thiazol-5-yl)phenyl]methyl]-1-[(2~{S})-2-[(1-fluoranylcyclopropyl)carbonylamino]-3/3-dimethyl-butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide,Cc1c(scn1)c2ccc(c(c2)OCCc3ccc(cc3)CN4CCN(CC4)c5cc(nnc5N)c6ccccc6O)CNC(=O)C7CC(CN7C(=O)C(C(C)(C)C)NC(=O)C8(CC8)F)O,6
8G4M,7,,,,,,8G4M,HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide.,Vaccine-elicited human antibody 2C06 in complex with HIV-1 envelope trimer BG505 DS-SOSIP,ANTIVIRAL PROTEIN,env,,GO:0044175/ GO:0020002/ GO:0005886/ GO:0019031/ GO:0055036/ GO:0042802/ GO:0005198/ GO:0075512/ GO:0039654/ GO:0019064/ GO:1903905/ GO:1903908/ GO:1903911/ GO:0019082/ GO:0019062/ IPR036377/ IPR037527/ IPR000328/ IPR000777,1,8G4M,mutant,Q2N0S6,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,10
8G4T,7,,,,,,8G4T,HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide.,Vaccine-elicited human antibody 2C09 in complex with HIV-1 envelope trimer BG505 DS-SOSIP,VIRAL PROTEIN/IMMUNE SYSTEM,env,,GO:0044175/ GO:0020002/ GO:0005886/ GO:0019031/ GO:0055036/ GO:0005198/ GO:0075512/ GO:0039654/ GO:0019064/ GO:1903905/ GO:1903908/ GO:1903911/ GO:0019082/ GO:0019062/ IPR036377/ IPR037527/ IPR000328/ IPR000777,1,8G4T,mutant,Q2N0S7,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,9
8GH7,7,,,,,,8GH7,Characterization of a Potent and Orally Bioavailable Lys-Covalent Inhibitor of Apoptosis Protein (IAP) Antagonist.,142D6 bound to BIR3-XIAP,SIGNALING PROTEIN/INHIBITOR,XIAP/ API3/ BIRC4/ IAP3,2.3.2.27,GO:0005737/ GO:0005829/ GO:0005654/ GO:0005634/ GO:0005876/ GO:0043027/ GO:0042802/ GO:0046872/ GO:0120283/ GO:0061630/ GO:0004842/ GO:0006974/ GO:0055070/ GO:0097340/ GO:1990001/ GO:0043066/ GO:0043154/ GO:0010804/ GO:0051402/ GO:0090263/ GO:0046330/ GO:1902530/ GO:0031398/ GO:0060785/ GO:0042981/ GO:0030510/ GO:0051726/ GO:0042127/ GO:0050727/ GO:0045088/ GO:0070424/ GO:0016055/ IPR001370/ IPR011029/ IPR042579/ IPR001841/ P98170,2,8GH7,wlidetype,P98170,UniProt,C14 H30 O7,310.384,7PE,2-(2-(2-(2-(2-(2-ETHOXYETHOXY)ETHOXY)ETHOXY)ETHOXY)ETHOXY)ETHANOL,CCOCCOCCOCCOCCOCCOCCO,4
8GK3,7,,,,,,8GK3,Human Cytochrome P450 3A7 Binding Four Copies of Its Native Substrate Dehydroepiandrosterone 3-Sulfate.,Cytochrome P450 3A7 in complex with Dehydroepiandrosterone sulfate,OXIDOREDUCTASE,CYP3A7,1.14.14.1,GO:0005789/ GO:0062183/ GO:0070330/ GO:0101020/ GO:0101021/ GO:0020037/ GO:0005506/ GO:0004497/ GO:0019825/ GO:0008401/ GO:0008395/ GO:0008210/ GO:0002933/ GO:0070989/ GO:0042573/ GO:0042572/ GO:0006694/ GO:0008202/ GO:0006805/ IPR001128/ IPR017972/ IPR008072/ IPR002402/ IPR036396/ P24462,1,8GK3,wlidetype,P24462,UniProt,C34 H32 Fe N4 O4,616.487,HEM,PROTOPORPHYRIN IX CONTAINING FE,Cc1c2n3c(c1CCC(=O)O)C=C4C(=C(C5=[N]4[Fe]36[N]7=C(C=C8N6C(=C5)C(=C8C)C=C)C(=C(C7=C2)C)C=C)C)CCC(=O)O,2
8GK3,7,,,,,,8GK3,Human Cytochrome P450 3A7 Binding Four Copies of Its Native Substrate Dehydroepiandrosterone 3-Sulfate.,Cytochrome P450 3A7 in complex with Dehydroepiandrosterone sulfate,OXIDOREDUCTASE,CYP3A7,1.14.14.1,GO:0005789/ GO:0062183/ GO:0070330/ GO:0101020/ GO:0101021/ GO:0020037/ GO:0005506/ GO:0004497/ GO:0019825/ GO:0008401/ GO:0008395/ GO:0008210/ GO:0002933/ GO:0070989/ GO:0042573/ GO:0042572/ GO:0006694/ GO:0008202/ GO:0006805/ IPR001128/ IPR017972/ IPR008072/ IPR002402/ IPR036396/ P24462,2,8GK3,wlidetype,P24462,UniProt,C19 H28 O5 S,368.488,ZQK,Dehydroepiandrosterone sulfate,CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)OS(=O)(=O)O)C,3
8GQU,7,,,,,,8GQU,Cryo-EM structures of ClC-2 chloride channel reveal the blocking mechanism of its specific inhibitor AK-42.,AK-42 inhibitor binding human ClC-2 TMD,MEMBRANE PROTEIN,CLCN2,,GO:0034707/ GO:0030425/ GO:0043204/ GO:0005886/ GO:0005247/ GO:0090425/ GO:0060689/ GO:0006821/ GO:0030324/ GO:0032347/ GO:0034765/ GO:0060041/ IPR046342/ IPR002244/ IPR014743/ IPR001807/ P51788/ Generic PDBTM,1,8GQU,wlidetype,P51788,UniProt,C19 H14 Cl2 N2 O3,389.232,GH6,2-[[2/6-bis(chloranyl)-3-phenylmethoxy-phenyl]amino]pyridine-3-carboxylic acid,c1ccc(cc1)COc2ccc(c(c2Cl)Nc3c(cccn3)C(=O)O)Cl,2
8GTO,7,,,,,,8GTO,Comprehensive structural analysis reveals broad-spectrum neutralizing antibodies against SARS-CoV-2 Omicron variants.,cryo-EM structure of Omicron BA.5 S protein in complex with XGv282,VIRAL PROTEIN/IMMUNE SYSTEM,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,8GTO,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
8GTP,7,,,,,,8GTP,Comprehensive structural analysis reveals broad-spectrum neutralizing antibodies against SARS-CoV-2 Omicron variants.,cryo-EM structure of Omicron BA.5 S protein in complex with XGv289,VIRAL PROTEIN/IMMUNE SYSTEM,,,,2,8GTP,mutant,,,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
8GTQ,7,,,,,,8GTQ,Comprehensive structural analysis reveals broad-spectrum neutralizing antibodies against SARS-CoV-2 Omicron variants.,cryo-EM structure of Omicron BA.5 S protein in complex with S2L20,VIRAL PROTEIN/IMMUNE SYSTEM,S/ 2,,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,1,8GTQ,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
8GZV,7,,,,,,8GZV,Structures of a FtsZ single protofilament and a double-helical tube in complex with a monobody.,Klebsiella pneumoniae FtsZ complexed with monobody (P212121),CELL CYCLE,ftsZ/ B5L96_26660/ BL124_00027905/ BN49_4241/ DN601_04890/ EAO17_18285/ FXN67_14780/ G7Z27_22770/ GJJ08_022520/ GJJ18_04480/ GJJ26_021835/ GNE24_10045/ HV479_18765/ NCTC11679_04745/ NCTC13465_04463/ NCTC3279_00274/ NCTC5052_02872/ NCTC9128_05382/ NCTC9140_01897/ NCTC9637_05610/ SAMEA3499874_03081/ SAMEA3499901_00812/ SAMEA3538828_00852/ SAMEA3649733_02938/ SAMEA3720909_02172/ SAMEA4364603_03522,,GO:0032153/ GO:0005737/ GO:0005525/ GO:0003924/ GO:0000917/ GO:0043093/ GO:0051258/ IPR000158/ IPR020805/ IPR045061/ IPR024757/ IPR008280/ IPR037103/ IPR018316/ IPR036525/ IPR003008,1,8GZV,wlidetype,W9BCK7,UniProt,C10 H15 N5 O11 P2,443.201,GDP,GUANOSINE-5'-DIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,3
8GZW,7,,,,,,8GZW,Structures of a FtsZ single protofilament and a double-helical tube in complex with a monobody.,Klebsiella pneumoniae FtsZ complexed with monobody (P21),CELL CYCLE,ftsZ/ B5L96_26660/ BL124_00027905/ BN49_4241/ DN601_04890/ EAO17_18285/ FXN67_14780/ G7Z27_22770/ GJJ08_022520/ GJJ18_04480/ GJJ26_021835/ GNE24_10045/ HV479_18765/ NCTC11679_04745/ NCTC13465_04463/ NCTC3279_00274/ NCTC5052_02872/ NCTC9128_05382/ NCTC9140_01897/ NCTC9637_05610/ SAMEA3499874_03081/ SAMEA3499901_00812/ SAMEA3538828_00852/ SAMEA3649733_02938/ SAMEA3720909_02172/ SAMEA4364603_03522,,GO:0032153/ GO:0005737/ GO:0005525/ GO:0003924/ GO:0000917/ GO:0043093/ GO:0051258/ IPR000158/ IPR020805/ IPR045061/ IPR024757/ IPR008280/ IPR037103/ IPR018316/ IPR036525/ IPR003008,1,8GZW,wlidetype,W9BCK7,UniProt,C10 H15 N5 O11 P2,443.201,GDP,GUANOSINE-5'-DIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,3
8GZX,7,,,,,,8GZX,Structures of a FtsZ single protofilament and a double-helical tube in complex with a monobody.,Escherichia coli FtsZ complexed with monobody (P212121),CELL CYCLE,ftsZ/ DNQ45_06620,,GO:0032153/ GO:0005737/ GO:0005525/ GO:0003924/ GO:0000917/ GO:0043093/ GO:0051258/ IPR000158/ IPR020805/ IPR045061/ IPR024757/ IPR008280/ IPR037103/ IPR018316/ IPR036525/ IPR003008,1,8GZX,wlidetype,A0A2W6PFK5,UniProt,C10 H15 N5 O11 P2,443.201,GDP,GUANOSINE-5'-DIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,3
8GZY,7,,,,,,8GZY,Structures of a FtsZ single protofilament and a double-helical tube in complex with a monobody.,Escherichia coli FtsZ complexed with monobody (P21),CELL CYCLE,ftsZ/ DNQ45_06620,,GO:0032153/ GO:0005737/ GO:0005525/ GO:0003924/ GO:0000917/ GO:0043093/ GO:0051258/ IPR000158/ IPR020805/ IPR045061/ IPR024757/ IPR008280/ IPR037103/ IPR018316/ IPR036525/ IPR003008,1,8GZY,wlidetype,A0A2W6PFK5,UniProt,C10 H15 N5 O11 P2,443.201,GDP,GUANOSINE-5'-DIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,3
8H06,7,,,,,,8H06,Structural basis for receptor binding and broader interspecies receptor recognition of currently circulating Omicron sub-variants.,Cryo-EM structure of SARS-CoV-2 Omicron BA.4/5 RBD in complex with human ACE2 (local refinement),HYDROLASE/VIRAL PROTEIN,S/ 2,3.4.17.23/ 3.4.17,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,2,8H06,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
8H5C,7,,,,,,8H5C,Structure of SARS-CoV-2 Omicron BA.2.75 RBD in complex with human ACE2,Structure of SARS-CoV-2 Omicron BA.2.75 RBD in complex with human ACE2,VIRAL PROTEIN,S/ 2,3.4.17.23/ 3.4.17,GO:0044173/ GO:0020002/ GO:0016020/ GO:0019031/ GO:0055036/ GO:0046789/ GO:0042802/ GO:0075509/ GO:0039654/ GO:0019064/ GO:0061025/ GO:0046598/ GO:0019065/ GO:0046813/ GO:0039587/ GO:0039502/ GO:0046718/ GO:0019058/ IPR032500/ IPR042578/ IPR043607/ IPR043473/ IPR043002/ IPR044341/ IPR018548/ IPR044366/ IPR036326/ IPR002552/ IPR044873/ IPR044874/ P0DTC2,2,8H5C,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
8HL6,7,,,,,,8HL6,Structural basis for recognition and methylation of p97 by METTL21D/ a valosin-containing protein lysine methyltransferase.,Crystal structure of human valosin-containing protein methyltransferase,PROTEIN BINDING,METTL21D/ VCPKMT/ C14orf138,2.1.1,GO:0005737/ GO:0005829/ GO:0032991/ GO:0051117/ GO:0016279/ GO:0032780/ GO:0018022/ GO:0018023/ GO:0006479/ IPR019410/ IPR029063/ Q9H867,1,8HL6,wlidetype,Q9H867,UniProt,C15 H22 N6 O5 S,398.437,SAM,S-ADENOSYLMETHIONINE,C[S+](CCC(C(=O)[O-])N)CC1C(C(C(O1)n2cnc3c2ncnc3N)O)O,2
8I6K,7,,,,,,8I6K,Structural mechanism of dsDNA recognition by the hMNDA HIN domain: New insights into the DNA-binding model of a PYHIN protein.,Structure of hMNDA HIN with dsDNA,DNA BINDING PROTEIN/DNA,MNDA,,GO:0035578/ GO:0005829/ GO:0070062/ GO:0005576/ GO:1904813/ GO:0043231/ GO:0005730/ GO:0005654/ GO:0003690/ GO:0002218/ GO:0050853/ GO:0006968/ GO:0006974/ GO:0035458/ GO:0030889/ GO:0043065/ GO:0032731/ IPR004020/ IPR011029/ IPR040205/ IPR004021/ IPR012340/ P41218,1,8I6K,wlidetype,P41218,UniProt,C4 H10 O3,106.12,PEG,DI(HYDROXYETHYL)ETHER,C(COCCO)O,3
8IUK,7,,,,,,8IUK,Ligand-induced activation and G protein coupling of prostaglandin F 2 alpha receptor.,Cryo-EM structure of the PGF2-alpha-bound human PTGFR-Gq complex,MEMBRANE PROTEIN,,,,1,8IUK,wlidetype,P62873,UniProt,C20 H34 O5,354.481,UGU,(Z)-7-[(1R/2R/3R/5S)-3/5-bis(oxidanyl)-2-[(E/3S)-3-oxidanyloct-1-enyl]cyclopentyl]hept-5-enoic acid,CCCCCC(C=CC1C(CC(C1CC=CCCCC(=O)O)O)O)O,7
8IUL,7,,,,,,8IUL,Ligand-induced activation and G protein coupling of prostaglandin F 2 alpha receptor.,Cryo-EM structure of the latanoprost-bound human PTGFR-Gq complex,MEMBRANE PROTEIN,,,,1,8IUL,wlidetype,P62873,UniProt,C23 H34 O5,390.513,7WT,Z-7-[(1R/2R/3R/5S)-3/5-bis(oxidanyl)-2-[(3R)-3-oxidanyl-5-phenyl-pentyl]cyclopentyl]hept-5-enoic acid,c1ccc(cc1)CCC(CCC2C(CC(C2CC=CCCCC(=O)O)O)O)O,6
8IUM,7,,,,,,8IUM,Ligand-induced activation and G protein coupling of prostaglandin F 2 alpha receptor.,Cryo-EM structure of the tafluprost acid-bound human PTGFR-Gq complex,MEMBRANE PROTEIN,,,,1,8IUM,wlidetype,P62873,UniProt,C22 H28 F2 O5,410.452,S2F,(~{Z})-7-[(1~{R}/2~{R}/3~{R}/5~{S})-2-[(~{E})-3/3-bis(fluoranyl)-4-phenoxy-but-1-enyl]-3/5-bis(oxidanyl)cyclopentyl]hept-5-enoic acid,c1ccc(cc1)OCC(C=CC2C(CC(C2CC=CCCCC(=O)O)O)O)(F)F,7
8ONE,7,,,,,,8ONE,"Identification of Regulatory Molecular ""Hot Spots"" for LH/PLOD Collagen Glycosyltransferase Activity.",Crystal Structure of full-length Human Lysyl Hydroxylase LH3 - Asp190Ser mutant - Cocrystal with Fe2+/ Mn2+/ UDP-Glucose,TRANSFERASE,PLOD3,1.14.11.4/ 2.4.1.50/ 2.4.1.66,GO:0062023/ GO:0005783/ GO:0005788/ GO:0005789/ GO:0070062/ GO:0005615/ GO:0005794/ GO:0005791/ GO:0005802/ GO:0005506/ GO:0031418/ GO:0050211/ GO:0033823/ GO:0008475/ GO:0070831/ GO:0030199/ GO:0032963/ GO:0001886/ GO:0048730/ GO:0046947/ GO:0001701/ GO:0060425/ GO:0021915/ GO:0017185/ GO:0008104/ GO:0006493/ GO:0042311/ IPR044861/ IPR029044/ IPR005123/ IPR006620/ IPR001006/ O60568,1,8ONE,mutant,O60568,UniProt,C15 H24 N2 O17 P2,566.302,UPG,URIDINE-5'-DIPHOSPHATE-GLUCOSE,C1=CN(C(=O)NC1=O)C2C(C(C(O2)COP(=O)(O)OP(=O)(O)OC3C(C(C(C(O3)CO)O)O)O)O)O,8
8OO7,7,,,,,,8OO7,Hexasome-INO80 complex reveals structural basis of noncanonical nucleosome remodeling.,CryoEM Structure INO80core Hexasome complex composite model state1,DNA BINDING PROTEIN,CTHT_0006820,3.6.4.12,GO:0031011/ GO:0035267/ GO:0097255/ GO:0005524/ GO:0016887/ GO:0003678/ GO:0006325/ GO:0006281/ IPR003593/ IPR027417/ IPR027238/ IPR041048/ IPR037938/ IPR042487/ IPR010339,1,8OO7,wlidetype,G0RYI5,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,13
8OO7,7,,,,,,8OO7,Hexasome-INO80 complex reveals structural basis of noncanonical nucleosome remodeling.,CryoEM Structure INO80core Hexasome complex composite model state1,DNA BINDING PROTEIN,H2AC6/ H2AFL/ HIST1H2AC,3.6.4.12,GO:0070062/ GO:0005654/ GO:0000786/ GO:0005634/ GO:0003677/ GO:0046982/ GO:0030527/ GO:0008285/ IPR009072/ IPR002119/ IPR007125/ IPR032454/ IPR032458/ Q93077,11,8OO7,wlidetype,Q93077,UniProt,Al F4,102.975,ALF,TETRAFLUOROALUMINATE ION,F[Al-](F)(F)F,14
8OO7,7,,,,,,8OO7,Hexasome-INO80 complex reveals structural basis of noncanonical nucleosome remodeling.,CryoEM Structure INO80core Hexasome complex composite model state1,DNA BINDING PROTEIN,HIST1H2BC/ H2BFL/ HIST1H2BE/ H2BFH/ HIST1H2BF/ H2BFG/ HIST1H2BG/ H2BFA/ HIST1H2BI/ H2BFK/ H2BC4/ H2BC6/ H2BC7/ H2BC8/ H2BC10,3.6.4.12,GO:0005829/ GO:0070062/ GO:0005615/ GO:0005654/ GO:0000786/ GO:0005634/ GO:0003677/ GO:0042802/ GO:0046982/ GO:0030527/ GO:0019731/ GO:0061844/ GO:0050830/ GO:0002227/ GO:0006334/ IPR009072/ IPR007125/ IPR000558/ P62807,12,8OO7,wlidetype,P62807,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,16
8OOP,7,,,,,,8OOP,Hexasome-INO80 complex reveals structural basis of noncanonical nucleosome remodeling.,CryoEM Structure INO80core Hexasome complex composite model state2,DNA BINDING PROTEIN,CTHT_0006820,3.6.4.12,GO:0031011/ GO:0035267/ GO:0097255/ GO:0005524/ GO:0016887/ GO:0003678/ GO:0006325/ GO:0006281/ IPR003593/ IPR027417/ IPR027238/ IPR041048/ IPR037938/ IPR042487/ IPR010339,1,8OOP,wlidetype,G0RYI5,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,13
8OOP,7,,,,,,8OOP,Hexasome-INO80 complex reveals structural basis of noncanonical nucleosome remodeling.,CryoEM Structure INO80core Hexasome complex composite model state2,DNA BINDING PROTEIN,H2AC6/ H2AFL/ HIST1H2AC,3.6.4.12,GO:0070062/ GO:0005654/ GO:0000786/ GO:0005634/ GO:0003677/ GO:0046982/ GO:0030527/ GO:0008285/ IPR009072/ IPR002119/ IPR007125/ IPR032454/ IPR032458/ Q93077,11,8OOP,wlidetype,Q93077,UniProt,Al F4,102.975,ALF,TETRAFLUOROALUMINATE ION,F[Al-](F)(F)F,15
8OOP,7,,,,,,8OOP,Hexasome-INO80 complex reveals structural basis of noncanonical nucleosome remodeling.,CryoEM Structure INO80core Hexasome complex composite model state2,DNA BINDING PROTEIN,HIST1H2BC/ H2BFL/ HIST1H2BE/ H2BFH/ HIST1H2BF/ H2BFG/ HIST1H2BG/ H2BFA/ HIST1H2BI/ H2BFK/ H2BC4/ H2BC6/ H2BC7/ H2BC8/ H2BC10,3.6.4.12,GO:0005829/ GO:0070062/ GO:0005615/ GO:0005654/ GO:0000786/ GO:0005634/ GO:0003677/ GO:0042802/ GO:0046982/ GO:0030527/ GO:0019731/ GO:0061844/ GO:0050830/ GO:0002227/ GO:0006334/ IPR009072/ IPR007125/ IPR000558/ P62807,12,8OOP,wlidetype,P62807,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,16
8OOS,7,,,,,,8OOS,Hexasome-INO80 complex reveals structural basis of noncanonical nucleosome remodeling.,CryoEM Structure INO80core Hexasome complex ATPase-hexasome refinement state 2,DNA BINDING PROTEIN,,,,2,8OOS,wlidetype,,,Al F4,102.975,ALF,TETRAFLUOROALUMINATE ION,F[Al-](F)(F)F,10
8OOS,7,,,,,,8OOS,Hexasome-INO80 complex reveals structural basis of noncanonical nucleosome remodeling.,CryoEM Structure INO80core Hexasome complex ATPase-hexasome refinement state 2,DNA BINDING PROTEIN,,,,3,8OOS,wlidetype,,,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,8
8PIF,7,,,,,,8PIF,KLHDC2 - The Next Level,Fragment 12 in complex with KLHDC2,LIGASE,KLHDC2/ HCA33,,GO:0031462/ GO:0016604/ GO:0031965/ GO:0005654/ GO:0005634/ GO:1990756/ GO:0043161/ GO:0016567/ GO:0140627/ IPR015915/ Q9Y2U9,1,8PIF,wlidetype,Q9Y2U9,UniProt,C6 H6 O3,126.11,YW6,2-(furan-3-yl)ethanoic acid,c1cocc1CC(=O)O,3
8S90,7,,,,,,8S90,Structure of human CALHM1 reveals key locations for channel regulation and blockade by ruthenium red,Cryo-EM structure of octameric human CALHM1 (I109W) in complex with ruthenium red (C1),MEMBRANE PROTEIN,CALHM1/ FAM26C,,GO:0016323/ GO:0005789/ GO:0005886/ GO:0005227/ GO:0042802/ GO:0005261/ GO:0005245/ GO:0005244/ GO:0015867/ GO:0006812/ GO:0051291/ GO:0051260/ GO:0034765/ GO:0050896/ GO:0050913/ GO:0050916/ GO:0050917/ IPR029569/ Q8IU99,1,8S90,mutant,Q8IU99,UniProt,H28 N14 O2 Ru3,559.525,R2R,ruthenium(6+) azanide pentaamino(oxido)ruthenium (1/4/2),N[Ru](N)(N)(N)(N)O[Ru](N)(N)(N)(N)O[Ru](N)(N)(N)(N)N,2
8SHJ,7,,,,,,8SHJ,Crystal structure of the WD-repeat domain of human WDR91 in complex with MR45279,Crystal structure of the WD-repeat domain of human WDR91 in complex with MR45279,TRANSPORT PROTEIN,WDR91/ HSPC049,,GO:0005829/ GO:0031901/ GO:0031313/ GO:0031902/ GO:0035014/ GO:0045022/ GO:0043551/ GO:0042176/ IPR015943/ IPR001680/ IPR036322/ IPR039724/ A4D1P6,1,8SHJ,wlidetype,A4D1P6,UniProt,C20 H21 Cl N2 O3,372.845,ZI8,N-[3-(4-chlorophenyl)oxetan-3-yl]-4-[(3S)-3-hydroxypyrrolidin-1-yl]benzamide,c1cc(ccc1C(=O)NC2(COC2)c3ccc(cc3)Cl)N4CCC(C4)O,2
8T55,7,,,,,,8T55,Co-crystal structure of the WD-repeat domain of human WDR91 in complex with MR46654,Co-crystal structure of the WD-repeat domain of human WDR91 in complex with MR46654,TRANSPORT PROTEIN,WDR91/ HSPC049,,GO:0005829/ GO:0031901/ GO:0031313/ GO:0031902/ GO:0035014/ GO:0045022/ GO:0043551/ GO:0042176/ IPR015943/ IPR001680/ IPR036322/ IPR039724/ A4D1P6,1,8T55,wlidetype,A4D1P6,UniProt,C22 H23 Cl N2 O3,398.883,ZI3,N-[3-(4-chlorophenyl)oxetan-3-yl]-1-propanoyl-1/2/3/4-tetrahydroquinoline-5-carboxamide,CCC(=O)N1CCCc2c1cccc2C(=O)NC3(COC3)c4ccc(cc4)Cl,2
8TBX,7,,,,,,8TBX,Crystal structure of human DDX1 helicase in complex with ADP,Crystal structure of human DDX1 helicase in complex with ADP,RNA BINDING PROTEIN,DDX1,3.6.4.13,GO:0071920/ GO:0005737/ GO:0010494/ GO:0005829/ GO:0016020/ GO:0005739/ GO:0005654/ GO:0005634/ GO:1990904/ GO:0072669/ GO:0005524/ GO:0016887/ GO:0003682/ GO:0003677/ GO:0033677/ GO:0003725/ GO:0004527/ GO:0004518/ GO:0008143/ GO:0003723/ GO:0003724/ GO:0003712/ GO:0051607/ GO:0032508/ GO:0006302/ GO:0045087/ GO:0090305/ GO:0043123/ GO:0002735/ GO:1903608/ GO:0006446/ GO:0043330/ GO:0000245/ GO:0006388/ IPR001870/ IPR043136/ IPR013320/ IPR011545/ IPR014001/ IPR001650/ IPR027417/ IPR014014/ IPR003877/ Q92499,1,8TBX,wlidetype,Q92499,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,2
